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ABSTRACT	  THE	  FUNCTION	  OF	  RENALASE	  by	  Brett	  A.	  Beaupre	  	  The	  University	  of	  Wisconsin-­‐Milwaukee,	  2016	  Under	  the	  Supervision	  of	  Professor	  Graham	  R.	  Moran	  	  	  Renalase	  was	  originally	  reported	  to	  be	  an	  enzyme	  secreted	  into	  the	  blood	  by	  the	  kidney	  to	  lower	  blood	  pressure	  and	  slow	  heart	  rate.	  Despite	  multiple	  reports	  claiming	  to	  confirm	  this	  activity	  in	  vivo	  there	  has	  been	  considerable	  discord	  in	  regards	  to	  the	  reaction	  catalyzed	  by	  renalase.	  The	  structural	  topology	  of	  renalase	  resembles	  that	  of	  known	  flavoprotein	  oxidases,	  monooxygenases	  and	  demethylases,	  but	  the	  conserved	  active	  site	  residues	  are	  unique	  to	  renalase.	  It	  has	  been	  reported	  that	  the	  catalytic	  function	  of	  renalase	  is	  to	  oxidize	  circulating	  catecholamines,	  however	  in	  vitro	  studies	  have	  failed	  to	  demonstrate	  a	  catalytic	  activity	  in	  the	  presence	  of	  such	  molecules.	  We	  have	  identified	  renalase	  as	  a	  novel	  oxidase	  enzyme	  which	  catalyzes	  the	  oxidation	  of	  both	  6-­‐dihydro	  NAD(P)	  and	  2-­‐dihydro	  NAD(P)	  to	  β-­‐NAD(P)+	  delivering	  the	  electrons	  harvested	  to	  dioxygen	  forming	  hydrogen	  peroxide.	  Catalysis	  involves	  the	  oxidation	  of	  the	  dihydropyridyl	  ring	  of	  the	  substrate	  by	  transferring	  two	  electrons	  to	  the	  flavin	  cofactor,	  followed	  by	  release	  of	  the	  oxidized	  β-­‐NAD(P)+	  product,	  and	  then	  the	  reoxidation	  of	  the	  reduced	  cofactor.	  Renalase	  substrates,	  2-­‐dihydro	  and	  6-­‐dihydro	  NAD(P)	  are	  thought	  to	  arise	  from	  non-­‐specific	  reduction	  of	  NAD(P)+	  or	  tautomerization	  of	  NAD(P)H.	  These	  aberrant	  nicotinamide	  isomers	  are	  potent	  inhibitors	  of	  dehydrogenase	  enzymes	  including	  those	  of	  glycolysis	  and	  the	  TCA	  cycle.	  It	  would	  therefore	  appear	  that	  the	  function	  of	  renalase	  is	  to	  eliminate	  this	  inhibitory	  threat	  to	  primary	  metabolism.	  In	  addition	  to	  identifying	  the	  true	  catalytic	  substrates	  and	  proposing	  a	  metabolic	  function	  we	  have	  also	  identified	  verifiably	  active	  forms	  of	  renalase	  from	  
	  	  	   iii	  
Psuedomonas	  phaseolicola	  and	  Pseudomonas	  aeruginosa,	  as	  well	  as	  crystal	  structures	  of	  renalase	  from	  P.	  phaseolicola	  in	  complex	  with	  β-­‐NAD+	  and	  β-­‐NADH.	  The	  data	  presented	  in	  this	  dissertaion	  chronolog	  the	  discovery	  of	  a	  genuine	  catalytic	  role	  for	  renalase	  that	  is	  likely	  an	  important	  housekeeping	  function	  for	  all	  life	  forms.	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   throughout	   this	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   for	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  nicotinamide	  bases.	  Early	  naming	  of	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  NAD(P)	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   therefore	   formally	   2,	   4,	   or	   6-­‐monohydronicotinamides.	  We	  have	   chosen	   instead	   the	   descriptive	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   xv	  
ACKNOWLEDGEMENTS	  	  	   First	   	   and	   foremost	   I	  would	   like	   to	   thank	  my	   thesis	  advisor	  Dr.	  Graham	  R.	  Moran,	  	  your	  enthusiasm	  propelled	  my	  curiosity	  and	  your	  shared	  knowlegde	  allowed	  me	  to	  apply	  this	   curiosity	   to	   sound	  discovery.	   	   Dr.	  Moran	   is	   a	   gifted	  mentor	   that	   shares	  his	   scientific	  passion	  to	  motivate	  everyone	  that	  enters	  the	  laboratory.	  	  	  	   I	  would	  also	  like	  to	  thank	  the	  member	  of	  my	  thesis	  comittee,	  Dr.	  Andy	  Pacheco,	  Dr.	  Nicholas	   Silvaggi,	   Dr.	   Gilherme	   Indig	   and	   Dr.	   Alan	   Schwabacher.	   	   Their	   combined	  knowledge	  has	  	  helped	  guide	  my	  research	  and	  provided	  creative	  solutions	  for	  a	  multitude	  of	  research	  related	  conundrums.	  Thank	  you	  all	  for	  your	  help	  and	  support.	  	   Furthermore,	  science	  is	  a	  team	  effort	  and	  without	  the	  support	  and	  collaboration	  of	  other	  gifted	   scientists	  progression	   is	  difficult.	  With	   that	   in	  mind	   I	  would	   like	   to	   thank	  all	  those	   that	   have	   contributed	   to	   this	   project,	   Dr.	   John	   Conrad,	  Dr.	   Dhara	   Shah,	  Matt	  Hoag,	  Joseph	  Roman,	  Brenton	  Carmicheal,	  Holger	  Foersterling	  and	  	  Neal	  Korfhage.	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  	   1	  
Chapter	  I.	  
	  
New	  Chemistry	  for	  an	  old	  Cofactor:	  Recent	  Advancements	  in	  the	  Study	  of	  
Flavoproteins	  
	  Brett	  A.	  Beaupre	  and	  Graham	  R.	  Moran	  	  
Abstract	  Flavin	  cofactors	  are	  commonly	  recruited	  by	  enzymes	  know	  as	  flavoproteins	  where	  the	   cofactor	   plays	   an	   important	   role	   catalyzing	  many	  diverse	   reactions	   in	   a	  multitude	   of	  different	   organism.	   Most	   commonly,	   flavins	   are	   employed	   to	   mediate	   redox	   reactions	  involving	  both	  one-­‐	  or	   two-­‐electron	   chemistries	  but	  have	   also	  been	  observed	   to	   catalyze	  many	  unique	  and	  unprecedented	  reactions.	  In	  this	  article	  we	  present	  recent	  advancements	  involving	  six	  unique	   flavoproteins;	  1)	   chorismate	  synthase	  and	  2)	  UDP-­‐galactorpyranose,	  which	   catalyze	   redox	   neutral	   reactions,	   3)	   UbiD/Fdc1,	   which	   require	   a	   unique	   4-­‐ringed	  modified	  flavin	  supplied	  by	  UbiX/Pad1,	  4)	  EncM,	  which	  requires	  a	  unique	  “super	  oxidized”	  flavin-­‐N(5)-­‐oxide	   species	   for	   catalysis,	   5)	   renalase,	   which	   uses	   a	   tradition	   flavin	   redox	  chemistries	  to	  oxidize	  a	  unique	  substrate	  	  and	  6)	  choline	  oxidase,	  which	  catalyzes	  a	  set	  of	  two	  reactions	  that	  normally	  requires	  two	  separate	  enzymes.	  	  
Introduction	  Enzymes	  catalyze	  chemical	  reactions	  and	  as	  such	  are	  integral	  to	  life.	  Collectively,	  enzymes	  exhibit	   a	  myriad	   of	   strategies	   to	   promote	   specific	   chemistries.	  While	  many	   enzymes	   are	  formed	   only	   from	  polymerization	   of	   the	   twenty	   known	  proteinogenic	   amino	   acids,	   some	  reactions	   require	   more	   specialized	   entities	   to	   facilitate	   chemistry.	   	   It	   is	   common	   for	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enzymes	  to	  contain	  an	  organic	  or	  inorganic	  prosthetic	  group	  that	  forms	  an	  association	  with	  the	   apoenzyme	   and	   is	   required	   for	   catalytic	   function.	   These	   groups	   are	   described	  collectively	   as	   cofactors.	   One	   of	   the	   most	   intensively	   studied	   cofactors	   is	   the	   flavin,	   a	  riboflavin	  derived	  cofactor	  that	  acts	  as	  a	  precursor	  for	  two	  nucleotide	  forms,	  flavin	  adenine	  dinucleotide	  (FAD),	  and	  flavin	  mononucleotide	  (FMN)	  	   Flavins	  are	  most	  often	  employed	  to	  mediate	  in	  oxidation/reduction	  reactions	  where	  the	   isoalloxazine	   ring	   system	   acts	   as	   both	   an	   oxidizing	   and	   reducing	   participant.	   This	  chemical	   capacity	   is	  made	  more	   versatile	   by	   the	   fact	   that	   the	   isoalloxazine	   can	   stabilize	  three	   redox	   states:	   oxidized,	   one-­‐electron	   reduced	   (semiquinone)	   and	   two-­‐electron	  reduced.	  	  	   In	  addition	  to	  redox	  chemistries,	  flavins	  have	  been	  shown	  to	  be	  involved	  in	  catalysis	  where	  no	  net	  redox	  change	  occurs.	  In	  this	  scenario	  the	  reduced	  isoalloxazine	  ring	  acts	  as	  an	  acid	  or	  a	  base	  to	  facilitate	  rebounding	  electron	  transfer	  or	  generate	  covalent	  intermediates.	  In	  this	  article	  we	  present	  relatively	  recently	   identified	  oddities	   in	  the	  spectrum	  of	  known	  catalytic	   chemistries	   facilitated	   by	   flavin	   cofactors.	   These	   include	   enzymes	   that	   utilize	   a	  flavin-­‐N(5)-­‐oxide	   (EncM),	   another	   that	   requires	   a	   four-­‐ringed	   prenylated	   flavin	  (UbiD/Fdc1),	   two	   examples	   of	   redox	   neutral	   flavin	   reactions	   (chorismate	   synthase	   and	  UDP	  galactopyranose	  mutase),	  an	  enzyme	  that	  takes	  advantage	  of	  traditional	  flavin	  redox	  roles	   to	   recognize,	   bind	   and	   react	   a	   unique	   substrate	   (renalase),	   and	   also	   a	   flavin	  dependent	   enzyme	   that	   undergoes	   two	   redox	   reactions	   to	   catalyze	   a	   reaction	   normally	  requiring	  two	  enzymes	  (choline	  oxidase).	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Renalase	  In	   2005	   a	   new	   gene	   product	   was	   discovered	   whose	   expression	   was	   prominent	   in	   the	  kidney.	  	  The	  primary	  structure	  of	  this	  protein,	  named	  renalase,	  bore	  a	  minor	  resemblance	  to	  monoamine	  oxidase	  enzymes	  (13	  -­‐	  17%	  amino	  acid	  identity).	  This	  low	  level	  of	  sequence	  similarity	   and	   an	   tenuous	   account	   of	   catecholamine	   oxidase	   activity	   was	   all	   that	   was	  offered	   to	   categorize	   renalase	   as	   the	   third	  monoamine	   oxidase,	  MAO	   C	   (1).	   Through	   the	  ensuing	   decade	   the	   renalase	   literature	   record	   has	   accrued	   an	   exponential	   increase	   in	  articles.	  These	  reports	  have	  purported	  multifarious	  claims	  of	  native	  catalytic	  activity	  and	  associated	  physiological	  effects	  (2-­‐35).	  This	  had	  occurred	  despite	  a	  near	  complete	   lack	  of	  verified	   in	   vitro	   catalytic	   activity.	   The	   current	   prevailing	   belief	   is	   that	   renalase	   is	   an	  enzyme/hormone	   that	   is	   secreted	  by	   the	  kidney	   to	   slow	   the	  heart	  and	  diminish	  vascular	  tone	  by	  oxidizing	  circulating	  catecholamine	  neurotransmitters	  (1-­‐29,	  31,	  35-­‐47).	  Attempts	  to	   challenge	   this	   notion	   have	   largely	   gone	   unheeded	   (48-­‐58).	   However,	   more	   recent	  evidence	  for	  an	  unexpected	  catalytic	  role	  for	  renalase	  undermines	  the	  prevalent	  notions	  of	  its	   function.	   In	   this	   newly	   discovered	   role,	   renalase	   has	   an	   apparent	   intracellular	  housekeeping	   function	   that	   ameliorates	   the	   threat	   of	   specific	   toxic	   isomers	   of	   NAD(P)H.	  The	  substrates	  identified	  were	  2-­‐dihydroNAD(P)	  and	  6-­‐dihydroNAD(P)	  both	  of	  which	  are	  highly	   isosteric	   with	   NADPH	   and	   inhibit	   enzymes	   that	   require	   reduced	   nicotinamide	  nucleotides	  as	  substrates	  (55).	  Despite	  the	  dissonance	  in	  literature	  the	  true	  substrates	  (53,	  
55)	  and	  the	  newly	  proposed	  metabolic	  role	  (55,	  56)	  for	  renalase	  represent	  an	  odd	  variant	  of	  what	   is	  otherwise	  common	  flavin/nicotinamide	  hydride	  transfer	  redox	  chemistry.	  This	  synopsis	  of	  the	  renalase	  literature	  is	  offered	  as	  a	  retrospective	  analysis	  of	  the	  bases	  of	  the	  misconceptions	  that	  have	  arisen	  and	  persisted	  for	  this	  enzyme.	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Renalase	  was	  originally	  identified	  from	  a	  2003	  genomic	  library	  in	  an	  attempt	  to	  find	  novel	  kidney	  secreted	  factors.	  The	  screen	  located	  a	  37.8	  kDa,	  apparently	  FAD-­‐	  dependent	  protein	  that	   could	   also	   be	   detected	   in	   heart	   skeletal	   muscle,	   and	   liver	   tissue	   (1).	   Claims	   of	  catecholamine	  oxidase	  activity	  highlight	  the	  inherent	  limitations	  of	  assigning	  function	  from	  sequence.	   	   The	   overall	   motif	   structure	   and	   length	   of	   the	   protein	   was	   reminiscent	  monoamine	   oxidases,	   and	   this	   otherwise	   isolated	   correlation	   resulted	   in	   a	   functional	  conclusion	  that	  in	  turn	  led	  directly	  to	  claims	  of	  a	  hemodynamic	  influence	  that	  was	  further	  compounded	   by	   corresponding	   claims.	   	   The	   initial	   work	   asserted	   that	   a	   single	   bolus	  injection	   of	   renalase	   decreased	   both	   systolic	   and	   diastolic	   pressure	   23-­‐33%	   in	   Sprague-­‐Dawley	   rats	   within	   30	   sec.	   This,	   now	   inexplicable	   claim	   led	   directly	   to	   the	   notion	   that	  renalase	   must	   function	   by	   eliminating	   catecholamines	   and	   presumably,	   based	   on	   the	  primary	  structure,	  by	  oxidation	  (1).	  	  	   Catalytic	   catecholamine	   oxidase	   activity	   was	   determined	   using	   a	   generic	   oxidase	  assay	   that	   employs	   Amplex	   red	   and	   peroxidase	   to	   report	   hydrogen	   peroxide	   (H2O2)	  concentration.	  In	  an	  incubation	  of	  catecholamines	  in	  the	  presence	  of	  renalase,	  0.25%	  of	  the	  dye	  was	   converted	   resulting	   from	  1.8	   to	   3.2	   nmol	  H2O2	  mg-­‐1	  min-­‐1	   or	   0.004	   s-­‐1.	  Multiple	  reports	   cite	   such	  minimal	   rates	  of	  H2O2	  evolution	  as	   resulting	   from	  non-­‐enzymatic	   redox	  chemistry	   (48,	   50,	   59).	   Both	   catecholamines	   and	   FADH2	   are	   able	   to	   participate	   in	  autoxidative	  single	  electron	  chemistries	  with	  dioxygen	  resulting	  in	  the	  generation	  of	  H2O2.	  Unfortunately,	  no	  control	  reactions	  were	  included	  in	  the	  experiments	  that	  initially	  claimed	  renalase's	   function.	   The	   reply	   to	   the	   criticism	   that	   the	   exceeding	   low	   rate	   of	   hydrogen	  peroxide	   production	  was	   likely	   non-­‐enzymatic	   autooxidation	   of	   catecholamines	  was	   that	  the	  claimed	  activity	  was	  observed	  in	  the	  absence	  of	   the	  co-­‐substrate	  β-­‐NAD(P)H	  and	  was	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therefore	  not	  the	  true	  chemistry	  (13).	  The	  Desir	  group	  referred	  to	  the	  presence	  of	  a	  GXXXG	  or	   Rossman	   fold	   motif	   close	   to	   the	   N-­‐terminus	   that	   would	   be	   available	   to	   bind	   the	  nicotinamide	  dinucleotide	  and	  reported	  that	  the	  addition	  of	  β-­‐NADH	  caused	  a	  pronounced	  increase	   in	  activity	  compared	  to	  earlier	  reports	  (2).	  A	  proposed	  overall	  reaction	  (Scheme	  1.1)	  was	   offered	   claiming	   as	   the	   aminochrome	   product	   (2).	   The	   reaction	  was	   said	   to	   be	  comprised	  of	  the	  renalase	  FAD	  cofactor	  being	  reduced	  by	  electrons	  received	  from	  β-­‐NADH	  and	  subsequently	  delivered	  to	  dioxygen	  generating	  a	  flavin	  semiquinone	  and	  a	  superoxide	  anion	  that	  exclusively	  oxidizes	  catecholamines	  in	  multiple	  one-­‐electron	  steps.	  	  	  
	  
Scheme	  1.1.	  The	  initial	  proposal	  for	  the	  reaction	  catalyzed	  by	  renalase	  	  	   The	  Aliverti	  group	  published	  a	  crystal	  structure	  of	  renalase	  from	  Homo	  sapiens	  (PDB	  code	   3QJ4)	   in	   2011.	   In	   this	   structure	   it	   was	   revealed	   that	   the	   function	   of	   the	   GXXXG	  Rossman	  fold	  motif	  was	  to	  bind	  the	  adenosine	  moiety	  of	  the	  FAD	  and	  there	  was	  no	  classical	  site	  for	  β-­‐NADH	  interaction	  (60).	  This	  group	  also	  conducted	  the	  first	  independent	  attempt	  to	  verify	  renalase	  activity	  with	  catecholamines	  concluded	  that	  compared	  to	  the	  appropriate	  control	  reactions,	  renalase	  did	  not	  oxidize	  catecholamines	  and	  the	  interaction	  between	  the	  renalase	   FAD	   and	   β	   -­‐NADH	   is	   due	   to	   the	   slow	   promiscuous	   redox	   chemistry	   of	   the	   two	  molecules	   (61).	   They	   also	   demonstrated	   that	   under	   anaerobic	   conditions	   prolonged	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incubation	  of	  renalase	  with	  β-­‐NADH	  results	   in	  the	  reduction	  of	  the	  FAD	  cofactor	  and	  that	  this	  was	  the	  rate	  limiting	  process	  in	  the	  experiments	  described	  by	  Desir	  et	  al.	  (2).	  Aliverti	  et	  al.	  also	  reported	  that	  renalase	  possesses	  diaphorase	  activity	  when	  incubated	  with	  either	  β-­‐NADH	  and	  β-­‐NADPH	  with	  a	  preference	  for	  β-­‐NADPH,	  and	  described	  kinetic	  parameters	  that	  parallel	  initial	  observations	  made	  by	  Desir	  et	  al.	  (2)	  in	  the	  presence	  of	  a	  variety	  of	  electron	  acceptors,	   concluding	   that	   this	   interaction	   is	   actually	   a	   predicted,	   non-­‐enzymatic	   side	  reactions	  facilitated	  by	  the	  large	  solvent	  exposed	  active	  site	  cavity	  which	  facilitates	  access	  for	  the	  redox	  interaction	  between	  the	  flavin	  and	  β-­‐NADH(51).	  	  	   Despite	   this	   apparently	   sound	   refutation,	   the	   prevalence	   of	   the	   belief	   in	   a	  physiological	   role	   for	   renalase's	   activity	   and	   function	   has	   remained	   and	   stands	   as	   an	  interesting	  example	  of	  the	  lasting	  influence	  of	  erroneous	  data	  in	  science.	  	  This	  synoposis	  of	  renalase	  will	  not	  focus	  further	  on	  the	  multifarious	  claims	  for	  the	  function	  of	  renalase.	  For	  a	  more	  comprehensive	  reviews	  of	  this	  topic	  see,	  Moran	  2016(58),	  Malyszko	  et	  al	  2014	  (52),	  and	   Baroni	   et	   al	   2013	   (51)	   and	   Li	   et	   al	   2014	   (7).	   The	   focus	   of	   this	   section	   will	   be	   the	  discovery	  of	  what	  appears	  to	  be	  a	  true	  catalytic	  function	  of	  for	  this	  enzyme.	  	   Our	   group	  presented	   the	   first	   report	  of	   genuinely	   catalytic	   activity	   for	   renalase	   in	  2013.	   We	   showed	   that	   under	   anaerobic	   conditions	   the	   renalase	   FAD	   cofactor	   could	  undergo	   rapid	   reduction	   (~40	   s-­‐1)	   when	   reacted	   with	   a	   contaminant	   found	   in	   β-­‐NADH	  (1.3%)	  or	  β-­‐NADPH	  (4%)	  (53,	  54)	  solutions.	  This	  rate	  was	  four-­‐orders	  of	  magnitude	  more	  rapid	  than	  prior	  activity	  reports	  (36).	  These	  apparent	  substrate	  molecules	  induce	  multiple	  enzymatic	   turnovers	  converting	   the	  contaminant	  β-­‐NAD(P)+	  and	  delivering	   two	  electrons	  to	   dioxygen	   resulting	   in	   the	   production	   of	   H2O2	   with	   1,1:1,1	   stoichiometry.	   The	   fleeting	  nature	  of	  the	  β-­‐NAD(P)H	  contaminant	  substrates	  required	  the	  establishment	  of	  regimented	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separation	  and	  purification	  techniques	  to	  obtain	  pure,	  quazi-­‐stable	  substrate.	  Initially	  only	  one	  form	  of	  the	  substrate	  was	  described	  (contaminant	  species),	  but	  guided	  by	  a	  literature	  trail	  dating	  back	  to	  the	  1950’s	  (62-­‐66)	  we	  determined	  that	  incubation	  of	  β-­‐NAD(P)+	  with	  a	  strong	  reductant	  (sodium	  borohydride)	  results	  in	  the	  formation	  of	  3	  distinct	  products	  with	  an	   observed	   extinction	   coefficients	   and	   absorbance	   maxima	   of,	   ε340nm	   =	   6220	   M-­‐1cm-­‐1,	  	  ε345nm	  =	  6580	  M-­‐1cm-­‐1	  and	  ε394nm	  =	  5360	  M-­‐1cm-­‐1.	  NMR	  and	  mass	  spectrometry	  confirmed	  that	   the	  species	  with	  340	  nm	  λmax	  was	  β-­‐NAD(P)H	  (4-­‐dihydroNAD(P)),	   that	   the	  345	  nm	  λmax	   species	  was	  6-­‐dihydroNAD(P)	  and	   the	  394nm	  λmax	   species	  was	  2-­‐dihydroNAD(P).	  Interestingly,	   both	   6-­‐dihydroNAD(P)	   (the	   initial	   contaminant	   identified)	   and	   2-­‐dihydroNAD(P)	  were	   substrates	   for	   renalase	   and	   both	   yield	  β-­‐NAD(P)+	  	   as	   product	   (55).	  These	  substrates	  induced	  reduction	  of	  the	  renalase	  cofactor	  with	  respective	  rate	  constants	  of	  230	  s-­‐1	  and	  860	  s-­‐1	  with	  associated	  dissociation	  constants	  (Kd)	  of	  166	  µM	  and	  173	  µM	  for	  the	   E•S	   complexes.	   	   The	   observed	   rate	   constant	   for	   flavin	   re-­‐oxidation	   by	   reducing	  dioxygen	   (kox)	  was	   5	   x	   103	  M-­‐1s-­‐1.	   To	   determine	   if	   flavin	   re-­‐oxidation	  was	   contingent	   on	  product	   release,	   reduction	  potential	  measurements	  were	   conducted	  and	   revealed	   similar	  reduction	  potentials	  (~150	  mV)	  for	  both	  the	  oxidized	  enzyme	  and	  the	  β-­‐NAD+	  (or	  product)	  complex	   suggesting	   that	   the	   propensity	   for	   re-­‐oxidation	   of	   the	   flavin	   cofactor	   is	   not	  influenced	  by	  the	  presence	  of	  the	  product.	  Moreover,	  it	  was	  shown	  that	  exogenous	  addition	  of	   β-­‐NAD+	   could	   not	   suppress	   the	   reoxidation	   rate	   constant	   even	   at	   near	   saturating	  concentrations,	   establishing	   that	   the	   free	   reduced	   enzyme	   and	   the	   enzyme	   product	  complex	   were	   equally	   able	   to	   reduce	   dioxygen.	   These	   results	   allowed	   us	   to	   construct	   a	  proposed	  mechanism	  for	  human	  renalase	  (Scheme	  1.2).	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Scheme	  1.2.	  Proposed	  chemical	  and	  kinetic	  mechanism	  of	  human	  renalase.	  (shown	  2-­‐dihydroNAD(P)	  as	  substrate).	  
	  
	  
	  	   Collectively,	  these	  observations	  permitted	  the	  proposal	  that	  renalase	  functions	  as	  a	  oxidase	   enzyme	   whose	   purpose	   is	   to	   recycle	   erroneous	   reduced	   forms	   of	   reduced	  nicotinamide	   nucleotides	   that	   are	   generated	   in	   non-­‐specific	   reduction	   reactions	   of	   β-­‐NAD(P)+	  (Scheme	  1.3).	  	  	  
	  
Scheme	  1.3.	  Reactions	  catalyzed	  by	  renalase.	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   The	  observations	  made	   in	  1961	  by	  Lowry	  et	  al,	  and	  Godtfredsen	  (67,	  68)	  not	  only	  aided	   our	   substrate	   identification,	   but	   they	   also	   prompted	   an	   investigation	   into	   the	  potential	   physiological	   function	   of	   renalase.	   We	   monitored	   turnover	   of	   malate	  dehydrogenase,	   lactate	   dehydrogenase,	   and	   dihydrolipoamide	   dehydrogenase	   in	   the	  presence	  of	  either	  2-­‐	  or	  6-­‐dihydroNAD.	  The	  data	  suggested	  that	  2-­‐	  and	  6-­‐position	  isomeric	  forms	   of	   β-­‐NAD(P)H	   pose	   a	   significant	   threat	   to	   primary	   metabolism	   dehydrogenase	  enzymes	  with	   inhibition	  constants	  (Ki)	  values	   in	  the	  nMolar	  range(55).	  Not	  only	  was	  this	  the	   first	   evidence	   for	   alternate	   configurations/isomers	   of	   β-­‐NAD(P)H	   being	   biologically	  active	  and	  the	  first	  evidence	  for	  their	  occurence	  in	  metabolism.	  	   The	   identification	   of	   apparent	   true	   substrates	   for	   renalase	   also	   verified	   that	   the	  enzyme	  was	  fully	  active	  and	  thus	  presented	  the	  opportunity	  to	  revisit	   the	   initial	  renalase	  observations	   and	   conduct	   the	   conclusive	   control	   reactions	   for	   claimed	   catecholamine	  oxidase	   activity.	   	   These	   experiments	   definitively	   demonstrated	   that	   renalase	   does	   not	  catalyze	  the	  oxidation	  of	  catecholamines	  to	  aminochromes	  and	  the	  accumulation	  of	  H2O2	  is	  a	   result	   of	   non-­‐enzymatic	   interactions	   between	  β-­‐NAD(P)H,	   FAD	   and	   dioxygen	   (57).	   The	  results	   also	   indicated	   that	   the	   generation	   of	   aminochrome	   is	   higher	   when	   renalase	   is	  replaced	   with	   FAD	   alone,	   supporting	   the	   idea	   that	   binding	   of	   FAD	   to	   renalase	   actually	  shelters	  the	  cofactor	  against	  NAD(P)H	  reduction.	  In	  this	  article	  it	  was	  also	  concluded	  that	  renalase	   does	   not	   have	   a	   prorenalase	   form	   that	   is	   only	   active	   in	   blood	   as	   previously	  proposed	  (11).	  The	  catalytic	  activity	  is	  not	  modulated	  in	  50%	  blood	  plasma	  and/or	  by	  the	  presence	  of	  catecholamines.	  	  	   The	  proposed	  amelioration	  of	   the	   threat	  posed	  by	  NAD(P)H	   isomers	  suggests	   that	  renalase	  should	  be	   found	   in	  other	   forms	  of	   life.	  However,	  BLAST	  sequence	  alignments	  do	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not	   recover	   sequences	   from	   Kingdoms	   other	   than	   the	   animalia.	   	   If	   renalase	   could	   be	  identified	   in	   an	   organism	   without	   a	   pulmonary	   system	   this	   would	   be	   at	   least	   partially	  antithetical	  to	  physiological	  claims	  for	  the	  role	  of	  renalases	  catalytic	  function.	  To	  this	  end,	  Hoag	  et	  al.,	  recently	  discovered	  a	  bacterial	  form	  of	  renalase	  from	  P.	  phaseolicola	  (56).	  This	  enzyme	   was	   previously	   labeled	   generically	   as	   an	   “amine	   oxidase”	   (from	   Psuedomonas	  
syringe	   VanHall	   pathovar	   phaseolicola	   strain	   1448A)	   and	   the	   crystal	   structure	   of	   this	  protein	  had	  been	  solved	  by	  the	  NESGC	  in	  2009	  (PDB	  cod	  KKJ).	  While	  this	  enzyme	  displayed	  only	   19%	   sequence	   identity	   to	   renalase	   from	  H.	  sapiens	   the	   active	   site	   constellation	  was	  highly	   similar.	   It	  was	   confirmed	   that	   this	   putative	   bacterial	   renalase	  was	   indeed	   able	   to	  rapidly	   oxidize	   the	   same	   isomers	   of	   β-­‐NAD(P)H.	   	   The	   crystal	   stuctures	   of	   this	   enzyme	  bound	  to	  β-­‐NAD+	  (2.0	  Å,	  PDB	  code	  4ZCD),	  the	  enzyme•product	  complex,	  and	  β-­‐NADH	  (1.66	  Å,	  PDB	  code	  4ZCC)	  which	  is	  representative	  of	  the	  enzyme•substrate	  complex	  gave	  the	  first	  insights	  into	  renalase	  active	  site	  interactions	  (vide	  infra)	  (56).	  	  	   The	  kinetic	  parameters	  obtained	  from	  transient	  state	  analysis	  of	  the	  reductive	  and	  oxidative	  half	  reactions	  of	  this	  bacterial	  renalase	  with	  all	  four	  known	  substrates	  (NAD	  and	  NADP	  derived)	  indicated	  unique	  substrate	  preferences	  with	  rate	  constants	  for	  reduction	  of	  130	   s-­‐1,	   4	   s-­‐1,	   0.4	   s-­‐1	  and	  0.5	   s-­‐1	   and	  dissociation	   constants	  of	  36	  µM,	  468	  µM,	  28	  µM	  and	  1380	   µM	   for	   2-­‐dihydroNAD,	   2-­‐dihydroNADP,	   6-­‐dihydroNAD	   and	   6-­‐dihydroNADP	  respectively.	   As	   such	   renalase	   from	   P.	   phaseolicola	   displays	   a	   preference	   for	   β-­‐NAD+	  derived	   substrates	   binding	   them	   10	   to	   50-­‐fold	   more	   tightly	   then	   β-­‐NADP+	   derived	  substrates	   as	   described	   by	   their	   dissociation	   constants.	   However,	   it	   also	   has	   a	   marked	  preference	   in	   terms	  of	  reduction	  rate	  constant	   for	  2-­‐dihydro-­‐	  over	  6-­‐dihydro-­‐	  substrates.	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This	   observation	   is	   in	   contrast	   to	   observed	   dissociation	   constants	   for	   renalase	   from	   H.	  
sapiens	   where	   only	   a	   2-­‐fold	   preference	   for	   6-­‐dihydroNAD	   when	   compared	   to	   6-­‐dihydroNADP	   and	   no	   pronounced	   isomer	   preference.	   The	   ratio	   of	   the	   reduction	   rate	  constant	  of	  the	  dissociation	  constant	  (kred/Kd)	  indicates	  that	  the	  bacterial	  enzyme	  has	  a	  20	  (2-­‐dihydroNADP)	  to	  10000	  (6-­‐dihydroNADP)-­‐fold	  preference	  for	  2-­‐dihydroNAD.	  	  	   While	   crystal	   structures	   did	   not	   provide	   a	   full	   explanation	   for	   β-­‐NAD	   versus	   β-­‐NADP-­‐derived	  isomer	  selectivity	  they	  did	  offer	  insight	  into	  isomer	  selectivity	  for	  the	  rates	  of	   reduction.	   	   β-­‐NADH	   binds	   to	   the	   active	   site	   in	   a	   conformation	   where	   the	   4-­‐dihydro-­‐nicotinamide	  moiety	  stacks	  above	  flavin	  isoalloxazine	  ring	  placing	  the	  2’-­‐hydrogen	  directly	  adjacent	  (3.6	  Å)	  to	  the	  flavin	  N5.	  This	  orientation	  is	  aided	  by	  Threonine	  185	  that	  forms	  a	  hydrogen	  bond	  with	   the	  nicotinamide	  amide.	  While	   the	   active	   site	   can	  accommodate	   the	  "flipped"	  conformation	  that	  would	  place	  the	  -­‐6-­‐position	  of	  the	  nicotinamide	  adjacent	  to	  N5,	  no	  evidence	  for	  this	  binding	  mode	  was	  observed	  in	  the	  E•β-­‐NADH	  structure.	  The	  basis	  for	  discrimination	   against	   the	   4-­‐dihydroNA(P)	   species	   was	   apparent	   as	   this	   position	   is	   not	  sufficiently	   proximal	   to	   flavin	   isoalloxazine	  N5	   to	   aid	   hydride	   transfer	   (in	   either	   binding	  mode)	  (Figure	  1.1).	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Figure	  1.1.	  	  Enzyme	  substrate	  complexes.	  A.	  Renalase	  from	  P.	  phaseolicola	  in	  complex	  with	  
β-­‐NADH.	  B.	  Glutathione	  reductase	  from	  H.	  sapiens	  in	  complex	  with	  β-­‐NADH.	  	  	  	  Comparisons	   of	   Ppren	   and	   Hsren	   active	   sites	   revealed	   that	  multiple	   conserved	   residues	  lined	   the	   internal	   cavity	   of	   the	   binding	   pocket	  where	  W276	   (HsRen	  W288),	   Y57	   (HsRen	  Y62)	   and	   H232	   (HsRen	   H245)	   are	   conserved	   and	   residues	   T185	   (HsRen	   R193),	   W212	  (HsRen	   F223)	   and	   F204	   (HsRen	   Y214)	   present	   a	   similar	   functional	   groups	   in	   conserved	  locations	   yet	   these	   residues	   arise	   from	   different	   portions	   of	   the	   secondary	   structure.	  (Figure	  1.2)	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Figure	   1.2.	   Overlay	   of	   crystal	   structures	   of	   renalase	   from	   P.	   phaseolicola	   (grey)	   and	  H.	  
sapiens	  (orange)	  and	  overlay	  of	  partially	  conserved	  active	  site	  residues.	  	  	  	  Though	  the	  bacterial	  form	  of	  renalase	  shows	  active	  site	  similarities	  and	  paralleled	  catalytic	  activity	   it	   was	   determined	   that	   the	   mechanism	   of	   action	   was	   slightly	   deviated	   from	   its	  human	   counterpart.	   The	   bimolecular	   rate	   constant	   (kox)	   for	   reoxidation	   of	   the	   flavin	  cofactor	  of	  renalase	  from	  P.	  phaseolicola	  (5	  x	  10-­‐3	  M-­‐1s-­‐1)	  was	  similar	  to	  that	  of	  the	  human	  enzyme	  (2.9	  x	  103	  M-­‐1s-­‐1).	  However,	  the	  reoxidation	  of	  bacterial	  renalase	  was	  inhibited	  by	  exogenous	   β-­‐NAD+	   yielding	   a	   dissociation	   constant	   (Kd)	   of	   230	   µM	   for	   the	   reduced	  enzyme•β-­‐NAD+	   complex.	   This	   observation	   is	   indicative	   of	   a	   ordered	   product	   release	  where	   the	   β-­‐NAD(P)+	   product	   must	   dissociated	   from	   the	   reduced	   enzyme	   before	  reoxidation	  of	  the	  flavin	  cofactor	  can	  occur.	  The	  proposed	  mechanism	  of	  renalase	  from	  P.	  
phaseolicola	  is	  presented	  in	  Scheme	  1.4.	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Scheme	  1.4.	  Proposed	  mechanism	  of	  bacterial	  renalase	  shown	  with	  2-­‐	  dihydroNAD(P)	  as	  substrate.	  	  	  	  	   A	   decade	   of	   discord	   has	   preceded	   the	   identification	   of	   a	   substantiated	   catalytic	  mechanism	   and	   metabolic	   function	   of	   enzyme	   renalase.	   Isomeric	   forms	   of	   reduced	  nicotinamide	   species	   pose	   an	   inhibitory	   threat	   to	   primary	  metabolism	   and	   renalase	   can	  alleviate	  this	  simply	  by	  oxidation	  to	  form	  β-­‐NAD(P)+	  .	  The	  observations	  made	  by	  the	  Moran	  group	   represent	   the	   first	   evidence	   for	   the	   in	  vivo	  occurrence	  of	  2-­‐dihydroNAD(P)	  and	  6-­‐dihydroNAD(P)	  which	  are	  presumably	  generated	   from	  nonspecific	   reduction	   reactions	  of	  
β-­‐NAD(P)+.	  The	  catalytic	  mechanism	  is	  a	  simple	  oxidase	  reaction	  where	  the	  true	  genius	  lies	  in	   the	  ability	   for	  renalase	  to	  accommodate	  hydride	  transfer	   from	  2	  different	  positions	  (2’	  and	  6’)	  on	  the	  nicotinamide	  ring	  while	  discriminating	  against	  a	  3rd	  position	  (4’)	  and	  couple	  this	   to	   the	   reduction	   of	   dioxygen	   providing	   a	   very	   high	   driving	   force	   (an	   therefore	  scavenging	  capacity)	  for	  the	  chemistry.	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Choline	  oxidase	  The	   4-­‐electron	   oxidation	   of	   choline	   to	   glycine	   betaine	   (trimethylglycine,	   TMG)	   is	   an	  important	   transformation	   for	   many	   forms	   of	   life.	   TMG	   plays	   an	   important	   role	   in	  osmoregulation	   where	   it	   is	   utilized	   as	   an	   organic	   osmolyte	   in	   both	   eukaryotes	   and	  prokaryotes	   in	   response	   to	   various	   sources	   of	   external	   stress	   including	   extreme	  temperature	  fluctuations	  and	  changes	  in	  osmotic	  pressure	  (69-­‐79).	  In	  bacteria	  omsomlytic	  control	   of	   the	   cytoplasm	   is	   imperative	   to	   survival	   and	   is	   largely	   controlled	   by	   the	  intercellular	  solute	  concentration	  failure	  to	  do	  so	  would	  result	   in	  plasmolysis	  or	  cytolysis	  as	  a	  result	  of	  the	  water	  flux.	  Studies	  have	  shown	  a	  large	  influx	  of	  choline	  and	  its	  precursors	  at	  sites	  of	   infection	  (80,	  81)	  and	  have	  also	  demonstrated	  that	  multiple	   infectious	  bacteria	  including	  Escherichia	  coli,	  vibrio	  cholera,	  Klesiella	  pneumonia,	  Enterococus	  faecalis,	  Listeria	  
monocytogenes	  and	  Pseudomonas	  aeruginosa	  modulate	  cytoplasmic	  concentrations	  of	  TMG	  which	  allows	   for	  growth	   in	  hyperosmotic	  media	   (82-­‐86).	  Furthermore	  observations	  have	  correlated	   high	   intracellular	   osmolarity	   with	   up	   regulation	   of	   the	   genes	   associated	  with	  virulence	  and	  cellular	   invasion	   in	  multiple	  human	  pathogens	  (87-­‐92).	  These	  observations	  have	  prompted	  investigations	  into	  the	  mechanism	  of	  enzymes	  involved	  in	  the	  oxidation	  of	  choline,	   specifically	   focusing	  on	   inhibition	  of	   choline	  oxidase	   to	   enhance	   susceptibility	   to	  conventional	  treatments	  (87).	  	  	   In	  plants	  TMG	  is	  found	  in	  the	  chloroplast	  where	  it	  is	  responsible	  for	  modulation	  of	  the	   thylakoid	   membrane	   in	   order	   to	   maintain	   photosynthetic	   efficiency	   in	   response	   to	  external	  stresses	  (93,	  94).	  It	  was	  shown	  that	  over-­‐production	  of	  the	  genes	  responsible	  for	  the	  regulation	  of	  TMG	  biosynthesis	  in	  transgenic	  species	  was	  shown	  to	  increase	  tolerance	  to	   osmotic	   fluctuations	   and	   temperature	   extremes	   (94,	   95).	   The	   implications	   of	   these	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observations	   have	   resulted	   in	   exploration	   enhancing	   TMG	   production	   as	   a	   method	   for	  bioengineering	  stress	  tolerant	  crops	  species	  (74,	  75,	  87).	  	  	   TMG	  is	  formed	  in	  three	  unique	  ways;	  in	  one	  pathway	  choline	  initially	  undergoes	  a	  2-­‐electron	   oxidation	   by	   choline	   dehydrogenase,	   which	   is	   found	   in	   mammals	   bacteria	   and	  fungi,	  resulting	  in	  the	  formation	  betaine	  aldehyde	  which	  is	  then	  gives	  a	  pair	  of	  electrons	  to	  betaine	  aldehyde	  dehydrogenase	  forming	  TMG.	  Plants	  lack	  choline	  dehydrogenase	  and	  thus	  utilize	  choline	  monooxygenase	  for	  the	  initial	  oxidation	  of	  choline	  to	  betaine	  aldehyde	  that	  is	   further	   oxidized	   to	   glycine	   betaine	   by	   betaine	   aldehyde	   dehydrogenase.	   The	   third	  pathway	  is	  found	  in	  Arthrobacter	  globiformis	  and	  is	  unique	  requiring	  only	  a	  single	  enzyme,	  choline	  oxidase	  to	  catalyze	  the	  4-­‐electron	  oxidation	  required	  to	  convert	  choline	  to	  glycine	  betaine.	  (Scheme	  1.5)	  
	  
Scheme	  1.5.	  Known	  pathways	  of	  oxidation	  of	  choline	  to	  glycine	  betaine.	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Despite	   the	   multiple	   pathways	   that	   utilize	   collectively	   four	   enzymes	   to	   oxidize	  choline	  to	  TMG	  the	  primary	  focus	  of	  the	  enzymology	  community	  has	  been	  the	  reaction	  of	  choline	   oxidase.	   Choline	   oxidase	   is	   a	   unique	   flavoprotein	   that	   catalyzes	   the	   4-­‐electron	  oxidation	  of	  choline,	   involving	  two	  separate,	  rate-­‐limiting	  hydride	  transfer	  steps	  (Scheme	  1.6).	   	  The	  biochemical	   function	  and	  mechanism	  of	   choline	  oxidase	  have	  been	  extensively	  investigated	   (87,	  96-­‐121)	   and	   have	   revealed	   a	   two-­‐step	   oxidation	   reaction	   involving	   two	  separate	  hydride	  transfers	  bridged	  by	  an	  aldehyde	  intermediate	  species	  (97,	  102,	  109).	  	  	  
	  
Scheme	  1.6.	  Proposed	  steps	  in	  the	  oxidation	  of	  choline	  to	  glycine	  betaine	  by	  choline	  oxidase	  from	  Arthrobacter	  globiformis.	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Initially,	   choline	   enters	   the	   active	   site	   via	   a	   small	   tunnel,	   lined	  with	   hydrophobic	  residues,	   extending	   from	   the	   active	   site	   to	   the	   solvent	   exposed	   surface	   of	   the	   enzyme	  mediated	  by	  a	  gated	  mechanism	  (114).	  Optimal	  positioning	  of	  the	  substrate	  is	  chaperoned	  by	   an	   electrostatic	   interaction	   between	   the	   side	   chain	   of	   E312	   and	   the	  trimethylammmonium	   group	   of	   choline	   (108)	   during	   a	   preorganization	   of	   the	   enzyme-­‐substrate	  complex	  required	  for	  efficient	  quantum	  mechanical	  tunneling	  of	  the	  hydride	  ion	  from	  the	  α-­‐carbon	  of	  choline	  to	  the	  flavin	  N5-­‐position	  (104).	  Both	  electrostatic	  interactions	  between	  side	  chains	  of	  multiple	  residues	  (E312	  and	  H466)	  and	  the	  oxygen	  of	  the	  alkoxide	  and	  a	  covalent	  linkage	  between	  H99	  and	  the	  flavin	  contribute	  to	  the	  preorganization	  of	  the	  binary	   complex	   (104,	   107,	   108,	   112,	   113).	   The	   hydride	   transfer	   reaction	   is	   assisted	   by	  His466,	  which	  acts	  as	  the	  catalytic	  base	  that	  abstracts	  a	  proton	  from	  the	  hydroxyl	  resulting	  in	   the	   formation	   of	   betaine	   aldehyde	   and	   anionic	   flavin	   hydroquinone	   (120).	   The	   bound	  betaine	   aldehyde	   intermediate	   (102,	  104)	   is	   rapidly	  hydrated	   to	   the	  gem-­‐diol	   form	   (105)	  while	   the	   anionic	   flavin	   hydroquinone	   is	   oxidized	   by	   dioxygen	   generating	   hydrogen	  peroxide	   (104).	   Oxygen	   accessibility	   to	   the	   reduced	   flavin	   is	   mediated	   by	   a	   gating	  mechanism	   that	   employs	   the	   phenyl	   ring	   of	   F357	   to	   block	   or	   allow	   access	   to	   the	  hydrophobic	   tunnel	   extending	   into	   the	   active	   site	   (121)	   (Figure	   1.3).	   Oxidation	   of	   the	  reduced	  flavin	  by	  dioxygen	  results	  in	  the	  generation	  of	  hydrogen	  perioxide	  (104).	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Figure	   1.3.	  Open	  and	  closed	  conformations	  of	  choline	  oxidase.	  Open	  (A)	  conformation	  of	  choline	  oxidase	  from	  Anthrobacter	  globiformis	   in	  complex	  with	  glycine	  betaine	  (PDB	  code	  4MJW).	   Closed	   (B)	   conformation	   of	   choline	   oxidase	   from	   Anthrobacter	   globiformis	   with	  DMSO	  bound	  in	  the	  active	  site	  (PDB	  code	  2JBV).	  	  	  The	  gem-­‐diol	  aldehyde	  intermediate	  is	  further	  oxidized	  to	  the	  glycine	  betaine	  product	  in	  a	  second	  flavin	  mediated	  hydride	  transfer	  reaction	  where	  the	  reduced	  flavin	  is	  reoxidized	  by	  a	   second	   dioxygen	   utilizing	   a	  mechanism	   that	  mimicks	   the	   first	   flavin	   reoxidation	   (105).	  The	  gem-­‐diol	   intermediate	   has	   been	   observed	   to	   remain	   bound	   to	   the	   active	   site	   during	  turnover	  of	  choline	  oxidase	  from	  bacteria	  (101)	  in	  contrast	  to	  fungal	  choline	  oxidase	  where	  the	  gem-­‐diol	  intermediate	  is	  released	  to	  bulk	  solvent	  after	  the	  initial	  hydride	  transfer	  (122).	  	  The	   first	   structural	   insights	   into	   the	  mechanism	  of	   choline	  oxidase	  came	   in	  2008	  when	  a	  crystal	  structure	  of	  wild	  type	  choline	  oxidase	  from	  Anthrobacter	  globiformis	  was	  solved	  at	  1.86Å	  (PDB	  code	  2JBV)	  (108)	  and	  revealed	  that	  choline	  oxidase	  forms	  a	  homodimer	  where	  monomers	  displayed	  a	   fold	  analogous	   to	  other	  members	  of	   the	  glucose-­‐methanol-­‐choline	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(GMC)	   oxidoreductase	   enzyme	   superfamily	   (123-­‐133)	   and	   included	   a	   loop	   domain	  (residues	  64	  to	  95)	  observed	  to	  enclose	  the	  proposed	  substrate	  domain	  in	  other	  members	  of	   the	  GMC	   family	   (126,	  129,	  133).	  The	  dimer	   interface	   is	   composed	  of	  2	   identical	   sets	  of	  intersubunit	   contacts	   (Asp72	   to	   Lys398,	   Asp250	   to	   Glu53,	   Arg255	   to	   Glu370,	   Asp358	   to	  Arg396,	  Arg363	  to	  Asp394	  and	  Arg363	  to	  Asp397)	  near	  opposite	  poles	  of	  the	  interface	  and	  a	  central	  portion	   lacking	  any	  substantial	   intersubunit	  contacts	  (108).	  Since	  2008	  multiple	  other	   crystal	   structures	  of	   choline	  oxidase	   from	  A.	  globiformis	  been	   solved	   including	   two	  active	   site	   mutant	   variants,	   Ser101Ala	   (2.47Å,	   PDB	   code	   3NNE)	   (134)	   and	   Val464Ala	  (2.20Å,	  PDB	  code	  3LJP)	  (135)	  and	  a	  wild	  type	  variant	  in	  complex	  with	  the	  reaction	  product	  glycine	   betaine	   (1.95Å,	   PDB	   code	   4MJW)	   (136)	   and	   had	   revealed	   many	   structural	   and	  mechanistic	  details.	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Figure	  1.4.	  	  Active	  site	  residues	  of	  choline	  oxidase	  predicted	  to	  play	  a	  role	  in	  catalysis.	  	  	  	  	   The	   FAD	   binding	   domain	   (residues	   1	   to	   159,	   201	   to	   311	   and	   464	   to	   527)	   is	  composed	   of	   a	   3-­‐stranded	   anti	   parallel	  β-­‐sheet	   on	   one	   end	   and	   a	   6-­‐stranded	   parallel	  β-­‐sheet	   at	   the	   apposing	   end	   surrounded	   by	   8	   α-­‐helices	   (108).	   A	   covalently	   bound	   FAD	  molecule	  was	  observed	  in	  crystal	  structures	  where	  the	  8α-­‐methyl	  of	  the	  FAD	  isoalloxazine	  ring	  is	  linked	  to	  the	  1	  position	  π	  nitrogen	  of	  histidine	  99	  (108)	  that	  was	  contrary	  to	  earlier	  reports	   that	   had	  proposed	   that	   histidine	  87	  was	   responsible	   for	   the	   covalent	   interaction	  with	  FAD	  (137).	  	  The	  covalently	  bound	  FAD	  cofactor	  is	  almost	  completely	  devoid	  of	  solvent	  exposure	  where	  only	  21.5	  Å2	  (2.1%)	  is	  solvent	  exposed	  (117)	  and	  is	  positioned	  such	  that	  the	  re-­‐face	  of	  the	  isoalloxazine	  moiety	  is	  exposed	  to	  the	  substrate	  binding	  pocket.	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   The	  substrate	  binding	  domain	  (residues	  160	  to	  200	  and	  312	  to	  463)	  is	  composed	  of	  a	  6-­‐stranded	  antiparallel	  β-­‐sheet	   in	  a	  distorted	  conformation	  positioned	  near	  one	  pole	  of	  the	  binding	  domain	  and	  a	  set	  of	  3	  α-­‐helices	  that	  extend	  out	  into	  bulk	  solvent	  are	  positioned	  on	   the	  opposite	  pole.	  This	   topology	   frames	  a	  125	  Å3,	   solvent	  excluded,	   substrate-­‐binding	  pocket	   adjacent	   to	   the	   re-­‐face	   of	   the	   FAD	   isoalloxazine	   ring.	   The	   crystal	   structure	   of	   the	  TMG	  complex	  had	  the	  oxygen	  atom	  of	  the	  product	  carboxylate	  moiety	  within	  2.7	  Å	  of	  the	  N(5)	  position	  of	  the	  isoalloxazine	  ring	  and	  also	  making	  interactions	  with	  the	  four	  position	  oxygen	   of	   the	   FAD,	   the	   side	   chain	   of	   Asn510	   and	   the	   2-­‐position	   (π)	   nitrogen	   of	   His466	  (136).	  It	  was	  also	  noted	  that	  the	  proximity	  and	  position	  of	  His466	  near	  the	  carboxylate	  of	  glycine	  betaine	  suggest	   that	   this	   residue	   is	   the	  active	   site	  base	   responsible	   for	   catalyzing	  the	  cleavage	  of	  alcohol	  O-­‐H	  bond(136).	  	  	   Comparative	   analysis	   of	   the	   crystal	   structures	   of	   WT	   choline	   oxidase	  product/glycine	  betaine	  complex	  and	  the	  WT	  enzyme	  with	  bound	  DMSO	  in	  the	  active	  site	  confirmed	   the	   existence	   of	   two	   differing	   protein	   conformations	   that	   exhibit	   substantial	  positional	   rearrangement	   of	   a	   loop	   found	   at	   each	   pole	   the	   dimer	   interface	   consisting	   of	  residues	  250	  to	  255	  from	  each	  monomer	  (118).	  The	  terms	  “closed”	  and	  “open”	  were	  coined	  to	   describe	   the	   orientation	   of	   residues	   associated	   with	   the	   glycine	   betaine-­‐bound	   and	  DMSO-­‐bound	   conformations	   respectively	   (Figure	   1.3).	   Overlay	   of	   the	   these	   two	   crystal	  structures	   revealed	   that	  disorder	   in	   the	   interface	   loop	   in	   the	  presence	  of	   glycine	  betaine	  results	  in	  the	  proximal	  rotation	  of	  Phe253	  positioning	  this	  residue	  within	  3.6	  Å	  of	  Tyr330.	  In	   contrast	   the	  open	   conformation,	   as	  displayed	  by	   the	  DMSO-­‐bound	   complex,	   stacks	   the	  aromatic	  ring	  of	  Phe253	  with	  the	  side	  chains	  of	  Met359,	  Phe357,	  Leu65,	  Met62	  of	  the	  other	  monomer(118).	   Both	   open	   and	   closed	   conformations	   were	   also	   observed	   in	   the	   in	   the	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crystal	  structure	  of	  Val464Ala	  mutant	  enzyme	  (135),	  but	  not	  the	  Ser101Ala	  mutant	  (134)	  where	  all	  monomers	  where	  observed	  in	  the	  closed	  conformation.	  	  	   The	   observed	   rotation	   of	   phenyl	   of	   Phe253	   results	   in	   a	   closed	   conformation	   that	  appears	  to	  block	  access	  to	  the	  entrance	  of	  the	  tunnel	  extending	  to	  the	  active	  site.	  Xin	  et	  al	  first	   predicted	   the	   tunnel	   in	   2009,	   where	   they	   describe	   a	   tunnel	   with	   a	   radius	   of	   1	   Å	  composed	   of	   hydrophobic	   residues	   (Met62,	   Leu65,	   Val355,	   Phe357	   and	   Met359)	   and	  predicted	  that	  these	  serve	  as	  a	  gating	  mechanism	  controlling	  access	  to	  the	  active	  site	  of	  the	  adjacent	  subunit	  (138).	  Site	  directed	  mutagenesis	  studies	  of	  multiple	  residues	  (Met62Ala,	  Phe357Ala	   and	   the	   Met62Ala-­‐Phe357Ala	   double	   mutant)	   of	   the	   hydrophobic	   tunnel	  confirmed	   that	  Phe357	   is	   the	   residue	   responsible	   for	  modulation	  of	   the	   reduced	  enzyme	  prior	  to	  reoxidation	  and	  controls	  dioxygen	  accessibility	  to	  the	  active	  site	  (121).	  	   Analysis	  of	  active	  site	  mutants	  revealed	   the	   function	  of	  multiple	  residues	   involved	  directly	   in	   catalysis.	   Residue	   Glu312	   was	   determined	   to	   be	   responsible	   for	   binding	   and	  proper	  positioning	  of	  the	  choline	  substrate	  for	  hydride	  transfer	  (108).	  It	  was	  reported	  that	  the	  hydroxyl	   of	   Ser101	  was	  demonstrated	   to	   stabilize	   the	   transition	   state	   for	   the	  proton	  transfer	  reaction	   that	  oxidizes	  choline	  and	   that	  mutation	  of	  Ser101	   to	   threonine,	  alanine,	  valine	  or	  cysteine	  results	  in	  at	  least	  a	  15-­‐fold	  decrease	  for	  the	  rate	  constants	  for	  the	  proton	  extraction/hydride	  transfer	  steps	  (139).	  Asp510	  was	  also	  determined	  to	  play	  an	  important	  role	   in	   catalysis	   where	   kinetic	   analysis	   of	   Asn510Ala	   variant	   displayed	   a	   4300-­‐fold	  decrease	  in	  kcat/Kcholine,	  a	  600-­‐fold	  decrease	  in	  kred,	  a	  660-­‐fold	  decrease	  in	  kcat,	  and	  a	  50-­‐fold	  decrease	   in	   kcat/KO2	  (116).	   These	   data	   suggest	   that	   that	   Asn510	   participates	   in	   both	   the	  oxidative	  and	  reductive	  half	  reactions	  where	  it	  is	  involved	  in	  relative	  timing	  of	  cleavage	  of	  choline	  OH	  and	  CH	  bonds.	  It	  was	  also	  demonstrated	  that	  mutation	  of	  Asn510	  could	  disrupt	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the	   covalent	   interaction	   between	   the	   FAD	   molecule	   and	   His99	   (116).	   Interestingly	  mutations	   of	   Val464	   had	   no	   effect	   on	   the	   reductive	   half	   reaction	   but	   Val464Ala	   and	  Val464Thr	  mutations	  resulted	  in	  a	  ~50-­‐fold	  decrease	  in	  rate	  constant	  for	  flavin	  reoxidation	  (kox)	  (135).	  	  Researchers	  suggested	  that	  hydrophobic	  character	  of	  Val464	  was	  responsible	  for	  the	  positioning	  of	  the	  oxygen	  atom	  with	  respect	  to	  the	  C(4a)	  atom	  of	  the	  reduced	  flavin	  (135).	  	  	  The	  identity	  of	  the	  active	  site	  base	  has	  been	  the	  subject	  to	  discord	  since	  the	  involvement	  of	  an	  active	  site	  catalytic	  base	  with	  an	  apparent	  pka	  =	  7.5	  described	   for	  both	  wild	   type	  and	  various	  mutant	  variants	  using	  multiple	  kinetic	  techniques(103-­‐105,	  108,	  110).	  His466	  was	  originally	   suggested	   to	   play	   the	   role	   of	   the	   active	   site	   base	   because	   it	   is	   completely	  conserved	  in	  the	  GMC	  oxidoreductase	  superfamily	  (140-­‐143).	  Despite	  the	  conserved	  nature	  of	   this	   residue,	   results	   of	   initial	   experiments	   using	   His466Ala	   variant	   enzyme	   (103)	  paralleled	   those	   of	   His351Ala	   mutant	   choline	   oxidase	   (110)	   and	   it	   was	   concluded	   that	  neither	   His466	   or	   His351	   act	   as	   the	   catalytic	   base	   (103,	   110,	   144).	   Inspection	   of	   crystal	  structure	  of	  choline	  oxidase	  in	  complex	  with	  glycine	  betaine	  revealed	  that	  the	  only	  residues	  that	   are	   in	   close	   enough	   proximity	   to	   the	   ligand	   carboxylate	   oxygen	   to	   function	   as	   the	  catalytic	   base	   are	   His466	   and	   His351(136)	   forcing	   re-­‐evaluation	   of	   the	   role	   of	   these	  residues.	   In	   2015	   variants	   His466Gln	   and	  His351Gln	   of	   choline	   oxidase	  were	   kinetically	  analyzed	  and	  revealed	  that	  although	  mutation	  of	  His351	  to	  Gln	  causes	  significant	  decreases	  in	   kcat	   and	   kcat/Km,	  mutation	   of	  His466	   to	   Gln	   completely	   abolishes	   catalytic	   activity	   and	  thus	  is	  a	  prime	  suspect	  for	  the	  catalytic	  base	  (120).	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EncM	  Flavins	  are	  one	  of	  the	  most	  intensively	  studied	  enzymatic	  cofactors	  and	  are	  found	  across	  all	  forms	   of	   life	   where	   they	   are	   required	   for	   catalysis	   by	   numerous	   classes	   of	   enzyme	   and	  participate	  in	  what	  is	  generally	  regarded	  as	  a	  defined	  set	  of	  reaction	  categories	  (145-­‐149).	  Flavin	   dependent	   monooxygenases	   identify	   as	   one	   of	   these	   classes	   and	   utilize	   a	   flavin	  cofactor	  to	  mediate	  oxygenation	  via	  a	  stabilized	  well	  documented	  C(4a)-­‐hydroperoxyflavin	  intermediate.	  Until	  recently	  the	  C(4a)-­‐peroxyflavin	  mechanism	  was	  thought	  to	  be	  the	  most	  common	   method	   of	   flavin	   mediated	   oxygenation	   where	   the	   distal	   oxygen	   atom	   is	  transferred	   from	   the	   electrophilic	   hydroperoxyflavin	   intermediate	   to	   an	   activated	  nucleophilic	  organic	  substrate	  (145,	  150,	  151).	   In	  2013,	  a	  unique	  bacterial	  enzyme,	  EncM,	  was	  described	  to	  catalyze	  the	  peroxyflavin	  independent	  oxygenation	  and	  dehydrogenation	  to	   promote	   the	   Favorskii-­‐like	   rearrangement	   of	   the	   poly(β-­‐carbonyl)	   substrate	   to	   the	  rearranged	  desmethyl-­‐5-­‐deoxyenerocin	  using	  a	  stable	  flavin	  oxygenating	  species	  proposed	  to	  be	  a	  flavin-­‐N5-­‐oxide(152,	  153).	  (Scheme	  1.7)	  	  	  	  
	  
Scheme	  1.7.	  Reaction	  catalyzed	  by	  EncM	  and	  subsequent	  conversion	  to	  enterocin	  by	  EncK	  and	  EncR	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Flavoprotein	   EncM	   plays	   an	   important	   role	   in	   the	   biosynthesis	   of	   enterocin	   in	   multiple	  streptomycete	   bacteria	   (154-­‐157).	   The	   dual	   oxidation	   reactions	   of	   the	   highly	   reactive	  poly(β-­‐carbonyl)	   substrate	   promote	   the	   subsequent	   Favorskii-­‐type	   rearrangement	  responsible	   for	   the	   formation	   of	   the	   lactam	   ring	   of	   enterocin	   (152,	   158).	   	   This	   highly	  unusual	  reaction	   is	   the	   first	  example	  of	  a	  ”superoxidized”	  or	   four-­‐electron	  oxidized	   flavin	  species	  (152).	  	  	   The	  crystal	  structure	  of	  EncM	  was	  solved	  (PDB	  code	  3W8W,	  1.95	  Å)	  in	  the	  presence	  of	  4mM	  NADPH	  (PDB	  code	  4XLO,	  1.67	  Å).	  This	  structure	  revealed	  that,	  consistent	  with	  in	  solution	  oligomer	  determinations,	   EncM	  crystallizes	   as	   a	   homodimer	  where	   the	   subunits	  are	   almost	   identical	   (0.19Å	   RMSD	   for	   Cα	   atoms)(152).	   	   Structures	   also	   revealed	   that	  residues	  2-­‐210	  and	  419-­‐461	  form	  FAD-­‐binding	  domain	  where	  covalent	  binding	  of	  the	  C8-­‐methyl	   of	   the	   isoalloxazine	   moiety	   to	   His78	   positions	   the	   reactive	   isoalloxazine	   moiety	  adjacent	  to	  the	  substrate	  binding	  domain	  forming	  the	  internal	  face	  of	  the	  active	  site.	   	  The	  active	  site	  resides	  at	  the	  end	  of	  an	  L-­‐shaped	  (~30	  Å)	  tunnel	  the	  extends	  to	  the	  surface	  of	  the	   enzyme	  near	   the	  dimer	   interface	   and	   studies	   suggest	   that	   the	   shape	  of	   this	   tunnel	   is	  largely	   complementary	   to	   the	   conformation	   of	   acyl	   carrier	   protein	   (ACP)-­‐derived	  phosphopantetheine	   arm,	   the	   octaketide	   chain	   and	   the	   terminal	   benzene	   moiety	   of	   the	  proposed	   1,3-­‐diketone	   substrate	   (152).	   Interestingly,	   a	   group	   of	   positively	   charged	  residues	  the	  forms	  a	  basic	  patch	  on	  the	  surface	  of	  the	  enzyme	  that	  is	  complementary	  to	  the	  negative	   surface	   area	   of	   ACP	   (157,	   159).	   On	   this	   basis	   it	   was	   proposed	   that	   this	   patch	  mediates	  a	  protein-­‐protein	  interaction	  between	  EncC	  and	  EncM	  where	  acyl	  carrier	  protein	  EncC	   transfers	   its	   product,	   elongated	   (1,3-­‐diketone)	   polyketide	   intermediates	   to	   EncM	  limiting	  deleterious	  side	  reactivity	  of	  the	  poly(β-­‐carbonyl)	  chain	  (152,	  154).	  Protein-­‐protein	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interaction	   between	   EncC	   and	   EncM	   is	   supported	   by	   computational	   docking	   simulations	  using	   an	   EncM	   homology	   model	   (152).	   Additionally,	   mutagenesis	   studies	   designed	   to	  disrupt	   the	   protein-­‐protein	   interface	   by	   mutating	   Arg210	   to	   glutamic	   acid	   resulted	   in	  ~40%	  decrease	  activity	  compared	  to	  wild	  type	  (152).	  	   Additional	   crystal	   structures	   of	   EncM	   where	   solved	   in	   complex	   with	   substrate	  analogs	   trifluorotriketide	   (PDB	   code	   3W8X,	   1.82	   Å)	   and	   hydroxytetraketide	   (PDB	   code	  3W8Z,	   1.80	   Å)	   (152).	   These	   structures	   revealed	   binding	   representative	   of	   the	   enzyme-­‐substrate	   complex	   where	   the	   terminal	   benzene	   group	   of	   the	   substrate	   analog	   forms	  multiple	  van	  der	  Waals	  and	  pi-­‐stacking	  interaction	  with	  the	  hydrophobic	  residues	  of	  EncM.	  These	   interactions	   position	   the	   enol	   at	   C1	   of	   the	   substrate	   analogs	   within	   hydrogen	  bonding	   distance	   (2.4	   Å)	   of	   the	   4-­‐oxygen	   of	   flavin	   cofactor.	   	   It	   was	   proposed	   that	   the	   L	  shaped	  binding	  tunnel	  of	  EncM	  is	  composed	  of	  2	  orthogonal	  sections	  whose	  function	  is	  to	  separate	   the	   triketide	   head	   from	   the	   pantothenate-­‐linked	   tetraketide	   tail	   of	   the	   highly	  reactive	   substrate	   that	   would	   otherwise	   undergo	   deleterious	   cyclization/aromatization	  reactions	   if	  not	  stabilized	  (152).	   	  The	  chemical	  and	  physical	   stabilization	  of	   the	  substrate	  provided	  by	  the	  enzyme	  scaffold	  also	  promotes	  the	  specific	  Favorskii	  rearrangement	  that	  is	  proposed	  to	  follow	  substrate	  oxidation(152).	  	   In	   initial	   biochemical	   analysis	   of	   EncM	   it	   was	   observed	   that	   enzyme	   activation	  occurred	   after	   several	   turnovers	   where	   inactivation	   results	   in	   large	   changes	   in	   the	  absorbance	   spectrum	   of	   active	   form	   of	   EncM	   and	   it	  was	   proposed	   that	   spectral	   changes	  occurred	  as	  a	  result	  of	  the	  loss	  of	  a	  flavin	  oxygenating	  species	  (152).	  As	  mentioned	  above,	  conventional	   flavin	   chemistry	   utilizes	   a	   flavin-­‐C4a-­‐peroxide	   (151,	   160,	   161)	   as	   an	  oxygenating	   species.	   However,	   this	   intermediate	   was	   ruled	   out	   due	   to	   distinct	   spectral	  
	  	  	   28	  
characteristics	  and	  greatly	  increased	  stability	  of	  the	  EncM	  oxygenating	  species	  (152).	  It	  was	  also	  observed	   that	   the	  generation	  of	  EncM	   flavin	  oxygenating	   species	   from	  anaerobically	  reduced	   enzyme	   required	   reoxidation	   by	   oxygen	   where	   anoxic	   chemical	   reoxidation	  resulted	   in	   inactive	   oxidized	   EncM	   (152).	   	   Additionally,	   18O-­‐labeling	   studies	   carried	   out	  using	  EncM	  that	  was	  reoxidized	  with	  18O	  and	  substrate	  analog	  that	  significantly	  resembles	  the	  proposed	  substrate	  but	  has	  a	  shortened	  polyketide	   tail	  described	  a	  1:1	  conversion	   to	  diastereomeric	  mixture	  of	  product	  identified	  by	  NMR	  and	  MS	  as	  the	  ring	  open	  derivatives	  of	   lactone	  (152).	  These	  studies	  also	  revealed	  that	  the	  substrate-­‐binding	  tunnel	  of	  EncM	  is	  specifically	   tailored	  to	  accommodate	  only	  the	  (R)-­‐enantiomer	  of	   the	  substrate	  supporting	  the	   observed	   retention	   of	   the	   configuration	   of	   the	   c4-­‐hydroxyl	   in	   the	   enterocin	   product	  (152).	  Based	  on	  these	  observations	  the	  identity	  of	  the	  EncM	  flavin	  oxygenating	  species	  was	  proposed	   to	   be	   the	   flavin-­‐N5-­‐oxide;	   a	   species	   introduced	   as	   a	   possible	   new	   flavin	  intermediate	  species	  of	  monoxygenases	  (152,	  162,	  163).	  	  	   Until	  recently	  intensive	  biochemical	  analysis	  required	  an	  arduous	  effort	  due	  to	  the	  high	   reactivity	   of	   the	   proposed	   substrate	  where	   substrate	   analogs	  where	   used	   to	  mimic	  catalysis	   (152).	   Biochemical	   analysis	   using	   multiple	   techniques	   including	   HPLC,	   UV-­‐Vis	  spectroscopy,	  NMR,	  and	  MS	  revealed	  many	  details	  about	  the	  mechanism	  of	  EncM	  turnover	  with	  a	  substrate	  analog	  and	  allowed	  researchers	  to	  propose	  a	  catalytic	  mechanism	  of	  EncM	  (152).	  In	  this	  mechanism	  the	  N5-­‐oxide	  of	  the	  flavin	  undergoes	  initial	  protonation	  by	  the	  C5-­‐enol	   hydroxyl	   of	   the	   substrate	   promoting	   tautomerization	   of	   the	   N5-­‐hydroxylamine	   and	  would	   result	   in	   the	   formation	   of	   the	   electrophilic	   oxoammonium	   species.	   The	  oxoammonium	  then	  oxygenates	  the	  enolate	  moiety	  of	  the	  substrate	  resulting	  in	  oxidation	  of	   the	   flavin	  cofactor	  and	  generation	  of	  a	  C4-­‐hydroxylated	   intermediate	   (shown	  as	  H2O),	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which	  is	  dehydrogenated	  to	  produce	  the	  C4-­‐ketone	  product	  in	  a	  reaction	  that	  is	  coupled	  to	  the	   reduction	   of	   the	   flavin	   cofactor	   to	   its	   reduced	   (FADH2)	   form.	   The	  C4-­‐ketone	  product	  would	  then	  undergo	  EncM	  mediated	  Favorskii	  rearrangement	  and	  would	  be	  susceptible	  to	  
retro-­‐Claisen	  transformation	  to	  produce	  the	  2	  sets	  for	  diastereomer	  products	  formed	  in	  the	  presence	  of	  glycerol	  or	  H2O	  (152).	  	  Direct	  evidence	   for	   the	  active	  N(5)-­‐oxide	   flavin	  came	  in	  2015	  when	  researchers	  analyzed	  peptide	  fragments	  generated	  by	  EncM	  digestion	  by	  protein	  kinase	  K	  using	  high	  resolution	  electrospray	   ionization	   liquid	   chromatography	   mass	   spectrometry	   (HR-­‐ESI-­‐LCMS)	   and	  identified	   a	   His78	   bound	   flavinN(5)-­‐oxide	   fragment	   (153).	   Psuedo-­‐MS3	   confirmed	   the	  presence	  of	  a	   flavin	  bound	  oxygen	  molecule	   (153).	  To	  definitively	  correlate	   the	  observed	  mass	  signal	  with	  the	  addition	  of	  a	  flavin-­‐bonded	  oxygen	  molecule	  chemically	  reduced	  EncM	  was	   reoxidized	   by	   18O	   and	   subject	   to	   digestion	   by	   protein	   kinase	   K	   and	   analyzed	   the	  fragments	   as	   discussed	   above	   and	   confirmed	   the	   generation	   of	   the	   flavin-­‐N(5)-­‐18oxide	  (153).	  	  	   Utilizing	  all	   the	  available	  biochemical,	  mechanistic	   and	   structural	  data	   a	  proposed	  mechanism	   of	   flavin-­‐N(5)-­‐oxide	   formation	   was	   presented	   where	   the	   N5-­‐position	   of	   the	  flavin	  undergoes	  a	  direct	  reaction	  with	  dioxygen	  (153)	  (Scheme	  1.8).	  In	  this	  mechanism	  the	  net	  equivalent	  of	  a	  hydrogen	  atom	  is	  transferred	  from	  the	  N5-­‐position	  of	  the	  reduced	  flavin	  to	   dioxygen	   resulting	   in	   a	   flavin-­‐N5-­‐peroxide	   that	   immediately	   undergoes	   water	  elimination	   to	   form	   the	   flavin-­‐N5-­‐oxoammonium,	   the	   resonance	   form	   of	   flavin-­‐N5-­‐oxide.	  The	   authors	   noted	   that	   the	   initial	   hydrogen	   transfer	   reaction	   could	   occur	   in	   a	   one	   step	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hydrogen	   transfer	   reaction	   or	   in	   a	   series	   of	   two	   steps	   where	   single	   electron	   transfer	   is	  preceded	  by	  proton	  transfer.	  	  	  
	  
Scheme	  1.8.	  Proposed	  catalytic	  mechanism	  of	  EncM	  with	  substrate	  analog.	  	  	   As	  previously	  discussed	  EncM	  does	  not	  have	  a	  catalytic	  requirement	  for	  NADPH	  and	  lacks	  a	   formal	  NADPH	  binding	  domain,	  however	   it	  was	  suggested	  that	  NADPH	  did	  have	  a	  biological	  role	  in	  regards	  to	  its	  relationship	  with	  this	  enzyme	  (153).	  	  NADPH	  was	  described	  to	   recover	   EncM	   that	   had	   undergone	   auto-­‐oxidation	   resulting	   in	   inactive,	   oxidized	   EncM	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and	  re-­‐reduce	  it	  so	  that	  it	  can	  undergo	  the	  desired	  activation	  by	  dioxygen.	  This	  proposal	  is	  supported	  by	  data	   that	  describes	  ~36-­‐fold	   lower	  binding	   affinity	   for	  NADH	  compared	   to	  NADPH	  while	  maintaining	   similar	   rate	   constants	   for	   flavin	   reduction	   (~0.100	   s-­‐1)	  where	  EncM	  displays	  a	  distinct	  selectivity	  for	  NADPH	  in	  the	  absence	  of	  formal	  NAD(P)H	  binding	  domain	  (153).	  	   EncM	  presents	   the	   first	   example	   of	   a	   flavoprotein	   that	   requires	   a	   “superoxidized”	  flavin	  cofactor	  (flavin-­‐N(5)-­‐oxide)	  for	  proper	  catalytic	  functioning.	  This	  new	  flavin	  cofactor	  role	  emerges	  from	  one	  of	  the	  most	  studied	  classes	  of	  enzyme,	  flavoprotein	  and	  hints	  at	  the	  immense	   diversity	   of	   biological	   systems.	   This	   begs	   the	   question,	   is	   EncM	   an	   extremely	  unusual	   flavoprotein	   that	   displays	   unique	   chemistry	   or	   is	   this	   just	   the	   first	   identified	  example	  of	  a	  class	  of	  as	  yet	  unidentified	  flavoproteins?	  	  	  
UbiX	  UbiD,	  Pad1	  Fdc1	  The	  bacterial	  genes	  ubiX	  (164)	  and	  ubiD	  (165)	  and	  fungal	  homologs	  pad1	  and	  fdc1	  encode	  for	   a	   pair	   of	   enzymes	   associated	   with	   a	   reversible,	   non-­‐oxidative	   decarboxylation	   of	   an	  aromatic	   substrate	   (166,	   167),	   an	   essential	   step	   in	   the	   biosynthesis	   of	   prokaryotic	  ubiquinone	   (or	   Coenzyme	   Q)	   (164,	   165,	   168-­‐170)	   or	   fungal	   degradation	   of	  phenylacrylic/aromatic	   acids	   (171-­‐174)	   which	   can	   cause	   the	   accumulation	   of	   volatile	  phenols	  in	  yeast	  containing	  food	  products.	  	  Until	  recently,	  proteins	  encoded	  by	  ubiX	  (UbiX,	  3-­‐otcaprenyl-­‐4-­‐hydroxybenzoate	   carboxy-­‐lyase)	   and	   ubiD	   (UbiD,	   3-­‐otcaprenyl-­‐4-­‐hydroxybenzoate	  carboxy-­‐lyase)	  or	  pad1	  (Pad1,	  phenylacrylic	  acid	  decarboxylase)	  and	  fdc1	  (Fdc1,	   ferulic	   acid	   decarboxylase)	  were	   believed	   to	   be	   isofuctional	   though	   they	   have	   no	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amino	   acid	   sequence	   similarities.	  However,	   both	   proteins	  where	   expressed	   together	   and	  thought	   to	   have	   redundant	   catalytic	   activity	  where	   bacterial	   UbiX	   and	  UbiD	   catalyze	   the	  decarboxylation	  of	  3-­‐octaprenyl-­‐4-­‐hydrozybenzoate	  to	  2-­‐octaprenylphenol	  (169,	  173,	  175-­‐
179)	   and	   eukaryotic	   Pad1	   and	   Fdc1	   catalyze	   the	   decarboxylation	   of	   cinnamic	   acid,	  coumaric	  acid	  and	  ferulic	  acid	  to	  styrene,	  4-­‐vinyl	  phenol	  and	  4-­‐vinyl	  benzene	  respectively	  (171,	  173,	  174,	  180).	   It	  was	   recently	  determined	   that	  UbiX	  and	   isofunctional	  pad1	  do	  not	  exhibit	  decarboxylase	  activity	  (181)	  and	  instead	  functions	  as	  a	  prenyltransferase	  catalyzing	  the	   formation	  of	   a	   4	   ring	  prenylated	   flavin	  mononucleotide	   that	   is	   required	   for	   the	  non-­‐oxidative	   reversible	   decarboxylation	   catalyzed	   by	   UbiD	   and	   Pad1	   enzymes	   (182,	   183).	  (Scheme	  1.9)	  	  
	  
Scheme	  1.9.	  Overview	  of	  the	  proposed	  reactions	  of	  UbiX,	  Pad1,	  UbiD,	  and	  Fdc1.	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Reduced	   flavin	  monophosphate	   (FMNH2)	   is	   prenylated	   by	   UbiX	   in	   bacteria	   and	   Pad1	   in	  yeast.	  The	  N5-­‐C6	  prenylated	  flavin	  mononucleotide	  (prFMNH2)	  can	  undergo	  oxidation	  via	  molecular	   oxygen	   to	   form	   a	   radical	   species	   (prFMNradical)	   or	   is	   utilized	   as	   a	   cofactor	   by	  apoUbiD/apoFdc1	  and	  oxidized	  to	  the	  catalytically	  active	  prenylated	  flavin	  mononucleotide	  imminium	  (prFMNimminium)	  form	  which	  catalyzes	  the	  prokaryotic	  (UbiD)	  decarboxylation	  of	  4-­‐hydroxy-­‐3-­‐octaprenylbenzoic	   acid	   to	   2-­‐polyprenylphenol	   or	   the	   eukaryotic	   (Fdc1)	  decarboxylation	   of	   cinnamic	   acid,	   courmic	   acid	   or	   ferulic	   acid	   to	   styrene,	   4-­‐vinyl	   phenol	  and	   4-­‐vinyl	   benzene	   respectively.	   Decarboxylation	   reactions	   are	   not	   uncommon	   in	   the	  chemistries	  of	  living	  organisms	  and	  there	  are	  even	  multiple	  examples	  of	  the	  enzymatic	  use	  of	  flavin	  mononucleotides	  for	  decarboxylation	  (184-­‐186)	  but	  the	  use	  of	  a	  prenylated	  FMN	  (182)	  is	  for	  this	  chemistry	  is	  novel.	  	  	  Initial	   reports	   of	   3-­‐octaprenyl-­‐4-­‐hydroxybenzoate	   carboxy-­‐lyase	   activities	   in	   Escherichia	  
coli	   biosynthesis	   of	   ubiquinone	   suggest	   that	   optimal	   activity	   of	   the	   decarboxylase	  enzyme(s)	  require	  the	  presence	  of	  Mn2+	  and	  a	  reductant	  (methanol	  or	  dithiothreitol)	  (165).	  It	  was	  later	  proposed	  that	  decarboxylase	  activities	  in	  the	  biosynthesis	  of	  ubiquinone	  in	  E.	  
coli	  was	  the	  result	  of	  two	  isofunctional	  enzymes,	  UbiX	  and	  UbiD	  (164)	  and	  that	  80%	  of	  this	  activity	  is	  correlated	  to	  UbiD	  as	  a	  result	  of	  weak	  promoter	  strength	  of	  the	  ubiX	  gene	  (187,	  
188).	   Despite	   being	   assigned	   isofuntional	   catalytic	   activities	   these	   enzymes	   display	   no	  sequence	   similarities	   where	   UbiX	   is	   21	   kDa	   and	   UbiD	   is	   55	   kDa	   and	   in	   2007	   it	   was	  suggested	   that	   UbiX	   and	   UbiD	   are	   not	   isofunctional	   but	   rather	   act	   together	   in	   the	  decarboxylation	  step	  of	  ubiquinone	  biosynthesis	  where	  UbiD	  induces	  the	  decarboxylation	  activity	  of	  UbiX	  (169).	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Homologous	  eukaryotic/yeast	  genes	  pad1	  and	  fdc1	  and	  their	  respective	  enzyme	  transcripts	  Pad1	  and	  Fdc1	  were	  first	  associated	  with	  Saccharomyces	  cerevisiae	  resistance	  to	  cinnamic	  acid	   through	  decarboxylation	   to	   styrene	   in	  1994	   (174).	  Overexpression	  of	   the	  pad1	  gene	  resulted	   additional	   resistance	   to	   ferulic	   acid	   (180)	   and	   in	   2007	   it	   was	   discovered	   that	  deletion	   of	   the	   pad1	   gene	   resulted	   in	   the	   inability	   to	   decarboxylate	   cinnamic	   acid	   and	  sorbic	   acid,	   adding	   sorbic	   acid	   to	   the	   list	   of	   potential	   substrates	   of	   Pad1	   (171).	   	   The	  homologous	   nature	   of	   pad1/fdc1	   and	   ubiX/ubiD	  was	   identified	   in	   2009	   and	   researchers	  demonstrated	  that	  both	  Pad1	  and	  Fdc1	  are	  required	  for	  the	  decarboxylation	  of	  phylacrylic	  acids	  in	  S.	  cerevisiae	  (172).	  	  Though	  homologous	  UbiX/UbiD	  and	  Pad1/Fdc1	  do	  not	  share	  a	  physiological	  function.	  	  
The	  first	  crystal	  structure	  of	  a	  3-­‐octaprenyl-­‐4-­‐hydroxybenzoate	  decarboxylase	  (UbiD)	  from	  
Escherichia	   coli	   (PDB	   code	   2IDB)	   was	   solved	   in	   2006	   by	   the	   Northeastern	   Structural	  Genomics	  Consortium	  revealing	  a	  hexameric	  quaternary	  structure,	  however	  the	  due	  to	  the	  resolution	   of	   the	   structure	   (2.9	   Å)	   specific	   details	   in	   regards	   to	   residue	   identity	   and	  position	  could	  not	  be	  determined.	  In	  2013	  a	  1.9Å	  crystal	  structure	  of	  the	  dimeric	  PA0254	  (UbiD)	   from	   Psuedomonas	   aeurginosa	   (PDB	   code	   4IP2)	   was	   solved	   and	   the	   associated	  electron	   density	   maps	   displayed	   clear	   difference	   electron	   density	   indicative	   of	   a	   metal	  center,	   in	  this	  case	  Mg2+	  (177).	   	  A	  large	  cleft	  on	  the	  face	  of	  the	  structure	  extends	  from	  the	  metal	  binding	  site	  across	  2	  domains	  and	   terminates	  near	  a	  pocket	  of	   conserved	  residues	  Arg170,	  Glu273	  and	  Glu278	  (Asp278	  in	  UbiD	  from	  Escherichia	  coli)	  and	  could	  represent	  a	  putative	   active	   site.	   Crystal	   structures	   have	   provided	   valuable	   information	   about	   the	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structure	   however	   in	   vitro	   attempts	   to	   verify	   carboxy-­‐lyase	   activity	   with	   shorter	   length	  substrate	  analogs	  vanillic	  acid	  cinnamic	  acid	  and	  ferulic	  acid	  but	  suggested	  this	  was	  due	  to	  the	  absence	  of	  a	  long	  polyprenyl	  tail	  found	  on	  the	  suspected	  true	  physiological	  substrate	  3-­‐octaprenyl-­‐4-­‐hydroxybenzoate	   which	   would	   interact	   with	   the	   surface	   cleft	   in	   a	   way	  required	   for	   correct	   positioning	   of	   the	   substrate	   (177).	   	   It	   was	   also	   noted	   that	   residues	  Glu229	  and	  His188	  from	  PA0254	  were	  structurally	  conserved	  with	  Glu105	  and	  His68	  from	  FMN-­‐binding	  protein	  from	  Methanobacterium	  thermoatuotrophicum	  (189)	  (PDB	  code	  1EJE)	  believed	   to	   be	   involve	   with	   the	   binding	   of	   flavin	   mononucleotide	   whose	   phosphate	   is	  bound	   to	   a	  metal	   ion	   similar	   to	   the	  Mg2+	   found	   in	   PA0254,	   however	   binding	   of	   FMN	   to	  PA0254	  could	  not	  be	  demonstrated	  by	  conventional	  methods	  (177).	  	  
	  
The	   first	   structural	   insights	   into	   functionality	   of	  UbiX/Pad1	   came	   in	  when	   a	  1.5Å	   crystal	  structure	  of	  UbiX	   from	  Psuedomonas	  aeruginosa	  was	  solved	   (190)	  and	   it	  was	  determined	  that	   Ubix	   assembles	   in	   to	   a	   deodecamer	   exhibiting	   a	   Rossman	   fold	   that	   harbors	   a	   FMN	  molecule	  located	  at	  the	  interface	  between	  two	  subunits	  where	  the	  ribityl	  moiety	  interacts	  with	   residues	   from	   2	   adjacent	   subunits.	   Crystal	   structures	   reveal	   a	   small	   hydrophilic	  pocket	   adjacent	   to	   the	   re	   face	   of	   the	   flavin	   isoalloxazine	  moiety	   constructed	   of	   residues	  from	   3	   separate	   subunits;	   neither	   face	   of	   the	   flavin	   isoalloxazine	   is	   accessible	   to	   bulk	  solvent.	   This	   suggests	   that	   incorporation	   of	   additional	   substrates	   would	   require	   large	  conformational	  changes,	  which	  is	  not	  consistent	  with	  current	  crystal	  structure	  data	  (190).	  These	   findings	   allowed	   researcher	   to	   classify	   UbiX	   and	   homologous	   Pad1	   as	   a	   FMN-­‐dependent	   decarboxylase	   enzymes.	   Despite	   structural	   similarities	   to	   multiple	   enzymes	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associated	   with	   classifications	   related	   to	   decarboxylase	   activity	   (185,	   186,	   191-­‐193)	   no	  activity	  was	  seen	  when	  UbiX	  from	  Psuedomonas	  aeruginosa	  was	  incubated	  with	  substrate	  analogs	   4-­‐hydroxybenzoic	   acid,	   vanillic	   acid	   and	   3-­‐carboxymethyl	   amino-­‐methyl-­‐4-­‐hydroxybenzoic	  acid	  (190)	  suggesting	  inactivity	  is	  due	  to	  substrate	  specificity,	  researchers	  did	  not	  have	  access	   to	   the	   true	  physiological	   substrate	   	  3-­‐octaprenyl-­‐4-­‐hydroxybenzoate.	  The	   redox	   role	   for	   FMN	   in	   the	   decarboxylation	   of	   benzoic	   acid	   derivatives	   (substrate	   of	  UbiD/UbiX)	   could	   not	   be	   established	   unless	   used	   as	   an	   acid-­‐base	   catalyst,	   however	  chemistries	  of	  phenylacrylic	  decarboxylases	  (Pad1/Fdc1)	  could	  accommodate	  the	  presence	  of	   a	   flavin	   mononucleotide(190).	   	   The	   crystal	   structure	   of	   UbiX	   form	   Colwellia	  
psychrerythraea	   (PDB	   code	   4RHE)	  was	   reported	   as	   solved	   along	  with	   the	   structure	   of	   a	  stable	   FMN-­‐free	   mutant	   (V47S)	   apo-­‐UbiX	   (PDB	   code	   4RHF)	   further	   confirming	   the	  presence	  of	  a	  UbiX/Pad1	  FMN	  cofactor	  (178,	  179).	  	  	  In	  2009	  Mukai	  et	  al	  examined	  a	  study	  (Ago,	  S.,	  Kawasaki,	  H.,	  and	  Kikuchi	  Y.,	  Abst.	  50th	  Annu.	  Meet.	  Soc.	  Biothechnol.	  p.24,	  1998)	  that	  demonstrated	  that	  sake	  yeast,	  normally	  devoide	  of	  ferulic	  acid	  decarboxylase	  activity	  due	  to	  lack	  of	  the	  fdc1	  gene,	  could	  exhibit	  resistance	  to	  ferulic	   acid	   when	   the	   gene	   fdc1	   (YDR539W)	   from	   wine	   yeast	   was	   incorporated	   into	   its	  genome	   which	   suggests	   that	   Pad1/fdc1	   (UbiX/UbiD)	   are	   not	   isofunctional	   and	   that	  expression	  of	  both	  genes	  is	  required	  for	  decarboxylation	  activity.	  Confirmation	  came	  when	  it	   was	   demonstrated	   that	   decarboxylase	   activity	   in	   Saccharomyces	   cerevisea	   could	   be	  ceased	  with	  the	  deletion	  of	  either	  the	  fdc1	  or	  pad1	  gene	  and	  that	  the	  resulting	  phenotype	  of	  both	   knockouts	   was	   identical	   to	   the	   double	   knockout	   (Δpad1fdc1)	   (172),	   however	   how	  their	  respective	  enzyme	  transcripts	  function	  together	  remains	  unknown.	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  Researchers	   form	   the	  University	   of	  Michigan	   proposed	   Pad1	   and	   Fdc1	   are	   part	   of	   a	   two	  component	  decarboxylase	  system	  where	  Pad1	  activates	  Fdc1	  and	  suggested	  it	  does	  so	  by	  providing	   Fdc1	  with	   a	   covalently	  modified	   flavin	  mononucleotide	   cofactor	   necessary	   for	  catalytic	   activity	   (181).	   On	   this	   basis	   UbiX	   was	   incubated	   with	   oxidized	   FMN	   and	  dimethylallyl	  monophosphate	   (DMAP)	   and	  perturbation	   of	   the	   FMN	  UV-­‐visible	   spectrum	  was	   observed	   (182)	   suggesting	   that	   DMAP	   binds	   in	   close	   proximity	   to	   the	   flavin.	   	   The	  binding	   of	   dimethylallyl	  monophosphate	  was	   confirmed	  by	   solving	   a	   crystal	   structure	   of	  the	  UbiX-­‐oxidized	  FMN-­‐DMAP	  (PDB	  code	  4ZAF)	  (182)	  complex	  where	  the	  DMAP	  binds	  to	  adjacent	   to	   the	   re	   face	   of	   the	   isoalloxizine	   moiety	   of	   the	   flavin	   monophosphate	   in	   a	  hydrophobic	  pocket	  that	  resembles	  that	  of	  terpene	  synthases	  and	  prenyl	  transferases	  (194-­‐
196).	  	  The	   identity	   of	   the	   modified	   flavin	   mononucleotide	   produced	   by	   UbiX	   and	   Pad1	   was	  determined	  when	  UbiX	   from	  Psuedomonas	  aeruginosa	  was	   incubated	  with	  oxidized	   flavin	  mononucleotide	   (FMN)	  and	  dimethylallyl	  monophosphate	   resulting	   in	   the	   formation	  of	   a	  prenylated	  flavin	  monocleotide	  (prFMNH2)	  (182).	  (Scheme	  1.9)	  	  	  Crystals	   of	   UbiX	   from	   Psuedomonas	   aeruginosa	   could	   undergo	   active	   turnover	   allowing	  researchers	   to	   use	   kinetic	   crystallography	   matched	   with	   mass	   spectroscopy	   and/or	   UV	  visible	   spectroscopy	   to	   confirm	   the	   binding	   of	   DMAP	   to	   the	   oxidized	   UbiX	   flavin	  monophosphate	   (UbiX-­‐FMN-­‐DMAP)(PDB	   code	   4ZAF)	   (Scheme	   1.10,	   1),	   reduction	   of	   the	  UbiX	  flavin	  cofactor	  (E49Q	  mutant	  UbiX-­‐FMNH2-­‐DMAP	  complex)(PDB	  code	  4ZAL)	  (Scheme	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1.10,	  2),	  the	  initial	  formation	  of	  N5-­‐C1’	  alkyl	  adduct	  (PDB	  code	  4ZAV)	  (Scheme	  1.10,	  3),	  the	  formation	   of	   the	   UbiX-­‐reduced	   prenylated	   FMN	   product	   complex	   (UbiX-­‐prFMNH2)	   (PDB	  code	   4ZAW)	   (Scheme	  10.1,	  7)	   and	   the	   oxidization	   of	   the	   reduced	  prenylated	   FMN	  to	   the	  purple	   shifted	   oxygen	   dependent	   radical	   species	   (UbiX-­‐prFMNradical)(PDB	   code	   4ZAX)	  formed	  at	  1-­‐5,	  20-­‐30,	  or	  30+	  seconds	  respectively	  when	  UbiX-­‐FMN-­‐DMAP	  where	  incubated	  with	  sodium	  dithionite	  using	  rapid	  freeze	  quench	  techniques	  to	  capture	  desired	  time	  points	  (182).	   	   Active	   site	  mutations	   of	  Psuedomonas	  aeruginosa	   UbiX	   revealed	   species	   (Scheme	  1.10,	  5a)	  and	  revealed	  that	  large	  conformational	  changes	  occur	  after	  the	  reduction	  species	  (Scheme	   1.10,	   3)	   to	   the	   stable	   N5	   adduct	   (Scheme	   1.10,	   4)	   and	   again	   during	   product	  formation	  (Scheme	  1.10,	  7),	  which	  could	  be	  the	  key	  to	  understanding	  UbiX	  catalysis	  (182).	  However	  no	  direct	  evidence	  of	  species	  (Scheme	  1.10,	  5b)	  or	  species	  (Scheme	  1.10,	  6)	  has	  been	  obtained.	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Scheme	   1.10.	   Proposed	   catalytic	   mechanism	   of	   UbiX/Pad1.	   Reduced	   flavin	  mononucleotide	  (FMNH2)	   is	  prenylated	  by	  UbiX/Pad1	  untilizing	  the	  cosubstrate	  dimethyl	  monophosphate	  to	  bridge	  the	  N5	  to	  the	  C6	  of	  the	  flavin.	  	  	  	  Ubix/Pad1	   offers	   the	   first	   example	   of	   a	   flavin	   monophosphate	   dependent	   prenyl	  transferase	   and	   the	   first	   description	   of	   a	   new	   flavin	   cofactor,	   a	   dimethyl	   four-­‐ring	  prenylated	  flavin	  linked	  at	  the	  N5	  and	  C6	  atoms	  of	  the	  isolalloxizine	  moiety.	  	  The	  enzymes	  UbiX	   and	   Fdc1	   have	   also	   found	   a	   unique	   way	   to	   ensure	   a	   stable	   N5-­‐alkyl	   adduct	   flavin	  species	   (prFMNH2)	   is	   favored	   over	   the	  N5-­‐imminium	  adduct	   (prFMNimminium)	   by	   utilizing	  the	   reduced	   from	   of	   the	   flavin	   monophosphate	   (FMNH2)	   to	   act	   as	   a	   nucleophile.	   This	  strategy	  ensures	  that	  the	  reduced	  prenylated	  flavin	  monophosphate	  (prFMNH2)	  product	  of	  UbiX/Pad1	  can	  be	  transferred	  to	  apo-­‐UbiD/fdc1	  before	  undergoing	  hydrolysis.	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Though	   no	   direct	   interactions	   have	   been	   observed	   between	   UbiX/Pad1	   and	   UbiD/Fdc1,	  when	  the	  fdc1	  gene	  from	  Aspergillus	  niger	  and	  the	  gene	  ubiX	  from	  E.	  coli	  were	  coexpressed	  in	   E.	   coli	   the	   resulting	   enzyme	   (Fdc1UbiX)	   displayed	   distinct	   spectral	   properties	   when	  compared	   to	   single	   express	   Fdc1	   and	   Fdc1UbiX	   catalyzed	   the	   decarboxylation	   of	  multiple	  aromatic	   carboxylic	   acids	   in	   vitro	   (183).	   	   This	   is	   the	   first	   genuine	   evidence	   of	   catalytic	  activity	   demonstrating	   that	   enzymes	   UbiD	   and	   homologous	   Fdc1	   are	   exclusively	  responsible	   for	   non-­‐oxidative	   reversible	   decarboxylation	   their	   of	   aromatic	   substrates.	  Researchers	   also	   demonstrated	   that	   decarboxylation	   activity	   requires	   a	   heavily	  modified	  flavin	  cofactor,	  product	  of	  UbiD/Pad1	  catalysis	  obtained	   in	  reduced	   form	  (prFMNH2)	  and	  they	  solved	  crystal	  structures	  of	  Fdc1UbiX	  using	  Fdc1	  from	  A.	  niger	  (1.22	  Å,	  PDB	  code	  4ZA4),	  
Camidida	  dubliensis(2.46	  Å,	  PDB	  code	  4ZAD)	  and	  Sacchromyces	  cerevisiae	  (1.65	  Å,	  PDB	  code	  4ZAC)	  confirming	  the	  identity	  of	  the	  prenylated	  flavin	  mononucleotide	  (prFMN)	  where	  an	  isopentenyl	  adduct	  is	  formed	  bridging	  N5	  to	  C6	  effectively	  forming	  a	  4th	  ring	  represented	  in	  an	  oxidized	  imminium	  form	  (prFMNimminium)	  (183).	  The	  crystal	  structures	  also	  revealed	  the	  presence	  of	  metal	  ions	  in	  complex	  with	  the	  phosphate	  tail	  of	  the	  prenylated	  flavin	  cofactor	  which	  were	   suggested	   based	   on	   electron	   density,	   to	   be	  Mn2+(confirmed	   by	   EPR)	   and	   K+	  (unconfirmed)	   (183)	   confirming	   earlier	   reports	   of	   the	   dependence	   of	   UbiX/Pad1	   and	  UbiD/Fdc1	   on	  Mn2+	  (165).	   To	   further	   probe	   for	   binding	   and	  mechanistic	   details	   crystals	  ofFdc1UbiX	  from	  A.	  niger	  were	  soaked	  with	  various	  trans-­‐cinnamic-­‐acid-­‐related	  compounds,	  4-­‐vinyl	   guaiacol	   (PDB	   code	   4ZAA),	   penta-­‐fluorocinnamic	   acid	   (PDB	   code	   4ZA8),	   phenyl	  pyruvate	   (PDB	   code	   4ZA9)	   and	   alpha-­‐fluoro	   cinnamic	   acid	   (PDB	   code	   4ZAB)	   (183).	  Structures	  were	  solved	  and	  revealed	  the	  substrates	  enoic	  acid	  double	  bonds	  stack	  directly	  above	  the	  oxidized	  prenylated	  flavin	  (prFMN)	  cofactor	  occupying	  the	  active	  site	   in	  one	  of	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two	  configurations,	  an	  isoalloxazine	  N5	  imminium	  adduct	  (prFMNimminium)	  or	  a	  N5	  ketamine	  species	  (prFMNketamine)	  (183).	  	  	  Because	  of	  the	  presence	  of	  two	  species	  of	  oxidized	  prFMN	  cofactor	  were	  found	  2	  possible	  mechanisms,	  where	  reduced	  prenylated	  flavin	  mononucleotide	  is	  derived	  from	  UbiX/Pad1	  and	  transferred	  to	  UbiD/Fdc1	  (182)	   in	   the	  reduced	  form	  (prFMNH2)	  which	  then	  requires	  activation	   by	   oxidation	   via	   dioxygen	   to	   either	   oxidized	   form	   isomer,	   the	   imminium	  (prFMNimminium)	  (Scheme	  1.11,	  3)	  or	  ketamine	  (prFMNketamine)	  (Scheme	  1.11,	  7)	  form	  (183).	  Acid	  base	  chemistry	  could	  utilize	  the	  N5	  of	  the	  secondary	  ketamine	  of	  the	  prFMNketamine	  as	  a	  catalyst	   taking	   advantage	   of	   the	   positioning	   of	   the	   substrates	   α,β-­‐unsaturated	   carbonyl	  above	   the	  prFMNketamine	  C4a	  and	  undergo	  a	  Michael	  addition-­‐like	  chemistry	  seen	   in	  other	  flavin	   containing	   enzymes	   (197,	  198),	   forming	   a	   transient	   C4a-­‐substrate	   adduct	   (Scheme	  1.11,	  8)	  preceding	  decarboxylation.	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Scheme	  1.11.	  Proposed	  catalytic	  mechanisms	  of	  Fdc1UbiX	  using	  both	  the	  prFMNketamine	  and	  prFMNimminium.	  	  	  The	  second	  proposed	  mechanism	  utilizes	  prFMNiminium	  (Scheme	  1.11,	  6)	  as	  the	  catalytically	  relevant	   form	   of	   the	   enzyme,	   where	   the	   substrate	   α,β-­‐unsaturated	   carbonyl,	   a	  dipolarophile,	   takes	   advantage	   of	   the	   1,3-­‐dipole	   arrangement	   	   of	   prFMNimminium,	   a	  configuration	  known	  to	  facilitate	  this	  type	  of	  reaction	  (199),	  undergoing	  what	  would	  be	  the	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first	   biological	   example	   of	   a	   1,3	   dipolar	   cycloaddition	   leading	   to	   the	   formation	   of	   a	  substrate-­‐prFMNimminium	  adduct	  bridging	  both	  the	  C4a	  and	  C1’	  of	  the	  prFMNimminium	  cofactor	  (Scheme	  1.11,	  4).	  The	  double-­‐bridged	  	  substrate-­‐prFMNimminium	  could	  then	  undergo	  a	  Grob-­‐like	  decarboxylative	  fragmentation(200)	  of	  the	  pyrrolidine	  adduct	  (Scheme	  1.11,	  4)	  could	  be	  coupled	  to	  cleavage	  of	  the	  C4a-­‐substrate	  bond	  resulting	  in	  a	  single-­‐bridged	  prFMNiminium	  C1’-­‐substrate	  adduct	  (Scheme	  1.11,	  5)	  where	  protonation	  via	  E282	  leading	  to	  the	  formation	  of	   the	   second	   double-­‐bridged	   pyrrolidine	   adduct	   (Scheme	   1.11,	   5a).	   This	   adduct	   would	  then	  be	   subject	   to	  “retro	  1,3-­‐dipolar	  cycloaddition”	   resulting	   the	   formation	  of	   the	  product	  complex	  (Scheme	  1.11,	  6).	  In	  an	  attempt	  to	  determine	  which	  pathway	  is	  utilized,	  Fdc1UbiX	  from	   A.	   niger	   was	   incubated	   phenylpyruvate	   resulting	   in	   reversible	   inhibition	   of	   the	  enzyme	   by	   the	   enol	   tautomer	   of	   phenylpyruvate,	   α-­‐hydroxycinnamic	   acid	   and	   crystal	  structure	   solutions	   of	   this	   complex	   revealed	   a	   α-­‐hydroxystyrene	   prFMNimminium	   adduct	  (183).	  The	  α-­‐hydroxystyrene	  adduct	  is	  the	  result	  of	  keto-­‐enol	  tautomerization	  of	  the	  single-­‐bridged	   prFMNiminium	   C1’-­‐substrate	   adduct	   (Scheme	   1.11,	  5)	   confirming	   prFMNimminium	   is	  the	   active	   form	   of	   the	   enzyme	   and	   suggests	   that	   the	   reversible	   non-­‐oxidative	  decarboxylation	  occurs	  via	  a	  1,3-­‐dipolar	  cycloaddition.	  	  	  It	  must	  be	  noted	  that	  in	  2004	  a	  2.0Å	  crystal	  structure	  of	  a	  tentative	  Pad1	  for	  Escherichia	  coli	  Q157:	  H7	   in	   complex	  with	  FMN	  (PDB	  code	   ISBZ)	  was	   solved	   (188).	  Even	   though	  Pad1	   is	  most	  commonly	  found	  in	  eukaryotic	  species	  this	  possible	  prokaryotic	  PAD1,	  a	  UbiX	  paralog	  with	   similar	   sequence	   identity	   to	   UbiX	   from	   Escherichia	   coli	   (51%)	   and	   Pad1	   from	  
Saccharomyces	  cervisiae	  (54%)	  has	  been	  identified	  in	  pathogenic	  strains	  of	  Escherichia	  coli.	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Although	  this	  prokaryotic	  Pad1	  displayed	  high	  sequence	  identity	  to	  other	  members	  of	  the	  HFCD	  superfamily	  no	  decarboxylase	  activity	  of	  phenylacrylic	  acids	  was	  ever	  demonstrated.	  	  	  
Chorismate	  Synthase	  Chorismate	  synthase	   is	  a	  unique	  FMN	  dependent	  flavoprotein	  that	  plays	  an	  essential	  role	  as	  the	  catalytic	  terminus	  of	  the	  shikamate	  pathway.	  The	  shikamate	  pathway	  is	  a	  seven	  step,	  seven	   enzyme,	   metabolic	   pathway	   found	   in	   bacteria,	   plants,	   fungi	   and	   anticomplexan	  parasites	   (201)	   responsible	   for	   the	  biosynthesis	   of	   a	  precursor	   (chorismate)	   for	  multiple	  essential	   compounds	   including	   multiple	   quinone	   species	   including	   ubiquinone,	  plastiquinone	   and	   vitamin	   K,	   tocopherols,	   folates,	   aromatic	   amino	   acids	   tryptophan,	  phenylalanine,	  and	  tyrosine	  as	  well	  as	  a	  number	  of	  secondary	  metabolites.	  (Scheme	  1.12)	  The	   absence	   of	   the	   shikimate	   pathway	   in	   mammalian	   metabolism	   has	   meant	   that	   the	  enzymes	  of	   this	  pathway	  are	   targets	   for	  neoteric	   antibiotics,	   herbicides	   and	  antiparasitic	  agents	  (201,	  202).	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Scheme	  1.12.	  Reactions	  involving	  chorismate.	  
	  Chorismate	   synthase	   (CS)	   is	   responsible	   for	   a	   novel	   FMN	   dependent	   enzymatic	   1,4-­‐anti	  elimination	   of	   the	   3-­‐phosphate	   and	   cleavage	   of	   the	   C6-­‐(proR)-­‐hydrogen	   from	   5-­‐enol-­‐pyruculshikimate	   3-­‐phosphate	   (ESPS)	   generating	   chorismate	   (203,	   204)	   (Figure	   1.5).	   CS	  displays	  an	  absolute	  requirement	  for	  reduced	  FMN	  for	  normal	  catalysis	  (205-­‐207);	  despite	  the	   reduced	   state	   of	   the	   flavin,	   turnover	   of	   this	   enzyme	   does	   not	   result	   in	   a	   net	   redox	  change	   (203,	   204,	   208,	   209).	   The	   classification	   of	   chorismate	   synthase	   is	   dictated	   by	   the	  acquisition	  of	  the	  required	  FMNH2	  cofactor;	  mono-­‐functional	  chorismate	  synthases	  acquire	  exogenously	  reduced	  FMN	  (Figure	  1.5)	  and	  are	  examples	  are	  found	  in	  bacteria	  and	  plants	  (202,	   205,	   210-­‐222),	   bi-­‐functional	   chorismate	   synthases	   exhibit	  β-­‐NADPH	   dehydrogenase	  activity	  and	  are	  able	  to	  intrinsically	  reduce	  FMN	  (Figure	  1.5)	  and	  are	  found	  in	  Neurospora	  
crassa	  and	  Saccharomyces	  cerevisiae	  (206,	  218,	  223,	  224).	  Despite	  differences	  in	  the	  means	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of	   FMN	   reduction	   both	  mono-­‐functional	   and	   bi-­‐functional	   chorismate	   synthases	   display	  similar	   phosphate	   elimination	   and	   hydrogen	   cleavage	   chemistries.	   One	   explanation	   for	  similarity	  is	  that	  all	  chorismate	  synthases	  share	  a	  common	  mono-­‐functional	  ancestor	  (218).	  	  
	  	  	  	  	  	  	  	  	  	   	  
Figure	  1.5.	  Comparison	  of	  mono-­‐	  and	  bi-­‐functional	  CS.	  Overlay	  of	  mono-­‐functional	  CS	  from	  
S.	  pneumonia	  (green)	  and	  bi-­‐functional	  CS	  from	  S.	  cerevisiae	  (blue).	  Reactions	  catalyzed	  by	  chorismate	  synthase.	  	  	  	  	  	  
	  	  This	   intriguing	  catalytic	  activity	  has	  been	  the	  target	  of	  extensive	  studies	  to	  determine	  the	  mechanism	  of	  action	  (203,	  204,	  208).	  This	  unusual	  chemistry	  was	  novel	  to	  any	  known	  flavin	  dependent	  enzymes	  where	  the	  flavin	  traditionally	  participates	  in	  single	  or	  double	  electron	  redox	  chemistries	  (150,	  225,	  226).	  Macheroux	  and	  colleagues	  noticed	  that	  mono-­‐functional	  chorismate	   synthase	   from	   E.	   coli	   binds	   oxidized	   FMN	   (Kd	   =	   30	   µM)	   three	   orders	   of	  magnitude	   (1000-­‐fold)	   tighter	   in	   the	   presence	   of	   EPSP	   (Kd	   =	   20	   nM)	   indicative	   of	   an	  ordered	  binding	  mechanism	  (215,	  227).	  	  	   Product	   analysis	   of	   the	   conversion	   of	   ESPS	   to	   chorismate	   by	   chorismate	   synthase	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revealed	  that	  catalysis	  involves	  an	  anti-­‐1,4-­‐	  elimination	  of	  the	  3-­‐phosphate	  and	  removal	  of	  the	   C6-­‐(proR)-­‐hydrogen	   (201).	   The	   anti	   stereochemistry	   of	   the	   product	   excludes	   the	  possibility	  of	  a	  concerted	  mechanism,	  supported	  by	  both	  theoretical	  and	  experimental	  data	  where	  the	  product	  of	  a	  concerted	  1,4	  elimination	  has	  syn	   stereochemistry	  (204,	  208,	  228-­‐
230).	  To	  determine	  if	  cleavage	  of	  the	  C6-­‐(proR)-­‐hydrogen	  occurs	  previous	  or	  subsequent	  to	  the	  anti-­‐1,4-­‐	  elimination	  of	  the	  3-­‐phosphate	  researchers	  measured	  the	  isotope	  effects	  when	  (6R)-­‐[6-­‐2H]-­‐EPSP	  was	  used	  as	  the	  substrate	  and	  observed	  a	  small	  effect	  (~1.3)	  interpreted	  to	  be	  a	  secondary	  isotope	  effect	  where	  the	  C6	  deuterium	  only	  slightly	  influenced	  the	  rate	  of	  	  C-­‐O	   bond	   cleavage	   (202).	   This	   interpretation	   implies	   that	   cleavage	   of	   the	   C-­‐O	  bond/elimination	  of	  the	  phosphate	  occurs	  before	  the	  liberation	  of	  the	  C6-­‐(proR)-­‐hydrogen	  and	  was	   supported	   by	   tritium-­‐isotope	   studies	   ([4-­‐2H]-­‐EPSP)	   using	   chorismate	   synsthase	  from	   both	   E.	   coli	   (S.	   Bornemann	   and	   R.N.F.	   Thorneley,	   personal	   communication)	   and	  confirmed	  by	  transient	  kinetic	  analysis	  (214).	  	  	   The	  non-­‐redox	   role	   of	   the	   reduced	  FMN	   cofactor	   in	   chorismate	   synthase	   catalysis	  was	   further	   invested	  by	  Macheroux	  where	  the	  FMN	  of	  chorismate	  synthase	  was	  replaced	  with	   multiple	   flavin	   derivatives	   (216)	   and	   results	   show	   that	   modulation	   of	   the	  microenvironment	   surrounding	   the	   reduced	   FMN	   cofactor	   is	   induced	   by	   the	   binding	   of	  EPSP	   results	   in	   a	   more	   negative	   redox	   potential,	   promotes	   the	   protonation	   of	   the	   N1	  position	   of	   isoalloxazine	  moiety	   and	   stablizes	   the	   flavin	   semiquinone	   (216).	   The	   neutral	  reduced	  FMN	  is	  an	  important	  intermediate	  species	  and	  its	  presence	  in	  turnover	  supports	  a	  role	  for	  the	  reduced	  flavin	  in	  catalysis	  participating	  in	  an	  electron	  transfer	  step	  (209,	  214).	  Kinetic	   studies	   conducted	   with	   (6S)-­‐6-­‐flouro-­‐EPSP	   and	   (6R)-­‐flouro-­‐EPSP	   where	   FMN	   is	  reduced	  using	  dithionite,	  demonstrate	  a	  slow	  product	  formation	  and	  in	  both	  cases	  a	  long-­‐
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lived	   semiquinone	   intermediate	   is	   observed	   (216).	   Interestingly,	   the	   reaction	  with	   (6R)-­‐flouro-­‐EPSP	   resulted	   in	   stable	   FMN	   semiquinone*product	   complex	   claimed	   to	   be	  essentially	   irreversible.	   These	   results	   provide	   evidence	   in	   support	   of	   a	   non-­‐concerted	  mechanism	   where	   the	   reduced	   flavin	   plays	   a	   role	   as	   an	   electron	   donor	   subsequent	   to	  activation	  induced	  by	  substrate	  binding	  (216).	  The	   lack	  of	  catalytic	  activity	  demonstrated	  with	  1,5-­‐dihydro-­‐5-­‐deaza-­‐FMN	  further	  supports	  this	  conclusion	  (217).	  	   The	   first	   structural	   insights	   into	   the	   catalytic	   mechanism	   of	   came	   in	   2003	   when	  Maclean	  et	  al.	   solved	   the	  2.0Å	  resolution	  crystal	   structure	  of	  mono-­‐functional	   chorismate	  synthase	  from	  Streptococcus	  pneumonia	  in	  complex	  with	  oxidize	  FMN	  and	  EPSP	  (PDB	  code	  1QXO)	  (219).	  Structural	  analysis	  suggests	  chorismate	  synthase	  forms	  a	  tetramer,	  composed	  of	   a	   pair	   of	   dimers,	   where	   each	   monomer	   displays	   a	   novel	   β-­‐α-­‐β	   fold.	   This	   structural	  topology	  was	  also	  observed	   in	  crystal	   structures	  of	  mono-­‐functional	   chorismate	  synthase	  from	  Aquifex	  aeolicus	  (2.05Å,	  PDB	  code	  1Q1L)	  (231)	  and	  bi-­‐functional	  chorismate	  synthase	  from	   Saccharomyces	   cerevisiae	   (2.2Å,	   PDB	   code	   1R53)	   (232).	   However,	   it	  must	   be	   noted	  that	   electron	   density	   is	   missing	   from	   23%	   of	   the	   structure	   from	   S.	   cerevisiae.	  Monomer	  structure	   is	   dominated	   by	   a	   single	   large	   core	   domain,	   consisting	   of	   4	   long	   a-­‐helices	  sandwiched	  between	  a	  pair	  of	  antiparallel	  β-­‐sheets	  (219)	  (Figure	  1.5).	  Multiple	  structural	  search	  methods	  could	  not	  locate	  any	  similar	  structures	  demonstrating	  this	  fold	  (233,	  234).	  Many	   hydrogen	   bonding	   interactions	   contribute	   to	   dimerization	   such	   as	   the	   β-­‐sheet	  extends	   from	   each	   monomer	   to	   form	   an	   eight-­‐stranded	   antiparallel	   b-­‐sheet	   forming	   4	  hydrogen	   bonds	   to	   equivalent	   sheet	   on	   the	   adjacent	   dimer	   but	   only	   a	   single	   ionic	  interaction	  occurs.	  This	  ionic	  interaction	  one	  of	  the	  monomers	  utilizes	  Lysine	  238	  to	  form	  a	  water-­‐bridge,	   contacting	   the	   phosphate	   of	   the	   FMN	   of	   an	   adjacent	   monomer.	   The	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predominantly	  hydrophobic	  tetramerization	  interface	  contains	  multiple	  hydrogen	  bonding	  interactions	  and	  salt-­‐bridges	  are	  formed	  between	  Arg	  13	  and	  Asp	  57	  on	  both	  dimers	  (219).	  Structural	   assessment	   of	   quaternary	   structure	   is	   consistent	   with	   a	   series	   of	  ultracentrifugation/	  chromatography	  studies	  done	  by	  Fitzpatrick	  et	  al	  (218).	  	   Further	   analysis	   revealed	   that	   three	   monomers	   in	   each	   tetramer	   represented	   a	  conformation	   deemed	   as	   “closed”,	   where	   loops	   from	   each	   monomer	   extend	   across	   the	  active	  site	  isolating	  it	  from	  bulk	  solvent	  (219).	  The	  fourth	  of	  the	  protomers	  was	  found	  to	  be	  in	  an	  “open”	  conformation	  where	   the	  position	  of	   the	  a	   loop	  near	   the	  active	  site	   involving	  residues	  332	  through	  338	  are	  in	  a	  position	  that	  makes	  the	  active	  site	  more	  accessible	  (219)	  (Figure	  1.6).	  The	  active	  site	  of	  mono-­‐functional	  chorismate	  synthase	  is	  formed	  by	  residues	  extending	  from	  multiple	  positions	  of	  secondary	  structure	  creating	  a	  hydrophobic	  pocket	  at	  the	  interface	  of	  the	  helical	  domain	  and	  a	  β-­‐sheet	  (β-­‐sheet	  2).	  	  
	  
Figure	   1.6.	   Monomer	   conformations	   displayed	   by	   crystal	   structures	   of	   chorismate	  synthase	   from	   S.	   pneumonia.	   Left	   structure	   represents	   the	   “open”	   conformation	   and	   the	  right	  structure	  represents	  the	  “closed”	  conformation.	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   The	   crystal	   structure	   data	   has	   also	   provided	   a	   structural	   explanation	   for	   the	  observations	  made	   by	  macheroux	   et	   al.	   where	   binding	   of	   FMN	   and	   EPSP	   are	   said	   to	   be	  ordered	  as	  the	  presence	  of	  EPSP	  causes	  a	  1000-­‐fold	  decrease	  in	  the	  dissociation	  constant	  for	   oxidized	   FMN	   (215).	   The	   phospho	   group	   of	   the	   FMN	   is	   buried	   deep	   within	   the	  secondary	  structure	  packing	   the	  re-­‐face	  against	   the	  binding	  cavity	  exposing	   the	  si-­‐face	  of	  the	   isoalloxazine	   to	   bulk	   solvent.	   EPSP	   stacks	   with	   the	   si-­‐face	   of	   the	   FMN	   isoalloxazine	  closing	   off	   the	   active	   site	   and	   excluding	   solvent	   physically	   hindering	   the	   dissociation	   of	  FMN	  from	  the	  tertiary	  complex.	  	  	   The	  binding	  of	  FMN	  is	  the	  result	  of	  multiple	  polar	  interactions	  between	  the	  hydroxyl	  and	  phosphate	  oxygen	  of	  the	  ribityl	  moiety	  of	  the	  FMN	  with	  the	  loop	  domain	  of	  the	  protein.	  The	  FMN	  phospho	  group	  resides	  at	  the	  dimer	  interface	  and	  interacts	  with	  the	  main	  chain	  nitrogen	  of	  Alanine	  252,	  the	  side	  chain	  of	  Lys	  311	  and	  the	  main	  chain	  nitrogen	  of	  Glycine	  296	   from	   the	   neighboring	   monomer.	   A	   multitude	   of	   well-­‐ordered	   water	   molecules	  surround	   the	   FMN	   phospho-­‐ribityl	   and	   are	   responsible	   for	   bridging	   interactions	   to	  surrounding	  residues.	  The	  hydrophobic	  isoalloxazine	  appears	  to	  stack	  with	  a	  hydrophobic	  pocket	  of	  the	  protein.	  	  	   The	  binding	  of	  EPSP	  to	  the	  si-­‐face	  of	  the	  FMN	  involves	  a	  significant	  number	  of	  polar	  interactions	  with	  the	  enzyme	  and	  induces	  in	  a	  large	  conformational	  change	  that	  completes	  further	  interactions	  between	  members	  of	  the	  oligomer	  (219).	  The	  hydrophilic	  EPSP	  binding	  pocket	   is	   lined	  with	   3	   clusters	   of	   basic	   residues	   (2	   histidine	   and	   6	   arginine	   residues)	   to	  form	  an	  environment	  complementary	  to	  EPSP.	  Site	  directed	  mutagenesis	  studies	  of	  his17	  to	  alanine	  mutants	  from	  Neurospora	  crassa	  displayed	  a	  five-­‐fold	  increase	  in	  the	  dissociation	  constant	   (Kd)	   for	   EPSP	   implying	   his17	   is	   involved	   with	   the	   binding	   of	   EPSP	   (220).	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Interestingly,	   there	   are	   no	   amino	   acid	   residues	   in	   the	   proximately	   of	   the	   C6-­‐position	   of	  EPSP	   leaving	   the	   5-­‐position	   nitrogen	   on	   the	   isoalloxazine	   ring	   of	   the	   FMN	   as	   the	   only	  candidate	  close	  enough	  to	  act	  as	  a	  base	  (219).	  	   The	   conformational	   change	   induced	   by	   the	   binding	   of	   EPSP	   positions	   His110	  proximal	   to	   the	  N1	  atom	  of	   the	  FMN	  close	  enough	  to	  promote	  protonation	  of	   the	  neutral	  reduced	  FMN,	  which	  suggests	   that	  His110	  plays	  an	   important	   role	   in	  catalysis.	   	  This	  was	  later	   confirmed	   but	   site	   directed	   mutagenesis	   where	   a	   histidine106	   (his110	   in	   S.	  
pneunomiae)	   to	   alanine	   mutant	   of	   bi-­‐functional	   chorismate	   synthase	   from	   Neurospora	  
crassa	   displayed	   a	   twenty-­‐fold	   reduction	   in	   elimination	   activity	   when	   compared	   to	  wildtype	  (220).	  His110	  was	  found	  in	  two	  different	  conformations	  in	  the	  crystal	  structure	  of	  enzyme	  from	  S.	  pneunomiae;	  in	  the	  open	  conformation	  his110	  is	  coordinated	  with	  2-­‐oxygen	  of	  the	  FMN	  and	  in	  the	  closed	  conformation	  his110	  contact	  both	  the	  5-­‐oxygen	  of	  EPSP	  and	  the	   main	   chain	   amide	   nitrogen	   of	   ala111.	   The	   mobility	   and	   the	   specific	   interactions	   of	  His110	  suggest	   that	   it	   is	   the	   functional	  active	  site	  acid	  responsible	   for	  protonation	  of	   the	  FMN	  2-­‐oxygen	  resulting	  in	  a	  neutral	  FMNH2	  (219).	  	  	   Based	   on	   these	   observations	   Maclean	   et	   al.	   proposed	   2	   possible	   mechanisms	   for	  chorismate	  synthase	  that	  differ	  in	  the	  role	  of	  the	  5-­‐nitrogen	  of	  the	  FMN	  during	  C6-­‐(pro-­‐R)	  hydrogen	   abstraction	   (219).	   (Scheme	   1.13)	   One	   proposed	   mechanism	   utilizes	   radical	  intermediates	  of	  both	  EPSP	  and	  FMN	  where	  the	  flavin	  N5	  hydrogen	  is	  involved	  in	  C6-­‐(pro-­‐R)	  hydrogen	  abstraction.	  In	  contrast,	  the	  cationic	  mechanism	  utilizes	  a	  proton	  from	  the	  5-­‐nitrogen	   of	   the	   FMN	   in	   C6-­‐(pro-­‐R)	   hydrogen	   abstraction	   and	   involves	   a	   cationic	   EPSP	  intermediate.	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Scheme	   1.13.	   Proposed	   mechanisms	   for	   the	   conversion	   of	   5-­‐enol-­‐pyruculshikimate	   3	  phosphate	  (EPSP)	  to	  chorismate	  by	  chorismate	  synthase.	  	  	  	   Both	  of	  these	  proposed	  mechanisms	  utilize	  the	  5-­‐nitrogen	  of	  the	  flavin	  as	  the	  active	  site	   base	  where	   hydrogen	   abstraction	   from	   the	   dephosporylated	   substrate	   is	   contingent	  upon	   deprotonation	   of	   this	   position	   (Scheme	   13).	   A	   proximal	   aspartate	   (Asp339	   in	   S.	  
pneumonia,	   Asp367	   in	  N.	   crassa)	   residue	  was	   proposed	   to	   be	   responsible	   for	   the	  water-­‐mediated	  deproptonation	   of	   the	   5-­‐position	  nitrogen	  of	   the	   acid	   FMN	   semiquinone	   (219).	  Analysis	  of	  asp367ala	  and	  asp367asn	  mutant	  chorismate	  synthases	  from	  N.	  crassa	  revealed	  a	  300	   to	  600	   fold	  decrease	   in	   activity	   and	   the	  mutations	  had	  no	   significant	   effect	   on	   the	  binding	  of	  EPSP	  or	  oxidized	  FMN	  when	  compared	  to	  wild	  type	  further	  supporting	  the	  role	  of	  this	  residue	  in	  catalysis	  (221).	  Rauch	  et	  al	  carried	  out	  additional	  mutagenesis	  exploring	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the	  role	  of	  two	  invariant	  active	  site	  serine	  residues	  (16	  and	  127)	  where	  both	  Ser16Ala	  and	  Ser127Ala	  mutants	   displayed	   a	  marked	   decrease	   in	   activity,	   70-­‐	   and	   6-­‐	   fold	   respectively	  compared	  to	  wild	  type	  and	  the	  Ser16ala-­‐Ser127Ala	  double	  mutant	  was	  completely	  inactive	  (222).	  On	   this	  basis	  a	   third	  mechanism	  was	  proposed,	  where	   residues	   ser16,	   ser127	  and	  his110	  along	  with	  multiple	  water	  molecules	  form	  a	  “proton	  relay	  system”	  responsible	  for	  the	  formation	  of	  the	  observed	  radical	  intermediate	  (222)	  (Scheme	  13).	  In	  this	  mechanism	  His106	   is	   responsible	   for	   abstracting	   a	   proton	   from	   the	   N(1)-­‐C(1)=O	   locus	   of	   the	  isoalloxazine	   ring	   using	   a	   two	   water	   shuttling	   system	   mediated	   by	   residues	   ser16	   and	  ser127,	  resulting	  in	  protonation	  of	  the	  phosphate	  ester	  oxygen	  facilitating	  elimination.	  	  	  	  
UDP-­‐galatopyranose	  mutase	  	   UDP	  galactopyranose	  mutase	  (UGM)	  is	  a	  flavin	  dependent	  protein	  that	  catalyzes	  the	  6	   to	   5	   member	   sugar	   ring	   contraction	   of	   UDP-­‐galactopyranose	   (UDP-­‐galp)	   to	   UDP-­‐galactofuranose	   (UDP-­‐galf)	   (Scheme	  1.14).	  This	   reaction	  has	  an	  equilibrium	  position	   that	  favors	  UDP-­‐galp	  (11:1)	  as	  a	  result	  of	  the	  increase	  ring	  stain	  generated	  by	  the	  compression	  of	  the	  sugar	  (235).	  Much	  like	  CS,	  the	  UGM-­‐dependent	  turnover	  of	  UDP-­‐galp	  is	  redox	  neutral.	  	  	  
	  
Scheme	  1.14.	  Reaction	  catalyzed	  by	  UDP-­‐galactopyranose	  mutase.	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   UDP-­‐galf	  is	  a	  required	  precursor	  for	  the	  biosynthesis	  of	  galactofuranose	  dependent	  glycoconjugates	  found	  in	  bacteria,	  fungi,	  and	  protists	  (236-­‐239).	  In	  Mycobacterium	  species	  UGM	   is	   responsible	   for	   the	   biosynthesis	   of	   precursors	   used	   for	   glycoconjugates	   which	  function	   in	   anchoring	   the	   out	   mycolic	   acid	   layer	   to	   the	   peptidoglycan	   of	   the	   cell	   wall.	  Mutant	  Mycobacterium	   smegmatis	   lacking	   the	   gene	   glf	   which	   codes	   for	   UGM	   lacked	   the	  ability	  to	  grow	  at	  non-­‐permissive	  temperatures	  confirming	  that	  UGM	  in	  these	  organisms	  is	  essential	  for	  growth	  (240).	  UGM	  was	  also	  shown	  to	  have	  importance	  in	  the	  fungi	  Aspergillus	  
fumigatus	   the	   causative	   agent	   of	   a	   condition	   that	   poses	   a	   lethal	   threat	   to	  immunocompromised	   individuals	   (241).	   Deletion	   of	   UGM	   in	   A.	   fumigatus	   resulted	   in	  attenuated	   virulence	   in	   a	   low	   dose	   mouse	   model	   and	   attributed	   to	   a	   decrease	   in	   the	  thickness	   of	   the	   cell	   wall	   correlating	   to	   an	   increased	   susceptibility	   to	   antifungal	   agents	  (242).	   In	   kinetoplastids	   such	   as	   the	   protozoan	   species	   Leishmania	   major	   the	  monosaccharide	  product	  of	  UGM	  catalysis	  serves	  as	  a	  precursor	  for	  galactofuranose,	  which	  anchor	   lipophosphoglycans	   and	   glycoinositolphopholipids	   to	   the	   cytosolic	   surface	   of	   the	  cell(243).	  Mutant	  L.	  major	  devoid	  of	  UGM	  activity	  paralleled	  growth	  of	  wild	  type	  species	  in	  
vitro	  but	  displayed	  attenuated	  virulence	  (244).	  These	  observations	  have	  spurred	  scientific	  investigation	  into	  the	  catalytic	  and	  structural	  characterization	  of	  UGM	  in	  these	  organisms	  as	   this	   activity	   is	   absent	   in	  higher	   eukaryotic	   species	   such	  as	  humans	  making	  UGM	   is	   an	  ideal	   target	   for	   anti-­‐microbial,	   -­‐fungal	   and	   -­‐parasitic	   agents	   (240,	   245).	   Several	   recent	  studies	  have	  presented	  several	  UGM	   inhibitor	  candidates	  with	  significant	   (µM)	   inhibition	  constants	  (KI)	  utilizing	  both	  substrate	  mimics	  (246-­‐250),	  transition	  state	  mimics	  (251)	  and	  novel	  designs	  (252-­‐254).	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   Initial	  reports	  indicated	  that	  UGM	  is	  FAD-­‐dependent	  (235).	  It	  was	  later	  determined	  that	  UGM	  is	  only	  active	  in	  when	  the	  flavin	  is	  in	  the	  reduced	  form	  (255-­‐259),	  though	  earlier	  reports	   suggested	   that	   the	   oxidized	   form	   of	   the	   enzyme	   does	   exhibit	   activity	   (260).	  	  Eukaryotic	   UGMs	   from	   fungi	   (A.	   fumigatus)	  and	   the	   protozoa	  T.	   cruzi,	   L.	  Mexicana	  and	  L.	  
infatum	  utilize	  NADPH	  as	  a	  co-­‐substrate	  and	  can	  stabilize	  the	  reduced	  form	  of	  the	  enzyme	  even	   under	   aerobic	   conditions	   (261-­‐263).	   It	   was	   also	   demonstrated	   that	   once	   reduced	  eukaryotic	   UGMs	   can	   complete	   several	   hundred	   turnovers	   before	   reoxidation	  (inactivation)	  occurs	   as	   a	   result	   of	   the	   rate	  of	   oxidation	   (kox)	  occurring	  200	   to	  1500-­‐fold	  slower	   than	   rate	   of	   reduction	   (kred)	   (262-­‐264).	   Bacterial	   UGM	   can	   also	   utilize	   NADPH	   as	  reducing	   equivalents	   for	   enzyme	   activation	   but	   requires	   a	   large	   excess	   of	   NADPH	   and	  extended	   incubation	   times	   (10,000	   fold	   reduction	   in	   kred	   compared	   to	   eukaryotic	   UGM	  (262)),	   suggesting	   that	   alternative	   physiological	   substrates	   exist	   (265).	   It	   was	   proposed	  that	   this	   is	   indicative	   of	   promiscuous	   activation	   where	   oxidized	   UGM	   could	   accept	   a	  hydride/reducing	  equivalent	  from	  multiple	  types	  of	  reduced	  donors	  (266).	  Kinetic	  analysis	  demonstrated	  that	  UGM	  from	  multiple	  eukaryotic	  species	  undergo	  reduction	  of	   the	   flavin	  cofactor	  by	  NADH	  7	   to	  17-­‐fold	   slower	   than	  by	  NADPH	  but	   exhibit	   dissociation	   constants	  that	   bind	   NADH	   5	   to	   10	   fold	   more	   tightly	   than	   NADPH	   for	   UGM	   from	   T.	   cruzi	   and	   A.	  
fumigatus	  respectively	  (264).	  	  	   The	   most	   widely	   accepted	   chemical	   mechanism	   for	   UGM	   utilizes	   the	   flavin	   as	   a	  nucleophile	  to	  facilitate	  an	  attack	  on	  the	  anomeric	  carbon	  of	  the	  substrate	  displacing	  UDP.	  In	  this	  mechanism	  the	  binding	  of	  the	  substrate	  (UDP-­‐galp)	  to	  the	  reduced	  (active)	  form	  of	  UGM	  results	  in	  a	  local	  reorganization	  of	  the	  active	  site	  resulting	  in	  positioning	  of	  the	  N(5)	  FAD	  proximal	   (3.4Å)	   to	   the	  C(1)-­‐Galp	   (262,	  267-­‐271).	  The	  new	  conformation	   facilitates	   a	  
	  	  	   56	  
direct	   attack	   of	   the	   substrate	   anomeric	   carbon	   by	   the	   reduced	   flavin	   N(5)	   position	   in	   a	  proposed	   SN2-­‐like	   mechanism	   (272).	   (Scheme	   1.15)	   Direct	   attack	   by	   the	   flavin	   is	   also	  supported	   by	   studies	   where	   substitution	   of	   UGM-­‐FAD	   with	   5-­‐deaza-­‐FAD	   resulted	   in	  inactive	   enzyme	   (273).	   Inactivity	   of	   5-­‐deaza-­‐FAD	   substituted	   UGM	   would	   be	   expected	  under	   such	   a	   mechanism	   as	   5-­‐deaza-­‐FAD	   would	   be	   unable	   to	   offer	   the	   5-­‐Nitrogen	   as	   a	  nucleophile.	   It	   must	   be	   noted	   that	   the	   results	   of	   5-­‐deaza-­‐FAD	   substitution	   studies	   were	  initially	   proposed	   to	   be	   evidence	   in	   support	   of	   a	   mechanism	   involving	   single	   electron	  transfer	   (273).	   Additionally,	   the	   kinetic	   linear	   free	   energy	   relationship	   of	   kcat	   to	   the	  nucleophiliicity	   of	   the	   N(5)	   position	   of	   UGM	   substituted	   with	   various	   flavin	   analogs	  resulted	  in	  a	  ρ	  =	  -­‐2.4,	  consistent	  with	  a	  direct	  attack	  mechanism	  (254).	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Scheme	  1.15.	  Proposed	  mechanism	  of	  UDP-­‐glactopyranose	  to	  UDP-­‐galactofuranose	  by	  UGM.	  	  	  	   The	  nucleophilic	  attack	  of	  the	  FAD	  N(5)	  of	  UGM	  on	  the	  C(1)	  of	  UDP-­‐galp	  results	   in	  the	  formation	  of	  a	  covalently	  bonded	  FAD-­‐sugar	  adduct	  and	  the	  displacement	  of	  the	  UDP.	  (Scheme	   15,	   3)	   The	   formation	   of	   a	   covalent	   bound	   FAD	   reaction	   intermediate	   was	  confirmed	  in	  eukaryotic	  UGMs	  by	  UV/vis	  spectrophotometry	  and	  mass	  spectrometry	  (261).	  The	  covalent	  FAD-­‐galactose	  intermediate	  was	  also	  confirmed	  in	  prokaryotic	  UGMs	  by	  mass	  spectrometry,	   NMR	   and	   most	   recently	   a	   solved	   crystal	   structure	   of	   M.	   tuberculosis	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(structure	  not	  yet	  deposited	  in	  PDB)	  (268,	  274,	  275).	   It	  was	  suggested	  that	  the	  sugar-­‐FAD	  adduct	   would	   facilitate	   ring	   opening	   and	   activation	   of	   the	   C(1)	   of	   galp	  where	   the	   flavin	  would	  act	  as	  a	  structural	  scaffold	  providing	  the	  dimensional	  constraints	  required	  for	  ring	  contraction	  (148,	  264,	  276).	  This	  mechanistic	  progression	  is	  also	  consistent	  with	  positional	  isotope	   exchange	   (PIX)	   studies	   that	   determined	   that	   the	   glycosidic	   bond	   of	   UDP-­‐galp	   is	  cleaved	   during	   catalysis	   (277,	   278).	   The	   exact	   identity	   of	   the	   captured	   covalent	   sugar	  adduct	   in	   crystal	   structures	   from	   T.	   cruzi	   could	   not	   be	   identified	   however	   researchers	  concluded	  it	  must	  be	  either	  species	  3	  or	  4	  of	  Scheme	  15	  (274).	  	  	   Kinetic	  studies	  conducted	  with	  UGM	  from	  Trypanosoma	  cruzi	  showed	  no	  evidence	  of	  the	  formation	  of	  a	  flavin	  semiquinone	  species	  during	  turnover	  (261)	  despite	  earlier	  reports	  suggesting	   the	   flavin	   semiquinone	   is	   stabilized	   by	   substrate	   binding	   (279).	   Absence	   of	   a	  flavin	   semiquinone	   during	   catalysis	   does	   not	   offer	   support	   for	   the	  mechanism	   involving	  single	   electron	   transfer.	   Interestingly,	   these	   kinetic	   studies	   did	   reveal	   the	   formation	   of	   a	  possible	   flavin	   imminium	   ion	   intermediate	   (Scheme	   15,	   5)	   during	   the	   turnover	   of	   UGM	  from	   T.	   cruzi	   (261).	   Hybrid	   quantum/classical	   calculations	   preformed	   at	   the	   density	  function	  theory	  level	  suggest	  that	  C(4)=O	  of	  the	  FAD	  accepts	  a	  proton	  from	  N(5)	  (Scheme	  15,	  4)	  of	  the	  FAD	  and	  subsequently	  donates	  it	  to	  the	  O(5)	  of	  Galp	  (280).	  FAD	  imminium	  ion	  formation	  would	  require	  deprotonation	  of	  the	  N(5)-­‐FAD	  of	  the	  covalent	  FAD-­‐sugar	  adduct	  thereby	  facilitate	  opening	  of	  the	  ring	  of	  galp	  between	  C(1)	  and	  the	  ether	  oxygen	  (Scheme	  15,	   5)	   (264).	   Hybrid	   simulations	   also	   predict	   that	   the	   proton	   for	   the	   C(4)-­‐OH	   of	   Galp	   is	  shuttled	   to	   the	   C(4)=O	   of	   FAD	   during	   the	   contraction	   of	   the	   ring	   resulting	   in	   a	   covalent	  FAD-­‐galf	  adduct	  (Scheme	  15,	  6)	  (280).	  To	  date	  there	  is	  no	  biochemical	  information	  on	  the	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mechanisms	  of	  cleavage	  of	  the	  covalent	  FAD-­‐galf	  complex	  or	  reconstruction	  of	  the	  galf-­‐UDP	  molecule	  or	  the	  order	  in	  which	  they	  occur.	  	  	   Kinetic	  analysis	  of	  UGM	  from	  T.	  cruzi	  demonstrated	  that	  the	  rate	  of	  the	  formation	  of	  the	  FAD	  imminium	  species	  (300	  s-­‐1)	  occurs	  much	  more	  rapidly	  than	  the	  observed	  rate	  of	  catalysis	   (kcat	  ~	   10	   s-­‐1)	   (261,	   264).	   	   Viscosity	   effects	   studies	   have	   also	   ruled	   out	   product	  release	   as	   the	   rate-­‐limiting	   step	   (261,	   264).	   On	   this	   basis	   it	   was	   proposed	   that	   rate	   of	  catalysis	  is	  governed	  by	  either	  the	  ring	  contraction	  or	  reattachment	  of	  UDP	  (261).	  	  
	   The	  3-­‐demensional	   structure	  of	  UGM	  has	  been	  extensively	  characterized.	   In	  all	  46	  structures	  from	  8	  different	  species	  including	  prokaryotic	  strains	  from;	  Camplobacter	  jejuni,	  
Corynebacterium	   diphtheriae,	   Dienococcus	   radiodurans,	   Klebsiella	   pnuemoniae,	  
Mycobacterium	   tuberculosis	   and	   Escherichia	   coli	   as	   well	   as	   eukaryotic	   strains	   from	   A.	  
fumigatus	   and	  T.	  cruzi	  have	  been	   solved	   (246,	  255,	  262,	  264,	  267-­‐269,	  271,	  275,	  281-­‐286).	  These	  structures	  included	  examples	  of	  UGM	  in	  both	  the	  oxidized	  and	  reduced	  forms	  and	  in	  complex	   with	   multiple	   ligands	   including	   NADH,	   NADPH,	   flavin	   mononucleotide	   (FMN),	  UDP-­‐phosphono-­‐galactopyranose,	   UDP-­‐galactose,	   UDP,	   UDP-­‐galp	   and	   dideoxy-­‐tetrafluorinated	  analogoues	  both	  the	  substrate	  and	  product,	  UDP-­‐F4-­‐galp	  and	  UDP-­‐F4-­‐galf	  as	   well	   as	   the	   potential	   inhibitor	   2-­‐[4-­‐(4-­‐chlorophenyl)-­‐7-­‐(2-­‐thienyl)-­‐2-­‐thia-­‐5,6,8,9-­‐tetrabicyclo[4.3.0]nona-­‐4,7,9-­‐trien-­‐3-­‐yl]acetic	  (246,	  262,	  268-­‐271,	  275,	  283,	  284).	  Single	  site	  directed	  mutant	  UGM	  structures	  of	  F66A,	  Y317A,	  N207A,	  Q107A,	  Y104A	  and	  H63A	  mutants	  from	  A.	  fumigatus	  have	  also	  been	  determined	  (264,	  267,	  285,	  286).	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Figure	   1.7.	   Crystal	   structures	   of	   UGM.	   Three-­‐dimensional	   cartoon	   representation	   of	  tetrameric	  UGM	  from	  eukaryotic	  A.	  fumigatus	  (left)	  and	  dimeric	  UGM	  from	  prokaryotic	  M.	  
tuberculosis	  (right).	  	  	  
	   The	  first	  crystal	  structure	  of	  prokaryotic	  UGM	  from	  Escherichia	  coli	  (PDB	  code	  1I8T)	  was	  solved	   in	  2001	  and	  revealed	  a	  complex	   topology	  consisting	  of	   three	  domains,	   two	  of	  which	   are	   non-­‐contiguous	   (255).	   The	   structure	   of	   domain	   1	   is	   non-­‐contiguous	   tripartite	  domain	  containing	  an	  abbreviated	  Rossman	  fold	  responsible	  for	  FAD	  binding.	  The	  motif	  is	  commonly	   required	   to	   bind	   a	   FAD	   molecule	   however,	   in	   UGM	   from	   E.	   coli	   it	   lacks	   the	  terminal	   strand	   of	   the	   6-­‐stranded	   sheet	   found	   In	   classic	   examples	   of	   the	   Rossman	   fold	  (287).	  Domain	  2	  is	  contiguous	  and	  is	  composed	  of	  a	  cluster	  of	  5	  alpha	  helices	  and	  contains	  the	   binding	   site	   the	   uridine	   group,	   the	   active	   site	   flap	   1	   (residues	   167	   to	   177	   in	   K.	  
pneumoniae)	  that	  undergoes	  UDP-­‐galp	  dependent	  conformational	  changes	  and	  also	  plays	  a	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role	  in	  dimerization	  (284).	  The	  third	  domain	  is	  bipartite	  and	  non-­‐contiguous	  and	  consists	  of	  a	  6-­‐stranded	  antiparallel	  β-­‐sheet.	  The	  structures	  of	  all	  bacterial	  UGMs	  are	  topologically	  similar	  where	   secondary-­‐structure	  matching	   (SSM)	   analysis	   revealed	   that	   73	   to	   96	  %	   of	  secondary	  structure	  elements	   found	  in	  UGM	  from	  E.	  coli	  are	  completely	  conserved	  across	  all	   other	   known	   bacterial	   UGMs	   (288)	   despite	   substantial	   variation	   in	   primary	   structure	  (37	  to	  44	  %	  pairwise	  identity	  with	  UGM	  from	  E.	  coli)	  (264).	  
	   Multiple	  challenges	   in	  structure	  determination	  were	  encountered	  using	  UGM	  from	  eukaryotic	   species	   both	   A.	   fumigatus	   (270,	   283,	   289)	   and	   L.	   major	   (271)	   including	  translational	   psuedo-­‐symmetry	   and	   crystal	   twinning.	   It	   was	   later	   determined	   that	  mutagenesis	  of	  long	  charged	  surface	  residues,	  specifically	  lysine	  and	  glutamine	  allowed	  for	  reproducible	  crystal	  growth	  that	  were	  free	  of	  crystallographic	  pathologies	  (283,	  290,	  291).	  Two	   independent	   groups	   solved	   the	  mutant	   crystal	   structures	   of	  UGM	   from	  A.	   fumigatus	  using	   either	   the	   double	   mutant	   K344A/K345A(283)	   or	   the	   single	   mutant	   R327A	   (271)	  strains	  where	  the	  two	  structures	  produced	  are	  almost	  identical.	  These	  structures	  revealed	  that	   eukaryotic	   UGM	   consists	   of	   3	   domains	   similar	   to	   UGMs	   from	   prokaryotes	   with	  noticeable	   variations.	   Domain	   one	   retains	   the	   shortened	   Rossman	   fold	   described	   for	  prokaryotic	  UGMs	  but	  has	  an	  additional	  4-­‐stranded	  antiparrellel	  β-­‐sheet	  that	  sits	  adjacent	  to	   the	   Rossman	   fold	   and	   an	   extended	   (~30	   residues)	   C-­‐terminus	   that	   play	   a	   role	   in	   the	  tetrameric	   assembly	   of	   UGM	   from	   A.	   fumigatus.	   Domain	   two	   consists	   of	   a	   bundle	   of	   α-­‐helices	   similar	   to	   prokaryotic	   enzymes	   but	   contains	   an	   additional	   α-­‐helix	   and	   a	   helical	  extension	  (~7	  residues),	  which	  are	  involved	  in	  tetramer	  formation.	  The	  extra	  α-­‐helix	  forms	  the	   scaffold	   for	   a	   additional	  mobile	   active	   site	   flap	   (flap	   2)	   absent	   in	   prokaryotic	   UGMs.	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Domain	  three	  contains	  a	  twisted,	  seven-­‐stranded	  antiparallel	  β-­‐sheet	  compared	  to	  the	  six-­‐stranded	  β-­‐sheet	  seen	  in	  prokaryotes.	  	  	   More	  recently	  the	  crystal	  structure	  of	  UGM	  from	  T.	  cruzi	  was	  solved	  in	  both	  oxidized	  (PDB	   code	   4DSG)	   and	   reduced	   (PDB	   code	   4DSH)	   form	   (282).	   The	   protomer	   structure	  obtained	   from	   crystals	   of	  T.	   cruzi	  was	   nearly	   identical	   to	   the	   protomers	   of	   UGM	   from	  A.	  
fumigatus	  (RMSD	  1.10	  Å)	  however	  the	  overall	  topology	  of	  the	  two	  differs	  greatly	  as	  a	  result	  of	   differences	   in	   oligomeric	   state	   (264).	  UGM	   from	  T.	  cruzi	   crystallized	   as	   a	  monomer	   as	  opposed	   to	   tetrameric	  UGM	   from	  A.	   fumigatus.	  The	   tetrameric	   state	  of	   crystal	   structures	  UGM	   from	   A.	   fumigatus	   are	   consistent	   with	   results	   of	   small	   angle	   X-­‐ray	   scattering	   that	  describe	  the	  formation	  of	  a	  dimer	  of	  dimers	  (282).	  	   Additionally,	  crystal	  structures	  of	  eukaryotic	  UGM	  from	  A.	  fumigatus	  were	  solved	  in	  complex	   with	   NADH	   (PDB	   code	   4GDD)	   and	   NADPH	   (PDB	   code	   4GDC)	   and	   provided	   a	  valuable	   description	   of	   the	   unique	   NAD(P)H	   binding	   site	   and	   interactions	   (262).	   	   The	  NAD(P)H	   molecule	   is	   sandwiched	   between	   domain	   one	   and	   three,	   forming	   interactions	  with	   both	   and	   is	   positioned	   in	   an	   unusually	   constrained	   conformation	   positions	   the	  adenine	  moiety	  within	   hydrogen	  bonding	   distance	   of	   the	   ribose	   hydroxyl	   (286)	  which	   is	  vastly	   different	   than	   the	  Rossman	  dinucleotide	   binding	   fold	   common	  described	   for	  most	  enzymes	   utilizing	  NAD(P)H	   as	   a	   substrate	   (292,	  293).	  Multiple	   conserved	   residues	   (N57,	  I65,	   F66,	   H68,	   R91,	   S93,	   Y	   104	   and	   Y317)	   are	   involved	   in	   stabilizing	   the	   E•NAD(P)H	  complex	  where	   hydrogen	   bonding	   between	   Y104	   and	   2’	   phosphoryl	   group	   of	   NADPH	   is	  responsible	   for	   the	  ~180-­‐	   fold	   preference	   (kcat/KD)	   for	  NADPH	   over	  NADH	   seen	   in	  UGM	  from	   A.	   fumigatus	   (262).	   However,	   binding	   of	   NAD(P)H	   molecules	   does	   not	   invoke	  conformational	  changes	   in	  either	  of	   the	  2	  active	  site	   flaps,	   flap	  1	   (residues	  179	   to	  187	   in	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UGM	   from	   A.	   fumigatus)	   or	   flap	   2	   (residues	   203	   to	   209	   in	   UGM	   from	   A.	   fumigatus)	  responsible	  for	  closure	  of	  the	  active	  site	  (262).	  Interestingly,	  the	  bound	  NAD(P)H	  molecule	  extends	  into	  the	  UPD-­‐galp	  binding	  pocket	  and	  implies	  that	  binding	  of	  NAD(P)H	  and	  UDP-­‐galp	  are	  mutually	  exclusive	  (264).	  	  Prokaryotic	  UGM	  lack	  all	  of	  the	  conserved	  residues	  that	  contact	   the	   ADP	  moiety	   of	   NAD(P)H	   seen	   in	   eukaryotic	   UGM	   indicating	   that	   prokaryotic	  UGM	   does	   not	   contain	   a	   NAD(P)H	   binding	   domain	  which	   is	   consistent	  with	   biochemical	  data	  (264).	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Chapter	  II.	  
Renalase	  is	  an	  α-­‐NAD(P)H	  Oxidase/Anomerase	  	   Brett	  A.	  Beaupre,	  Brenton	  R.	  Carmichael,	  Matthew	  R.	  Hoag,	  Dhara	  D.	  Shah	  and	  Graham	  R.	  Moran	  	  
Abstract	  	   Renalase	  is	  a	  protein	  hormone	  secreted	  into	  blood	  by	  the	  kidney	  that	  is	  reported	  to	  lower	  blood	  pressure	  and	  slow	  heart	   rate.	  Since	   its	  discovery	   in	  2005,	   renalase	  has	  been	  the	   subject	   of	   conjecture	   pertaining	   to	   its	   catalytic	   function.	   While	   it	   has	   been	   widely	  reported	   that	   renalase	   is	   the	   third	   monoamine	   oxidase	   (monoamine	   oxidase	   C)	   that	  oxidizes	   circulating	   catecholamines	   such	   as	   epinephrine,	   there	   has	   been	   no	   convincing	  demonstration	   of	   this	   catalysis	   in	   vitro.	   Renalase	   is	   a	   flavoprotein	   whose	   structural	  topology	   is	   similar	   to	   known	   oxidases,	   lysine	   demethylases	   and	   monooxygenases,	   but	  whose	   active	   site	   bears	   no	   resemblance	   to	   that	   of	   any	   known	   flavoprotein.	   We	   have	  identified	  the	  catalytic	  activity	  of	  renalase	  as	  an	  α-­‐NAD(P)H	  oxidase/anomerase,	  whereby	  low	   equilibrium	   concentrations	   of	   the	   α-­‐anomer	   of	   NADPH	   and	   NADH	   initiate	   rapid	  reduction	  of	  the	  renalase	  flavin	  cofactor.	  The	  reduced	  cofactor	  then	  reacts	  with	  dioxygen	  to	  form	   hydrogen	   peroxide	   and	   releases	   nicotinamide	   dinucleotide	   product	   in	   the	   β-­‐form.	  These	  processes	  yield	  an	  apparent	  turnover	  number	  (0.5	  s-­‐1	  in	  atmospheric	  dioxygen)	  that	  is	   at	   least	   two-­‐orders	   of	  magnitude	  more	   rapid	   than	   any	   reported	   activity	  with	   catechol	  neurotransmitters.	   This	   highly	   novel	   activity	   is	   the	   first	   demonstration	   of	   a	   role	   for	  naturally	  occurring	  α-­‐NAD(P)H	  anomers	  in	  mammalian	  physiology	  and	  the	  first	  report	  of	  a	  flavoprotein	  catalyzing	  an	  epimerization	  reaction.	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Introduction	  	   Human	  renalase	  was	  first	  discovered	  in	  2005	  by	  Xu	  et	  al.	  (1,	  294)	  and	  its	  discovery	  spurred	  considerable	  interest	  as	  the	  protein	  was	  reported	  to	  be	  secreted	  into	  blood	  by	  the	  kidney	   as	   a	   hormone	   to	   down-­‐modulate	   blood	   pressure	   and	   cardiac	   output.	   (61)	   These	  observations	  have	  since	  been	  associated	  with	  the	  high	  incidence	  of	  cardiovascular	  disease	  in	   patients	   with	   end-­‐stage	   renal	   disease	   (4),	   emphasizing	   that	   diminishment	   of	   the	  endocrine	   function	  of	   the	  kidney	   is	  wholly	  detrimental	   to	  cardiac	   function.	  (1,	  25,	  295)	   In	  addition,	  mice	  deficient	  in	  renalase	  have	  been	  reported	  to	  exhibit	  elevated	  blood	  pressure	  (4)	  and	  human	  renalase	  polymorphisms	  have	  been	   linked	  with	  an	   increased	   incidence	  of	  diabetes	   and	   stroke.	   (296,	   297)	   Since	   its	   discovery	   a	   definitive	   demonstration	   of	   the	  catalytic	  function	  of	  renalase	  has	  remained	  elusive.	  While	  it	  has	  been	  widely	  reported	  that	  renalase	   lowers	   blood	   pressure	   and	   modifies	   heartbeat	   by	   catabolizing	   circulating	  catecholamines	  (2,	  3,	  5,	  12,	  14,	  16,	  36),	  neither	  the	  specific	  substrate(s)	  and	  product(s)	  nor	  the	  overall	  stoichiometry	  for	  the	  reaction	  has	  been	  convincingly	  established.	  In	  vivo	  studies	  in	   rodents	   show	   that	   the	   concentration	   of	   circulating	   catecholic	   neurotransmitters	   is	  lowered	  by	  intravenous	  injection	  of	  renalase.	  (1,	  4,	  36)	  However,	  in	  vitro	  studies	  have	  failed	  to	   demonstrate	   significantly	   catalytic	   consumption	   of	   catecholic	   neurotransmitters	   (or	  their	   precursors).	   (36,	  51)	   It	   has	   been	   claimed	   that	   renalase	  mobilizes	   four	   electrons	   by	  acquiring	   two	   electrons	   from	  NAD(P)H	   in	   order	   to	   catalyze	   a	   net	   two-­‐electron	   oxidation	  and	   cyclization	   of	   epinephrine	   to	   form	   adrenochrome.	   (2)	   Such	   a	   transformation	   for	  epinephrine	  is,	  however,	  facile	  in	  the	  absence	  of	  an	  enzyme	  catalyst	  and	  readily	  observed	  in	  oxygenated	  solutions	  under	  a	  variety	  of	  conditions.	  (298,	  299)	  Similarly,	  the	  observation	  of	  apparent	   slow	   oxidation	   of	   reduced	   pyridine	   nucleotide	   cofactors	   in	   the	   presence	   of	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renalase	  is	  complicated	  by	  the	  inherent	  instability	  of	  these	  molecules	  at	  pH	  values	  near	  or	  below	   neutral	   pH.	   (300)	   As	   a	   consequence,	   claims	   of	   renalase	   directly	   catalyzing	   the	  breakdown	   of	   catecholamines	   has	   been	   challenged	   in	   both	   letters	   and	   research	   articles.	  (48,	  51,	  301)	  	  	   The	   discord	   in	   regard	   to	   the	   activity	   of	   renalase	   has	   developed	   both	   from	   its	  reported	  physiological	  function	  and	  from	  its	  structural	  similarity	  to	  known	  redox	  enzymes.	  The	   primary	   structure	   of	   the	   protein	   has	   at	   least	   4	   forms	   that	   result	   from	  RNA	   splicing	  patterns	  for	  seven	  exons.	  Only	  the	  two	  longest	  sequences	  that	  include	  protein	  derived	  from	  at	   least	   six	   exons	   show	   direct	   similarity	   to	   known	   flavoproteins.	   (12,	   301)	   The	   three-­‐dimensional	  structure	  of	  renalase	  isoform	  1	  (342	  amino	  acids)	  was	  published	  by	  Milani	  et	  al.	   2011.	   (60)	   This	   structure	   indicated	   a	   fold	   consistent	  with	   a	   large	   structural	   family	   of	  flavoproteins	  that	   include	  oxidases,	   lysine	  demethylases,	  and	  monooxygenases.	   (302-­‐306)	  	  The	  apparent	  active	  site	  of	  renalase	  was	  observed	  to	  be	  a	  clearly	  delineated	  pocket	  in	  the	  surface	  of	   the	  protein	   that	  provides	  access	   to	   the	  si-­‐face	  of	  a	  non-­‐covalently	  bound	   flavin	  adenine	  dinucleotide	  (FAD)	  cofactor.	  Within	   this	  cavity,	   the	  constellation	  of	   residues	   that	  are	   conserved	   in	   renalase	   primary	   structures	   gave	   no	   clear	   indication	   for	   any	   known	  activity	  of	  a	  flavoprotein.	  However,	  renalase	  was	  observed	  to	  readily	  form	  an	  adduct	  with	  sulfite	   ions	   at	   the	   FAD	   isoalloxazine	   N5	   position,	   a	   curious	   characteristic	   that	   is	   most	  commonly	  associated	  with	  oxidase	  activity.	  (60,	  307,	  308)	  	   In	   this	   article	  we	   identify	   renalase	   as	   an	  α-­‐NAD(P)H	  oxidase/anomerase	  whereby	  the	  substrate	  α-­‐dihydropyridyl	  ring	  is	  oxidized	  by	  transferring	  two	  electrons	  to	  the	  flavin	  cofactor	  and	  the	  configuration	  of	  the	  ribose	  C1	  is	  converted	  from	  α	  to	  β.	  The	  reduced	  FAD	  cofactor	   then	   reoxidizes	   by	   reacting	   with	   dioxygen	   to	   yield	   hydrogen	   peroxide	   (Scheme	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2.1).	  This	  highly	  novel	   transformation	   is	  both	  unprecedented	  catalytic	   chemistry	  and	   the	  first	  physiological	  link	  to	  α-­‐pyridine	  nucleotides	  in	  higher	  organisms.	  
	  
Scheme	  2.1.	  	  Reaction	  catalyzed	  by	  renalase.	  	  	  
Materials	  and	  Methods	  	  
Materials:	   Plasmids	   were	   purified	   using	   the	   Qiagen	   Midi-­‐Prep	   plasmid	   preparation	   kit.	  Oligonucleotides	   were	   synthesized	   by	   Operon.	   Vector	   pET28a(+)	   was	   obtained	   from	  Novagen.	  Restriction	  enzymes,	  DNA	  modification	  enzymes	  and	  competent	  (DH5α	  and	  BL21	  (DE3))	   E.	   coli	   were	   obtained	   from	   New	   England	   Biolabs.	   FAD,	   (4-­‐(2-­‐hydroxyethyl)-­‐1-­‐piperazineethanesulfonic	   acid	   (HEPES),	   potassium	   phosphate,	   isopropyl-­‐β-­‐thiogalactopyranoside	   (IPTG)	   and	   sodium	   chloride	   were	   from	   ACROS.	   Electrophoretic	  grade	  agarose	  was	  obtained	   from	  ICN	  Biomedicals.	  Luria	  Bertani	  broth	   (Lennox)	  powder	  was	  from	  Fisher	  Scientific.	  Kanamycin	  and	  β-­‐NADPH	  were	  purchased	  from	  Alexis.	  β-­‐NADP+	  was	   purchased	   from	   Calbiochem.	   β-­‐NADH,	   β-­‐NAD+	   and	   epinephrine	   were	   from	   Sigma-­‐Aldrich.	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Cloning	   and	   expression	   of	   Human	   Renalase:	   The	   gene	   encoding	   full	   length	   WT	   Human	  renalase	  (isoform	  1)	  optimized	  for	  expression	  in	  E.	  coli	  and	  incorporating	  Nde	  I	  and	  Xho	  I	  sites	  at	  the	  5’	  and	  3’	  ends	  was	  purchased	  from	  Enzymax.	  The	  gene	  was	  supplied	  in	  plasmid	  pUC57	  and	  subcloned	   into	   the	  Nde	  I	  and	  Xho	   I	  restriction	  sites	  of	  pET-­‐28a(+)	  expression	  vector	   (Novagen).	  The	  Nde	   I	   insertion	  of	  pET-­‐28a(+)	  plasmid	   incorporates	  an	  N-­‐terminal	  His-­‐Tag	   fusion.	  This	  plasmid	  (pHSRENHT)	  was	   transformed	   into	  chemically	  competent	  E.	  
coli	   BL21	   (DE3)	   cells	   (Novagen).	   All	   media	   used	   with	   transformed	   cells	   included	   100	  
µg/mL	   kanamycin.	   Transformants	  were	   plated	   onto	   LB	   agar	   and	   a	   single	   isolated	  E.	   coli	  colony	  was	  cultured	  in	  LB	  broth.	  Individual	  1	  mL	  cell	  stocks	  were	  made	  by	  adding	  sterile	  glycerol	   to	  a	   final	  concentration	  of	  20%	  to	  cells	  grown	  to	  early	   log	  phase	  and	  these	  were	  then	  stored	  at	  -­‐80°C.	  	  
Renalase	  Expression	  and	  Purification:	  For	  expression,	  1	  mL	  cell	  stocks	  were	  thawed,	  plated	  onto	  LB	  agar,	  100	  µg/mL	  kanamycin,	  and	  grown	  overnight	  at	  37°C	  (50	  µL/plate).	  The	  lawn	  of	  cells	  obtained	  were	  then	  transferred	  to	  LB	  broth	  (two	  plates/L	  of	  broth)	  and	  grown	  at	  37oC	   in	   a	   shaking	   incubator	   (220	   rpm)	   to	   mid-­‐log	   phase	   (OD600nm=0.5)	   and	   the	  temperature	  lowered	  to	  22oC.	  The	  culture	  was	  then	  grown	  to	  ~	  OD600nm=1.0	  (~1	  hr)	  and	  induced	  with	   0.1	  mM	   IPTG	   and	   left	   to	   express	   renalase	   for	   20	   hrs	   before	   the	   cells	  were	  harvested	  by	  centrifugation	  (4,000	  g	   for	  30	  min).	  Unless	  otherwise	  stated,	  all	  subsequent	  purification	  steps	  were	  performed	  at	  4°C.	  Cell	  pellets	  were	  resuspended	  in	  20	  mM	  HEPES	  buffer	   pH	  7.5	   (approximately	  10	  mL/L	   culture)	   and	   lysed	  by	   sonication	  using	   a	  Branson	  450	   sonicator	   (3	   x	   240	   seconds	   at	   50	  W).	   The	   temperature	   of	   the	   cell	   suspension	   was	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maintained	  below	  10°C	  by	  immersing	  the	  sample	  vessel	  in	  a	  slurry	  of	  ice	  and	  water.	  Lysed	  cells	   were	   centrifuged	   at	   32,800	   x	   g	   for	   30	   min,	   the	   pellet	   was	   discarded	   and	   the	  supernatant	  loaded	  onto	  a	  12.5	  x	  150	  mm	  Co2+	  Talon	  column	  (BD	  Biosciences)	  equilibrated	  with	  20	  mM	  HEPES	  buffer	  pH	  7.5.	  Protein	  was	  eluted	  with	  a	  1	  mL/min	  two-­‐step	  protocol.	  Initially	   contaminating	   proteins	   were	   eluted	   with	   150	   mL	   of	   10	   mM	   imidazole,	   50	   mM	  HEPES	  buffer	  pH	  7.5,	  then	  a	  gradient	  from	  10	  mM	  to	  150	  mM	  imidazole	  in	  the	  same	  buffer	  was	  used	  to	  elute	  renalase.	  Distinctly	  yellow	  fractions	  were	  pooled.	  Imidazole	  was	  removed	  and	   the	  buffer	   exchanged	   to	  PBS	   (10	  mM	  Na2HPO4,	   2	  mM	  KH2PO4,	   2.7	  mM	  KCl,	   137	  mM	  NaCl,	   pH	   7.4)	   by	   repeated	   concentration	   and	   dilution	   using	   10	   kDa	   nominal	   molecular	  weight	   cut-­‐off	   centrifugal	   concentrator	   (Millipore,	   Amicon)	   to	   achieve	   a	   net	   ≥1000-­‐fold	  exchange.	  Aliquots	  of	  purified	  concentrated	  renalase	  were	  then	  stored	  at	  -­‐80°C.	  	  
Quantitation:	  The	  concentration	  of	  NADPH	  and	  NADH	  solutions	  were	  determined	  using	  the	  published	  340	  nm	  extinction	   coefficient	  of	  6200	  M-­‐1cm-­‐1	   (309).	  The	  extinction	   coefficient	  for	  Renalase	  was	  determined	  by	  liberating	  the	  FAD	  cofactor	  from	  the	  protein.	  Initially,	  the	  absorption	   spectrum	   of	   9	   µM	   renalase	   was	   recorded	   using	   a	   Hewlett	   Packard	   8453	  spectrophotometer.	  SDS	  to	  1%	  final	  concentration	  was	  then	  added	  to	  denature	  the	  protein	  and	  release	  the	  flavin	  and	  the	  spectrum	  was	  again	  recorded.	  The	  spectrum	  of	  the	  unbound	  flavin	  was	  then	  corrected	  for	  dilution	  and	  the	  known	  extinction	  coefficient	  for	  this	  molecule	  at	   450	   nm	   (e450nm	   =	   11,300	   M-­‐1cm-­‐1)	   was	   used	   to	   calculate	   the	   extinction	   coefficient	   of	  renalase	  (e458nm	  =	  11,330	  M-­‐1cm-­‐1).	  Epinephrine	  was	  quantified	  by	  weight.	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Substrate/Product	   Analysis:	   The	   apparent	   substrate	   for	   renalase	   was	   detected	   as	   a	  contaminant	   of	   β-­‐NAD(P)H	   stocks	   that	   caused	   rapid	   reduction	   of	   the	   renalase	   flavin	  cofactor.	   The	   proportion	   of	   the	   substrate	   in	   NAD(P)H	   solutions	  was	   determined	   by	   two	  methods.	  First,	  relatively	  high	  concentrations	  of	  β-­‐NADPH	  were	  mixed	  with	  renalase	  using	  a	  Hi-­‐Tech	  (now	  TgK)	  stopped-­‐flow	  spectrophotometer	  under	  anaerobic	  conditions.	  Prior	  to	  the	   experiment,	   the	   instrument	   was	   scrubbed	   of	   residual	   dioxygen	   for	   ~16	   hrs	   using	   a	  solution	   of	   50	  mM	   glucose	   and	   15.5	   U/mL	   glucose	   oxidase.	   Renalase	   in	   PBS	   buffer	   was	  prepared	   in	   a	   tonometer	   by	   adding	   8	   µM	   enzyme	  with	   1	  mM	  glucose	   in	   the	   body	   of	   the	  vessel	  and	  16	  U	  of	  glucose	  oxidase	  in	  a	  side	  arm	  (U	  is	  defined	  as	  1	  unit	  of	  enzymatic	  activity	  or	  1	  µmole/min).	  The	  tonometer	  was	  then	  subject	  to	  45	  cycles	  of	  low	  vacuum	  followed	  by	  argon	   gas	   with	   mild	   agitation	   to	   exchange	   all	   dissolved	   dioxygen.	   Once	   anaerobic,	   the	  renalase/glucose	   solution	   was	  mixed	   with	   the	   glucose	   oxidase	   from	   the	   tonometer	   side	  arm	  and	  the	  vessel	  was	  mounted	  onto	  the	  stopped-­‐flow	  instrument.	  NADPH	  solutions	  were	  prepared	  with	  1	  mM	  glucose	  and	  made	  anaerobic	  by	  sparging	  with	  argon	  for	  5	  minutes	  and	  then	  adding	  in	  8	  U	  of	  glucose	  oxidase	  immediately	  prior	  to	  mounting	  onto	  the	  instrument.	  Renalase	   and	   NADPH	   were	   then	   mixed	   and	   the	   extent	   of	   flavin	   cofactor	   reduction	   was	  recorded	  at	  458	  nm.	  The	  second	  method	  used	  to	  determine	  the	  proportion	  of	  substrate	  in	  NAD(P)H	   solutions	  was	   to	   observe	   the	   change	   in	  molecular	   oxygen	   concentration	  when	  high	  concentrations	  of	  NAD(P)H	  were	  added	  to	   low	  µMolar	  concentrations	  of	   renalase	   in	  PBS	   buffer	   using	   a	   Hansetech	   dioxgen	   electrode.	   Assuming	   1:1	   substrate	   to	   dioxygen	  reaction	   stoichiometry	   (vide	   infra),	   the	   concentration	   of	   substrate	   could	   be	   determined	  from	  the	  amplitude	  of	  the	  observed	  change	  in	  molecular	  oxygen	  concentration.	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   Evidence	   for	   the	   identity	   of	   the	   substrate	   was	   obtained	   from	   HPLC	   analysis.	  NAD(P)H	  solutions	  (10	  mM)	  were	  diluted	  by	  a	  factor	  of	  50	  and	  filtered	  using	  a	  Millipore	  0.5	  mL	  10	  kDa	  nominal	  molecular	  weight	  centrifugal	   filter	  device.	  50	  µL	  of	   this	   solution	  was	  then	  injected	  onto	  a	  Waters	  Xterra	  C18	  cartridge	  column	  (4.6	  x	  150	  mm)	  run	  isocratically	  at	  0.5	  mL/min	  with	  10	  mM	  NaPi	  pH	  7.5	  coupled	  to	  a	  waters	  600E	  pump	  and	  Waters	  2487	  detector.	  The	  elution	  of	  components	  was	  observed	  at	  both	  260	  and	  340	  nm.	  The	  dominant	  components	   having	   absorbance	   at	   340	   nm	  were	   collected	   and	   their	   spectra	   recorded.	   A	  second	   sample	   was	   then	   prepared	   in	   an	   equivalent	   manner	   but	   with	   the	   addition	   of	  renalase	  to	  5	  µM.	  After	  incubation	  for	  2	  min	  this	  sample	  was	  filtered	  to	  remove	  the	  enzyme	  and	  subject	  to	  HPLC	  analysis.	  	  	   HPLC	  identification	  of	  the	  product	  of	  the	  renalase	  reaction	  was	  based	  on	  co-­‐elution.	  Chromatography	  conditions	  were	  as	  described	  above.	  Initially,	  a	  50	  µL	  control	  sample	  from	  a	   solution	   of	   340	   µM	   NADH	   in	   PBS	   buffer	   was	   separated	   into	   its	   α	   and	   β-­‐NADH	  components.	  A	  second	  50	  µL	  sample	  was	   then	  reacted	  with	  5	  µM	  renalase	   for	  2	  minutes	  and	   filtered	   using	   a	  Millipore	   0.5	  mL	  10	   kDa	  nominal	  molecular	  weight	   centrifugal	   filter	  device	  before	  being	  chromatographed	  in	  an	  equivalent	  manner.	  A	  third	  340	  µM	  sample	  was	  then	   prepared	  with	   the	   addition	   of	   15	  µM	  β-­‐NAD+	   and	   chromatographed.	   The	   retention	  time	   of	   the	   product	   of	   the	   renalase	   reaction	  was	   compared	   to	   that	   of	   the	   sample	   spiked	  with	  β-­‐NAD+	  to	  identify	  the	  product.	  	   The	   nicotinamide	   product	   of	   a	   renalase/NADPH	   reaction	   was	   identified	   as	   β-­‐NAD(P)+	  by	  nuclear	  magnetic	  resonance	  (NMR).	  A	  40	  mM	  solution	  of	  NADPH	  was	  prepared	  in	  10	  mM	  NaPi	  buffer	  pH	  7.4	  in	  deuterium	  oxide	  solvent.	  The	  1H	  NMR	  spectrum	  was	  then	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recorded	   by	   collecting	   and	   transforming	   256	   FIDs	   soon	   after	   preparing	   the	   sample	   on	   a	  Bruker	  300	  MHz	  NMR	  instrument.	  Renalase	  (10	  µM	  –	  0.3	  U)	  and	  catalase	  (0.2	  U)	  were	  then	  added	   to	   the	  NMR	   tube	  and	  mixed	  by	   repeated	  pipetting	  with	   a	  Pasteur	  pipette.	   Further	  spectra	  were	  then	  recorded	  at	  specific	  times	  over	  the	  next	  100	  minutes.	  A	  control	  NADPH	  sample	  was	   then	   prepared	   at	   the	   same	   concentration	   in	   the	   same	   buffer	   and	  monitored	  similarly.	  Prior	  to	  each	  spectrum	  (sample	  and	  control)	  the	  contents	  of	  the	  NMR	  tube	  were	  re-­‐equillibrated	   with	   atmospheric	   molecular	   oxygen	   by	   repeatedly	   drawing	   the	   solution	  into	   a	   Pasteur	   pipette.	   The	   concentration	   of	   the	   product	   was	   approximated	   from	   the	  relative	   integrations	   of	   known	   resonances	   for	   β-­‐NADPH	   and	   the	   singlet	   resonance	   for	  proton	  N2	   (2	  position	  of	   the	  nicotinamide)	   of	   the	   species	   observed	   to	   accumulate	   in	   the	  reaction.	  These	  spectra	  were	  compared	  to	  the	  proton	  spectra	  of	  1	  mM	  β-­‐NADP+	  alone	  and	  1	  mM	  β-­‐NADP+	  in	  the	  presence	  of	  40	  mM	  β-­‐NADPH.	  	  
Evaluation	  of	  Epinephrine	  as	  a	  Substrate	  for	  Renalase:	  Epinephrine	  was	  tested	  as	  a	  substrate	  for	   renalase	   using	   four	   approaches.	   In	   the	   first,	   the	   reported	   accumulation	   of	  adrenochrome	  in	  the	  presence	  of	  renalase	  was	  evaluated.	  The	  concentration	  dependence	  of	  the	   formation	   of	   adrenochrome	   was	   observed	   by	   adding	   varied	   concentrations	   of	  epinephrine	   (0-­‐400	   µM)	   (prepared	   in	   10	  mM	  HCl)	   to	   a	   solution	   of	   PBS	   buffer	   and	   then	  observing	   the	   increase	   in	   absorbance	   at	   480	   nm	   at	   25oC.	   The	   initial	   rate	   at	   each	  epinephrine	  concentration	  was	  measured	  by	  fitting	  the	  first	  200	  seconds	  to	  a	  straight	  line	  and	  dividing	  the	  slope	  by	  the	  extinction	  coefficient	  for	  adrenochrome	  (4020	  M-­‐1cm-­‐1).	  (299)	  To	  determine	  if	  renalase	  and/or	  NADPH	  accelerates	  this	  process,	  10	  µM	  renalase	  and	  then	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10	   µM	   renalase	   with	   freshly	   prepared	   β-­‐NADPH	   to	   400	   µM	   was	   added	   to	   400	   µM	  epinephrine	  (final)	  and	  the	  initial	  rate	  recorded.	  	  	   In	   the	   second	   approach	   the	   effect	   of	   epinephrine	  on	   the	  observed	   single-­‐turnover	  kinetics	  was	  assessed	  by	  stopped-­‐flow	  spectrophotometry.	  Non-­‐pseudo	  first	  order	  single-­‐turnover	  reactions	  were	  initiated	  by	  mixing	  a	  limiting	  concentration	  of	  the	  α-­‐NADPH	  (~6	  
µM	  in	  400	  µM	  β-­‐NADPH)	  in	  PBS	  buffer	  equilibrated	  with	  atmospheric	  dioxygen	  (~250	  µM)	  with	   11.4	   µM	   aerobic	   renalase	   in	   the	   same	   buffer.	   The	   reaction	   was	   monitored	   by	  observing	   the	   reduction	   and	   reoxidation	   of	   enzymes’	   flavin	   cofactor	   at	   458	   nm.	  Epinephrine	   (400	   µM)	   was	   then	   added	   to	   the	   α-­‐NADPH	   solution	   and	   the	   observation	  repeated.	   In	  order	   to	  evaluate	   if	   some	  soluble	   component	  of	  blood	  modulated	  or	   reacted	  with	   renalase,	   this	   observation	   was	   repeated	   with	   the	   α-­‐NADPH/epinephrine	   solution	  prepared	   in	   fresh	   cell	   free	   blood	   plasma.	   Solely	   for	   comparison	   the	   data	   were	   fit	   to	  Equation	  2.1	   that	   describes	   three	   successive	   first	   order	   events.	   In	   this	   equation	  k1	   is	   the	  rate	   apparent	   constant	   for	   reduction,	   k2	   is	   an	   additional	   unassigned	   phase	   and	   k3	   is	   the	  apparent	  rate	  constant	  for	  reoxidation,	  DA1-­‐3	  are	  the	  respective	  absorbance	  amplitudes	  for	  the	  phases	  observed,	  and	  C	  is	  the	  endpoint	  absorbance.	  	  	  Equation	  2.1.	  	  	  	   A458nm	  =	  ΔA1e-­‐k1t	  +	  ΔA2e-­‐k2t	  +ΔA3e-­‐k3t	  +	  C	  	  	   Isothermal	   titration	   calorimetry	  was	  used	   to	  assess	   if	   epinephrine	  associates	  with	  renalase.	   Renalase	   (350	   µL	   of	   339	   µM	   in	   PBS	   buffer	   at	   25oC	   )	   was	   injected	   into	   a	   TA	  instruments	   Nano	   ITC	   Model	   5303	   microcalorimeter.	   This	   sample	   then	   had	   21,	   2	   µL	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additions	  of	  1.84	  mM	  epinephrine	  injected	  over	  2	  h.	  The	  pattern	  of	  heat	  liberated	  was	  then	  fit	   to	   a	   single	   independent	   site	   model	   correcting	   for	   constant	   cell	   volume	   and	   injection	  dilution	  using	  NanoAnalyze	  Data	  Analysis	  software	  (TA	  instruments)	  to	  obtain	  a	  measure	  of	  the	  binding	  constant	  for	  the	  renalase•epinephrine	  complex.	  (310)	  	  	  	   Perturbation	  of	  the	  renalase	  flavin	  absorption	  and	  fluorescence	  emission	  spectra	  in	  the	   presence	   of	   epinephrine	  was	   used	   as	   a	   qualitative	  measure	   to	   evaluate	   if	   the	   ligand	  formed	  a	  complex	  with	  the	  enzyme	  that	  had	  close	  association	  with	  the	  FAD	  isoalloxazine.	  Absorption	   spectra	   of	   renalase	   (30	   µM)	   were	   measured	   at	   25oC	   in	   PBS	   buffer	   in	   the	  presence	   and	   absence	   of	   epinephrine	   (100	   µM)	   using	   a	   Cary	   3	   dual	   beam	  spectrophotometer.	   The	   free	   enzyme	   spectrum	   was	   then	   subtracted	   from	   the	   spectrum	  obtained	   in	   the	   presence	   of	   the	   ligand	   to	   obtain	   the	   difference	   spectrum	   and	   accentuate	  changes.	  Similarly,	  fluorescence	  emission	  spectra	  were	  obtained	  under	  the	  same	  conditions	  with	  excitation	  at	  450	  nm.	  The	  emission	  spectrum	  (475-­‐650	  nm)	  of	  4	  µM	  renalase	  in	  PBS	  buffer	  was	  recorded	  in	  the	  absence	  and	  presence	  of	  40	  µM	  epinephrine	  using	  an	  Hitachi	  F-­‐4500	  spectrofluorometer	  at	  25oC.	  	  
	  
Results	  
Expression	   and	   purification:	   Human	   N-­‐terminally	   His-­‐tagged	   renalase	   isoform	   1	   was	  expressed	   in	   BL21	   DE3	   E.	   coli	   to	   highest	   yield	   at	   22	   oC.	   Typically	   the	   yield	   of	   purified	  enzyme	  was	  6	  mg/L	  of	   culture.	   	  The	  enzyme	  was	  purified	   to	  homogeneity	  using	  a	   cobalt	  affinity	  column	  from	  which	  it	  eluted	  at	  approximately	  30	  mM	  imidazole	  and	  was	  assessed	  to	  be	  greater	   than	  95%	  pure	  by	  SDS	  polyacrylamide	  gel	   electrophoresis.	   Consistent	  with	  prior	  reports,	  the	  renalase	  flavin	  spectrum	  was	  red-­‐shifted	  compared	  to	  that	  of	  free	  flavin	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(Figure	  2.1)	  .	  (60,	  61)	  The	  two	  visible	  maxima	  of	  the	  enzyme	  bound	  flavin	  spectrum	  occur	  at	   387	   and	   458	   nm	   with	   extinction	   coefficients	   of	   ε387nm	   =	   10,750	   M-­‐1cm-­‐1	  and	   ε458nm	   =	  11,330	  M-­‐1cm-­‐1.	  The	  purified	  enzyme	  was	  stable	  in	  PBS	  buffer,	  could	  be	  stored	  indefinitely	  at	  -­‐80oC	  and	  did	  not	  exhibit	  diminished	  activity	  with	  thawing.	  Heterologous	  expression	  of	  renalase	   in	  E.	  coli	   resulted	   in	   significant	   inclusion	  body	  accumulation	  at	  all	   temperatures	  tested.	   Attempts	  were	  made	   to	   refold	   this	   peptide	   to	   form	   active	   renalase	   following	   the	  methods	  of	  Desir	  et	  al.	  2012.	  (36)	  The	  refolded	  peptide	  acquired	  FAD	  and	  was	  soluble	   to	  high	   concentration,	   but	   had	   a	   cofactor	   spectrum	   ostensibly	   unchanged	   from	   free	   FAD	  (Figure	  2.1).	  Moreover,	  the	  refolded	  material	  did	  not	  have	  the	  activity	  described	  hereafter	  and	  was	  deemed	  to	  be	  misfolded	  inactive	  protein.	  
	  	  
Figure	   2.1	   Flavin	   Spectra	   of	   Native	   and	   Refolded	   Renalase.	   Spectra	   shown	   are	   for	  heterologously	   expressed	   renalase	   from	   the	   soluble	   (solid	   line)	   and	   refolded	   from	   the	  insoluble	   or	   inclusion	   body	   (dashed	   line)	   fractions.	   The	   insoluble	   fraction	   was	   refolded	  using	  the	  methods	  of	  Desir	  et	  al.	  2012.(36)	  The	  extinction	  coefficients	  of	  both	  forms	  were	  determined	  as	  described	  in	  the	  methods	  section.	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Identification	  of	  a	  Renalase	  Substrate	  in	  NAD(P)H	  Stock	  Solutions:	  A	  substrate	  for	  renalase	  was	  detected	  whilst	  validating	  prior	  claims	  that	  β-­‐NAD(P)H	  can	  serve	  as	  a	  renalase	  reductant	  in	  the	  production	  of	  adrenochrome	  from	  epinephrine.	  (2)	  Figure	  2.2	  depicts	  quantitative	  evidence	  for	  a	  renalase	  substrate	  occurring	  as	  a	  1-­‐4%	  impurity	  in	  β-­‐NAD(P)H	  solutions.	  Figure	  2.2A	  shows	  that	  rapid	  fractional	  reduction	  of	  renalase	  occurs	  when	  the	  enzyme	  is	  mixed	  with	  relative	  high	  concentrations	  of	  NADPH	  under	  strict	  anaerobic	  conditions.	  The	  measured	  Δε458nm	  value	  (7945	  M-­‐1cm-­‐1)	  for	  reduction,	  obtained	  when	  the	  substrate	  contaminant	  was	  added	  in	  apparent	  excess	  (449	  µM	  NADPH	  reduction	  trace),	  permitted	  the	  concentration	  of	  the	  actual	  substrate	  at	  all	  limiting	  values	  to	  be	  calculated.	  When	  the	  concentration	  of	  fractionally	  reduced	  renalase	  was	  plotted	  against	  the	  NADPH	  stock	  concentrations	  a	  slope	  of	  1.3%	  was	  determined	  (Figure	  2.2B).	  In	  a	  separate	  experiment,	  high	  concentrations	  of	  NADPH	  were	  added	  to	  5	  µM	  renalase	  in	  a	  dioxygen	  electrode	  and	  the	  concentration	  of	  oxygen	  consumed	  was	  measured	  (Figure	  2.2C).	  The	  amplitude	  measured	  in	  this	  experiment	  indicated	  that	  the	  substrate	  contaminant	  was	  present	  to	  1.5%	  of	  the	  total	  NADPH	  concentration.	  Higher	  apparent	  substrate	  fractions	  (4-­‐5%)	  were	  observed	  with	  NADH	  stock	  solutions	  (Figure	  2.2D).	  When	  catalase	  was	  included	  in	  these	  assays	  close	  to	  one	  half	  of	  the	  dioxygen	  consumed	  by	  renalase	  was	  regained	  from	  the	  catalase	  disproportionation	  reaction	  indicating	  that	  hydrogen	  peroxide	  is	  a	  product	  of	  renalase	  activity.	  	  Collectively	  these	  data	  establish	  multiple	  characteristics	  of	  the	  renalase	  reaction.	  In	  regard	  to	  the	  contaminant	  substrate,	  the	  proportion	  in	  NAD(P)H	  solutions	  is	  small	  and	  can	  vary	  with	  the	  parent	  molecule	  suggesting	  degradation	  and/or	  equilibrium	  processes	  result	  in	  the	  substrate	  accumulation.	  The	  complete	  and	  monophasic	  reduction	  of	  the	  flavin	  cofactor	  in	  excess	  substrate	  under	  anaerobic	  conditions	  (Figure	  2.2A	  –	  449	  µM	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NADPH	  trace)	  suggests	  that	  one	  substrate	  molecule	  transfers	  two	  electrons	  to	  the	  flavin.	  The	  dioxygen	  electrode	  assays	  define	  that	  dioxygen	  is	  also	  a	  substrate	  for	  renalase	  with	  an	  observed	  rate	  of	  dioxygen	  consumption	  in	  solutions	  equilibrated	  with	  atmospheric	  dioxygen	  (~250	  µM)	  of	  ~0.5	  s-­‐1.	  The	  total	  dioxygen	  consumption	  also	  indicated	  that	  multiple	  (Figure	  2.2	  C&D)	  turnovers	  occurred	  in	  the	  presence	  of	  the	  substrate	  component	  of	  both	  NADPH	  and	  NADH	  solutions.	  	  That	  the	  reduction	  (Figure	  2.2A)	  and	  dioxygen	  uptake	  (Figure	  2.2C)	  experiments	  indicate	  a	  similar	  proportion	  of	  substrate	  in	  the	  NADPH	  stocks	  suggests	  that	  the	  stoichiometry	  of	  the	  reaction	  is	  1:1	  for	  dioxygen	  and	  the	  NADPH	  contaminant.	  Moreover,	  that	  we	  regain	  0.5	  equivalents	  of	  O2	  in	  the	  presence	  of	  renalase	  and	  catalase	  suggests	  that	  the	  product	  stoichiometry	  is	  also	  1:1;	  product:H2O2.	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Figure	   2.2.	   Evaluation	   of	   the	   Renalase	   Active	   Fraction	   in	   NAD(P)H	   Stock	   Solutions.	   A:	  Stopped-­‐flow	   traces	   of	   fractional	   reduction	   of	   renalase	   as	   observed	   at	   458	   nm.	  Renalase	  (4.0	  µM)	  was	  mixed	  under	  anaerobic	  conditions	  with	  varied	  concentrations	  of	  NADPH	  as	  shown.	  B:	  The	  fraction	  of	  NADPH	  consumed	  in	  the	  reduction	  in	  A	  based	  on	  the	  change	  in	  extinction	  coefficeint	  of	  the	  renalase	  flavin	  cofactor	  at	  458	  nm	  vs	  the	  stock	  concentration	  of	  NADPH.	  C:	  Demonstration	  of	  multiple	  turnovers	  with	  excess	  substrate.	  5	  µM	  renalase	  was	  added	  to	  PBS	  buffer	  in	  a	  dioxygen	  electrode	  and	  3	  mM	  of	  NADPH	  was	  added	  at	  the	  arrow.	  
D:	  Stoichiometry	  of	  the	  renalase	  reaction	  with	  respect	  to	  dioxygen.	   	  Renalase	  (1	  µM)	  was	  mixed	  with	  1	  mM	  NADH	  with	  and	  without	  1	  U	  of	  catalase.	  The	  traces	  shown	  in	  C	  and	  D	  are	  representative	  traces	  of	  typically	  3-­‐5	  replicates	  for	  each	  observation.	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HPLC	  product	  analysis	  was	  used	  to	  separate	  the	  components	  present	  in	  NADPH	  solutions	  and	  identify	  the	  substrate	  component	  (Figure	  2.3).	  HPLC	  chromatograms	  were	  collected	  at	  known	  maxima	  for	  NADPH	  and	  NADH	  (340,	  260	  nm).	  Chromatograms	  collected	  at	  340	  nm	  indicated	  respective	  ~1.5%	  and	  4%	  contaminants	  (by	  area)	  for	  NADPH	  and	  NADH	  solutions	  (Figure	  2.3A	  &	  B).	  This	  component	  was	  largely	  consumed	  when	  the	  sample	  was	  incubated	  with	  renalase	  for	  two	  minutes	  (Figure	  2.3A	  and	  B	  –	  red	  chromatograms)	  while	  the	  area	  of	  the	  major	  components	  (β-­‐NADPH	  and	  β-­‐NADH)	  remained	  unchanged.	  	  This	  indicated	  that	  the	  reactive	  component	  absorbed	  light	  at	  340	  nm	  and	  that	  this	  absorption	  was	  lost	  when	  reacted	  with	  renalase.	  An	  increase	  in	  absorption	  at	  260	  nm	  coinciding	  with	  a	  component	  already	  present	  in	  the	  NADH	  solution	  was	  observed	  in	  the	  sample	  to	  which	  renalase	  was	  added	  (Figure	  2.3A	  lower).	  Coinjection	  of	  15	  µM	  of	  β-­‐NAD+	  in	  the	  control	  sample	  identified	  the	  product	  of	  the	  renalase	  reaction	  as	  β-­‐NAD+	  and	  indicated	  that	  the	  substrate	  concentration	  in	  the	  unreacted	  sample	  was	  ~13	  µM	  (4.0%).	  For	  NADPH	  and	  NADH	  samples,	  the	  spectra	  of	  the	  substrate	  components	  (Figure	  2.3C)	  exhibited	  maxima	  at	  260	  and	  346	  nm	  suggesting	  that	  the	  nicotinamide	  and	  adenine	  bases	  are	  intact	  in	  the	  substrate	  molecule.	  The	  loss	  of	  the	  346	  nm	  absorption	  of	  the	  substrate	  component	  when	  reacted	  with	  renalase	  is	  consistent	  with	  the	  dihydropyridyl	  base	  transferring	  a	  hydride	  equivalent	  to	  enzyme	  cofactor.	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Figure	  2.3.	  HPLC	  Identification	  of	  α-­‐NAD(P)H	  as	  the	  Substrate	  for	  Renalase	  Occuring	  as	  a	  Contaminant	  of	  β-­‐NAD(P)H	  Solutions.	  A&B:	  Species	  were	  separated	  using	  a	  Xterra	  reverse	  phase	  C18	  column	  running	  isocratically	  in	  10	  mM	  sodium	  phosphate	  buffer,	  pH	  7.5.	  In	  each	  the	  blue	   line	   is	   the	   control	  β-­‐NAD(P)H	  stock	  while	   the	   chromatograms	  depicted	  as	   a	   red	  line	  were	  prepared	  identically	  to	  the	  control	  sample	  but	  were	  reacted	  with	  5	  µM	  renalase	  and	  then	  filtered	  to	  remove	  the	  enzyme.	  The	  chromatogram	  depicted	  with	  a	  green	  line	  in	  A	  is	   the	   same	   as	   the	   control	   sample	   but	   with	   15	   µM	   β-­‐NAD+	   added.	  A:	   Chromatographic	  separation	   of	   NADH	   solutions	   detected	   at	   340	   nm	   (upper)	   and	   260	   nm	   (lower-­‐7-­‐fold	  smaller	  scale)	  B:	  Chromatographic	  separation	  of	  NADPH	  solutions	  detected	  at	  340	  nm.	  C:	  Spectra	  of	  the	  renalase	  substrate	  species	  resolved	  in	  A&B.	  The	  spectrum	  represented	  with	  an	   unbroken	   line	   is	  β-­‐NADPH	   and	  was	   included	   for	   reference.	   The	   dotted	   line	   spectrum	  was	  of	  the	  substrate	  peak	  in	  A.	  The	  dashed	  line	  spectrum	  was	  of	  the	  substrate	  peak	  in	  B.	  	  Spectra	  were	  normalized	  at	  260	  nm	  for	  clarity.	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Red-­‐shifted	   nicotinamide	   spectra	   of	   the	   active	   components	   of	   NADPH	   and	   NADH	  solutions	   is	   characteristic	   of	  α-­‐NAD(P)H	  molecules.	   (309,	  311)	   In	   amongst	   the	  numerous	  decay	  paths	  possible	  for	  pyridine	  nucleotides	  are	  anomerization	  equilibria	  that	  bring	  about	  the	  accumulation	  of	  a	  small	  fraction	  of	  the	  α-­‐dihydronicotinamides	  in	  dissolved	  β-­‐NAD(P)H	  solutions	  (312)	  (Scheme	  2.1).	  Anomerization	   is	  only	  possible	   for	   the	  reduced	   form	  as	   the	  ribose	   ring-­‐open	   Schiff	   base	   intermediate	   can	   form	   only	   when	   electrons	   are	   delocalized	  from	   the	   electron-­‐replete	   dihydropyridyl	   ring;	   the	   oxidized	   forms	   are	   thus	  configurationally	   stable.	   Reduced	   nicotinamide	   nucleotides	   are	   one	   of	   the	   two	   naturally	  occurring	   nucleotides	   that	   exhibit	   anomerization	   in	   solution,	   the	   other	   being	  pseudouridine	  nucleotide.(313)	  The	  α/β	  equilibrium	  constants	   for	  NADPH	  and	  NADH	  are	  reported	  as	  0.015	  and	  0.11	  respectively	  (309),	  largely	  consistent	  with	  the	  ~1.5%	  and	  ~5%	  fractions	  observed	  for	  the	  experiments	  described	  above.	  	  NMR	   was	   used	   to	   confirm	   the	   product	   of	   the	   renalase	   reaction.	   The	   oxidized	  nicotinamide	  proton	  resonances	  of	  the	  α	  and	  β	   forms	  of	  NAD(P)	  are	  readily	  discerned	  by	  NMR.	   (300)	  With	   respect	   to	   β-­‐NAD(P),	   the	   resonances	   of	   protons	   of	   the	  α-­‐nicotinamide	  moiety	   move	   to	   higher	   field	   while	   the	   discriminating	   proton	   attached	   to	   the	   anomeric	  carbon	  of	  the	  nicotinamide	  ribose	  moves	  downfield.	  Figure	  4A	  depicts	  proton	  NMR	  spectra	  for	   the	   accumulation	   of	   β-­‐NADP+	   from	   a	   stock	   solution	   (40	   mM)	   of	   β-­‐NADPH	   in	   the	  presence	   of	   renalase	   (blue	   spectra).	   In	   such	   a	   reaction	   α-­‐NADPH	   is	   expected	   to	   be	  consumed	  by	  renalase	  as	  a	  burst	  of	  product	  formation	  before	  the	  reaction	  becomes	  limited	  by	  both	  available	  dioxygen	  and/or	  the	  rate	  of	  anomerization.	  What	  is	  observed	  is	  an	  ~200	  
µM	  burst	  in	  product	  accumulation	  that	  did	  not	  occur	  in	  the	  absence	  of	  renalase	  (Figure	  4B).	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That	  the	  observed	  product	  nicotinamide	  resonances	  are	  shifted	  upfield	  relative	  to	  those	  of	  
β-­‐NADP+	  alone	  (Figure	  4A	  green	  and	  blue	  spectra)	  indicates	  only	  the	  influence	  of	  the	  high	  concentration	   of	   β-­‐NADPH	   in	   these	   samples.	  When	   the	   proton	   resonances	   and	   coupling	  constants	  are	  compared	  to	  those	  of	  a	  control	  sample	  having	  the	  same	  ratio	  of	  β-­‐NADP+	  to	  β-­‐NADPH,	   the	  product	   and	   control	   spectra	   coincide	   (Figure	  2.4A	  orange	  and	  blue	   spectra),	  indicating	  that	  the	  product	  of	  the	  reaction	  is	  β-­‐NADP+.	  	  	  
	  	  
Figure	   2.4.	   Identification	   of	   β-­‐NAD(P)H	   as	   the	   Nicotinamide	   Product	   of	   the	   Renalase	  Reaction.	  A:	  300	  MHz	  1H	  NMR	  spectra.	  Blue	  spectra	  show	  the	  accumulation	  of	  resonances	  when	  10	  µM	  renalase	  was	  added	  to	  a	  freshly	  prepared	  solution	  of	  40	  mM	  β-­‐NADPH	  in	  10	  mM	   sodium	  phosphate	   buffered	   deuterium	   oxide,	   pH	   7.4.	   The	   upper	   spectra	   are	   control	  samples.	   For	   positional	   assignments	   the	   N	   designation	   refers	   to	   the	   nicotinamide	   base,	  while	  A	  references	  the	  adenine	  base.	  	  	  The	  green	  spectrum	  is	  that	  of	  1	  mM	  β-­‐NADP+	  and	  the	  orange	  spectrum	  is	  that	  of	  1	  mM	  β-­‐NADP+	  in	  the	  presence	  of	  40	  mM	  β-­‐NADPH	  (both	  control	  samples	   prepared	   in	   10	   mM	   sodium	   phosphate	   buffered	   deuterium	   oxide,	   pH	   7.4).	  	  Assignments	  of	  the	  shifts	  of	  the	  nicotinamide	  are	  shown	  to	  the	  right	  of	  the	  control	  spectra.	  	  	  
B:	  Relative	  accumulation	  of	  β-­‐NADP+	  in	  the	  presence	  and	  absence	  of	  renalase	  based	  on	  the	  integration	  of	  the	  N2	  proton	  and	  the	  known	  concentration	  of	  the	  β-­‐NADPH	  in	  the	  sample.	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Evaluation	  of	  Epinephrine	  as	  a	  Substrate	  for	  Renalase:	  The	  substrate	  for	  renalase	  has	  been	  the	  subject	  of	  some	  dispute	  since	  the	  discovery	  of	  the	  enzyme	  in	  2005.	  (48,	  51,	  59)	  Figure	  2.5	   summarizes	   the	   data	   obtained	   for	   three	   approaches	   used	   to	   assess	   the	   response	   of	  renalase	   to	   the	   presence	   of	   epinephrine.	   In	   Figure	   2.5A,	   non-­‐pseudo-­‐first	   order	   single	  turnover	   reactions	   of	   renalase	   with	   limiting	   α-­‐NADPH	   and	   atmospheric	   dioxygen	  (observed	  at	  458	  nm)	  indicated	  reduction	  and	  reoxidation	  of	  the	  flavin	  cofactor.	  Under	  the	  conditions	   used	   these	   data	   could	   be	   fit	   to	   three	   exponential	   phases	   without	   significant	  systematic	   error	   in	   the	   residuals	   (11.6	   s-­‐1,	   1.63	   s-­‐1,	   0.54	   s-­‐1).	   However,	   the	   number	   of	  phases,	   the	   values	   for	   rate	   constants	   and	   absorbance	   amplitudes	   are	   only	   apparent	  measures	  of	  the	  single	  turnover	  kinetics	  that	  provide	  a	  means	  to	  compare	  the	  data	  in	  the	  presence	   of	   and	   absence	   of	   epinephrine.	   	   It	   has	   been	   suggested	   that	   renalase	   obtains	  reducing	   equivalents	   from	   β-­‐NADPH	   and	   then	   catalyzes	   a	   net	   two-­‐electron	   oxidation	   of	  epinephrine	  to	  form	  adrenochrome,	  a	  process	  that	  would	  mobilize	  four	  electrons.	  (2)	  The	  addition	  of	  200	  µM	  epinephrine	  to	  single	  turnover	  reactions	  with	  α-­‐NADPH	  and	  dioxygen	  did	   not	   change	   the	   observed	   kinetics	   (11.0	   s-­‐1,	   1.82	   s-­‐1,	   0.66	   s-­‐1)	   indicating	   that	   no	   rate	  constant	   is	   significantly	  altered	  and	  no	  new	   intermediates	  accumulate	   in	   response	   to	   the	  catechol.	  It	  has	  been	  suggested	  that	  renalase	  is	  only	  activated	  in	  blood	  and	  is	  isolated	  as	  a	  relatively	   inactive	   pro-­‐renalase.	   (12)	   In	   order	   to	   assess	   if	   some	   additional	   soluble	  component	   of	   blood	   is	   required	   to	   activate	   renalase	   to	   consume	   epinephrine	   the	  experiment	  was	  repeated	  in	  50%	  fresh	  cell-­‐free	  human	  blood	  plasma.	  This	  condition	  also	  did	  not	  significantly	  alter	  the	  observed	  single	  turnover	  kinetics	  (12.1	  s-­‐1,	  1.90	  s-­‐1,	  0.64	  s-­‐1).	  The	  conclusion	  is	  that	  epinephrine	  is	  not	  catalytically	  consumed	  by	  renalase	  as	  isolated	  and	  that	  no	  soluble	  ligand	  in	  blood	  activates	  the	  enzyme	  to	  display	  this	  activity.	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Figure	   2.5.	   Evaluation	  of	  Epinephrine	  as	   a	   Substrate	   for	  Renalase.	  A:	   Single	  Turnover	  of	  renalase	  with	   limiting	  α-­‐NADPH.	  Traces	  were	  observed	  at	  458	  nm	  when	  5.7	  µM	  renalase	  was	  reacted	  with	  with	  ~6	  µM	  α-­‐NADPH	  at	  atmospheric	  concentrations	  of	  molecular	  oxygen	  (~250	  µM).	  Dashed	  red	  lines	  indicate	  fits	  to	  Equation	  1.	  B:	  Isothermal	  titration	  calorimetry	  of	   339	   µM	   renalase	   with	   21,	   2	   µL	   injections	   of	   1.84	   mM	   Epinephrine.	   C:	   The	   extent	   of	  spectrophometric	   perturbation	   of	   the	   flavin	   spectrum	   by	   epinephrine.	   C1:	   Black	   line	   -­‐	  flouresence	   emission	   spectrum	   of	   4	   µM	   renalase	   when	   excited	   at	   450	   nm.	   Red	   line	   -­‐	  flouresence	  emission	  spectrum	  of	  4	  µM	  renalase	  plus	  40	  µM	  Epinephrine	  when	  excited	  at	  450	   nm.	   C2:	   Absorption	   difference	   spectra.	   Black	   line	   –	   zero	   perturbation	   difference	  spectrum	  of	   20	   µM	   renalase.	   Red	   line	   –	   difference	   spectrum	   (sample-­‐control)	   for	   20	   µM	  renalase	  plus	  200	  µM	  epinephrine.	  	  	   	  To	   evaluate	   if	   renalase	   binds	   epinephrine,	   the	   enzyme	   was	   titrated	   with	  epinephrine	   in	   an	   isothermal	   titration	   calorimeter	   (Figure	   2.5,	   B).	   The	   data	   obtained	  suggest	   an	   exothermic	   binding	   event	   with	   a	   dissociation	   constant	   for	   the	  renalase•epinephrine	   complex	   of	   ~8	   µM.	   This	   complexation	   is	   either	   adventitious	   (and	  coincidental)	  or	   is	  a	  binding	  event	  whose	   link	  to	  physiology	  is	  yet	  to	  be	  established.	   	  The	  lack	  of	   influence	  of	  epinephrine	  on	   the	  observed	  kinetics	  of	   reduction	  and	  reoxidation	  of	  renalase	  by	  α-­‐NADPH	  implies	  that	  the	  binding	  of	  epinephrine	  does	  not	  occur	  in	  the	  active	  site	   of	   the	   enzyme.	   To	   test	   this	   hypothesis,	   spectrophotometric	   observations	   using	   the	  flavin	   absorption	   and	   emission	   spectra	   as	   sensitive	   measures	   of	   ligand	   proximity	   were	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undertaken	   (Figure	   2.5C).	   These	   experiments	   show	   no	   appreciable	   perturbation	   of	   the	  flavin	   environment	   in	   the	   presence	   of	   epinephrine	   concentrations	   at	   least	   4-­‐fold	   higher	  than	   the	  measured	   binding	   constant,	   suggesting	   that	   the	   binding	   site	   for	   epinephrine	   is	  distant	  from	  the	  active	  site.	  	   The	  accumulation	  of	  adrenochrome	   from	  epinephrine	  can	  be	  observed	  at	  480	  nm.	  (299)	  Our	   experiments	   indicated	   that	   the	   initial	   rate	  of	   oxidation	  of	   epinephrine	   to	   form	  adenochrome	  in	  atmospheric	  oxygen	  at	  25	  oC	  oxygen	  in	  PBS	  buffer	  was	  ostensibly	  zero	  for	  all	   concentrations	   tested.	  The	  addition	  of	   freshly	  dissolved	  β-­‐NADPH	  did	  not	  bring	  about	  adrenochrome	  formation	  nor	  did	  the	  addition	  of	  10	  µM	  renalase	  (data	  not	  shown).	  As	  such	  it	  was	   concluded	   that	   renalase	  does	  not	  utilize	  β-­‐NAD(P)H	   (or	  α-­‐NAD(P)H)	   to	   catalyze	   a	  reaction	  that	  forms	  adrenochrome.	  	  	  
Discussion	  	   Eight	   years	   after	   its	   initial	   discovery,	   we	   have	   identified	   an	   activity	   for	   human	  renalase	  as	  an	  α-­‐NAD(P)H	  oxidase/anomerase.	  This	  activity	  is	  the	  first	  demonstration	  of	  a	  potential	   physiological	   role	   for	   α-­‐NAD(P)H	   in	   mammals	   and	   the	   first	   example	   of	   a	  flavoprotein	   catalyzing	   an	   anomerization	   reaction.	   This	   discovery	   runs	   contrary	   to	   the	  persistent	   assertion	   that	   renalase	   catabolizes	   adrenergic	   catecholamines.	   Renalase	   has	  often	  been	  described	  as	  “MAO	  C”;	  the	  third	  monoamine	  oxidase	  (2,	  11,	  36)	  that	  oxidizes	  the	  catechol	  ring	  rather	  than	  the	  distal	  amine.	  We	  suggest	  that	  epinephrine	  and	  other	  catechols	  have	  most	  often	  been	  reported	  as	  the	  substrate	  for	  renalase	  as	  they	  exhibit	  instability	  at	  or	  above	   neutral	   pH	   values	   and	   form	   chromophoric	   products	   (aminochromes)	   that	  may	   be	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easily	   taken	   for	   slow	   catalytic	   activity.	   (2)	   Our	   data	   suggest	   that	   epinephrine	   has	   no	  influence	  on	  the	  activity	  of	  the	  enzyme.	  	  	   It	  may	  be	  possible	  to	  reconcile	  our	  observations	  with	  the	  majority	  of	  earlier	  reports	  of	   adrenochrome	   formation	   by	   renalase.	   In	   vitro	   catalytic	   adrenochrome	   production	   by	  renalase	   are	   solely	   for	   the	   refolded	   renalase	  peptide.	   (36)	   In	   our	  hands,	   this	   form	  of	   the	  protein	  exhibits	  none	  of	   the	  α-­‐NADPH	  oxidase/anomerase	  activity	  described	  herein.	   It	   is	  thus	   tentatively	   proposed	   that	   the	   refolded	   form	   may	   have	   a	   solvent	   exposed	   flavin	  isoalloxazine	  ring	  (Figure	  2.1)	  that	  due	  to	  the	  difference	  in	  reduction	  potentials	  (-­‐320	  vs	  -­‐207mV)	   will	   be	   reduced	   by	   NADPH	   in	   a	   slow	   steady-­‐state	   reaction	   that	   forms	   H2O2	  autocatalytically.	  This	  molecule	  will	  readily	  oxidize	  epinephrine	  to	  initially	  form	  a	  quinone	  species	   prior	   to	   nucleophilic	   attack	   by	   the	   distal	   amine	   of	   the	   side	   chain	   to	   yield	   the	  adenochrome	   product.	   The	   natively	   folded	   renalase	   enzyme	   does	   not	   promote	   this	  chemistry	   to	   any	   significant	   extent	   as	   it	   selects	   against	   binding	   of	   the	   β-­‐form	   from	   the	  NAD(P)H	  reductant	  pool	  (Figures	  2.1,	  2.2	  and	  2.3).	  Moreover,	  it	  may	  be	  possible	  to	  observe	  the	   accumulation	   of	   aminochromes	   with	   natively	   folded	   renalase	   in	   the	   presence	   of	  reduced	  nicotinamide	  dinucleotides	  when	  long	  incubations	  are	  employed	  as	  non-­‐enzymatic	  anomerization	  will	   form	  α-­‐NAD(P)H	  as	   a	  minor	   component	   resulting	   in	   the	   formation	  of	  product	  H2O2	  and	  hence	  promote	   the	  ensuing	  non-­‐enzymatic	  oxidation	  and	  cyclization	  of	  the	  catechol.	  	  	   From	   an	   experimental	   perspective	   α-­‐NAD(P)H	   molecules	   are	   highly	   elusive.	   The	  apparent	  rate	  constants	  to	  attain	  equilibrium	  from	  the	  α-­‐NAD(P)H	  anomer	  on	  the	  order	  of	  10-­‐5-­‐10-­‐6	  s-­‐1.	  (309)	  As	  such	  the	  concentration	  of	  pure	  α-­‐NADPH	  is	  altered	  within	  hours	  of	  a	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solution	   being	   prepared,	   to	   some	   extent	   undermining	   the	   systematic	   use	   of	   the	   pure	  substrate	   in	   activity	   assays.	   The	   use	   of	   the	   β-­‐anomer	   to	   obtain	   the	   α-­‐form	   requires	  prolonged	  incubation	  to	  reach	  anomer	  equilibrium	  and	  verification	  of	  the	  α-­‐fraction	  before	  use	  as	  a	  stock	  solution	  but	  has	  the	  advantage	  of	  supplying	  a	  constant	  α/β	  ratio	  throughout	  the	   period	   of	   observation.	  While	  α-­‐NAD(P)H	   will	   invariably	   be	   the	   minor	   component	   it	  must	  be	  assumed	  that	  renalase	  is	  highly	  discriminatory	  for	  the	  α-­‐anomer	  given	  that	  it	  was	  destined	  to	  function	  in	  an	  environment	  in	  which	  the	  β-­‐anomer	  is	  predominant.	  	   More	   evidence	   is	   needed	   to	   define	   the	   means	   by	   which	   the	   activity	   of	   renalase	  transmits	  a	  signal	  to	  the	  circulatory	  system	  to	  induce	  the	  reported	  vasodilation.	  However,	  this	   oxidase/anomerase	   activity	  may	   have	   a	   core	   physiological	   role	   that	   is	   separate	   and	  more	  pervasive	  than	  blood	  pressure	  modulation.	  The	  necessity	  for	  renalase	  to	  harbor	  two	  functionalities	  may	  arise	  from	  the	  fact	  that	  α-­‐NAD(P)+	  molecules	  are	  metabolically	  isolated.	  In	  Scheme	  2.2	  the	  α/β	  equilibria	  are	  depicted	  with	  the	  redox	  pathways	  for	  both	  anomers	  of	  NAD(P)H	  molecules.	  The	  inherently	  lower	  reduction	  potential	  of	  α-­‐NAD(P)	  molecules	  and	  the	   lack	   of	   participation	   in	   other	   metabolic	   pathways	   dictates	   that	   there	   would	   be	   an	  inexorable	   loss	  of	  nicotinamide	  dinucleotide	  cofactors	  as	  a-­‐NAD(P)+.	  Without	  considering	  other	  redox	  partners,	  the	  anomer	  equilibrium	  and	  redox	  potential	  difference	  would	  predict	  that	  ~50%	  of	  the	  β-­‐NAD(P)H	  would	  ultimately	  accumulate	  as	  α-­‐NAD(P)+.	  (300)	  If	  renalase	  were	   not	   to	   catalyze	   oxidation	   in	   addition	   to	   anomerization	   these	   molecules	   would	  accumulate	  and	  deplete	  both	  the	  total	  concentration	  of	  NAD(P)H	  molecules	  and	  the	  normal	  NAD(P)H/NAD(P)+	   ratio.	   The	   α-­‐NAD(P)H	   oxidation	   couples	   the	   reaction	   to	   dioxygen	  reduction	   providing	   a	   large	   driving	   force	   that	   in	   concert	  with	   the	   anomerization	   activity	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recycles	   α-­‐NAD(P)H	   molecules	   back	   to	   the	   β-­‐pool	   maintaining	   the	   α-­‐NAD(P)H	  concentration	  near	  zero.	  	  
	  
Scheme	  2.2.	  Initial	  proposed	  physiological	  function	  of	  renalase.	  	  This	   activity	   for	   renalase	   raises	   numerous	   chemical	   and	   physiological	   questions.	  From	  an	  enzyme	  chemistry	  perspective,	  hydride	  transfer	  to	  a	  flavin	  is	  not	  unusual,	  though	  the	   timing	  of	   this	  process	  with	  respect	   to	   the	  anomerization	  reaction	   is	  highly	   intriguing.	  While	   it	  may	  be	   reasonable	   to	   conclude	   that	   anomerization	  occurs	  after	   reduction	  of	   the	  FAD	  cofactor	  in	  order	  that	  the	  enzyme	  be	  selective	  for	  α-­‐NAD(P)H,	  this	  raises	  the	  question	  as	  to	  what	  redox	  state	  of	  renalase	  catalyzes	  the	  anomerization.	  That	  is,	  is	  α-­‐NAD(P)+	  (or	  β-­‐
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NAD(P)+)	   a	   substrate	   for	   the	   reduced	   or	   oxidized	   enzyme	   and	   if	   the	   reduced	   enzyme	  catalyzes	  anomerization	  of	   the	  oxidized	  nicotinamide	  dinucleotide	  how	   is	   the	   ribose	   ring	  cleaved	  if	  the	  otherwise	  requisite	  schiff	  base/ring	  open	  intermediate	  can	  no	  longer	  form?	  A	  hypothetical	   mechanism	   that	   circumvents	   these	   apparent	   conundrums	   is	   depicted	   in	  Scheme	   2.3.	   In	   this	   mechanism	   the	   oxidized	   enzyme	   is	   selective	   for	   the	   α-­‐NAD(P)H	  substrate	  and	  first	  promotes	  the	  formation	  of	  a	  ring	  open	  ribose/Schiff	  base	  intermediate.	  It	   is	   then	   this	   intermediate	   that	   reduces	   the	   flavin,	   concomitantly	   forming	   the	  β-­‐NAD(P)+	  product	  prior	  to	  reoxidation.	  	  
	  
Scheme	  2.3.	  Initial	  proposed	  mechanism	  of	  renalase	  	   	  This	   research	   does	   not	   address	   the	   manner	   in	   which	   this	   newly	   identified	   activity	   of	  renalase	  is	  imparted	  in	  vivo	  in	  regard	  to	  vasodilation.	  It	  may	  be	  ventured	  that	  the	  observed	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decrease	  in	  blood	  pressure	  and	  slowing	  of	  the	  heart	  rate	  is	  not	  a	  result	  of	  diminishment	  of	  either	   of	   the	   substrates	   or	   the	   accumulation	   of	   the	   β-­‐NAD(P)+	   product	   as	   each	   of	   these	  molecules	   are	   ubiquitous	   in	   mammalian	   circulation.	   	   It	   therefore	   seems	   reasonable	   to	  implicate	  H2O2	  as	  the	  signal	  for	  vasodilation	  arising	  from	  renalase	  activity.	  (314-­‐316)	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CHAPTER	  III	  
Kinetics	  and	  Equilibria	  of	  the	  Reductive	  and	  Oxidative	  Half-­‐Reactions	  of	  Human	  
Renalase	  with	  α-­‐NADPH	  	   Brett	  A.	  Beaupre,	  Matthew	  R.	  Hoag,	  Brenton	  R.	  Carmichael	  and	  Graham	  R.	  Moran	  	  
Abstract	  Renalase	  is	  a	  recently	  discovered	  flavoprotein	  that	  has	  been	  reported	  to	  be	  hormone	  produced	  by	  the	  kidney	  to	  down-­‐modulate	  blood	  pressure	  and	  heart	  rate.	  The	  consensus	  belief	  has	  been	  that	  renalase	  oxidizes	  circulating	  catecholamine	  neurotransmitters	  thereby	  attenuating	  vascular	  tone.	  However,	  a	  convincing	  in	  vitro	  demonstration	  of	  this	  activity	  has	  not	   been	   made.	   We	   have	   recently	   discovered	   that	   renalase	   has	   α-­‐NAD(P)H	  oxidase/anomerase	   activity.	   Unlike	   most	   naturally	   occurring	   nucleotides,	   NAD(P)H	   can	  accumulate	  small	  amounts	  of	  the	  α-­‐anomers	  that	  once	  oxidized	  are	  configurationally	  stable	  and	  unable	  to	  participate	  in	  cellular	  activity.	  Thus	  anomerization	  of	  NAD(P)H	  would	  result	  in	  a	  continual	   loss	  of	  cellular	  redox	  currency.	  As	  such,	   it	  appears	  that	  the	  root	  purpose	  of	  renalase	  is	  to	  return	  α-­‐anomers	  of	  nicotinamide	  dinucleotides	  to	  the	  β-­‐anomer	  pool.	  In	  this	  article	   we	   measure	   the	   kinetics	   and	   equilibria	   of	   renalase	   in	   turnover	   with	   α-­‐NADPH.	  Renalase	   is	  selective	   for	  the	  α-­‐anomer	  that	  binds	  with	  a	  dissociation	  constant	  of	  ~20	  ±	  3	  
µM.	  This	  association	  precedes	  monophasic	  two-­‐electron	  reduction	  of	  the	  FAD	  cofactor	  with	  a	   rate	   constant	   of	   40.2	   ±	   1.3	   s-­‐1.	   The	   reduced	   enzyme	   then	   delivers	   both	   electrons	   to	  dioxygen	   in	   a	   second	   order	   reaction	  with	   a	   rate	   constant	   of	   ~2900	  M-­‐1s-­‐1.	   Renalase	   has	  modest	   affinity	   for	   its	   β-­‐NADP+	   product	   (Kd	   =	   2.2	   mM),	   and	   the	   FAD	   cofactor	   has	   a	  reduction	   potential	   of	   -­‐155	  mV	   that	   is	   unaltered	   by	   saturating	  β-­‐NADP+.	   Together	   these	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data	  suggest	   that	   the	  products	  are	   formed	  and	  released	   in	  a	  kinetically	  ordered	  sequence	  (β-­‐NADP+	   then	   H2O2),	   however,	   the	   reoxidation	   of	   renalase	   is	   not	   contingent	   on	   the	  dissociation	  of	  β-­‐NADP+.	  Neither	   the	  oxidized	  nor	   the	  reduced	   form	  of	  renalase	   is	  able	   to	  catalyze	   anomerization,	   implying	   that	   the	   redox	   and	   anomerization	   chemistries	   are	  inextricably	  linked	  through	  a	  common	  intermediate.	  	  
Introduction	  Reported	   initially	   in	   2005,	   renalase	   was	   said	   to	   be	   a	   new	   renal	   hormone	   that	   is	  secreted	  into	  blood	  by	  the	  kidney	  to	  induce	  lower	  blood	  pressures	  and	  slowed	  heart	  rate.	  (1,	  317)	   In	   subsequent	   studies	   it	   has	   been	   reported	   that	  mice	   deficient	   in	   renalase	   have	  elevated	  blood	  pressures	  and	  that	  renalase	  polymorphisms	  result	  in	  a	  higher	  incidence	  of	  stroke	  and	  diabetes.	  (10,	  296,	  297)	  The	  consensus	  belief	  has	  been	  that	  renalase	  imparts	  its	  physiological	   response	   by	   catabolizing	   circulating	   catecholamine	   neurotransmitters	  (chiefly	  adrenaline)	  thereby	  attenuating	  vascular	  tone.	  (1,	  4,	  36)	  The	  expression	  of	  renalase	  has	  been	  reported	  in	  additional	  tissues	  (1,	  12,	  301)	  with	  at	  least	  four	  variants	  arising	  from	  altered	  splicing	  of	  seven	  exons.	  (12,	  301)	  The	  X-­‐ray	  structure	  of	  the	  longest	  variant,	  isoform	  1,	  (342	  amino	  acids)	  was	  published	  in	  2011,	  revealing	  a	  protein	  whose	  structural	  topology	  was	   similar	   to	   known	   flavoprotein	   oxidases,	   monooxygenases	   and	   demethylases,	   but	  whose	  activity	  could	  not	  be	  readily	  discerned	  from	  conserved	  active	  site	  residues.	  (51,	  60,	  
302-­‐305)	  Given	  the	  similarity	  of	  the	  structural	  fold	  of	  renalase	  to	  monoamine	  oxidases	  A	  &	  B,	   catabolism	   of	   catecholamines	   would	   appear	   to	   be	   a	   reasonable,	   albeit	   contextual,	  function	   for	   renalase.	   However,	   there	   has	   been	   considerable	   difficulty	   establishing	   this	  activity	   in	  vitro,	  leading	   to	   the	  assertion	   that	  renalase	  as	   isolated	   is	   “prorenalase”;	  a	   form	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that	   must	   be	   activated	   in	   blood	   by	   catecholamines	   or	   other	   modifiers.	   (11)	   Slow	  accumulations	  of	  adrenochrome	  in	  the	  presence	  of	  renalase,	  epinephrine	  and	  NADPH	  have	  been	  offered	  as	  evidence	   that	   renalase	  catalyzes	   the	  oxidation	  of	   the	  catecholamines	  and	  promotes	  nucleophilic	  attack	  by	  the	  side-­‐chain	  distal	  amine.	  (2)	  The	  difficulty	  is	  that	  this	  is	  a	   facile,	   well-­‐established	   degradative	   reaction	   for	   catecholamines	   that	   exhibits	  measureable	  rates	  under	  mildly	  oxidizing	  conditions	  in	  the	  absence	  of	  an	  enzyme	  catalyst.	  (298,	  299,	  318)	  Moreover,	  the	  stoichiometry	  of	  such	  a	  reaction	  in	  regard	  to	  the	  fate	  of	  the	  mobilized	   electrons	   has	   not	   been	   established.	   (2)	   As	   such,	   the	   claim	   that	   renalase	  catabolizes	   circulating	   catecholamines	   has	   been	   questioned	   by	   a	   number	   of	   researchers.	  (48,	  51,	  59)	  
	  
Scheme	  3.1.	  Initial	  proposed	  activity	  of	  renalase.	  	  We	   have	   recently	   discovered	   an	   activity	   for	   renalase	   as	   a	   bifunctional	   α-­‐NAD(P)H	  oxidase/anomerase.	   (319)	   Renalase	   oxidizes	   the	   dihydropyridyl	   ring	   of	   α-­‐pyridine	  nucleotides,	   that	   aris	   naturally	   as	   a	   small	   equilibrium	   component	   of	   NAD(P)H	   solutions,	  and	   manages	   to	   also	   epimerize	   the	   nicotinamide	   ribose	   to	   form	   β-­‐NAD(P)+	   products	  (Scheme	  3.1).	   Importantly,	  renalase	  does	  this	  chemistry	  at	   least	   two	  orders	  of	  magnitude	  more	  rapidly	   than	  any	  reported	   turnover	  rate	   for	  catecholamine	  oxidation.	  The	  electrons	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acquired	   from	   the	   α-­‐NAD(P)H	   substrate	   are	   initially	   transferred	   to	   the	   enzyme’s	   FAD	  cofactor	  and	  then	  to	  dioxygen	  to	  yield	  hydrogen	  peroxide.	  How	  and	  if	  this	  activity	  is	  linked	  to	   the	   reported	   physiological	   response	   to	   renalase	   has	   not	   been	   addressed,	   but	   the	   only	  known	  vasoactive	  molecule	  to	  be	  consumed	  or	  arise	   from	  this	  activity	   is	  H2O2.	  (315,	  316)	  Coupling	  NAD(P)H	  oxidation	  to	  α-­‐β	  anomerization	  and	  dioxygen	  reduction	  provides	  a	  large	  driving	  force	  for	  this	  chemistry	  and	  suggests	  the	  more	  pervasive	  physiological	  function	  for	  renalase	  is	  to	  drive	  the	  α/β	  NAD(P)	  ratio	  to	  zero.	   In	  this	  article	  we	  offer	  evidence	  for	  the	  kinetics	   and	   equillibria	   of	   the	   reductive	   and	   oxidative	   half	   reactions	   of	   human	   renalase	  reacting	  with	  α-­‐NADPH.	  	  
Materials	  and	  Methods	  
Materials:	   Potassium	   phosphate,	   isopropyl-­‐β-­‐thiogalactopyranoside	   (IPTG)	   and	   sodium	  chloride	  were	  obtained	  from	  ACROS.	  Luria	  Bertani	  broth	  (Lennox)	  powder	  was	  from	  Fisher	  Scientific.	  Kanamycin	  and	  β-­‐NADPH	  were	  purchased	  from	  Alexis.	  β-­‐NADP+	  was	  purchased	  from	  Calbiochem	  and	  Axxora.	  β-­‐NADH,	  β-­‐NAD+,	  xanthine,	  methyl	  viologen	  and	  epinephrine	  were	   from	   Sigma-­‐Aldrich.	   Indigo	   carmine	  was	   from	   ICN.	   Xanthine	   oxidase	  was	   acquired	  from	  Calzyme.	  Renalase	  was	  expressed	  and	  purified	  according	  to	  our	  previously	  published	  methods.	  (319)	  α-­‐NADPH	  was	  from	  the	  α/β-­‐NAD(P)H	  equilibrium	  mixture	  (reliably	  1.5%	  (NADPH)	   and	   4%	   (NADH)	   alpha	   anomers	   at	   equilibrium).	   Anomer	   equilibrium	   was	  achieved	   by	   dissolving	  β-­‐NADPH	   in	   PBS	   or	   HEPES	   pH	   7.5	   and	   placing	   this	   solution	   in	   a	  sealed	   vessel	   at	   4oC	   for	  ~72	   hours.	   (309)	   Prior	   to	   using	   stock	   solutions,	   the	  α-­‐NAD(P)H	  concentration	  was	  determined	  by	  dioxygen	  electrode.	  Typically	  1-­‐2	  µM	  renalase	  was	  added	  
	  	  	   95	  
to	   1-­‐3	   mM	   of	   the	   NAD(P)H	   solution	   in	   PBS	   buffer	   at	   25	   oC.	   The	   observed	   amplitude	   of	  dioxygen	  consumption	  was	  used	  to	  define	  the	  fraction	  of	  the	  α-­‐NAD(P)H	  component.	  
	  
Quantitation:	  The	  concentration	  of	  NADPH	  and	  NADH	  solutions	  were	  determined	  using	  the	  published	  340	  nm	  extinction	  coefficient	  of	  6200	  M-­‐1cm-­‐1.	  (309)	  An	  extinction	  coefficient	  for	  renalase	  was	  determined	  in	  prior	  work	  (ε458nm	  =11,330	  M-­‐1cm-­‐1).	  (319)	  NADP+	  and	  NAD+	  solutions	  were	  quantified	  using	  published	  260	  nm	  extinction	  coefficients.	  (311)	  	  
	  
Reduction	   Potentials	   Measurements	   and	   β-­‐NADP+	   Binding	   Affinity.	   Reduction	   potentials	  were	  measured	  for	  unliganded	  oxidized	  renalase	  and	  the	  Renox•β-­‐NADP+	  complex	  using	  the	  xanthine/	   xanthine	   oxidase	   reduction	   system	   of	   Massey.	   (320)	   A	   Hewlett	   Packard	   8453	  diode-­‐array	   spectrophotometer	  was	   used	   to	  monitor	   the	   reduction	   of	   the	   enzyme	   in	   the	  presence	   of	   indigo	   carmine	   (Eo	   =	   -­‐130	   mV).	   The	   reaction	   mixture	   was	   placed	   in	   an	  anaerobic	  cuvette	  and	  consisted	  of	  300	  µM	  xanthine,	  5	  µM	  methyl	  viologen,	  10	  µM	  of	  indigo	  carmine,	  10	  µM	  renalase	  (with	  or	  without	  30	  mM	  β-­‐NADP+)	  in	  PBS	  buffer	  pH	  7.5	  at	  25°	  C.	  Once	   the	   mixture	   was	   made	   anaerobic	   by	   45	   cycles	   of	   argon	   and	   vacuum	   (as	   above),	  xanthine	  oxidase	  (1-­‐2	  µM	  final)	  was	  added	  from	  a	  side	  arm	  to	  initiate	  the	  reduction	  of	  both	  the	   enzyme	   and	   dye.	   Spectra	  were	   recorded	   every	   two	  minutes	   until	   both	   species	  were	  fully	   reduced.	   The	   data	   were	   analyzed	   at	   wavelengths	   where	   the	   dye	   (610	   nm)	   or	   the	  enzyme	   (470	   nm)	   had	   absorption	   contributions	   that	   were	   spectrophotometrically	  independent	  of	  the	  other	  chromophore.	  At	  each	  of	  these	  wavelengths	  the	  ratio	  of	  oxidized	  and	   reduced	   species	   was	   determined.	   The	   log	   of	   the	   ratio	   of	   the	   oxidized	   and	   reduced	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forms	  of	  indigo	  carmine	  was	  then	  plotted	  against	  the	  log	  of	  the	  same	  ratio	  for	  renalase	  and	  the	   indigo	  carmine	  midpoint	  was	  substituted	   into	  the	  pH-­‐corrected	  Nernst	  equation(321)	  to	  obtain	  the	  reduction	  potential	  for	  the	  renalase	  flavin	  cofactor.	  	   The	   dissociation	   constant	   for	   the	   Renox•β-­‐NADP+	   complex	   was	   measured	   by	  monitoring	   the	   spectrophotometric	   perturbation	   of	   the	   flavin	   cofactor	   between	   400	   and	  600	  nm	  when	  β-­‐NADP+	  was	  titrated	  to	  the	  oxidized	  enzyme.	  Renalase	  (20	  µM)	  in	  PBS	  buffer	  at	   25oC	  was	   titrated	  with	   β-­‐NADP+	   (0-­‐8	  mM).	  With	   each	   addition	   of	   β-­‐NADP+	   the	   flavin	  absorption	   spectrum	   was	   measured.	   All	   spectra	   were	   corrected	   for	   dilution	   and	   the	  fractional	   occupancy	   assessed	   by	   the	   fraction	   of	   the	   extrapolated	   total	   perturbation	  observed	   at	   each	   β-­‐NADP+	   concentration.	   This	   value	   was	   then	   used	   to	   obtain	   the	  concentration	  of	  unbound	  ligand.	  Plotting	  fractional	  occupancy	  versus	  unbound	  ligand	  gave	  a	   hyperbola	   that	   was	   fit	   to	   Equation	   3.1,	   where	   f	   is	   fractional	   occupancy,	   Kβ-­‐NADP+	   is	   the	  dissociation	  constant	  for	  the	  Renox•β-­‐NADP+	  complex	  and	  [β-­‐NADP+f]	   is	  the	  concentration	  of	  unbound	  β-­‐NADP+.	  	  Equation	  3.1	  	   	   f	  =	  [β-­‐NADP+f]/(	  Kβ-­‐NADP+	  +	  [β-­‐NADP+f])	  
	  
Reductive	   Half-­‐Reaction:	   The	   reduction	   of	   the	   renalase	   flavin	   cofactor	   was	   observed	   by	  mixing	  the	  anaerobic	  enzyme	  with	  anaerobic	  NADPH	  solutions	  at	  anomer	  equilibrium	  on	  a	  stopped	   flow	   spectrophotometer.	   Prior	   to	   the	   experiment	   the	   instrument	   was	   made	  anaerobic	  by	  introducing	  a	  solution	  of	  glucose	  (20	  mM)	  and	  glucose	  oxidase	  (15.5	  U/mL)	  for	   approximately	   16	   hrs.	   Renalase	   (4	  µM)	   in	   PBS	   buffer	  with	   1	  mM	   glucose	  was	  made	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anaerobic	  by	  placing	   it	   in	   a	   tonometer	   and	  exchanging	   the	  dissolved	  dioxygen	   for	   argon.	  Prior	   to	   sealing	   the	   vessel,	   ~16	   U	   of	   glucose	   oxidase	   was	   added	   to	   the	   side	   arm	   of	   the	  tonometer.	  The	  tonometer	  was	  then	  sealed	  and	  connected	  to	  an	  anaerobic	  manifold	  where	  45	   cycles	   of	   argon	   and	   mild	   vacuum	   were	   applied.	   Between	   each	   three	   exchanges,	   the	  solution	  was	  gently	  agitated	  to	  promote	  exchange	  of	  gases	  in	  the	  headspace	  of	  the	  vessel.	  After	   this	   procedure	   the	   renalase/glucose	   solution	   was	   mixed	   with	   the	   glucose	   oxidase	  from	   the	   sidearm	   and	   then	   mounted	   onto	   a	   Hi-­‐Tech	   (now	   TgK)	   DX-­‐2	   stopped-­‐flow	  spectrophotometer.	  This	  solution	  was	  then	  reacted	  with	  varied	  concentrations	  of	  α-­‐NADPH	  (~20-­‐300	  µM).	   Substrate	   solutions	  were	   prepared	   in	   PBS	  buffer	  with	   1	  mM	  glucose	   and	  sparged	   in	   an	   inverted	   glass	   syringe	   with	   purified	   Argon	   for	   10	   minutes	   before	   8	   U	   of	  glucose	  oxidase	  was	  added	  and	  the	  syringe	  was	  mounted	  to	  the	  stopped-­‐flow	  instrument.	  The	   two	   solutions	   were	   then	   mixed	   and	   the	   bleaching	   of	   the	   flavin	   cofactor	   during	  reduction	  was	  observed	  at	  458	  nm.	  The	  data	  obtained	  was	  fit	  to	  a	  single	  exponential	  decay	  according	  to	  Equation	  3.2,	  where	  kobs	  is	  the	  observed	  rate	  constant	  for	  reduction	  of	  the	  FAD	  cofactor,	  ΔA	  is	  the	  amplitude	  for	  the	  absorbance	  change	  and	  C	  is	  the	  Abs458nm	  endpoint.	  	  Equation	  3.2.	  	  	  	   A458nm	  =	  ΔA1e-­‐kobst	  +	  C	  	  	  The	   dependence	   of	   the	   observed	   rate	   constant	   was	   then	   plotted	   against	   α-­‐NADPH	  concentration	   and	   fit	   to	   Equation	   3.3	   to	   determine	   the	   limit	   of	   the	   rate	   constant	   of	  reduction	  (kred)	  and	  the	  dissociation	  constant	  for	  α-­‐NADPH	  (Kα-­‐NADPH).	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Equation	  3.3	  	   	   kobs	  =	  kred[α-­‐NADPH]/(Kα-­‐NADPH	  +	  [α-­‐NADPH])	  
	  In	  order	  to	  observe	  potential	  NADP/FAD	  charge-­‐transfer	  bands	  at	  longer	  wavelengths,	  the	  reductive	  process	  was	  also	  observed	  for	  20	  µM	  (final)	  renalase	  prepared	  in	  an	  equivalent	  manner	  and	  mixed	  with	  saturating	  α-­‐NADPH	  (328	  µM).	  	  
	  
Oxidative	   Half-­‐Reaction.	   The	   reoxidation	   of	   the	   renalase	   cofactor	   in	   the	   presence	   of	  dissolved	   dioxygen	   was	   observed	   in	   single	   turnover	   reactions	   by	   stopped-­‐flow	  spectrophotometry.	  Renalase	  (14	  µM)	  was	  prepared	  in	  tonometer	  in	  an	  equivalent	  manner	  to	  that	  described	  above.	  This	  solution	  was	  then	  mixed	  with	  α/β-­‐NADPH	  mixture	  of	  known	  ratio	   to	   supply	   sufficient	   α-­‐NADPH	   to	   achieve	   ~50%	   reduction.	   The	   dissolved	   oxygen	  concentration	  in	  this	  solution	  was	  defined	  by	  sparging	  an	  inverted	  syringe	  containing	  the	  
α/β-­‐NADPH	  mixture	  with	  blended	  nitrogen	  and	  oxygen	  gases	  of	  known	  partial	  pressures	  supplied	   by	   a	   Maxtec	   maxblend	   gas	   mixer.	   The	   concentration	   of	   dissolved	   oxygen	   was	  confirmed	  by	  first	  sparging	  the	  reaction	  chamber	  of	  a	  Hansatech	  dioxygen	  electrode	  filled	  with	  PBS	  buffer	  with	  the	  blended	  gases	  to	  define	  the	  equilibrium	  concentration	  of	  dissolved	  dioxygen.	   Once	   the	   molecular	   oxygen	   concentration	   was	   established,	   the	   gas	   blend	   was	  applied	   to	   the	   α/β-­‐NADPH	   mixture	   and	   sparged	   for	   10	   minutes	   before	   mounting	   the	  solution	  on	  the	  stopped-­‐flow	  instrument.	  The	  solutions	  were	  then	  mixed	  and	  the	  reduction	  and	   ensuing	   reoxidation	  were	   observed	   at	   458	   nm.	   The	   data	  were	   fit	   to	   Equation	   3.4	   in	  which	   kred	   is	   the	   apparent	   rate	   constant	   for	   reduction	   and	   kox	   is	   the	   rate	   constant	   for	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reoxidation,	  ΔA1	   and	  ΔA2	   are	   the	   amplitudes	   for	   the	   two	   phases,	   and	   C	   is	   the	   endpoint	  absorbance.	  	  	  Equation	  3.4.	  	  	   	  A458nm	  =	  ΔA1e-­‐kredt	  +	  ΔA2e-­‐koxt	  +	  C	  	  	  	   The	   influence	   of	   exogenous	  β-­‐NADP+	  on	   the	   kinetics	   of	   the	   oxidative	   half	   reaction	  was	  observed	  by	  reacting	  renalase	  (10	  µM)	  with	  excess	  α-­‐NADPH	  (20	  µM)	  in	  the	  presence	  of	  250	  µM	  dioxygen	  and	  varied	  β-­‐NADP+	  concentration	  (100-­‐1600	  µM).	  The	  reductive	  and	  oxidative	  processes	  were	  observed	  at	  458	  nm.	  	  
The	  Extent	  of	  Anomerization	  of	  an	  α/β-­‐NADP+	  Mixture	  by	  Renalase:	  The	  capacity	  of	  renalase	  to	   catalyze	   anomerization	   independent	   of	   FAD	   cofactor	   reduction	   by	   α-­‐NAD(P)H	   was	  assessed	   by	   incubation	   with	   an	   NADP+	   solution	   of	   known	   α/β	   ratio	   followed	   by	   high	  pressure	   liquid	  chromatography	  (HPLC).	   	  A	  1/2.66	  mixture	  of	  α/β-­‐NADP+	  (275	  µM	  total)	  was	  prepared	  by	  placing	  40	  mM	  β-­‐NADPH	  in	  a	  solution	  of	  10	  mM	  sodium	  phosphate	  pH	  7.4	  and	   allowing	   it	   to	   age	   at	   room	   temperature	   for	   14	   days.	   The	   inherently	   lower	   reduction	  potential	  of	  α-­‐NADP	  and	   the	  anomer	  bias	   for	   the	  β-­‐form	  ensures	   that	  similar	  amounts	  of	  the	  α	  and	  β	  NADP+	  anomers	  accumulate.	  (300)	  The	  oxidized	  forms	  were	  separated	  from	  the	  reduced	  and	  other	  contaminants	  by	   loading	   the	  aged	  sample	  onto	  a	  20	  cm	  x	  12.5	  mm	  Q-­‐sepharose	   column	   and	   eluting	  with	   a	   linear	   gradient	   of	   NaCl	   from	   0-­‐150	  mM.	   The	  α/β-­‐NADP+	  mixture	  was	  then	  diluted	  to	  75	  µM	  and	  50	  µL	  chromatographed	  using	  a	  4.6	  x	  150	  mm	  Xterra	  C18	  reverse	  phase	  column	  coupled	  to	  a	  Waters	  600	  E	  HPLC	  pump	  and	  a	  Waters	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2487	  dual	  wavelength	  detector.	  The	  α	  and	  β-­‐anomer	  mixture	  was	  then	  separated	  using	  an	  isocratic	  mobile	   phase	   of	   10	  mM	   sodium	  phosphate	   pH	  7.5.	   Renalase	   (5.6	  µM	   final)	  was	  then	  added	   to	   the	  α/β	  NADP+	   solution	  and	  50	  µL	  volumes	  were	  withdrawn	  periodically,	  filtered	  through	  a	  0.5	  mL	  Amicon	  10	  KDa	  centrifugal	  filter	  and	  chromatographed	  as	  above.	  	  	   The	  propensity	   of	   the	   reduced	   enzyme	   to	   catalyze	   anomerization	   of	  NAD(P)+	  was	  assessed	   using	   similar	   methods	   but	   with	   prior	   reduction	   of	   renalase.	   The	   enzyme	   was	  reduced	   using	   an	   adaptation	   of	   the	   methods	   used	   to	   reduce	   the	   chromophores	   in	   the	  reduction	  potential	  measurements	  described	  above.	  The	  reaction	  mixture	  was	  placed	  in	  an	  anaerobic	   cuvette	   and	   consisted	   of	   300	   µM	   xanthine,	   2	   µM	   methyl	   viologen,	   6.0	   µM	  renalase	   in	  PBS	  buffer	  pH	  7.5	  at	  25°	  C.	  The	  mixture	  was	  made	  anaerobic	  by	  45	  cycles	  of	  argon	  and	  vacuum	  (as	  above)	  and	  then	  xanthine	  oxidase	  (1-­‐2	  µM	  final)	  was	  added	  from	  a	  side	   arm	   to	   initiate	   the	   reduction	   of	   the	   enzyme.	   The	   extent	   of	   reduction	   was	   assessed	  spectrophotometrically	  using	  a	  Hewlett	  Packard	  8453	  spectrophotometer.	  75	  µM	  (final)	  of	  a	  1/2.66	  mixture	  of	  α/β-­‐NADP+	  was	  then	  added	  from	  a	  second	  sidearm	  and	  the	  sample	  was	  allowed	   to	   incubate	   for	  60	  minutes	  before	   removing	   the	  protein	   components	  by	   filtering	  through	   a	   10	   KDa	   nominal	   molecular	   weight	   centrifugal	   filter.	   The	   chromatograms	  obtained	   were	   then	   compared	   to	   two	   controls,	   the	   first	   that	   included	   all	   reaction	  components	  minus	  the	  mixture	  of	  α/β-­‐NADP+	  and	  the	  second	  that	  included	  only	  the	  α/β-­‐NADP+	  mixture.	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Results	  
Redox-­‐Linked	  Measurement	  of	  β-­‐NADP+	  Binding	  Affinities.	  The	  renalase	  reduction	  potential	  was	  determined	  using	  a	  spectrophotometric	  method	  that	  compares	  the	  extent	  of	  reduction	  of	   the	   enzyme	   relative	   to	   a	   dye	   of	   known	   potential	   when	   electrons	   are	   supplied	   from	  xanthine	   oxidase	   reacting	   with	   xanthine	   under	   anaerobic	   conditions.	   (320)	   In	   this	  experiment	  the	  dye	  serves	  a	  similar	   function	  to	  that	  of	  a	  reference	  electrode.	  Figure	  3.1A	  includes	   spectra	   obtained	   as	   renalase	   and	   indigo	   carmine	   are	   reduced	   by	   the	  xanthine/xanthine	  oxidase	  system.	  Figure	  3.1B	  shows	  the	  midpoint	  for	  the	  dye	  compared	  to	  extent	  of	  reduction	  of	  renalase.	  This	  plot	  allowed	  a	  reduction	  potential	  for	  renalase	  of	  -­‐155	   mV	   to	   be	   calculated.	   The	   experiment	   was	   repeated	   with	   saturating	   β-­‐NADP+	   (vide	  
infra)	  to	  obtain	  a	  reduction	  potential	  for	  the	  Renox•β-­‐NADP+	  complex	  of	  -­‐151	  mV.	  No	  flavin	  semiquinone	  is	  observed	  to	  accumulate	  during	  reduction	  suggesting	  that	  the	  second	  one-­‐electron	  potential	   is	  higher	   than	   the	   first.	  The	  reduction	  potential	   for	  α-­‐NAD(P)H	   is	   -­‐340	  mV	   (300)	   indicating	   that	   the	   redox	   driving	   force	   (excluding	   the	   contribution	   of	   anomer	  equilibria)	   for	   the	   reduction	  of	   the	   flavin	   is	   -­‐35.6	  kJ/mole.	  Coupling	   this	   the	   reduction	  of	  dioxygen	  yields	  -­‐122.5	  kJ/mole	  driving	  force	  for	  the	  complete	  catalytic	  cycle.	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Figure	  3.1.	  Redox	  States	  of	  Renalase.	  A:	  Simultaneous	  reduction	  of	  renalase	  (10	  µM)	  and	  indigo	   carmine	   (10	   µM)	   when	   reacted	   with	   150	   nM	   xanthine	   oxidase,	   5	   μM	   methyl	  viologen,	  300	  μM	  Xanthine	  in	  PBS	  buffer	  under	  anaerobic	  conditions.	  B:	  Analysis	  of	  the	  data	  in	  A.	   The	   extent	   reduced	   for	   the	   enzyme	   and	   the	   dye	  was	   assessed	  where	   neither	   had	   a	  changing	  contribution	  from	  the	  other;	  470	  nm	  for	  renalase	  and	  610	  nm	  for	  indigo	  carmine.	  The	  data	  for	  Renox	  are	  depicted	  in	  open	  circles	  and	  that	  for	  Renox•β-­‐NADP+	  are	  shown	  as	  filled	  circles.	  C:	  Measurement	  of	  the	  dissociation	  constant	  for	  the	  Renox•β-­‐NADP+	  complex.	  Renalase	  (20	  µM)	  was	  titrated	  with	  β-­‐NADP+	  and	  the	  perturbation	  of	   the	   flavin	  spectrum	  observed.	  Inset	  depicts	  the	  ~80%	  saturation	  difference	  spectrum.	  	  	  	   The	   dissociation	   constant	   for	   the	   renalase	   product	   complex	   (Renox•β-­‐NADP+)	  was	  measured	   using	   perturbation	   of	   the	   flavin	   absorption	   spectrum	   in	   the	   presence	   of	   the	  ligand	   (Figure	   3.1C).	   These	   data	   indicate	   a	   relatively	   weak	   complex	   with	   a	   dissociation	  constant	  of	  2.2	  mM	  and	  are	  consistent	  with	  the	  prior	  work	  of	  Milani	  et	  al.	  who	  measured	  a	  value	  of	  1.6	  mM	  under	  similar	  conditions.	   (60)	  The	  reduction	  potentials	  of	  Renox	  and	   the	  Renox•β-­‐NADP+	   complex	   and	   the	   dissociation	   constant	   for	   the	   Renox•β-­‐NADP+	   complex	  complete	   three	   sides	   of	   a	   thermodynamic	   box	   linking	   enzyme	   reduction	   and	   β-­‐NADP+	  complexation.	   The	   small	   difference	   in	   reduction	   potentials	   for	   Renox	   and	   Renox•βNADP+	  indicate	   that	   the	   dissociation	   constants	   of	   the	   oxidized	   or	   reduced	   renalase	   β-­‐NADP+	  complexes	  are	  similar	  (Scheme	  3.2).	  These	  data	  suggest	  that	  in	  the	  Renox•β-­‐NADP+	  complex	  
!1
0
1
!2 !1 0
log(ox)
/(red)/
renalas
e
log(ox)/(red)/IC
BRenox////////////////////////!155/mVRenox•β!NADP+///!151/mV
0
0.1
0.2
350 450 550 650
Abs
Wavlength/(nm)
A
0
0.2
0.4
0.6
0.8
0 2000 4000 6000 8000
Fractio
nal/Sat
uration
unbound/[β!NADP+]/µM
C Kβ!NADP+//2.2/±/0.1/mM
0200
400600
800
400 500 600
De/(M!1 c
m!1 )
Wavelength/(nm)
	  	  	   103	  
the	   nicotinamide	   ring	   and	   the	   isoalloxazine	   ring	   of	   the	   renalase	   FAD	   cofactor	   are	   not	   in	  sufficient	  proximity	  to	  influence	  the	  cofactor’s	  reduction	  potential.	  
\	  
Scheme	  3.2.	  Thermodynamic	  box	  linking	  renalase	  reduction	  and	  β-­‐NADP+	  complexation.	  	  	  
	  
Figure	   3.2.	   Reductive	   Half	   Reaction	   of	   Renalase.	  A:	   Initial	   (solid	   line)	   and	   final	   (dashed	  line)	  absorption	  spectra	  when	  328	  µM	  α-­‐NADPH	  was	  reacted	  with	  20	  µM	  renalase	  under	  anaerobic	   conditions.	   The	   dotted	   line	   spectrum	   is	   the	   spectrum	   of	   resting	   oxidized	  renalase.	  B:	  Absorbance	  traces	  at	  458	  nm	  and	  690	  nm	  when	  328	  µM	  α-­‐NADPH	  was	  reacted	  with	  20	  µM	  renalase	  under	  anaerobic	  conditions.	  The	  dashed	  line	  is	  the	  fit	  (red)	  to	  a	  single	  exponential	   phase	   (Equation	   3.2)	   with	   a	   rate	   constant	   of	   41	   s-­‐1.	   Upper	   trace	   is	   for	   the	  reaction	   of	   20	   µM	   renalase	   with	   200	   µM	   solution	   freshly	   dissolved	   β-­‐NADPH	   under	  anaerobic	   conditions.	   C:	   Dependence	   of	   the	   observed	   rate	   constant	   for	   reduction	   when	  when	   varied	   pseudo-­‐first	   order	   concentrations	   of	   α-­‐NADPH	   were	   reacted	   with	   2	   µM	  renalase	   under	   anaerobic	   conditions.	   The	   fit	   is	   to	   equation	   3.3	   and	   gave	   a	   limiting	   rate	  constant	  for	  reduction	  of	  40±1	  s-­‐1	  and	  a	  dissociation	  constant	  for	  α-­‐NADPH	  of	  19.8±2.6	  µM.	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Reductive	  Half-­‐Reaction:	  The	  reductive	  half	  reaction	  of	  renalase	  was	  observed	  independent	  of	   oxidative	   chemistry	   by	   combining	   the	   enzyme	  with	  α-­‐NADPH	   and	   excluding	   dioxygen	  (Figure	  3.2).	  The	  α-­‐NADPH	  substrate	  was	  supplied	  from	  a	  solution	  of	  NADPH	  at	  anomeric	  equilibrium	   (1.5%	   α-­‐anomer).	   Under	   these	   conditions	   the	   α-­‐NADPH	   substrate	   initiates	  reduction	   of	   the	   flavin	   observed	   as	   a	   decrease	   in	   the	   absorption	   transitions	   centered	  around	   458	   nm	   (Figure	   3.2A	   &	   B).	   Freshly	   dissolved	   β-­‐NADPH	   does	   not	   induce	   flavin	  reduction	  (Figure	  3.2B).	  The	  dependence	  of	  the	  observed	  rate	  constant	  for	  reduction	  of	  the	  renalase	   flavin	   cofactor	   on	   the	   α-­‐NADPH	   concentration	   could	   be	   fit	   to	   a	   rectangular	  hyperbola	   according	   to	   Equation	   3.2	   (Figure	   3.2C).	   This	   equation	   assumes	   rapid	  equilibrium	   binding	   that	   diminishes	   the	   observed	   rate	   constant	   of	   reduction	   at	  subsaturating	   substrate	   concentrations.	   (322)	  The	  asymptote	   is	   thus	   the	   limit	  of	   the	   rate	  constant	   for	   reduction	   (kred	   =	   40.2±1.3	   s-­‐1)	   and	   the	   concentration	   at	  which	   the	   observed	  rate	   constant	   for	   reduction	   is	  half	  maximal	   is	   the	  dissociation	   constant	   for	  α-­‐NADPH	  (Kα-­‐
NADPH	  =	  19.9±2.6	  µM).	  These	  experiments	  required	  the	  use	  of	  low	  renalase	  concentration	  (2	  µM)	   in	   order	   to	   be	   pseudo-­‐first	   order	   with	   a	   range	   of	   α-­‐NADPH	   concentrations	   that	  reasonably	  span	  the	  α-­‐NADPH	  binding	  isotherm	  according	  to	  the	  Kα-­‐NADPH	  value.	  A	  second	  experiment	  was	  also	  undertaken	  with	  relative	  high	  renalase	  concentration	  (20	  µM)	  and	  α-­‐NADPH	  (328	  µM)	  concentrations	  in	  order	  to	  observe	  potential	  charge-­‐transfer	  absorption	  transitions	   at	   longer	  wavelengths	   that	  would	   indicate	   proximity	   of	   the	   nicotinamide	   and	  FAD	   isoalloxazine	   rings	   (Figure	   3.2,	   A	   &	   B).	   (323,	   324)	   Figure	   3.2B	   includes	   a	   long	  wavelength	  trace	  that	   indicates	  no	  significant	  accumulation	  of	  charge-­‐transfer	   transitions	  before,	   during	   or	   after	   reduction.	   Figure	   3.2A	   includes	   deconvoluted	   component	   spectra	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obtained	   from	   single	   exponential	   fits	   to	   photo-­‐diode	   array	   data	   for	   the	   reductive	   half	  reaction.	  These	  spectra	  also	  show	  that	  no	  significant	  new	  absorbance	  transitions	  indicative	  of	   charge-­‐transfer	   absorption	   transitions	  were	   observed.	   It	   is	   therefore	   conceivable	   that	  neither	  α-­‐NAD(P)H	  nor	  β-­‐NAD(P)+	   nicotinamide	   rings	   stack	  with	   the	   flavin	   isoalloxazine	  ring	  (vide	  infra).	  The	  first	  spectrum	  acquired	  at	  1.54	  ms	  indicates	  that	  the	  flavin	  absorption	  transitions	   become	   resolved	   directly	   prior	   to	   reduction	   (Figure	   3.2A	   –	   solid	   line).	   This	  perturbation	  may	   arise	   either	   in	   the	   Renox•α-­‐NADPH	   complex	   or	   potentially	   in	   a	   ribose	  ring-­‐open	   iminium	   ion	   complex	   that	   forms	   rapidly	   prior	   to	   flavin	   reduction	   such	   as	  proposed	  in	  the	  hypothetical	  catalytic	  cycle	  depicted	  in	  Scheme	  3.3.	  	  
	  
Scheme	  3.3.	  The	  proposed	  catalytic	  cycle	  of	  renalase	  as	  and	  oxidase/anomerase.	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Oxidative	  Half-­‐Reaction.	  The	  oxidative	  half	  reaction	  of	  renalase	  is	  observed	  as	  a	  monophasic	  return	   to	   the	   oxidized	   state	   of	   the	   flavin	   cofactor.	   Figure	   3.3A	   summarizes	   the	   data	  obtained	   when	   renalase	   was	   reduced	   by	   limiting	   concentrations	   of	   α-­‐NADPH	   in	   the	  absence	  or	  presence	  of	  pseudo-­‐first	  order	   concentrations	  of	  dioxygen.	  The	   reductive	  and	  oxidative	  processes	  differ	  sufficiently	  to	  allow	  both	  phases	  to	  be	  observed.	  When	  dioxygen	  concentration	   was	   titrated	   in	   successive	   reactions	   the	   observed	   rate	   constant	   for	  reoxidation	  had	   a	   linear	  dependence	  on	   the	  molecular	   oxygen	   concentration	   that	   passed	  through	  the	  origin	  (Figure	  3.3B).	  This	  indicates	  that	  the	  reaction	  of	  reduced	  renalase	  with	  dioxygen	   is	   reliant	  on	  collision	  without	  prior	   complexation.	  The	  slope	  of	   the	  dependence	  indicated	  a	  rate	  constant	  of	  2.95	  x103	  ±	  70	  M-­‐1s-­‐1,	  a	  value	  similar	  to	  that	  of	  autooxidation	  of	  FAD	  in	  solution	  (325)	  suggesting	  that	  renalase	  does	  not	  promote	  the	  reaction	  of	  its	  cofactor	  with	  dioxygen	  and	  dictating	  that	  reoxidation	  will	  generally	  be	  the	  rate-­‐limiting	  process	   in	  
vitro	  under	  conditions	  of	  atmospheric	  dioxygen	  (~250	  µM).	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Figure	  3.3.	  Single	  Turnover	  of	  Renalase	  with	  Limiting	  α-­‐NADPH.	  A:	  Traces	  observed	  at	  458	  nm	  when	  14	  µM	  renalase	  was	  reacted	  with	  5.7	  µM	  α-­‐NADPH	  in	  varied	  pseudo-­‐first	  order	  concentrations	  of	  molecular	  oxygen.	  The	   traces	   shown	   in	  ascending	  order	  are	   for	  0,	  107,	  215,	  317,	  514	  µM	  dioxygen.	  Data	  obtained	  without	  dioxygen	  were	  fit	  to	  a	  single	  exponetial	  decay	  (Equation	  3.2)	  and	  data	  obatined	  with	  dioxygen	  were	  fit	  to	  two	  exponential	  phases	  (Equation	  3.4)	  (fits	  shown	  as	  dashed	  red	   lines).	   	  B:	  The	  dependence	  of	   the	  observed	  rate	  constant	  for	  reoxidation	  (k2)	  on	  the	  concentration	  of	  molecular	  oxygen	  fit	  to	  a	  straight	  line	  that	  passes	  through	  the	  origin.	  The	  slope	  of	  the	  line	  indicates	  a	  second	  order	  rate	  constant	  for	  the	  addition	  of	  dioxygen	  of	  2.9	  x	  103	  M-­‐1s-­‐1.	  C:	  Influence	  of	  β-­‐NADP+	  on	  Single	  Turnover	  Kinetics.	  Renalase	  (10	  µM)	  was	  mixed	  with	  α-­‐NADPH	  (20	  µM)	  and	  varied	  β-­‐NADP+	  (0-­‐1600	  µM)	   in	  the	  presence	  of	  250	  µM	  dioxygen.	  The	  traces	   in	  ascending	  order	  are	   for	  100,	  200,	  400,	  800,	  1600	  µM	  	  β-­‐NADP+.	  	  	  	  	   In	  order	  to	  evaluate	  the	  timing	  of	  the	  release	  of	  the	  β-­‐NAD(P)+	  product	  with	  respect	  to	  reoxidation	  of	  the	  flavin	  cofactor,	  exogenous	  β-­‐NAD(P)+	  was	  titrated	  in	  single	  turnover	  reactions	   (Figure	   3.3C).	   These	   data	   indicated	   that	   increasing	   concentrations	   of	   the	   β-­‐nicotinamide	   product	   had	   no	   influence	   on	   the	   observed	   rate	   constant	   for	   reoxidation	  suggesting	  that	  reoxidation	  is	  not	  contingent	  on	  the	  release	  of	  β-­‐NAD(P)+.	  Consistent	  with	  the	  observed	  complexation	  of	  β-­‐NADP+	  with	  the	  oxidized	  enzyme,	  our	  data	  show	  that	  this	  molecule	   is	   weakly	   competitive	   with	  α-­‐NADPH	   as	   the	   observed	   rate	   of	   reduction	   slows	  with	   increasing	  β-­‐NADP+	   concentration	   (observed	  as	   a	  decrease	   in	   the	   amplitude	   for	   the	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reductive	   phase).	   Therefore	   we	   conclude	   that	   dioxygen	   and	   the	   nicotinamide	   ring	   of	   β-­‐NAD(P)+	   do	   not	   compete	   for	   access	   to	   the	   reduced	   flavin	   cofactor	   during	   reoxidation.	  Overall	   the	   data	   are	   consistent	   with	   a	   kinetically	   ordered	   release	   of	   products	   with	   β-­‐NAD(P)+	   dissociating	   prior	   the	   reoxidation	   of	   the	   enzyme.	   Exogenous	   β-­‐NAD(P)+	   can	  populate	   the	  Renox•β-­‐NAD(P)+	   complex	   and	   hinder	  α-­‐NADPH	   association	   to	   the	   oxidized	  enzyme,	   however,	   the	   physiological	   relevance	   of	   this	   observation	   is	   negligible	   as	   the	  concentration	  of	  β-­‐NAD(P)+	  in	  the	  blood	  is	  low	  relative	  to	  its	  dissociation	  constant.	  (326)	  	  
Extent	   of	   Anomerization	   of	  α/β-­‐NADP+	   by	   Oxidized	   Renalase:	   The	   ability	   of	   oxidized	   and	  reduced	  renalase	  to	  catalyze	  non-­‐redox	  coupled	  anomerization	  was	  assessed	  by	  incubating	  oxidized	  or	  reduced	  renalase	  with	  an	  α/β-­‐NADP+	  mixture	  of	  known	  anomer	  ratio.	  The	  ratio	  of	  both	  anomers	  was	  remeasured	  after	   incubations	  with	  oxidized	  or	  reduced	  renalase	  for	  defined	  times	  over	  an	  hour.	  Figure	  3.4	  illustrates	  that	  for	  renalase	  in	  either	  oxidation	  state	  the	  ratio	  of	  α-­‐	  to	  β-­‐NADP+	  is	  unchanged.	  This	  establishes	  that	  anomerization	  does	  not	  occur	  before	  FAD	  cofactor	  reduction,	  while	  it	  is	  reduced	  or	  after	  its	  reoxidation	  and	  suggests	  that	  the	   oxidative	   and	   epimerization	   activities	   of	   renalase	   are	   mechanistically	   linked	   via	   a	  common	  intermediate.	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Figure	  3.4.	  Extent	  of	  Anomerization	  by	  Renalase	  in	  the	  Oxidized	  and	  Reduced	  States.	  Data	  depict	  the	  extent	  of	  anomerization	  of	  a	  75	  μM	  mixture	  of	  1/2.66	  α/β-­‐NADP+	  in	  the	  presence	  of	  5.6	  μM	  oxidized	  (black	  line)	  and	  6.0	  µM	  reduced	  (red	  line)	  renalase.	  The	  observed	  α/β	  NADP+	  ratio	  was	  based	  on	  HPLC	  peak	  area	  integration.	  The	  inset	  shows	  HPLC	  data	  for	  the	  oxidized	   enzyme	   experiment	   (four	   overlaid	   chromatograms	   are	   shown).	   Species	   were	  separated	  using	  a	  Xterra	  reerse	  phase	  C18	  column	  running	  isocratically	  in	  10	  mM	  sodium	  phosphate	  buffer,	  pH	  7.5.	  	  	  	  
Discussion	  
	   Renalase	  is	  a	  recently	  discovered	  flavoprotein	  that	  has	  been	  widely	  reported	  to	  be	  a	  kidney	   hormone	   whose	   endocrine	   function	   is	   to	   lower	   circulating	   concentrations	   of	  catecholamine	   neurotransmitters,	   such	   as	   epinephrine,	   thereby	   lowering	   blood	   pressure	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and	  heart	  rate.	  (1)	  Reported	  slow	  rates	  of	  turnover	  with	  catecholamine	  substrates	  in	  vitro	  do	  not	  address	  catalytic	  enhancements,	  nor	  do	  they	  offer	  a	  definitive	  demonstration	  of	  the	  products	   formed	   or	   the	   reaction	   stoichiometry(2,	   11).	   As	   such	   the	   claimed	   “monoamine	  oxidase	  C”	  activity	  of	  renalase	  continues	  to	  be	  challenged	  in	  the	  literature(48-­‐50,	  59).	  The	  identification	  of	  α-­‐NAD(P)H	  oxidase/anomerase	  activity	  for	  renalase	  calls	  for	  re-­‐evaluation	  of	  many	  of	  the	  reported	  physiological	  observations	  as	  the	  only	  known	  vasoactive	  molecule	  to	  be	  consumed	  or	  liberated	  by	  this	  activity	  is	  H2O2.	  (314-­‐316)	  However,	  the	  concentration	  of	  this	  product	  is	  contingent	  on	  the	  low	  equilibrium	  concentration	  of	  α-­‐NADPH	  that	  would	  be	  maintained	  near	  zero	  by	  renalase	  activity,	  meaning	  that	  the	  rate	  of	  H2O2	  production	  by	  renalase	  would	  be	  dependent	  on	  the	   in	  vivo	  β	   to	  α	  NAD(P)H	  anomerization	  rate	  constant	  (ca	  10-­‐6	  s-­‐1).	  (309)	  	  	   Reconciling	   each	   of	   the	   observations	   and	   conclusions	   made	   for	   renalase	   is	  complicated	   by	   the	   use	   of	   different	   preparations	   of	   the	   enzyme.	   Renalase	   was	   initially	  expressed	   as	   a	   recombinant	   glutathione	   synthase	   fusion	   and	   isolated	   using	   glutathione	  sepharose.	  (1)	  Later	  preparations	  were	  isolated	  from	  urine	  using	  an	  anti-­‐renalase	  affinity	  column.(1,	  11)	  More	  recent	  preparations	  have	  used	  heterologous	  expression	  in	  E.	  coli	  from	  a	   synthetic	   codon-­‐optimized	   renalase	   gene.	   Heterologous	   expression	   from	   the	   optimized	  gene	   yields	   a	   modest	   fraction	   of	   folded	   enzyme	   and	   a	   large	   fraction	   of	   inclusion	   body	  peptide.	   (36)	  The	   smaller,	   as	   expressed,	   soluble	   fraction	   can	  be	  purified	  by	   conventional	  methods	  (60,	  61,	  319)	  and	  was	  the	  form	  used	  to	  obtain	  the	  available	  X-­‐ray	  crystal	  structure	  (60).	  It	  is	  likely	  that	  this	  is	  the	  native	  form	  of	  renalase	  as	  it	  is	  this	  form	  that	  exhibits	  the	  α-­‐NAD(P)H	   oxidase/anomerase	   activity	   described	   herein.	   (319)	   The	   second	   reported	  
	  	  	   111	  
preparation	  method	  involves	  solubilizing	  inclusion	  body	  peptide	  and	  refolding	  by	  dilution	  and	   pH	   titration.	   (36)	   This	   form	   of	   renalase	   does	   not	   have	   the	   spectrophotometric	  properties	  of	  the	  soluble	  fraction	  and	  does	  not	  exhibit	  the	  α-­‐NAD(P)H	  oxidase/anomerase	  activity	  (319)	  but	  has	  been	  used	  in	  a	  number	  of	  physiological	  studies	  of	  renalase	  that	  report	  vasoactivity(2,	  36).	  	   We	   have	   completed	   a	   preliminary	   examination	   of	   the	   catalytic	   cycle	   of	   the,	   as	  expressed,	  soluble	  renalase	  reacting	  with	  α-­‐NADPH.	  We	  define	  substrate	  affinities,	  the	  rate	  constants	   for	   those	   steps	   that	   contribute	   to	   the	   turnover	   number	   and	   propose	   a	  hypothetical	   mechanism	   for	   the	   observed	   activity.	   Scheme	   3,3	   depicts	   an	   annotated	  chemical	  mechanism	   that	   accounts	   for	   each	   of	   the	   observations	  made	   in	   this	   study.	   The	  data	   suggest	   the	   redox	  and	  anomerization	  activities	  of	   renalase	  are	   coupled	  via	  a	   shared	  intermediate	  as	  neither	  the	  oxidized	  nor	  the	  reduced	  enzyme	  can	  catalyze	  anomerization	  of	  NADP+	  (Figure	  3.4).	  Catalysis	  commences	  with	  the	  association	  of	  α-­‐NAD(P)H	  to	  renalase	  to	  form	  the	  Renox•α-­‐NAD(P)H	  complex	  (Kd	  ~	  20	  µM).	  The	  lack	  of	  charge-­‐transfer	  absorbance	  transitions	   for	   this	   complex	   suggests	   that	   the	  nicotinamide	  base	  does	   not	   stack	  with	   the	  flavin	  isoalloxazine	  (Figure	  3.2).	  (327)	  It	  is	  proposed	  instead	  that	  rapid	  delocalization	  of	  the	  dihydropyridine	  lone	  pair	  and	  protonation	  of	  the	  bridging	  oxygen	  atom	  of	  the	  ribose	  ring	  forms	   a	   iminium	   ion	   intermediate.	   The	   iminium	   ion	   then	   recyclizes	   at	   the	   ribose,	  simultaneously	  causing	  the	  formation	  the	  β-­‐NAD(P)+	  product	  with	  concerted	  reduction	  of	  the	  flavin	  cofactor	  (kred	  ~40	  s-­‐1).	  Much	  like	  the	  Renox•α-­‐NAD(P)H	  complex,	  the	  nicotinamide	  ring	  of	   the	  Renred•β-­‐NAD(P)+	   complex	   is	   oriented	  with	   respect	   to	   the	   flavin	   isoalloxazine	  ring	  system	  such	  that	  it	  does	  not	  promote	  charge-­‐transfer	  transitions	  (Figure	  3.1C	  &	  Figure	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3.2B).	   In	   this	   position,	   the	   β-­‐nicotinamide	   of	   the	   product	   complex	   does	   not	   impede	   the	  reaction	   of	   the	   reduced	   flavin	  with	  dioxygen	   (kox	  ~2.9x103	  M-­‐1s-­‐1)	   so	   that	   the	  β-­‐NAD(P)+	  release	  and	  reoxidation	  steps	  occur	  independently	  (Figure	  3.3C).	  Further	  evidence	  for	  this	  is	   that	   the	   reduction	   potentials	   of	   the	   unliganded	   oxidized	   enzyme	   and	   the	   Renox•β-­‐NAD(P)+	  complex	  are	  ostensibly	  the	  same.	  This	  also	  indicates	  that	  the	  dissociation	  constant	  of	  the	  Renox•β-­‐NAD(P)+	  complex	  (Kd	  ~2.2	  mM)	  is	  similar	  to	  the	  Renred•β-­‐NAD(P)+	  complex	  (Figure	  3.1,	  Scheme	  3.2,	  Scheme	  3.3).	  In	  addition,	  the	  lack	  of	  influence	  of	  β-­‐NAD(P)+	  on	  the	  observed	  rate	  constant	  for	  reoxidation	  indicates	  that	  the	  rate	  constant	  for	  reoxidation	  (kox	  ~	   2.9	   x	   103	   M-­‐1s-­‐1)	   is	   the	   same	   for	   the	   unliganded	   reduced	   enzyme	   and	   the	   Renred•β-­‐NAD(P)+	  complex	  (Figure	  3.3C).	  A	  weak	  reassociation	  propensity	  of	  β-­‐NADP+	  with	  oxidized	  renalase	   forms	   a	   dead-­‐end	   complex	   that	   can	   retard	   binding	   of	  α-­‐NAD(P)H	   (Figure	   3.3C)	  suggesting	   that	   the	   nicotinamide	   substrate	   and	   product	   occupy	   the	   same	   or	   overlapping	  binding	  pockets.	  	   Renalase	  turnover	  has	  two	  rate	  contributing	  chemistries,	  two-­‐electron	  reduction	  of	  the	   flavin	   (~40	  s-­‐1)	  and	   its	   subsequent	   re-­‐oxidation	   (2.9	  x	  103	  M-­‐1s-­‐1).	  The	   latter	  of	   these	  will	   typically	   have	   the	   greatest	   contribution	   to	   the	   turnover	   number	   in	   vitro	   under	  conditions	  of	  atmospheric	  oxygen	  (~250	  µM	  O2).	  However,	   in	  blood	   the	  concentration	  of	  available	  α-­‐NAD(P)H	  will	  be	  negligible	  as	  a	  consequence	  of	  the	  large	  driving	  force	  for	  the	  renalase	  reaction	  (ΔG~120	  kJ/mol)	  (309),	  while	  dissolved	  dioxygen	  will	  be	  approximately	  constant	  at	  ~140	  µM.	  Under	  these	  conditions	  renalase	  activity	  will	  be	  primarily	  responsive	  to	  the	  α-­‐NAD(P)H	  concentration,	  consistent	  with	  a	  role	  for	  renalase	  of	  minimizing	  the	  α/β-­‐NAD(P)	  ratio.	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Figure	  3.5.	  Conservation	  Within	  the	  Renalase	  Active	  Site.	  Structure	  shown	  is	  for	  human	  renalase	  (PDB	  ID	  3QJ4).	  Sequence	  data	  are	  for	  the	  primary	  structures	  of	  renalase	  and	  unconfirmed	  renalase-­‐like	  proteins	  from	  a	  number	  of	  divergent	  phyla.	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Renalase	   is	   reported	   to	   be	   expressed	   in	   numerous	   tissues	   (1,	   301)	   and	   the	  conserved	  active	  site	  residue	  motif	  can	  be	  identified	  in	  homologous	  proteins	  from	  animals	  such	   as	   anemones,	   polycheates,	   daphnia	   and	   even	   single-­‐celled	   organisms	   such	   as	  cyanobacteria	  (Figure	  3.5).	  This	  implies	  that	  the	  root	  physiological	  role	  of	  renalase	  is	  more	  pervasive	   than	   vasodilation.	   The	   α-­‐NAD(P)H	   oxidase/anomerase	   activity	   of	   renalase	   is	  significantly	   exothermic	   which	   implies	   that	   the	   purpose	   of	   this	   activity	   is	   to	   use	   the	  considerable	  oxidative	  power	  of	  dioxygen	  to	  deplete	  the	  α-­‐NAD(P)H	  concentration.	  In	  the	  absence	  of	   renalase,	   the	   inherently	   lower	   reduction	  potential	   of	  α-­‐NAD(P)H	  molecules	   (-­‐340	  mV)	   dictates	   that	   they	   will	   tend	   to	   oxidize	   by	   reducing	   β-­‐NAD(P)+	   or	   other	   singlet	  molecules	   of	   higher	   potential	   and	   become	   isolated,	   unable	   to	   be	   reincorporated	   into	  metabolism.	   This	   would	   result	   in	   a	   steady	   but	   inexorable	   loss	   of	   function	   for	   a	   major	  fraction	   of	   available	   NAD(P)	   molecules.	   It	   is	   therefore	   reasonable	   to	   conclude	   that	   the	  renalase	  α-­‐NAD(P)H	  oxidase/anomerase	  activity	  is	  important	  to	  all	  metabolism	  in	  order	  to	  maintain	   the	   α/β-­‐NAD(P)H	   ratio	   at	   ostensibly	   zero	   such	   that	   the	   preponderance	   of	  nicotinamide	  dinucleotides	  remain	  available	  for	  redox	  cycling.	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CHAPTER	  IV	  
A	  Metabolic	  Function	  for	  Human	  Renalase:	  Oxidation	  of	  Isomeric	  Forms	  
of	  β-­‐NAD(P)H	  that	  are	  Inhibitory	  to	  Primary	  Metabolism.	  	  Brett	  A.	  Beaupre,	  Matt	  R.	  Hoag,	  Joseph	  Roman,	  F.	  Holger	  Försterling,	  Graham	  R.	  Moran	  	  
Abstract	  Renalase	   is	   a	   recently	   identified	   flavoprotein	   that	   has	   been	   associated	   with	   numerous	  physiological	   maladies.	   There	   remains	   a	   prevailing	   belief	   that	   renalase	   functions	   as	   a	  hormone,	   imparting	  an	   influence	  on	  vascular	   tone	  and	  heart	   rate	  by	  oxidizing	  circulating	  catecholamines,	   chiefly	   epinephrine.	   This	   activity	   however,	   has	   not	   been	   convincingly	  demonstrated	   in	   vitro,	   nor	   has	   the	   stoichiometry	   of	   this	   transformation	   been	   shown.	   In	  prior	   work	   we	   demonstrated	   that	   renalase	   induced	   rapid	   oxidation	   of	   low-­‐level	  contaminants	   of	   β-­‐NAD(P)H	   solutions.	   (54,	   319)	   Slow	   aqueous	   speciation	   of	   β-­‐NAD(P)H	  resulted	   in	   the	   production	   of	   renalase	   substrate	   molecules	   whose	   spectrophotometric	  characteristics	  and	  equilibrium	  fractional	  accumulation	  closely	  matched	  those	  reported	  for	  
α-­‐anomers	   of	   NAD(P)H.	   The	   fleeting	   nature	   of	   these	   substrates	   precluded	   structural	  assignment.	   Here	  we	   structurally	   assign	   and	   identify	   two	   substrates	   for	   renalase.	   These	  molecules	  are	  2-­‐,	  and	  6-­‐dihydroNAD(P),	  isomeric	  forms	  of	  β-­‐NAD(P)H	  that	  arise	  either	  by	  non-­‐specific	   reduction	   of	   β-­‐NAD(P)+	   or	   by	   tautomerization	   of	   β-­‐NAD(P)H	   (4-­‐dihydroNAD(P)).	  The	  pure	  preparations	  of	   these	  molecules	   induce	  rapid	  reduction	  of	   the	  renalase	  flavin	  cofactor	  (230	  s-­‐1	  for	  6-­‐dihydroNAD,	  850	  s-­‐1	  for	  2-­‐dihydroNAD)	  but	  bind	  only	  a	   few	   fold	   tighter	   than	  β-­‐NADH.	  We	   also	   show	   that	   2-­‐,	   and	   6-­‐dihydroNAD(P)	   are	   potent	  inhibitors	   of	   primary	   metabolism	   dehydrogenases	   and	   therefore	   conclude	   that	   the	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metabolic	   function	   of	   renalase	   is	   to	   oxidize	   these	   isomeric	   NAD(P)H	   molecules	   to	   β-­‐NAD(P)+,	  eliminating	  the	  threat	  they	  pose	  to	  normal	  respiratory	  activity.	  	  
Introduction	  
	   Renalase	   is	   a	   flavoprotein	   that	   has	   been	   proposed	   to	   be	   an	   enzyme/hormone	  produced	  by	  the	  human	  kidney	  to	  attenuate	  blood	  pressure	  and	  slow	  the	  heart	  (1).	  It	  has	  been	   asserted	   that	   this	   physiological	   response	   is	   achieved	   by	   catabolizing	   circulating	  catecholamines	   (11).	   However,	   this	   claimed	   activity	   has	   never	   been	   convincingly	  demonstrated	   and	   a	   number	   of	   factors	   portend	   a	   more	   prevalent	   metabolic	   role	   for	  renalase.	  The	  first	  is	  that	  renalase	  transcripts	  have	  been	  detected	  in	  numerous	  mammalian	  tissues	  (301,	  328).	  The	  second	  is	  that	  the	  X-­‐ray	  crystal	  structure	  of	  renalase	  has	  revealed	  a	  unique	   constellation	   of	   conserved	   residues	   about	   an	   active	   site	   flavin	   isoalloxazine	   ring	  that	   form	   a	   structural	   motif	   that	   is	   identifiable	   in	   homologs	   as	   far	   removed	   as	   the	  cyanobacteria	   (54,	  60).	   Despite	   numerous	   reports	   of	   physiological	   relevance,	   a	   definitive	  catalytic	   reaction	   for	   renalase	   has	   remained	   elusive	   (22-­‐25,	   51,	   329-­‐332).	   The	   most	  persistent	  claim	   is	   that	   renalase	  acts	  as	   the	   third	  monoamine	  oxidase	   (MAO	  C),	  oxidizing	  and	   cyclizing	   epinephrine	   and	   requiring	  NADH	   as	   a	   reductant	   to	   form	   the	   aminochrome	  molecule,	   adrenochrome	   (2,	   22).	   The	   reported	   rates	   for	   this	   conversion,	   however,	   are	  exceedingly	   slow	   and	   the	   apparent	   odd	   stoichiometry	   of	   this	   reaction,	   in	   which	   four	  electrons	  are	  mobilized,	  has	  not	  been	  established.	  	  	   In	  prior	  work,	  we	  identified	  fleeting	  minor	  contaminants	  of	  β-­‐NAD(P)H	  solutions	  as	  substrates	   for	   renalase.	  These	  molecules	   induced	   rapid	   reduction	  of	   the	  active	   site	   flavin	  that	   then	   reoxidized	  by	   reduction	  of	  dioxygen.	  Product	  analysis	   indicated	  β-­‐NAD(P)+	  and	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hydrogen	   peroxide	   as	   products	   in	   1:1:1:1	   stoichiometry	   leading	   to	   the	   conclusion	   that	  renalase	  is	  an	  oxidase.	  On	  the	  basis	  of	  both	  spectrophotometric	  characteristics	  and	  aqueous	  equilibrium	   proportions	  we	   erroneously	   proposed	   that	   the	   substrates	   for	   renalase	  were	  the	   α-­‐anomers	   of	   NAD(P)H	   (54,	   309,	   319,	   333)	   and	   that	   the	   function	   of	   renalase	   was	  therefore	   to	   oxidize	   and	   epimerize	   α-­‐NAD(P)H	   anomers	   to	   avoid	   an	   inexorable	   loss	   of	  cellular	   redox	   currency	   as	  α-­‐NAD(P)+	   (molecules	   that	   have	   no	   known	  metabolic	   role	   in	  mammalian	   metabolism).	   This	   proposed	   activity	   seemed	   to	   satisfy	   a	   long	   standing	  conundrum	   whereby	   despite	   reported	   lower	   reduction	   potentials	   for	   α-­‐anomers,	   α-­‐NAD(P)+	   molecules	   are	   not	   observed	   to	   accumulate	   to	   any	   significant	   level	   in	   normal	  metabolism	  (300).	  The	   purpose	   of	   this	   article	   is	   to	   correct	   the	   renalase	   literature,	   provide	   direct	  evidence	   for	   the	   structure	   of	   the	   renalase	   substrate(s)	  molecules	   described	   in	   our	   prior	  reports	  and	   link	  these	  molecules	  to	  an	  apparent	   important	  metabolic	  role	   for	   the	  activity	  observed.	   In	   this	   study	   we	   show	   that	   the	   substrate(s)	   for	   renalase	   are	   2-­‐dihyhdroNAD	  (2DHNAD(P))	   and	   6-­‐	   dihydroNAD	   (6DHNAD(P)),	   both	   of	  which	   are	   isomeric	   forms	   of	  β-­‐NAD(P)H	  where	   the	   hydride	   equivalent	   resides	   on	   either	   the	   2	   or	   the	   6	   position	   of	   the	  nicotinamide	   instead	   of	   the	   native	   4	   position.	   These	   molecules	   arise	   from	   non-­‐specific	  (non-­‐enzymatic)	   reduction	   of	   β-­‐NAD(P)+	   or	   tautomerization	   of	   β-­‐NAD(P)H	   and	   can	  multiple	   dehydrogenase	   enzymes	   of	   primary	   metabolic	   pathways.	   Renalase	   would	  therefore	   appear	   to	   alleviate	   this	   inhibition	  by	   oxidizing	  2DHNAD(P)	   and	  6DHNAD(P)	   to	  form	  β-­‐NAD(P)+	  (Scheme	  4.1).	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Scheme	  4.1.	  	  Catalysis	  of	  renalse	  using	  isomers	  of	  β-­‐NAD(P)H	  as	  substrates.	  
	  
Materials	  and	  Methods	  
Materials.	   β-­‐NADH	   (disodium	   salt,	   trihydrate)	   was	   obtained	   from	   Amresco.	   β-­‐NAD+,	  oxaloacetate,	  (±)-­‐α-­‐lipoamide	  and	  lactate	  dehydrogenase	  (LDH)	  (rabbit	  muscle)	  were	  each	  sourced	   from	   Sigma-­‐Aldrich.	   Sodium	   borohydride,	   potassium	   phosphate	   (mono	   and	  dibasic),	   β-­‐mercaptoethanol	   and	   pyruvate	   were	   from	   Acros.	   Deuterium	   oxide	   was	   from	  Cambridge	   Isotopes.	   Sep-­‐Pak	   cartridges	  were	  purchased	   from	  Waters.	   Competent	  NEB5a	  and	  BL21	  DE3	  Escherichia	  coli	  cells	  were	  obtained	  from	  New	  England	  Biolabs.	  Q-­‐sepharose	  was	  from	  Bio	  Rad.	  Lipoamide	  dehydrogenase	  (DLD)	  (porcine	  heart)	  was	  from	  Calzyme.	  	  Malate	  dehydrogenase	   (MDH)	  was	   cloned	   from	  E.	  coli.	   Genomic	  DNA	  was	   isolated	  from	  100	  mL	  of	  log-­‐phase	  cells	  (OD600nm	  ~0.5)	  using	  a	  Qiagen	  Genomic	  DNA	  preparation	  kit	  and	  protocol.	  The	  MDH	  gene	  was	  amplified	  using	  oligonucleotides	  complementary	  to	  the	  3’	  and	  5’	   ends	  of	   the	  gene	   that	   incorporated	  respective	  Nde	   I	  and	  Xho	   I	   restriction	  sites	   (5’	  ATTATTATTATTCATATGAAAGTCGCAGTCCTCGCGT	   3’,	   5’	   TTTTTTTTTTTTTTCTGGAG	  
TTATTACTTATTAACGAACTTCGCC	   3’;	   start	   and	   stop	   codons	   are	   depicted	   bolded	   and	  restriction	   sites	   underlined).	   The	   amplified	   gene	   was	   then	   digested	   with	   the	   above	   two	  restriction	  enzymes	  and	  ligated	  with	  pET17b	  plasmid	  that	  had	  been	  digested	  in	  the	  same	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way.	  The	  ligation	  was	  then	  transformed	  into	  competent	  NEB5a	  E.	  coli	  cells	  and	  plated	  onto	  Luria	   Bertani	   (LB)	   agar,	   100	   µg/mL	   ampicillin.	   Transformant	   cultures	   prepared	   from	  individual	  colonies	  were	  grown	  in	  LB	  broth,	  100	  µg/mL	  ampicillin	  and	  were	  screened	  for	  the	   correct	   plasmid	   insert	   by	   agarose	   gel	   electrophoresis.	   Plasmid	   DNA	   from	   each	  transformant	   was	   prepapred	   using	   the	   Qiagen	   Mini-­‐prep	   kit	   and	   protocol	   followed	   by	  digestion	  with	  Nde	   I	   and	   Xho	   I	   restriction	   enzymes.	   The	   plasmid	   from	   verified	   cell	   lines	  were	  then	  prepared	  in	  sufficient	  quantity	  for	  DNA	  sequencing	  using	  the	  Qiagen	  Midi-­‐prep	  kit	  and	  protocol.	  After	  sequence	  confirmation	  the	  plasmid,	  pECMDH,	  was	  then	  transformed	  into	   competent	   BL21(DE3)	   E.	   coli.	   A	   single	   colony	   was	   selected	   and	   grown	   in	   LB	   broth	  medium	  containing	  100	  µg/mL	  ampicillin.	  Cells	   from	  this	  culture	  were	  harvested	  in	  early	  log	  phase	  and	  mixed	  with	  0.22	  µm	  filter	  sterilized	  glycerol	  to	  a	  final	  concentration	  of	  20%	  v/v	  and	  stored	  as	  1	  mL	  aliquots	  at	  -­‐80	  oC.	  	  MDH	  was	  expressed	  and	  purified	  by	  thawing	  cell	  stocks	  and	  plating	  100	  µL	  per	  plate	  onto	  LB	  agar	  plates	  (100	  µg/mL	  ampicillin)	  and	  grown	  at	  37	  oC	  for	  16	  hrs.	  The	  lawn	  of	  cells	  from	  two	  plates	  was	  then	  resuspended	  into	  10	  mL	  of	  LB	  broth	  and	  used	  as	  an	  inoculum	  for	  1	   L	   LB	   broth	   culture	   (100	   µg/mL	   ampicillin)	   pre-­‐warmed	   to	   37	   oC.	   The	   cell	   culture	  was	  then	  shaken	  at	  220	  rpm	  and	  the	  temperature	  maintained	  at	  37	  oC.	  When	  the	  density	  of	  the	  culture	  reached	  OD600nm~1.0,	  0.1	  mM	  isopropyl-­‐b-­‐thiogalactopyranoside	  (IPTG)	  was	  added	  to	  induce	  over-­‐expression	  of	  the	  MDH	  protein.	  After	  two	  hours	  the	  culture	  was	  harvested	  by	  centrifugation	  at	  4000	  g	  in	  an	  RC-­‐3C	  Sorvall	  centrifuge	  and	  the	  cell	  pellet	  resuspended	  in	   20	  mL	   of	   ice-­‐cold	   20	  mM	  HEPES	   buffer,	   2	  mM	   β-­‐mercaptoethanol	   (βME),	   pH	   7.0.	   All	  subsequent	  methods	  maintained	  the	   temperature	  of	   the	  sample	  at	  4	   oC,	  unless	  otherwise	  noted.	   The	   cell	   slurry	   was	   then	   sonicated	   for	   a	   total	   of	   5	   minutes	   at	   20	   Watts	   using	   a	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Branson	  sonicator	  fit	  with	  a	  blunt	  tungsten	  tip.	  The	  resulting	  sonicate	  was	  then	  centrifuged	  at	  15,600	  g	  for	  30	  minutes	  using	  an	  Eppendorf	  5804R	  centrifuge.	  The	  supernatant	  was	  then	  brought	  to	  1.5%	  streptomycin	  over	  a	  period	  of	  20	  minutes	  and	  centrifuged	  at	  12,850	  g	  for	  10	   minutes.	   The	   supernatant	   obtained	   was	   decanted	   and	   brought	   to	   45%	   ammonium	  sulfate	  saturation	  over	  25	  minutes	  and	  centrifuged	  again	  at	  12,850	  g	   for	  10	  minutes.	  The	  supernatant	  was	  retained	  and	  brought	  to	  75%	  ammonium	  sulfate	  saturation	  over	  a	  period	  of	  25	  minutes	  and	  centrifuged	  at	  12,850	  g	   for	  10	  minutes.	  The	  pelleted	  protein	  was	   then	  redissolved	  in	  20	  mM	  HEPES,	  2	  mM	  bME,	  pH	  7.0	  (100	  mL	  per	  liter	  of	  culture)	  and	  loaded	  onto	  a	  2.5	  x	  ~25	  cm	  Q-­‐sepharose	  column	  at	  a	  flow	  rate	  of	  2	  mL/min.	  Pure	  MDH	  protein	  was	  then	  eluted	  using	  a	  linear	  gradient	  to	  200	  mM	  NaCl	  spanning	  a	  volume	  of	  400	  mL	  supplied	  from	   a	   Biorad	   Biologic	   LC	   chromatographic	   system.	   The	   MDH	   obtained	   was	   then	  concentrated	   using	   15	   mL	   Amicon,	   10	   kDa	   nominal	   molecular	   weight	   cutoff	   centrifugal	  concentrator	   and	   stored	   at	   -­‐80	   oC.	   The	   pure	   enzyme	  was	   quantified	   using	   the	   calculated	  extinction	  coefficient	  for	  280	  nm	  of	  6085	  M-­‐1cm-­‐1	  (334).	  	  	   The	  gene	   for	  Saccharomyces	  cerevisiae	  old	  yellow	  enzyme	  (OYE,	   isoform	  1)	  cloned	  into	  the	  Nde	  I	  and	  Xho	  I	  restriction	  sites	  of	  pET28a	  was	  obtained	  from	  Enzymax	  as	  an	  E.	  coli	  XL-­‐1	  blue	  transformant	  culture.	  Cloning	  into	  the	  Nde	  I	  restriction	  site	  fuses	  the	  OYE1	  gene	  to	   an	  N-­‐terminal	  His-­‐Tag.	  A	  50	  µL	   aliquot	   of	   these	   cells	  was	  used	   to	  make	   cell	   stocks	  by	  culturing	  in	  20	  mL	  of	  LB	  broth	  (25	  µg/mL	  kanamycin)	  incubated	  at	  37	  oC	  with	  shaking	  at	  220	   rpm	  for	   6	   hrs.	   Cells	   from	   this	   culture	  were	   stored	   in	   sterile	   20%	   glycerol	   at	   -­‐80	   oC.	  Plasmid	  (pSCOYE)	  was	  prepared	  from	  5	  mL	  cultures	  of	  these	  cells	  using	  the	  Qiagen	  mini-­‐prep	  kit	  and	  protocol	  and	  transformed	  into	  E.	  coli	  BL21(DE3)	  and	  prepared	  as	  cell	  stocks	  from	   a	   single	   colony	   as	   described	   above	   for	   pECMDH	   plasmid.	   OYE	   was	   expressed	   and	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purified	  by	  spread	  plating	  onto	  LB	  agar	  (25	  µg/mL	  kanamycin,	  100	  µL	  of	  cells	  per	  plate)	  and	  incubating	  at	  37	  oC	  for	  20	  hrs.	  The	  lawn	  of	  cells	   from	  two	  plates	  was	  resuspended	  in	  ~20	  mL	   of	   LB	   broth	   and	   used	   as	   an	   inoculum	   for	   a	   1	   L	   culture	   of	   LB	   both	   (25	   µg/mL	  kanamycin).	   Expression	   of	   the	   OYE	   protein	   and	   harvesting	   of	   the	   cells	   proceeded	   in	   an	  identical	  manner	  to	  that	  described	  above	  for	  E.	  coli	  MDH.	  	   To	  prepare	  pure	  OYE	  the	  harvested	  cells	  were	  resuspended	  20	  mL/L	  of	  culture,	  20	  mM	  HEPES	  pH	  7.5	  and	  sonicated	  for	  ~10	  min	  at	  20	  Watts.	  Thεe	  lysed	  cell	  slurry	  was	  then	  centrifuged	   at	   15,600	   g	   for	   30	  minutes	   and	   the	   supernatant	   (~25	  mL/L	   of	   culture)	  was	  then	  loaded	  onto	  a	  Talon	  cobalt	  affinity	  column	  at	  a	  flow	  rate	  of	  1	  mL/min	  and	  the	  column	  was	  washed	  with	  200	  mL	  50	  mM	  HEPES,	  10	  mM	  imidazole,	  pH	  7.5.	  OYE	  was	  then	  eluted	  with	  a	  400	  mL	  linear	  gradient	  to	  50	  mM	  HEPES,	  300	  mM	  imidazole,	  pH	  7.5	  using	  a	  Biorad	  Biologic	  liquid	  chromatography	  device.	  Fractions	  containing	  OYE	  activity	  were	  then	  pooled	  and	  the	  buffer	  exchanged	  to	  10	  mM	  potassium	  phosphate	  buffer,	  pH	  7.5	  using	  an	  Amicon	  15	  mL,	  10,000	  nominal	  molecular	  weight	  cutoff	  filter/concentrator.	  The	  pure	  OYE	  obtained	  was	  then	  aliquoted	  and	  stored	  at	   -­‐80	  oC.	  OYE	  was	  quantified	  using	  the	  461	  nm	  extinction	  coefficient	   of	   the	   flavin	   cofactor	   (10,400	   m-­‐1cm-­‐1)	   that	   was	   determined	   using	   an	   SDS	  denaturation	  method	  based	  on	  the	  extinction	  coefficient	  of	  free	  flavin	  (319).	  	  
Preparation,	   Separation	   and	   Analysis	   of	   2	   &	   6DHNAD.	   2-­‐	   &	   6DHNAD	   were	   prepared	   by	  reduction	  of	  β-­‐NAD+.	  The	  ratio	  of	  reactants	  used	  was	  developed	  empirically	  such	  that	  the	  fractional	   accumulation	   of	   2DHNAD	   (the	   less	   stable	   of	   the	   products)	  was	   comparable	   to	  that	  of	  6DHNAD	  and	  β-­‐NADH	  (4DHNAD).	   Initially,	  a	  37	  mM	  sodium	  borohydride	  solution	  was	  prepared	   in	  20	  mM	  potassium	  phosphate	   titrated	   to	  pH	  11.	  A	  200	  µL	  aliquot	  of	   this	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solution	  was	   then	   added	   to	   a	   freshly	   prepared	   15.5	  mM	   solution	   of	  β-­‐NAD+	   in	   100	  mM	  potassium	   phosphate	   pH	   7.5.	   Analytical	   high-­‐pressure	   liquid	   chromatography	   (HPLC)	  separation	  of	  the	  products	  of	  β-­‐NAD+	  reduction	  was	  achieved	  using	  an	  Xterra	  C18	  reverse	  phase	  column	  (4.6	  x	  150	  mm,	  3.5	  µM	  particle	   size)	   run	   isocratically	  at	  0.5	  mL/min	   in	  10	  mM	   potassium	   phosphate	   buffer	   pH	   7.5.	   Purification	   of	   2	   &	   6DHNAD	   was	   achieved	   by	  preparative	  HPLC.	  The	  partially	  reduced	  β-­‐NAD+	  solution	  was	  injected	  (50-­‐500	  μL)	  onto	  a	  Phenomenex	   reverse-­‐phase	   phenyl	  HPLC	   column	   (21.2	   x	   250	  mm)	   run	   isocratically	   at	   5	  mL/min	  with	  a	  mobile	  phase	  of	  10	  mM	  potassium	  phosphate,	  pH	  7.5.	  Both	   the	  analytical	  and	   preparative	   columns	   were	   coupled	   to	   a	   Waters	   600E	   pump	   and	  Waters	   2487	   dual	  wavelength	  detector	  and	  the	  elution	  of	  component	  species	  was	  observed	  simultaneously	  at	  260	  and	  340	  (or	  394)	  nm.	  To	  prepare	  samples	  for	  nuclear	  magnetic	  resonance	  (NMR)	  and	  mass	  spectrometry,	  reduced	  products	  were	  collected	  individually	  into	  400	  mL	  glass	  vessels	  immersed	  in	  liquid	  nitrogen.	  The	  pure	  dilute	  solutions	  were	  then	  thawed	  and	  desalted	  at	  4	  
oC	   by	   loading	   onto	   a	   35	   cc	   C18	   Sep-­‐Pak	   cartridge	   (Waters)	   and	   eluted	   with	   a	   200	   mL	  gradient	  from	  10	  mM	  to	  0	  mM	  potassium	  phosphate	  pH	  7.0	  using	  a	  Biorad	  Biologic	  liquid	  chromatography	  device.	  The	  desalted	  samples	  were	  then	  dried	  by	  lyophilization	  (in	  order	  to	   minimize	   ambient	   temperature	   decomposition,	   the	   lyophilization	   vessels	   were	  embedded	   in	   ice	   throughout).	  Each	  of	   the	  desalted,	  dry	  and	  pure	  reduction	  products	  was	  then	   dissolved	   in	   cooled	   deuterium	   oxide	   (D2O)	   and	   used	   immediately	   for	   NMR	   or	  dissolved	  in	  cooled	  water	  for	  mass	  spectrometry.	  For	  kinetic	  studies,	  the	  product	  identified	  as	  6DHNAD	  was	  collected,	  desalted	  and	  concentrated	  and	  redissolved	  in	  D2O	  as	  described	  above	  and	  stored	  at	  -­‐80	  oC.	  The	  product	  identified	  as	  2DHNAD	  could	  not	  be	  stored	  due	  to	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pronounced	   instability	   and	   was	   instead	   collected	   from	   the	   HPLC	   and	   used	   immediately	  (within	  1-­‐5	  mins).	  	  
Spectrophotometric	   Quantification	   of	   NAD	   Molecules.	   The	   concentration	   β-­‐NADH	   was	  determined	   using	   published	   340	   nm	   extinction	   coefficient	   of	   6220	   M-­‐1	   cm-­‐1	   (309).	  Dihydronicotinamide	   chromophore	   extinction	   coefficients	   for	  2	  &	  6DHNAD	   (and	   the	  260	  nm	   extinction	   coefficient	   for	   β-­‐NAD+)	   were	   obtained	   using	   renalase	   to	   oxidize	   both	  molecules	  to	  β-­‐NAD+.	  Initially,	  the	  spectrum	  of	  each	  of	  the	  HPLC	  purified	  molecule	  (70-­‐90	  µM)	   was	   acquired	   using	   a	   Hewlett	   Packard	   8453	   spectrophotometer.	   The	   2	   &	   6DHNAD	  were	  then	  oxidized	  to	  β-­‐NAD+	  by	  adding	  30	  nM	  renalase.	  4DHNAD	  (β-­‐NADH)	  prepared	  in	  the	   same	   manner	   was	   oxidized	   to	   β-­‐NAD+	   by	   the	   addition	   of	   30	   nM	   OYE.	   Under	   these	  conditions	  complete	  oxidation	  was	  achieved	  in	  2-­‐3	  minutes.	  The	  pairs	  of	  fully	  reduced	  and	  fully	   oxidized	   spectra	   obtained	   from	   each	   reaction	   were	   then	   multiplied	   by	   the	   factor	  required	  to	  normalize	  the	  β-­‐NAD+	  spectra	  and	  then	  all	  spectra	  were	  multiplied	  by	  the	  factor	  required	  to	  convert	  the	  β-­‐NADH	  spectrum	  to	  equal	  its	  known	  extinction	  coefficient	  at	  340	  nm.	  This	  method	  gave	  extinction	  coefficient	  of	  ε	  394nm	  =	  5360	  M-­‐1cm-­‐1	  for	  2DHNAD,	  ε	  345nm	  =	  6580	  M-­‐1cm-­‐1	  for	  6DHNAD	  (cf.	  α-­‐NADH	  ε345nm	  =	  6170	  M-­‐1cm-­‐1)	  and	  ε	  260nm	  =	  18800	  M-­‐1cm-­‐1	  for	  β-­‐NAD+.	  	  
Mass	   Spectrometry.	   For	   both	   2	   &	   6DHNAD,	   an	   HPLC	   purified	   and	   C18	   Sep-­‐Pak	   desalted	  sample	   (~50-­‐100	   µM,	   prepared	   as	   described	   above)	   was	   collected.	   This	   sample	   was	  injected	   via	   a	   Shimadzu	  LC-­‐2010C	   liquid	   chromatography	   system	  onto	   a	   Shimadzu	  2020	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mass	  spectrometer.	  In	  each	  case,	  10	  µL	  of	  sample	  was	  delivered	  in	  a	  1:1	  mixture	  of	  water	  and	  methanol.	  Data	  were	  collected	  in	  negative	   ion	  mode	  in	  the	  mass	  range	  100-­‐800.	  This	  procedure	  was	  also	  followed	  for	  β-­‐NADH,	  β-­‐NAD+	  as	  controls.	  	  	  
Nuclear	  Magnetic	  Resonance.	  NMR	  experiments	  were	   carried	  out	  at	  280	  K	   in	  D2O	  solvent	  using	   a	  Bruker	  DRX-­‐500	  NMR	   spectrometer	   equipped	  with	   a	   triple	   axis	   gradient	   inverse	  (BBI)	  probe	  operating	  at	  a	  frequency	  of	  499.832389	  MHz	  for	  proton	  and	  125.6936644	  MHz	  for	   13C.	  Chemical	  shifts	  are	  reported	  relative	   to	   the	  methyl	  signal	  of	   the	  sodium	  salt	  of	  3-­‐(trimethylsilyl)	  propanesulfonic	   acid	   using	   the	   residual	  HDO	   signal	   as	   indirect	   reference.	  One-­‐dimensional	  experiments	  were	  performed	  by	  accumulating	  128	  scans	  using	  a	  spectral	  width	   of	   10330	   Hz	   (1H)	   and	   20161	   Hz	   (31P)	   and	   using	   relaxation	   delays	   of	   1s	   and	   3s,	  respectively.	  For	  a	  typical	  gradient	  selected	  DQF	  -­‐COSY	  experiment	  960	  t1	  increments	  with	  32	  transients	  of	  2048	  points	  covering	  a	  spectral	  width	  of	  5000	  Hz	  were	  acquired.	  1H(158)-­‐HSQC	  spectra	  were	  acquired	  with	  gradient	  selection	  and	  multiplicity	  editing,	  using	  730	  t1	  increments	  with	  64	   transients	  of	  1600	  points	  each,	  covering	  a	  spectral	  width	  of	  5000	  Hz	  and	  22624	  Hz	  in	  f2	  and	  f1,	  respectively.	  A	  mixing	  time	  of	  3.4	  ms	  was	  used.	  1H(158)-­‐HMBC	  spectra	  utilized	  gradient	  selection	  acquiring	  820	  t1	  increments	  with	  160	  transients	  of	  4096	  data	  points	  each	  with	  a	  spectral	  widths	  in	  f2	  and	  f1	  of	  5000	  Hz	  and	  25140	  Hz,	  respectively,	  and	   a	   mixing	   time	   of	   50	   ms.	   A	   low-­‐pass	   filter	   was	   employed	   to	   suppress	   one	   bond	   JCH	  couplings.	   All	   spectra	   were	   analyzed	   and	   assigned	   using	   Topspin	   3.2	   software	   (Bruker	  BioSpin).	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Reductive	   Half-­‐Reaction	   of	   Renalase	   with	   2	   &	   6DHNAD.	   The	   reductive	   half-­‐reaction	   of	  renalase	  could	  be	  observed	  independent	  of	  subsequent	  oxidative	  processes	  by	  exclusion	  of	  dioxygen.	  Renalase	  (5	  mL,	  20	  µM)	  in	  2	  x	  PBS	  buffer	  containing	  1	  mM	  dextrose	  was	  added	  to	  the	  main	  chamber	  of	  a	  glass	  tonometer	  and	  glucose	  oxidase	  (25	  µL,	  25	  units)	  was	  added	  to	  a	  detachable	   side	  arm.	  The	   tonometer	  was	   then	  assembled	  and	  embedded	   in	   ice	  and	   the	  renalase	   and	   glucose	   oxidase	   solutions	   were	   made	   anaerobic	   by	   exchanging	   argon	   for	  dissolved	   dioxygen.	   This	   was	   achieved	   by	   45	   alternating	   cycles	   of	   low-­‐level	   vacuum	  followed	   by	   the	   introduction	   high-­‐purity	   argon	   gas	   (at	   5	   psi).	   The	   argon	   was	   passed	  through	   an	   Alltech	   oxygen-­‐reactive	   cartridge	   and	   sparged	   through	   anaerobic	   water.	  Throughout	   this	   procedure	   the	   sample	   was	   equilibrated	   with	   the	   argon	   atmosphere	   by	  gentle	  agitation	  after	  each	  set	  of	  three	  exchange	  cycles.	  Once	  anaerobic,	  the	  glucose	  oxidase	  was	  combined	  with	  the	  renalase/dextrose	  solution	  and	  mounted	  onto	  a	  Hitech	  (now	  TgK)	  DX2	  stopped	   flow	   instrument.	  6DHNAD	  samples	  were	   thawed	  (see	  above)	  and	  diluted	   to	  target	  concentrations	   in	  water	  containing	  1	  mM	  glucose.	  Each	  6DHNAD	  sample	  was	   then	  placed	   in	   a	   glass	   syringe,	   inverted	   and	   sparged	   with	   argon	   gas	   for	   5	   minutes.	   Before	  capturing	   and	  mounting	   the	   substrate	   solution	   to	   the	   stopped	   flow	   instrument,	   10	  µL	  of	  glucose	  oxidase	  (10	  units)	  was	  injected	  via	  the	  luer	  tip.	  2DHNAD	  substrate	  solutions	  were	  prepared	   in	   an	   equivalent	   manner	   but	   were	   collected	   directly	   from	   preparative	   HPLC	  purification	  (50-­‐90	  µM)	  and	  used	  immediately	  (see	  above).	  	  	   Renalase	  and	  substrate	  solutions	  were	  mixed	  and	  reduction	  of	  the	  renalase	  cofactor	  was	  observed	  at	  458	  nm.	  The	  stability	  of	  6DHNAD	  substrate	  allowed	  it	   to	  be	  prepared	  in	  sufficient	   concentrations	   to	   achieve	   pseudo-­‐first	   order	   reaction	   conditions.	   As	   such	   the	  data	   for	   this	   substrate	   was	   fit	   to	   a	   linear	   combination	   of	   two	   exponentials	   according	   to	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Equation	  4.1	  using	  Kinetic	   Studio	   software	   (TgK	  Ltd).	   In	   this	   equation	  A1	   and	  A2	   are	   the	  amplitudes	   associated	  with	   the	   first	   and	   second	   rate	   constants,	  k1obs	   and	  k2,	   and	  C	   is	   the	  absorbance	  at	  end	  of	  the	  reaction.	  The	  dependence	  of	  the	  k1obs	  values	  determined	  was	  then	  fit	   to	   the	  hyperbolic	   form	  of	   the	   single-­‐site	  binding	   equation	   (Equation	  4.2)	   according	   to	  Strickland,	   where	   kred	   is	   the	   limiting	   rate	   constant	   for	   reduction	   and	   K6DHNAD	   is	   the	  dissociation	  constant	  for	  6DHNAD	  (322).	  	  Equation	  4.1	   	   	  	  𝐴!"# = 𝐴! 𝑒!!!!"#! +   𝐴! 𝑒!!!! + 𝐶	  	  Equation	  4.2	   	   𝑘!"# = !!"# !!"#$!(!!!"#$!! !!"#$! )	  	  	   For	  2DHNAD,	  100	  µM	  was	  the	  approximate	  maximum	  concentration	  obtained	  from	  preparative	  HPLC;	  as	  such,	   the	  reductive	  half-­‐reaction	  with	   this	  substrate	  was	  conducted	  under	   second-­‐order	   reactant	   conditions	   and	   the	   data	   obtained	   were	   fit	   globally	   using	  Kintec	   Explorer	   to	   the	   model	   shown	   in	   Scheme	   4.2.	   In	   this	   model	   the	   Renox•2DHNAD	  complex	  kon	  rate	  constant	  was	  arbitrarily	  assigned	  to	  ~108	  M-­‐1s-­‐1,	  and	  the	  ratio	  of	  the	  k3	  and	  
k-­‐3	   for	   the	   Renred•β-­‐NAD+	   complex	   was	   confined	   to	   equal	   the	   measured	   dissociation	  constant	  for	  the	  Renox•β-­‐NAD+	  complex	  (for	  justification,	  see	  below).	  	  
	  
Scheme	  4.2.	  Model	  of	  renlase	  reductive	  half-­‐reaction	  of	  renalase	  using	  2DHNAD	  as	  a	  substrate.	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The	   Dissociation	   Constants	   for	   the	   Renox•β-­‐NADH	   and	   Renox•β-­‐NAD+	   Complexes.	   The	  dissociation	  constants	  for	  the	  Renox•β-­‐NADH	  and	  Renox•β-­‐NAD+	  complexes	  were	  measured	  by	  perturbation	  of	  the	  renalase	  flavin	  spectrum	  in	  the	  presence	  of	  each	  ligand.	  In	  order	  to	  avoid	  slow	  non-­‐specific	  reduction	  of	  the	  renalase	  flavin	  by	  β-­‐NADH	  during	  the	  experiment,	  a	  ~10	  mL	  stock	  of	  renalase	  (15	  µM)	  was	  prepared	  in	  PBS	  buffer	  at	  25	  oC.	  From	  this	  stock	  a	  0.9	  mL	  aliquot	  was	  added	  to	  a	  1.5	  mL	  quartz	  cuvette	  and	  0.1	  mL	  of	  β-­‐NADH	  was	  added	  to	  this	   sample	   from	   a	   set	   of	   eight	   2-­‐fold	   serially	   diluted	   stocks.	   As	   such	   the	  spectrophotometric	   data	   are	   compiled	   from	   eight	   separate	   renalase	   samples	   observed	  shortly	   after	   the	   addition	   of	  β-­‐NADH	   for	   concentrations	   that	   spanned	   the	   range	   0	   -­‐	   3.51	  mM.	  The	  dissociation	  constant	  for	  the	  Renox•β-­‐NAD+	  complex	  was	  measured	  by	  preparing	  a	  single	   20	   µM	   solution	   of	   renalase	   in	   PBS	   buffer	   at	   25	   oC.	   To	   this	   solution	   β-­‐NAD+	   was	  titrated	   such	   that	   a	   range	   of	   concentrations	   from	   0-­‐~6mM	   was	   achieved	   (higher	  concentrations	  induced	  marked	  precipitation	  of	  the	  enzyme).	  	  	   For	   both	  β-­‐NADH	  and	  β-­‐NAD+	   titrations,	   spectra	   (250-­‐900	  nm)	  were	   acquired	   for	  each	  ligand	  concentration	  using	  a	  Shimadzu	  1800	  spectrophotometer.	  After	  correction	  for	  dilution,	   the	   change	   in	   absorption	   at	   550	   nm	   and	   500	   nm	   was	   used	   to	   determine	   the	  dissociation	  constant	  for	  the	  Renox•β-­‐NADH	  and	  the	  Renox•β-­‐NAD+	  complexes	  respectively.	  The	   changes	   in	   absorbance	   were	   fit	   to	   the	   hyperbolic	   form	   of	   the	   single	   site	   binding	  equation	   (Equation	   4.3)	   in	   which	  𝑓	  is	   fractional	   saturation	   and	   Kligand	   is	   the	   dissociation	  constant	  for	  either	  β-­‐NADH	  or	  β-­‐NAD+	  for	  the	  respective	  Renox	  complex.	  	  Equation	  4.3	   	   	  𝑓 = [!"#$%&](!!"#$%&! !"#$%& )	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2	   &	   6DHNAD	   Dehydrogenase	   Inhibition.	   Inhibition	   of	   dehydrogenases	   from	   primary	  metabolism	  by	  2	  &	  6DHNAD	  was	  assessed	  using	  two	  approaches.	  The	  relative	  stability	  of	  6DHNAD	   allowed	   the	   collection	   of	   a	   series	   of	   nested	   Michealis-­‐Menten	   curves	   each	  acquired	  in	  the	  presence	  of	  a	  different	  concentration	  of	  the	  candidate	  inhibitor.	  The	  relative	  instability	   of	   2DHNAD	   dictated	   that	   the	   50%	   inhibitory	   concentration	   (IC50)	  method	   of	  Cheng	  and	  Prusoff	  was	  used	  for	  determination	  of	  Ki	  (335,	  336).	  Via	  this	  approach,	  2DHNAD	  need	  only	  be	  separated	  from	  6DHNAD	  and	  β-­‐NADH	  using	  preparative	  HPLC,	  quantified	  and	  diluted	  to	  the	  target	  concentration	  before	  adding	  to	  the	  assay;	  as	  such	  the	  pure	  2DHNAD	  is	  used	  within	  five	  minutes	  of	  purification.	  	   6DHNAD	  and	  2DHNAD	  Ki	  values	  were	  measured	  for	  three	  dehydrogenase	  enzymes	  of	  primary	  metabolism;	  malate	  dehydrogenase	  (MDH),	   lactate	  dehydrogenase	  (LDH),	  and	  lipoamide	  dehydrogenase	  (DLD).	  To	  limit	  the	  influence	  of	  enzyme	  instability	  encountered	  with	  the	  MDH	  and	  LDH	  enzymes,	  a	  solution	  of	  0.3	  U/mL	  was	  prepared	  in	  10	  mM	  potassium	  phosphate	   pH	   7.5	   and	   then	   frozen	   at	   -­‐80	   oC	   as	   2	  mL	   aliquots.	   These	   samples	  were	   then	  thawed	   and	   used	   as	   required.	   By	   contrast,	   DLD	   (0.3	   U/mL)	   maintained	   activity	   when	  incubated	  at	  4	  oC	  and	  so	  was	  prepared	  in	  100	  mM	  potassium	  phosphate	  pH	  7.5	  and	  placed	  on	  ice	  until	  used	  in	  assays.	  For	  assessment	  of	  6DHNAD	  inhibition	  of	  MDH	  and	  LDH	  a	  series	  of	  five	  Michaelis-­‐Menten	  analyses	  were	  completed	  using	  β-­‐NADH	  concentrations	  from	  0-­‐80	  µM	  in	  the	  presence	  of	  saturating	  respective	  oxaloacetate	  (0.4	  mM)	  and	  pyruvate	  (0.5	  mM).	  For	  MDH	  and	  DLD,	  6DHNAD	  were	  varied	  from	  0-­‐2	  µM,	  while	  for	  LDH	  the	  range	  of	  6DHNAD	  used	  was	  0-­‐20	  µM.	  The	  data	  obtained	  for	  MDH	  and	  LDH	  were	  fit	  globally	  to	  the	  competitive	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inhibition	  model	  using	  the	  non-­‐linear	  least	  squares	  analysis	  provided	  by	  Prism	  6	  software	  (Graphpad	  Software	  Inc.).	  	   Ki	   values	   for	   2DHNAD	   with	   MDH,	   LDH,	   and	   DLD	   were	   assessed	   using	   the	   IC50	  method.	  In	  this	  method	  the	  extent	  of	  inhibition	  for	  a	  range	  of	  2DHNAD	  concentrations	  was	  measured	  at	  a	  concentration	  of	  β-­‐NADH	  equivalent	  to	  the	  measured	  Michaelis	  constant	  for	  this	  substrate.	  This	  value	  was	  determined	  in	  the	  absence	  of	  inhibitor	  and	  at	  near	  saturating	  concentrations	   of	   the	   oxidized	   substrate	   (0.4	  mM	   oxaloacetate,	   0.5	  mM	   pyruvate,	   1	  mM	  lipoamide	  acid	  for	  MDH,	  LDH	  and	  DLD	  respectively).	  All	  data	  were	  fit	  using	  non-­‐linear	  least	  squares	   analysis	   available	   from	  KaleidaGraph	   software	   (Synergy	   Software	   Inc).	   The	   data	  obtained	   in	   the	   absence	   of	   the	   inhibitor	   was	   fit	   to	   Equation	   4.4,	   the	   Michaelis-­‐Menten	  equation,	  where	  v	  is	  the	  observed	  rate,	  Vmax	  is	  the	  maximal	  rate	  of	  reaction	  and	  Kβ-­‐NADH	  is	  the	  Michaelis	  constant	  for	  β-­‐NADH.	  The	  extent	  of	  inhibition	  was	  then	  measured	  for	  a	  range	  of	  2DHNAD	  concentrations	  and	  the	  data	  obtained	  was	  fit	  to	  the	  Hill	  equation	  (equation	  4.5)	  to	  derive	  the	  IC50	  mid-­‐point	  as	  a	  measure	  of	  the	  Ki	  value	  for	  2DHNAD.	  	  	  Equation	  4.4	  	   	     𝑣 = !!"#[!!!"#$](!!!!"!"! !!!"#$ )	  	  Equation	  4.5	   	  	   𝑣 = 𝑉!"# + !!"#!!!"#(!!  ([!!"#$!]!! )	  	  	  
Results	  
Renalase	  Substrates	  are	  Generated	  by	  Non-­‐Specific	  Reduction	  of	  β-­‐NAD+.	   In	   prior	  work	  we	  identified	   small	   equilibrium	   proportions	   of	  molecules	   in	  β-­‐NAD(P)H	   solutions	   that	  were	  
	  	  	   130	  
oxidized	   by	   renalase.	   The	   absorption	   maxima,	   extinction	   coefficients	   and	   apparent	  equilibrium	   proportions	   correlated	  well	  with	   those	   reported	   for	  α-­‐anomers	   of	   NAD(P)H	  molecules,	   but	   the	   fleeting	   behavior	   of	   these	   molecules	   precluded	   rigorous	   structural	  assignment.	  We	  have	  since	  devised	  methods	  to	  both	  form	  larger	  fractional	  accumulations	  of	   these	   molecules	   by	   reduction	   of	   β-­‐NAD+	   and	   prolong	   the	   decay	   half-­‐life	   such	   that	  structural	   assignments	   can	   be	   made.	   Figure	   4.1A	   illustrates	   the	   chromatographic	  separation	  of	  the	  reduced	  products	  obtained	  when	  β-­‐NAD+	  is	  reduced	  by	  both	  hydrosulfite	  and	   borohydride.	   While	   hydrosulfite	   (Eo=-­‐0.62	   V)	   yields	   only	   β-­‐NADH	   (4DHNAD),	  reduction	  by	  borohydride	  (Eo=-­‐1.24	  V)	  yields	  three	  products,	  two	  of	  which	  are	  substrates	  for	  renalase	  (Figure	  4.1B).	  The	  third	  component,	  that	  was	  not	  a	  substrate	  for	  renalase,	  had	  a	  retention	  time	  identical	  to	  that	  of	  β-­‐NADH.	  When	  reacted	  with	  renalase,	  the	  product	  from	  both	   substrate	   molecules	   was	   identified	   here	   (and	   in	   prior	   work)	   as	   β-­‐NAD+	   and	   this	  product	  was	  made	  in	  near	  equimolar	  concentration	  to	  the	  amount	  of	  dioxygen	  consumed	  (Figure	  4.1B	  inset)(319).	  The	  absorption	  spectra	  of	  the	  reduction	  products	  indicate	  distinct	  UV/Vis	  maxima	  at	  345,	  394,	  and	  340	  nm	  for	  the	  dihydro-­‐nicotinamide	  moiety	  in	  each	  case	  (Figure	  4.1C).	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Figure	  4.1.	  Generation	  of	  Renalase	  Substrates	  by	  Reduction	  of	  β-­‐NAD+.	  A:	  Analytical	  HPLC	  chromatograms	   recorded	   after	   the	   reduction	   of	   50	   µM	   β-­‐NAD+	   with	   50	   µM	   sodium	  hydrosulfite	   (blue	   line)	   or	   50	   µM	   sodium	   borohydride	   (red	   line).	   B:	   Analytical	   HPLC	  chromatograph	   demonstrating	   the	   consumption	   of	   two	   of	   the	   three	   products	   of	   sodium	  borohydride	   reduction	   by	   the	   addition	   of	   2.4	   µM	   renalase.	   The	   inset	   is	   taken	   from	  observation	   of	   the	   reaction	   shown	   in	   B	   using	   a	   Clark-­‐type	   dioxygen	   electrode.	   After	  cessation	  of	  dioxygen	  consumption	  (~100	  s)	  the	  sample	  was	  filtered	  using	  an	  Amicon	  0.5	  mL	  10	  kDa	  centrifugal	  filtration	  device	  and	  re-­‐chromatographed	  as	  described	  (gray	  vs	  red	  chromatogram).	   C:	   Molar	   absorptivity	   absorption	   spectra	   of	   the	   purified	   reduction	  products.	  	  	  	  	  
Structural	  Assignment	  of	  Renalase	  Substrates.	  The	  unique	  absorption	  maxima	  of	  each	  borohydride	  reduction	  product	  were	  used	  to	  aid	  isolation	  of	  sufficient	  quantities	  by	  preparative	  HPLC	  for	  structural	  characterization.	  The	  mass	  of	  all	  reduction	  products	  was	  found	  to	  be	  664.40±0.05,	  equal	  to	  the	  mass	  of	  the	  β-­‐NADH	  control.	  The	  mass	  of	  the	  product	  formed	  from	  renalase	  activity	  was	  662.40±0.00,	  equivalent	  to	  that	  of	  the	  β-­‐NAD+	  control.	  NMR	  spectra	  were	  recorded	  at	  280	  K	  in	  D2O	  solvent.	  For	  each	  product,	  one-­‐dimensional	  H1	  (1D),	  H1	  homonuclear	  correlation	  (COSY),	  H1-­‐C13	  heteronuclear	  single	  quantum	  coherence	  (HSQC)	  and	  H1-­‐C13	  heteronuclear	  multiple	  bond	  correlation	  (HMBC)	  spectra	  were	  obtained.	  Chemical	  shift	  and	  H1	  coupling	  assignments	  are	  included	  in	  Table	  4.1.	  Figure	  4.2	  depicts	  the	  proton	  resonances	  assigned	  to	  the	  dihydronicotinamide	  rings	  of	  three	  products	  obtained	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from	  borohydride	  reduction.	  In	  terms	  of	  homonuclear	  H1	  geminal	  and	  vicinal	  coupling,	  nicotinamide	  dinucleotides	  have	  four	  isolated	  sets	  of	  protons;	  those	  for	  the	  adenine	  and	  nicotinamide	  bases	  and	  two	  for	  the	  ribose	  moieties.	  Structural	  assignment	  of	  the	  nicotinamide	  bases	  therefore	  relies	  heavily	  on	  HMBC	  spectra	  to	  link	  the	  proton	  residing	  on	  the	  ribose	  anomeric	  carbon	  to	  the	  proximal	  N2	  and	  N6	  carbons	  and/or	  the	  protons	  residing	  on	  N2	  and	  N6	  to	  the	  anomeric	  carbon.	  These	  multi-­‐bond	  heteronuclear	  couplings	  both	  orient	  the	  nicotinamide	  nuclear	  spin-­‐system	  with	  respect	  to	  the	  ribose	  and	  also	  permit	  deconvolution	  of	  the	  individual	  ribose	  resonances	  that	  are	  then	  identified	  by	  sequential	  geminal	  homonuclear	  coupling.	  The	  pivotal	  geminal,	  vicinal	  homonuclear	  couplings	  and	  heteronuclear	  multiple	  bond	  couplings	  are	  indicated	  in	  Figure	  4.2	  by	  respective	  blue	  and	  red	  arrows.	  Correlations	  of	  this	  type	  were	  readily	  made	  for	  the	  340	  nm	  and	  345	  nm	  absorption	  maxima	  species,	  and	  these	  were	  assigned	  as	  4-­‐	  (β-­‐NADH),	  and	  6DHNAD	  respectively	  (Figure	  4.2A	  &	  4.2B).	  Note	  that	  the	  multiplet	  for	  the	  nicotinamide	  N5’	  proton	  of	  6DHNAD	  is	  obscured	  by	  the	  residual	  water	  resonance	  and	  is	  instead	  depicted	  inset	  as	  the	  homonuclear	  coupling	  crosspeak	  to	  the	  N6’	  protons.	  The	  relative	  instability	  of	  the	  reduction	  product	  that	  exhibited	  the	  394	  nm	  absorption	  maximum	  precluded	  obtaining	  assignments	  by	  this	  approach.	  Control	  H1	  1D	  NMR	  spectra	  taken	  before	  and	  after	  two-­‐dimensional	  heteronuclear	  spectra	  acquisition	  repeatedly	  indicated	  substantial	  degradation	  of	  the	  394	  nm	  species.	  As	  such	  the	  structural	  assignment	  of	  the	  394	  nm	  species	  as	  2DHNAD	  is	  principally	  based	  on	  H1	  homonuclear	  couplings.	  For	  this	  species	  we	  observe	  a	  ~6-­‐7	  Hz	  geminal	  coupling	  for	  the	  N4’	  (d),	  N5’(m)	  and	  N6’(d)	  protons	  and	  a	  absence	  of	  geminal	  couplings	  in	  the	  resonances	  assigned	  to	  N2’	  protons	  that	  each	  exhibit	  only	  a	  vicinally	  coupled	  ~12	  Hz	  doublet	  (Figure	  4.2C,	  Table	  4.1).	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Table	  4.1.	  NMR	  Chemical	  Shift	  Assignments	  for	  2-­‐,	  4-­‐	  and	  6DHNAD.	  
	  	   β-­‐NADH	   	   	   6DHNAD	   	   	   2DHNAD	   	  Position	   1H	  Shift	  (ppm)	   multip.,J(Hz)	   13C	  Shift	  (ppm)	   1H	  Shift	  (ppm)	   multip.,J(Hz)	   13C	  Shift	  (ppm)	   1HShift	  (ppm)	   multip.,J	  (Hz)	  N2	   6.57	   s	   138.3	   6.74	   s	   145.1	   3.25	  3.68	   d,	  12.4	  d,	  12.9	  N4	   2.38	  	  2.22	   dt,17.8,	  2.2	  dd,	  18.4,	  3.1	   21.7	   5.42	   d	   119.0	   6.31	   d,	  6.1	  N5	   4.39	   dd,	  	   74.4	   4.67	   m*	   112.6	   4.45	   t,	  6.7	  N6	   5.61	   d,	  8.14	   122.9	   3.60	  3.40	   dd,	  15.1,	  2.9	  dt,	  15.1,	  2.9	   42.1	   6.10	   d,	  7.1	  	  	   	   	   	   	   	   	   	   	  R1	  1	   4.44	   d,	  7.48	   94.7	   4.51	   d,	  7.21	   97.1	   4.48	   d,	  7.48	  R1	  2	   3.85	   dd,	  7.48,	  6.73	   	   3.98	   dd,	  7.26,	  5.46	   67.9	   4.02	   m,	  nm	  R1	  3	   3.94	   m	   64.8	   3.88	   m	   70.5	   3.89	   m,	  nm	  R1	  4	   3.90	   m	   n/a	   3.79	   m	   82.1	   3.84	   m	  	  R1	  5	  	   3.766	   m	   65.8	   3.74	   m	   65.6	   3.62	   m	  	   	   	   	   	   	   	   	   	  R2	  1	   5.79	   d,	  5.4	   86.6	   5.78	   d,	  5.8	   86.5	   5.75	   d,	  5.7	  R2	  2	   4.37	   dd,	  5.42,	  5.16	  	   74.4	   4.41	   dd,	  5.39,5.99	   74.2	   4.38	   t,	  5.4	  R2	  3	   4.17	   dd,	  5.16,	  4.13	  	   70.0	   4.18	   dd,	  5.14,	  3.58	   70.0	   4.17	   m	  R2	  4	   4.050	   m,	  n/a	   83.5	   4.04	   m	   83.5	   4.07	   m	  R2	  5	   3.90	   dd,dd,	  	   65.0	   3.89	   m	   64.9	   4.00	   m	  	  	   	   	   	   	   	   	   	   	  A2	   7.87	   s	   152.3	   7.88	   s	   152.3	   7.89	   s	  A8	   8.15	   s	   139.5	   8.18	   s	   139.1	   8.17	   s	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Figure	  4.2.	  NMR	  Identification	  of	  the	  Purified	  Products	  of	  Sodium	  Borohydride	  reduction	  of	   β-­‐NAD+.	   Spectra	   were	   recorded	   at	   280	   K	   in	   deuterium	   oxide.	   Structures	   to	   the	   right	  depict	   the	  primary	  couplings	  used	   for	   identification	  of	   the	  β-­‐NADH	   isomers.	  Blue	  arrows	  indicate	   homonuclear	   coupling,	   while	   red	   arrows	   indicate	   heteronuclear	   multi-­‐bond	  coupling.	  	  	  	  
Renalase	  Reductive	  Half-­‐Reaction.	  In	  prior	  work	  we	  published	  data	  for	  the	  reductive	  half-­‐reaction	  of	  renalase	  (54).	  In	  these	  experiments	  the	  substrate	  was	  supplied	  to	  the	  enzyme	  in	  an	  apparent	  equilibrium	  mixture	  arising	  from	  aqueous	  speciation	  of	  β-­‐NADPH	  (Scheme	  4.3).	  As	  such	  the	  data	  obtained	  were	  not	  for	  a	  pure	  substrate	  molecule	  and	  included	  potential	  competitive	  inhibition	  effects	  from	  the	  β-­‐NADPH	  background	  (see	  below).	  Here	  we	  show	  the	  reductive	  half-­‐reactions	  for	  renalase	  with	  pure	  2-­‐	  and	  6DHNAD.	  While	  6DHNAD	  has	  sufficient	  stability	  to	  be	  purified	  and	  stored	  for	  use	  in	  such	  experiments,	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2DHNAD	  does	  not	  and	  typically	  decomposes	  with	  a	  half-­‐life	  of	  approximately	  30	  minutes.	  For	  this	  reason	  2DHNAD	  was	  used	  immediately	  after	  preparative	  HPLC	  isolation	  and	  was	  limited	  to	  ~100	  µM	  concentration	  by	  the	  capacity	  to	  resolve	  2DHNAD	  from	  other	  reduction	  products	  with	  the	  preparative	  reverse-­‐phase	  phenyl	  HPLC	  column	  used	  for	  purification.	  To	  observe	  reduction	  of	  the	  renalase	  flavin	  cofactor	  by	  2-­‐	  and	  6DHNAD,	  anaerobic	  renalase	  (10	  µM	  final)	  was	  mixed	  with	  varied	  concentrations	  of	  the	  anaerobic	  substrates.	  For	  6DHNAD	  the	  range	  of	  substrate	  concentration	  used	  spanned	  approximate	  pseudo-­‐first	  order	  reactant	  ratios	  (50-­‐800	  µM).	  The	  data	  obtained	  were	  thus	  fit	  to	  exponential	  decay(s)	  (Equation	  4.1).	  Two	  phases	  were	  observed	  in	  the	  reduction	  traces.	  The	  first	  phase	  accounted	  for	  ~90%	  of	  the	  amplitude	  change	  and	  was	  indicative	  of	  flavin	  reduction.	  The	  rate	  constants	  for	  this	  phase	  (k1obs)	  derived	  from	  fitting	  displayed	  a	  hyperbolic	  dependence	  that	  was	  fit	  to	  Equation	  4.2	  to	  derive	  the	  limiting	  rate	  constant	  for	  reduction	  from	  the	  asymptote	  (234	  s-­‐1)	  and	  the	  dissociation	  constant	  for	  the	  Renox•6DHNAD	  complex	  (173	  
µM).	  The	  rate	  constant	  for	  the	  second	  phase	  did	  not	  exhibit	  a	  6DHNAD	  dependence,	  and	  was	  fit	  to	  ~20	  s-­‐1	  in	  all	  traces.	  We	  propose	  that	  flavin	  reduction	  forms	  the	  Renred•β-­‐NAD+	  complex	  whose	  flavin	  spectrum	  is	  altered	  by	  the	  proximity	  of	  the	  flavin	  and	  nicotinamide	  rings.	  This	  phase	  is	  thus	  tentatively	  assigned	  as	  the	  decay	  of	  the	  Renred•β-­‐NAD+	  complex	  with	  the	  egress	  of	  β-­‐NAD+	  from	  the	  active	  site.	  A	  complete	  mechanistic	  assignment	  of	  the	  reductive	  half-­‐reaction	  is	  beyond	  the	  scope	  of	  this	  study.	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Scheme	  4.3.	  Aquaeous	  speciation	  of	  nicotinamide	  dinucleotide	  species.	  	  Our	   limited	   capacity	   to	   isolate	   and	   stabilize	   2DHNAD	   dictated	   that	   the	   reductive	  half-­‐reaction	  for	  renalase	  oxidizing	  this	  substrate	  was	  observed	  within	  a	  range	  of	  substrate	  concentrations	  that	  were	  second-­‐order	  with	  respect	  to	  the	  enzyme	  concentration.	  As	  such	  the	   data	   obtained	   could	   only	   be	   analyzed	   by	   fitting	   the	   integrated	   rate	   expression	   for	   a	  more	  complete	  kinetic	  model	  as	  shown	  in	  Scheme	  4.2.	  In	  this	  model	  the	  ratio	  of	  the	  β-­‐NAD+	  dissociation	   and	   association	   rate	   constants	   (k3:k-­‐3)	   was	   fixed	   to	   that	   defined	   by	   the	  dissociation	  constant	   for	   the	  Renox•β-­‐NAD+	  complex.	  This	   fitting	  restriction	  was	  based	  on	  our	  prior	  observation	  that	  the	  β-­‐NAD+	  product	  does	  not	  modulate	  the	  reduction	  potential	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of	   the	   flavin	  cofactor	  and	   therefore	  has	  equal	  affinity	   for	   the	  Renox	  and	  Renred	   forms	  (see	  below)	   (54).	   In	   addition	   the	   reductive	   step	   (k2)	   in	   which	   the	   hydride	   equivalent	   is	  transferred	   from	   2DHNAD	   to	   the	   flavin	   was	   defined	   as	   irreversible	   in	   accord	   with	   the	  assumption	  that	  the	  difference	   in	  reduction	  potential	  of	   these	  two	  species	   is	  greater	  than	  100	   mV	   (ΔG>-­‐20	   kJ/mole).	   Lastly,	   the	   association	   rate	   constant	   for	   2DHNAD	   (k1)	   was	  confined	  as	  ~108	  M-­‐1s-­‐1,	  close	  to	  the	  limit	  of	  diffusion.	  The	  fit	  obtained	  indicated	  a	  kred	  for	  2DHNAD	  of	   860	   s-­‐1,	   3.6-­‐fold	   faster	   than	   that	  measured	   for	   6DHNAD	  but	  with	   a	   similar	   a	  dissociation	  constant	  of	  166	  µM.	  	  	  
Dissociation	  Constants	  for	  the	  Renox•β-­‐NADH	  and	  Renox•β-­‐NAD+	  Complexes.	  We	  propose	  that	  the	   metabolic	   function	   of	   renalase	   is	   to	   alleviate	   inhibition	   of	   primary	   metabolism	   by	  oxidizing	  isomers	  of	  β-­‐NAD(P)H	  molecules	  that	  arise	  through	  tautomerization	  and/or	  non-­‐specific	  reduction	  of	  β-­‐NAD+	  (Scheme	  4.4).	  As	  such	  renalase	  operates	  in	  an	  environment	  ofnear-­‐isosteric	  non-­‐substrate	  molecules	  such	  as	  β-­‐NAD(P)H	  and	  β-­‐NAD(P)+	  that	  are	  present	  in	   considerably	   higher	   concentration	   and	   presumably	   inhibitory.	   In	   order	   to	   gauge	  selectivity	   for	   2-­‐	   and	   6DHNAD	   the	   dissociation	   constants	   for	   the	   Renox•β-­‐NADH	   and	  Renox•β-­‐NAD+	   complexes	   were	   measured	   using	   perturbation	   of	   the	   renalase	   flavin	  spectrum	   as	   physical	   evidence	   of	   association.	   These	   data	   fit	  well	   to	   a	   single	   site	   binding	  equation	  (Equation	  4.3)	  and	   indicated	  that	  renalase	   is	  only	  three-­‐fold	  selective	  against	  β-­‐NADH	  (Kβ-­‐NADH	  =	  570±90	  µM)	  (Figure	  4.4A),	  but	  is	  34-­‐fold	  selective	  against	  β-­‐NAD+	  (Kβ-­‐NAD+	  =	  5960±800	  µM)	  (Figure	  4B).	  Association	  of	  β-­‐NADH	  induced	  new	  absorption	  transitions	  at	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long	  wavelength	   indicative	  of	   charge-­‐transfer	  presumably	  made	  possible	  by	  proximity	  of	  the	  dihydronicotinamide	  and	  flavin	  rings	  (323)	  (Figure	  4.4A	  inset).	  	  
	  
Figure	  4.3.	  The	  Reductive	  Half-­‐Reactions	  of	  Renalase	  with	  2	  &	  6DHNAD.	  A:	  Reduction	  of	  the	   renalase	   cofactor	   (10	   µM)	   in	   the	   presence	   of	   6DHNAD.	  Traces	   shown	   are	   for	   25,	   50,	  100,	   200,	   400,	   and	   800	   µM	   6DHNAD.	   The	   data	   were	   fit	   (red	   dashed	   lines)	   to	   a	   linear	  combination	   of	   two	   exponential	   decays	   according	   to	   Equation	   1.	   Inset	   shows	   the	  dependence	  of	  the	  observed	  rate	  constants	  on	  the	  concentration	  of	  6DHNAD	  fit	  to	  Equation	  4.2.	   B:	   Reduction	   of	   the	   renalase	   cofactor	   (10	   µM)	   in	   the	   presence	   of	   2DHNAD.	   Traces	  shown	  are	   for	  3.7,	  14.5,	  21.3,	  30.0,	  43.5	  µM	  2DHNAD.	  These	  data	  were	   fit	   globally	   to	   the	  kinetic	  model	  depicted	  in	  Scheme	  4.2.	  	  	  
	  	  
Scheme	  4.4.	  	  Proposed	  metabolic	  function	  of	  renalase.	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Figure	  4.4.	  Measurement	  of	  the	  Dissociation	  Constants	  for	  the	  Renox•β-­‐NADH	  and	  Renox•β-­‐NAD+	   Complexes.	   A:	   Difference	   absorption	   spectra	   for	   the	   renalase	   flavin	   at	   various	  concentrations	  of	  β-­‐NADH.	  Inset	  (left)	  shows	  the	  charge	  transfer	  absorption	  band	  observed	  when	   3.51	   mM	   β-­‐NADH	   was	   added	   (dashed	   line)	   to	   renalase.	   Inset(right)	   depicts	   the	  perturbation	  of	  the	  flavin	  spectrum	  at	  550	  nm	  as	  a	  function	  of	  β-­‐NADH	  concentration	  fit	  to	  Equation	   4.3.	   B:	   Difference	   absorption	   spectra	   for	   the	   renalase	   flavin	   at	   various	  concentrations	  of	  β-­‐NAD+.	  Inset	  depicts	  the	  perturbation	  of	  the	  flavin	  spectrum	  at	  550	  nm	  as	  a	  function	  of	  β-­‐NADH	  concentration	  fit	  to	  Equation	  4.3.	  	  	  	  
Dehydrogenase	   Inhibition.	   Lowry	   et	   al.	   and	   Dalziel	   reported	   that	   β-­‐NADH	   preparations	  contained	   contaminants	   that	   were	   inhibitory	   to	   LDH	   (67,	   68),	   and	   this	   observation	   has	  since	  been	  confirmed	  by	  numerous	  other	  authors	  (66,	  337-­‐339).	  In	  this	  study	  we	  measure	  Ki	  values	  for	  2-­‐	  and	  6DHNAD	  to	  three	  dehydrogenase	  enzymes	  from	  primary	  metabolism.	  These	  data	  are	  summarized	  in	  Figure	  4.5.	  Predictably,	  6DHNAD	  inhibition	  was	  best	  fit	  to	  a	  competitive	   pattern	   with	   respect	   to	   β-­‐NADH.	   The	   instability	   of	   2DHNAD	   precluded	  categorization	   the	   inhibition	  pattern,	   though	   it	   can	  be	   reasonably	  assumed	   that	  2DHNAD	  competes	  with	  β-­‐NADH	   similarly.	   The	  data	   indicate	   that	   both	  2-­‐	   and	  6DHNAD	  have	  high	  affinity	  for	  dehydrogenases	  and	  therefore	  pose	  a	  threat	  to	  primary	  metabolism.	  For	  E.	  coli	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MDH,	   6DHNAD	   has	   exceedingly	   high	   affinity	   (Ki	   =	   34	   ±	   3	   nM)	   while	   2DHNAD	   has	   only	  modest	   inhibitory	  affinity	   for	  this	  enzyme	  (Ki	  =	  3.05	  ±	  0.33	  µM).	  LDH	  from	  rabbit	  muscle	  shows	  similar	  high	  affinity	  for	  both	  2-­‐	  and	  6DHNAD	  (Ki	  ~	  500-­‐600	  nM).	  DLD	  is	  a	  β-­‐NADH-­‐dependent	  dehydrogenase	  component	  of	  both	  the	  pyruvate	  decarboxylase	  complex	  and	  the	  
α-­‐ketoglutarate	  decarboxylase	  complex.	  Curiously,	  this	  dehydrogenase	  does	  not	  appear	  to	  bind	   either	   2-­‐	   or	   6DHNAD	   with	   significant	   affinity.	   Collectively	   these	   data	   establish	   a	  credible	   metabolic	   function	   for	   renalase;	   oxidation	   of	   NAD(P)H	   isomers	   that	   arise	   from	  tautomerization	   or	   non-­‐specific	   reduction	   of	   β-­‐NAD(P)+	   in	   order	   to	   alleviate	   stringent	  inhibition	  of	  essential	  dehydrogenase	  enzymes.	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Figure	   4.5.	   Inhibition	   of	   dehydrogenases	   from	   primary	  metabolism	   by	   2-­‐	   and	   6DHNAD.	  Panels	   A	   and	   D	   depict	   evidence	   for	   the	   inhibition	   of	   E.	   coli	   malate	   dehydrogenase	   by	  2DHNAD	  and	  6DHNAD,	  respectively.	  In	  D	  the	  6DHNAD	  concentrations	  used	  were	  0,	  20,	  40,	  80,	  160,	  320	  nM.	  Panels	  B	  and	  E	  depict	  evidence	  for	  the	  inhibition	  of	  porcine	  heart	  lactate	  dehydrogenase	   by	   2DHNAD	   and	   6DHNAD.	   In	   panel	   E	   the	   6DHNAD	   concentrations	   used	  were	   0,	   2,	   5,	   10,	   20	   μM.	   Panels	   C	   and	   F	   depict	   evidence	   for	   the	   absence	   of	   inhibition	   of	  rabbit	  muscle	  lipoamide	  dehydrogenase	  by	  2DHNAD	  and	  6DHNAD	  respectively.	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Discussion	  In	  this	  report	  we	  provide	  a	  credible	  thesis	  for	  the	  metabolic	  function	  of	  renalase.	  We	  assert	   that	   renalase	  oxidizes	   inhibitory	   isomers	  of	  β-­‐NADH,	   forming	  β-­‐NAD+	  and	  delivers	  the	  electrons	  harvested	  to	  dioxygen.	  We	  offer	  evidence	  for	  the	  structures	  of	  two	  substrate	  molecules	   that	   arise	   from	   non-­‐specific	   reduction	   of	   β-­‐NAD+	   and	   present	   an	   initial	  characterization	   of	   the	   kinetics	   of	   the	   reductive	   half-­‐reaction	   observed	   with	   these	  substrates.	   This	   study	   also	   serves	   to	   correct	   our	   earlier	   erroneous	   claim	   that	   renalase	  oxidizes	  α-­‐NADH	  molecules	  (54,	  319).	  The	  data	  presented	  here	  indicate	  that	  the	  substrate	  molecule	   identified	   in	  prior	  work	  was	  not	  α-­‐NAD(P)H	  but	   instead	  6DHNAD(P),	   a	   species	  that	   has	   the	   same	  λmax	   (345	  nm),	   ostensibly	   the	   same	  extinction	   coefficient	   and	   similar	  reported	  aqueous	  fractional	  accumulation	  at	  equilibrium	  (309).	  	  	   In	   1953	   Mathews	   and	   Conn	   noted	   that	   the	   β-­‐NADH	   prepared	   by	   borohydride	  reduction	  was	  only	  partially	  oxidized	  by	  LDH	  and	  proposed	  that	  in	  addition	  to	  β-­‐NADH	  (4-­‐DHNAD),	   2-­‐DHNAD	   and	   6DHNAD	  were	   produced	   and	   that	   these	   forms	  were	   not	   able	   to	  react	  with	  enzymes	  (340).	  Later	  Chaykin	  and	  Meissner	  reported	  absorption	  spectra	  of	  the	  partially	   purified	   products	   of	   borohydride	   reduction	   and	   used	   tritium	   label	   elimination	  methods	  to	  establish	  the	  positions	  of	  reduction	  on	  the	  nicotinamide	  ring	  (65).	  A	  number	  of	  other	   studies	   have	   examined	   the	   properties	   of	   these	   non-­‐specific	   reduction	   products	  (including	  a	  variety	  of	  misidentifications)	  (63-­‐66),	  but	  it	  was	  Lowry	  et	  al.	  and	  Dalziel	  who	  first	   reported	   that	  β-­‐NADH	  preparations	   contained	   contaminants	   that	  were	   inhibitory	   to	  LDH.	  Soon	  after,	  Godtfredsen	  and	  Ottesen	  described	  6DHNAD	  as	  a	  humidity-­‐induced	  lactate	  dehydrogenase	   inhibitor	   that	   arises	   in	   NADH	   powder	   (339,	   341).	   Together,	   these	   and	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numerous	   other	   studies	   establish	   that	   lactate	   dehydrogenase	   inhibitors	   arise	   by	   non-­‐specific	   reduction	   of	   β-­‐NAD+	   and/or	   via	   tautomerization	   of	   β-­‐NADH	   (Scheme	   4.3).	   The	  activity	  we	  have	  observed	  for	  renalase	  suggests	  that	  non-­‐enzymatic	  redox	  and/or	  proton-­‐movement	   mediated	   intercoversion	   of	   NAD(P)+/NAD(P)H	   isomers	   is	   also	   an	   in	   vivo	  phenomenon	  that	  suppresses	  primary	  metabolism.	  	  	   We	  also	  show	  that	  renalase	  catalytically	  oxidizes	  both	  known	  isomeric	  forms	  of	  the	  
β-­‐NAD(P)H	  nicotinamide	   ring.	   Positionally,	   the	  2	   and	  6	   carbons	   of	   the	  nicotinamide	   ring	  are	  equivalent	  if	  the	  base	  is	  allowed	  to	  pivot	  about	  the	  glycosidic	  bond.	  This	  suggests	  that	  the	   nicotinamide	   amide	   substituent	   can	   be	   accommodated	   in	   two	   locations	   within	   the	  renalase	   active	   site	   and	   in	   these	   two	   binding	   modes	   the	   substrates	   are	   otherwise	  conformationally	  equivalent.	  Two	  orientations	  for	  the	  nicotinamide	  base	  implies	  there	  are	  also	   two	   binding	   modes	   for	   β-­‐NAD(P)H	   and	   for	   β-­‐NAD(P)+	   and	   that	   the	   dissociation	  constant	  measured	  for	  these	  molecules	  is	  an	  average	  of	  both	  binding	  modes.	  Moreover,	   it	  also	   follows	   that	  up	   to	  half	  of	   the	  binding	  events	   for	  2-­‐	  and	  6DHNAD	  result	   in	   inhibitory	  complexes	  that	  cannot	  transfer	  the	  hydride	  equivalent	  to	  the	  renalase	  flavin;	  that	  we	  do	  not	  observe	   any	   inhibitory	   delay	   in	   the	   reductive	   half	   reaction	   suggests	   that	   binding	   and	  release	  of	  2-­‐	  and	  6DHNAD	  from	  Renox	  is	  rapid.	  	   In	  prior	  studies	  we	  observed	   the	  reductive	  half-­‐reaction	  of	  renalase	  by	  mixing	   the	  enzyme	  with	  an	  apparent	  equilibrium	  mixture	  of	  β-­‐NADH	  and	  6DHNAD	  (54).	  Here	  we	  use	  pure	  preparations	  of	  2DHNAD	  and	  6DHNAD	  to	  show	  that	  the	  rate	  constant	  for	  reduction	  is	  dramatically	   more	   rapid	   than	   previously	   reported.	  We	   observe	   rate	   constants	   for	   flavin	  reduction	  of	  230	  s-­‐1	  for	  6DHNAD	  and	  860	  s-­‐1	  for	  2DHNAD	  as	  opposed	  to	  ~40	  s-­‐1	  observed	  
	  	  	   144	  
with	   the	   equilibrium	  mixture.	   We	   also	   show	   that	   renalase	   has	   only	   a	   modest	   ability	   to	  distinguish	   between	   the	   2-­‐,	   4-­‐	   and	   6DHNAD	   molecules	   (Figure	   4.3	   &	   4.4)	   as	   β-­‐NADH	  (4DHNAD)	  binds	  to	  renalase	  forming	  a	  complex	  with	  a	  dissociation	  constant	  of	  ~600	  µM,	  only	  ~3.5-­‐fold	  weaker	   than	   that	   observed	   for	   2-­‐	   and	   6DHNAD.	   However,	   renalase	   has	   a	  considerably	   greater	   capacity	   to	   distinguish	   between	   its	   substrates	   and	   β-­‐NAD(P)+	  molecules,	   the	   renalase	   complex(es)	   of	   which	   has	   an	   order	   of	   magnitude	   higher	  dissociation	   constant	   (Figure	   4.4B)(54).	   As	   such	   the	   relative	   high	   background	   of	   β-­‐NAD(P)H	  and	  β-­‐NAD(P)+	  in	  the	  cellular	  environment	  will	  populate	  and	  inhibit	  renalase	  to	  some	   extent.	   Given	   the	   ostensibly	   isosteric	   form	   of	   all	   three	   reduced	   isomers	   it	   is	   not	  unexpected	   that	   β-­‐NAD(P)H	   would	   compete	   for	   access	   to	   the	   renalase	   active	   site.	   The	  apparent	   lack	   of	  β-­‐NAD(P)H	   isomer	   binding	   stringency	   is	   only	   a	   limitation	   to	   the	   extent	  that	   2-­‐	   and	   6DHNAD	   accumulate	   in	  vivo.	   The	   considerable	   driving	   force	   for	   the	   renalase	  reaction	  derived	  from	  the	  reduction	  of	  dioxygen	  provides	  a	  rather	  unrelenting	  capacity	  to	  scavenge	  these	  substrates.	  Provided	  renalase	  activity	  can	  scavenge	  both	  isomers	  at	  a	  rate	  that	  meets	  or	  exceeds	  their	  formation,	  its	  metabolic	  contribution	  is	  sufficient.	  	  	  	  We	  have	  assessed	  the	  interaction	  of	  2-­‐	  and	  6DHNAD	  with	  three	  dehydrogenases	  from	  primary	  metabolic	  pathways.	  2-­‐	  and	  6DHNAD	  presumably	  act	  as	  inhibitors	  of	  these	  enzymes	  as	  they	  are	  highly	  similar	  in	  shape	  and	  electrostatic	  character	  to	  β-­‐NADH,	  yet	  cannot	  associate	  in	  a	  manner	  that	  permits	  hydride	  transfer.	  These	  data	  indicate	  that	  both	  MDH	  and	  LDH	  are	  subject	  to	  inhibition	  by	  both	  2-­‐	  and	  6DHNAD	  while	  DLD	  is	  not.	  Given	  the	  structural	  similarity	  of	  2-­‐,	  4-­‐	  and	  6DHNAD	  it	  is	  interesting	  that	  DLD	  can	  select	  only	  the	  4-­‐
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dihydro	  isomer	  while	  renalase,	  the	  enzyme	  apparently	  destined	  to	  rid	  the	  cell	  of	  2-­‐	  and	  6DHNAD,	  cannot.	  The	  inhibition	  of	  MDH	  by	  6DHNAD	  is	  an	  order	  of	  magnitude	  more	  potent	  suggesting	  that	  this	  interaction	  is	  the	  principal	  threat	  to	  primary	  metabolism	  from	  β-­‐NAD(P)H	  isomers.	  While	  the	  in	  vivo	  concentrations	  of	  2-­‐	  and	  6DHNAD	  are	  not	  known,	  such	  high	  affinity	  would	  suggest	  that,	  in	  the	  absence	  of	  renalase,	  even	  minute	  accumulations	  of	  6DHNAD	  would	  undermine	  primary	  energy	  pathways.	  While,	  2-­‐DHNAD	  is	  much	  less	  stable	  than	  6DHNAD,	  on	  a	  molecular	  timescale	  its	  half-­‐life	  is	  more	  than	  sufficient	  to	  expect	  that	  it	  will	  also	  exert	  an	  influence	  over	  key	  dehydrogenase	  enzymes.	  The	  extent	  of	  the	  threat	  these	  molecules	  pose	  is	  likely	  to	  be	  organism	  specific	  and	  it	  cannot	  yet	  be	  stated	  that	  dehydrogenase	  inhibition	  of	  this	  type	  is	  a	  universal	  phenomenon.	  That	  porcine	  DLD	  is	  not	  inhibited	  by	  either	  2-­‐	  or	  6DHNAD	  indicates	  that	  binding	  selectivity	  for	  these	  three	  forms	  of	  reduced	  β-­‐NADH	  is	  possible.	  However,	  renalase	  is	  found	  throughout	  the	  animalia	  implying	  that	  key	  dehydrogenases	  found	  within	  all	  organisms	  of	  this	  kingdom,	  such	  as	  rabbit	  LDH	  shown	  here,	  are	  subject	  to	  inhibition	  by	  β-­‐NADH	  isomers.	  	   As	   stated,	   in	   prior	   work	  we	  mistakenly	   proposed	   that	  α-­‐NAD(P)H	   anomers	  were	  substrates	   for	   renalase.	   It	   now	   seems	   appropriate	   to	   graft	   our	   earlier	   mechanistic	  observations	  with	  the	  data	  obtained	  in	  this	  study	  using	  pure	  2-­‐	  and	  6DHNAD.	  Scheme	  4.5	  depicts	  the	  proposed	  mechanism	  for	  renalase	  based	  on	  prior	  and	  current	  observations.	  For	  simplicity	  this	  scheme	  depicts	  only	  the	  catalytic	  cycle	  for	  the	  6DHNAD	  substrate	  though	  it	  is	   assumed	   that	   catalysis	   in	   the	   presence	   of	   2DHNAD	   differs	   only	   in	   the	   position	   of	   the	  nicotinamide	   amide	   substituent	   (meta	   with	   respect	   to	   the	   position	   depicted).	   In	   this	  catalytic	   cycle	   6DHNAD	   associates	   rapidly	   with	   a	   dissociation	   constant	   for	   the	   Renox•β-­‐
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6DHNAD(P)	  complex	  of	  170	  µM.	  The	  nicotinamide	   locates	   in	   the	  active	  site	  such	  that	   the	  ortho	  positions	  with	   respect	   to	   the	  dihydropyridyl	  nitrogen	  are	  adjacent	   to	   the	   flavin	  N5	  and	  oriented	  for	  conventional	  hydride	  transfer.	  Reduction	  of	  the	  flavin	  forms	  the	  Renred•	  β-­‐NAD(P)+	  complex.	  Our	  prior	  studies	   indicated	  that	  the	  reoxidation	  of	   this	  complex	  occurs	  by	  a	  bimolecular	  reaction	  with	  dioxygen	  with	  a	  rate	  constant	  of	  2.9x103	  M-­‐1s-­‐1	   that	   forms	  hydrogen	  peroxide	   and	   is	   fully	   rate	  determining	  under	   conditions	  of	   normal	  mammalian	  physiological	  oxygen	  concentration	  (~	  140	  µM)	  (54).	  The	  rate	  constant	  for	  reoxidation	  was	  not	   influenced	   by	   the	   addition	   of	   exogenous	  β-­‐NAD(P)+	   indicating	   that	   the	   reaction	  with	  dioxygen	   is	  neither	  contingent	  on	  nor	   influenced	  by	   the	   release	  of	  β-­‐NAD(P)+.	  Consistent	  with	   this	   observation	  was	   that	   the	   reduction	   potential	   of	   the	   renalase	   flavin	   is	   the	   same	  within	  error	   for	   the	  unliganded	  oxidized	  enzyme	  and	   the	  Renred•β-­‐NAD(P)+	   complex(54).	  As	  such	  the	  reoxidation/product	  release	  phase	  of	  catalysis	  is	  represented	  as	  random,	  but	  is	  kinetically	  ordered	  by	  the	  fact	  that	  β-­‐NAD(P)+	  is	  released	  somewhat	  more	  rapidly	  (20	  s-­‐1)	  than	  the	  reaction	  of	  the	  reduced	  enzyme	  with	  dioxygen	  under	  physiological	  conditions	  (0.4	  s-­‐1).	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Scheme	  4.5.	  The	  catalytic	  cycle	  of	  HsRen.	  	  	   The	  number	  and	  breadth	  of	  physiological	  observations	  associated	  with	  renalase	   is	  expanding	   in	   an	   exponential	  manner.	   In	   addition	   to	   being	   linked	   to	   the	   control	   of	   blood	  pressure	  and	  heart	  rate(1,	  6),	  renalase	  has	  also	  been	  associated	  with	  renal	  dopamine	  and	  phosphate	   metabolism	   (24,	   25),	   diabetes	   (15,	   330,	   342),	   and	   amelioration	   of	   myocardial	  damage	   (4).	   Our	   earlier	   conclusions	   were	   based	   on	   recycling	   of	  α-­‐anomers	   of	   NAD(P)H	  molecules	  and	  could	  not	  be	  linked	  to	  any	  known	  endocrine	  or	  other	  physiological	  role	  for	  renalase.	   While	   we	   make	   no	   attempt	   here	   to	   connect	   our	   current	   data	   to	   specific	  physiological	  responses,	  it	  does	  seem	  that	  the	  threat	  to	  normal	  primary	  metabolism	  posed	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by	   β-­‐NAD(P)H	   isomers	   does	   allow	   for	   renalase	   deficiencies	   to	  manifest	   as	   physiological	  abnormalities,	  in	  particular	  those	  associated	  with	  local	  ischemia.	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CHAPTER	  V	  
Renalase	  Does	  Not	  Catalyze	  the	  Oxidation	  of	  Catacholamines	  
	  Brett	  A.	  Beaupre,	  Matthew	  R.	  Hoag	  and	  Graham	  R.	  Moran	  	  
Abstract	  	   It	   is	   widely	   accepted	   that	   the	   function	   of	   human	   renalase	   is	   to	   oxidize	  catecholamines	  in	  blood.	  However,	  this	  belief	  is	  based	  on	  experiments	  that	  did	  not	  account	  for	   slow,	   facile	   catecholamine	   autoxidation	   reactions.	   Recent	   evidence	   has	   shown	   that	  renalase	   has	   substrates	   with	   which	   it	   reacts	   rapidly.	   The	   reaction	   catalyzed	   defines	  renalase	  is	  an	  oxidase,	  one	  that	  harvests	  two	  electrons	  from	  either	  2-­‐dihydroNAD(P)	  or	  6-­‐dihydroNAD(P)	   to	   form	   β-­‐NAD(P)+	   and	   hydrogen	   peroxide.	   The	   apparent	   metabolic	  purpose	   of	   such	   a	   reaction	   is	   to	   avoid	   inhibition	   of	   primary	   dehydrogenase	   enzymes	   by	  these	  β-­‐NAD(P)H	   isomers.	   This	   article	   demonstrates	   that	   renalase	   does	   not	   catalyze	   the	  oxidation	   of	   neurotransmitter	   catecholamines.	   Using	   high-­‐performance	   liquid	  chromatography	   we	   show	   that	   there	   is	   no	   evidence	   of	   consumption	   of	   epinephrine	   by	  renalase.	   Using	   time-­‐dependent	   spectrophotometry	   we	   show	   that	   the	   renalase	   FAD	  cofactor	   spectrum	   is	  unresponsive	   to	  added	  catecholamines,	   that	  adrenochromes	  are	  not	  observed	  to	  accumulate	  in	  the	  presence	  of	  renalase	  and	  that	  the	  kinetics	  of	  single	  turnover	  reactions	  with	  6-­‐dihydroNAD	  are	  unaltered	  by	   the	   addition	  of	   catecholamines.	   Lastly	  we	  show	  using	  an	  oxygen	  electrode	  assay	   that	  plasma	   renalase	  activity	   is	  below	   the	   level	  of	  detection	  and	  only	  when	  exogenous	  renalase	  and	  6-­‐dihydroNAD	  are	  added	  can	  dioxygen	  be	  observed	  to	  be	  consumed.	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Introduction.	  
	   Renalase	   is	   widely	   defined	   to	   be	   a	   kidney-­‐derived	   flavoprotein	   enzyme/hormone	  whose	   function	   is	   to	  oxidize	   circulating	   catecholamines	   in	  order	   to	   lower	  blood	  pressure	  and	  slow	  the	  rate	  of	  contraction	  of	  the	  heart	  (1,	  5,	  6,	  8,	  10-­‐12).	  The	  initial	  basis	  of	  this	  claim	  for	   renalase	   activity	  was	   an	   exceedingly	   small	   accumulation	  of	   hydrogen	  peroxide	   in	   the	  presence	   of	   common	   neurotransmitter	   catecholamines	   when	   assayed	   using	   a	   generic	  Amplex	  Red-­‐based	  oxidase	  assay.	  However,	  in	  these	  initial	  experiments	  no	  account,	  in	  the	  form	   of	   a	   control	   reaction,	   was	   made	   for	   background	   autoxidation	   (1,	   2,	   5,	   11,	   36).	  Catecholamines	  are	  prone	  to	  oxidation	  in	  the	  presence	  of	  dioxygen	  due	  to	  their	  capacity	  to	  form	   semiquinones	   (343).	   The	   superoxide	   ion	   that	   results	   rapidly	   disproportionates	   to	  dioxygen	  and	  hydrogen	  peroxide	  providing	  a	  steady	  non-­‐enzymatic	  background	  signal	  for	  an	   Amplex	   Red	   assay	   (Scheme	   5.1).	   The	   very	   low	   level	   of	   H2O2	   production	   was	  subsequently	   rationalized	  by	  proposing	   that	   renalase	   is	   isolated	   in	  a	  quiescent	   state	   that	  can	  only	  be	  activated	  in	  blood	  in	  the	  presence	  of	  specific	  catecholamine	  neurotransmitters	  (11,	   36).	   The	   chemical	   transformation	   ultimately	   claimed	   for	   renalase	  was	   that	   oxidized	  and	  cyclized	  aminochrome	  molecules	  were	  the	  native	  products	  and	  that	  the	  reaction	  was	  somewhat	  faster	  in	  the	  presence	  of	  NAD(P)H	  (36).	  However,	  even	  in	  these	  latter	  studies,	  no	  control	   was	   made	   for	   the	   addition	   of	   the	   catecholamine	   or	   the	   reductant,	   despite	   that	  	  NAD(P)H	  would	  greatly	  increase	  the	  complexity	  of	  the	  assay	  by	  increasing	  the	  number	  of	  non-­‐enzymatic	   redox	   reactions	   that	   yield	   H2O2	   (Scheme	   5.1).	   That	   no	   control	   reactions	  were	   used	   to	   support	   any	   of	   the	   early	   catalytic	   claims	   emphasizes	   the	   overall	   tenuous	  foundation	  on	  which	  renalase	  catecholamine	  oxidase	  activity	  is	  based.	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Scheme	  5.1.	  Non-­‐enzymatic	  redox	  reations	  in	  renalase	  catecholamine	  oxidase	  assays.	  	  	   Boomsma	  and	  Tipton	  were	  first	  to	  register	  well-­‐reasoned	  skepticism	  concerning	  a	  catecholamine	  oxidase	  role	  for	  renalase	  (48)	  and	  were	  joined	  by	  others	  expressing	  similar	  dissent	  and	  eventually	  direct	  experimental	  refutation	  was	  presented	  by	  Pandini	  et	  al.	  (20,	  
51,	  59).	  However,	  the	  flawed	  initial	  in	  vitro	  evidence	  and	  counter	  evidence	  have	  been	  insufficient	  to	  quell	  the	  passive	  consensus	  that	  the	  function	  of	  renalase	  is	  to	  oxidatively	  consume	  catecholamine	  neurotransmitters	  from	  blood.	  Consequently,	  the	  early	  claims	  for	  catecholamine	  oxidase	  activity	  continue	  to	  be	  adduced	  and	  correlated	  with	  a	  wide	  variety	  of	  physiological	  measurements	  (2-­‐29,	  31,	  37,	  39,	  332).	  	  	   We	  recently	  demonstrated	  that	  2-­‐dihydroNAD	  (2DHNAD(P))	  and	  6-­‐dihydroNAD(P)	  (6DHNAD(P)),	   both	   isomers	   of	   β-­‐NAD(P)H	   (4DHNAD(P)),	   rapidly	   reduce	   the	   FAD	  coenzyme	  of	  renalase	  (230	  s-­‐1	  for	  6DHNAD,	  850	  s-­‐1	  for	  2DHNAD)	  and	  in	  doing	  so	  become	  oxidized	  to	  β-­‐NAD(P)+.	  The	  reduced	  enzyme	  then	  reoxidizes	  by	  reducing	  molecular	  oxygen	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to	  H2O2	  (2.9	  x	  103	  M-­‐1s-­‐1)	  (Scheme	  5.2).	  Moreover,	  this	  genuinely	  catalytic	  reaction	  has	  an	  apparent	  metabolic	  purpose,	  as	  both	  2DHNAD	  and	  6DHNAD	  that	  are	  inhibitory	  to	  primary	  metabolism	  dehydrogenases	  (55,	  339).	  The	  fundamental	  purpose	  of	  this	  study	  is	  corrective;	  using	   a	   verifiably	   active	   form	   of	   renalase,	   we	   demonstrate	   that	   no	   catalytic	   link	   exits	  between	   renalase	   and	   catecholamine	   oxidation.	   We	   show	   also	   that	   renalase	   it	   is	   not	  activated	  by	  blood	  plasma	  nor	  is,	  what	  we	  surmise	  to	  be,	  the	  native	  activity	  influenced	  by	  the	  presence	  catecholamines.	  
	  
Scheme	  5.2.	  Proposed	  native	  catalytic	  chemistry	  of	  renalase.	  	  
Materials	  and	  Methods.	  
Materials.	  Potassium	  phosphate,	  L-­‐DOPA,	  epinephrine	  hydrochloride,	  and	  sodium	  chloride	  were	   obtained	   from	   ACROS.	   Dopamine	   hydrochloride	   was	   purchased	   from	   Alfa	   Aesar.	  Renalase	  was	  expressed	  and	  purified	  according	  to	  our	  previously	  published	  methods(319).	  
β-­‐NADH	   (disodium	   salt,	   trihydrate)	  was	   obtained	   from	  Amresco;	  β-­‐NAD+	  was	   purchased	  from	  Sigma.	  6DHNAD	  was	  prepared	  by	  reduction	  of	  β-­‐NAD+	  as	  previously	  described	  (55).	  Human	  blood	  plasma	  was	  a	  gift	   from	  Dr.	   Julie	  A.	  Oliver	   (Biological	   Sciences	  Department-­‐Univeristy	   of	   Wisconsin-­‐Milwaukee).	   Freshly	   drawn	   blood	   was	   treated	   with	   10	   U/mL	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heparin	  (Sagent	  Pharmaceuticals)	  to	  inhibit	  clotting.	  The	  sample	  was	  centrifuged	  at	  2,200	  rpm	  until	  blood	  cell	  pellet	  was	  formed	  (~15	  minutes).	  The	  plasma	  was	  separated	  from	  the	  blood	   cell	   pellet	   and	   hematocrit	   and	   stored	   on	   ice	   until	   needed.	   Plasma	   samples	   were	  collected,	  purified,	  diluted	  (50%	  PBS),	  and	  used	  in	  experiments	  within	  3	  hours.	  	  
HPLC	   Product	   Analysis:	   In	   order	   to	   demonstrate	   the	   extent	   to	   which	   epinephrine,	   the	  catecholamine	  most	  often	  claimed	  or	  accepted	  as	  a	  substrate	  for	  renalase	  (1,	  3,	  6,	  10,	  11),	  is	  consumed	   by	   renalase,	   a	   mixture	   of	   β-­‐NADH	   (50	   µM)	   and	   epinephrine	   (150	   µM)	   was	  prepared	  in	  PBS	  buffer	  at	  25	  oC.	  The	  sample	  was	  then	  divided	  into	  two	  and	  renalase	  (9	  µM	  final)	  was	  added	  to	  one	  while	  the	  other	  served	  the	  role	  of	  a	  sample	  age	  control.	  A	  second	  set	  of	  mixtures	  were	  prepared	  in	  an	  identical	  manner,	  but	  FAD	  (9	  µM	  final)	  was	  added	  in	  place	  of	  renalase.	  All	  samples	  were	  incubated	  for	  10	  minutes	  prior	  to	  ultrafiltration	  using	  a	  0.5	  mL	  Amicon	  10	  KDa	   centrifugal	   filter	   (removing	   renalase	   from	   the	  mixture).	   50	  µL	  of	  each	   filtrate	   was	   then	   chromatographed	   by	   HPLC	   using	   a	   Xterra	   C18	   reversed	   phase	  column	   (4.6	   x	   150	   mm,	   3.5	   µM	   particle	   size)	   run	   isocratically	   at	   0.4	   ml/min	   in	   10	   mM	  potassium	   phosphate	   pH	   7.5	   coupled	   to	   a	   600	   E	   HPLC	   pump	   and	   Waters	   2487	   dual	  wavelength	   detector	   (260nm	   and	   340nm).	   Components	   eluting	   from	   the	   HPLC	   column	  were	   identified	  by	   their	   characteristic	   retention	   time	   compared	   to	   authentic	   compounds.	  The	   chromatograms	   derived	   from	   the	   renalase	   and	   FAD	   samples	  were	   corrected	   for	   the	  minor	  dilution	  that	  occurred	  with	  the	  addition	  of	  these	  components.	  
Spectrophotometric	  Evidence	  of	  Neurotransmitter	  Oxidation:	  Reactions	  were	  performed	  to	  assess	  the	  rates	  of	  autoxidation	  of	  catecholamines	  in	  the	  presence	  of	  renalase	  (or	  FAD	  control)	  when	  incubated	  with	  a	  reductant	  (β-­‐NADH	  or	  6DHNAD).	  Renalase	  was	  prepared	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by	  dilution	  to	  40	  µM	  in	  2x	  PBS	  buffer	  and	  mounted	  onto	  a	  onto	  a	  Hitech-­‐DX2	  (now	  TgK)	  stopped-­‐flow	  spectrophotometer	  instrument.	  Reaction	  mixtures	  in	  which	  renalase	  (or	  FAD	  control)	  was	  combined	  with	  100	  µM	  catecholamine	  (epinephrine,	  dopamine	  or	  L-­‐DOPA)	  and	  15	  µM	  β-­‐NADH	  (or	  6DHNAD	  control)	  in	  water	  were	  observed	  at	  458	  nm	  which	  allows	  observation	  of	  both	  the	  FAD	  redox	  state	  and	  the	  formation	  of	  aminochrome	  species	  (lmax~480	  nm).	  All	  solutions	  were	  equilibrated	  with	  atmosphere	  at	  25	  oC	  and	  contained	  ~250	  µM	  dioxygen.	  	   To	  assess	  if	  catecholamine	  neurotransmitters	  (epinephrine,	  dopamine	  and	  L-­‐DOPA)	  modulate	  the	  catalytic	  behavior	  of	  renalase,	  single	  turnover	  reactions	  with	  6DHNAD	  were	  performed	  in	  the	  presence	  and	  absence	  of	  catecholamines	  with	  atmospheric	  dioxygen	  (~250	  µM).	  Under	  these	  conditions	  the	  reduction	  and	  subsequent	  reoxidation	  of	  the	  renalase	  flavin	  coenzyme	  can	  be	  clearly	  observed.	  A	  native	  substrate	  solution,	  6DHNAD	  (30	  µM),	  was	  prepared	  in	  H2O.	  This	  solution	  was	  mounted	  onto	  the	  stopped-­‐flow	  spectrophotometer	  and	  mixed	  with	  the	  renalase	  (40	  µM)	  sample	  described	  above	  and	  the	  turnover	  was	  observed	  at	  458	  nm,	  the	  visible	  absorption	  maximum	  for	  the	  FAD	  coenzyme	  bound	  to	  the	  enzyme.	  To	  determine	  if	  catecholamine	  neurotransmitters	  modulate	  the	  turnover	  of	  renalase,	  200	  µM	  of	  epinephrine,	  dopamine	  or	  L-­‐DOPA	  was	  added	  to	  the	  6DHNAD	  solution	  before	  mixing.	  	  
	  
Dioxygen	  Consumption	  to	  Assess	  Renalase	  Activity	  in	  Blood	  and	  the	  Affect	  of	  Preincubation:	  In	  order	  to	  establish	  the	  constitutive	  level	  of	  renalase	  activity	  in	  human	  blood	  and	  the	  effect	  of	  preincubation	  with	  plasma	  and/or	  epinephrine	  as	  compared	  to	  PBS	  buffer	  control,	  a	  variety	  of	  assays	  were	  monitored	  by	  dioxygen	  consumption.	  Reactions	  were	  observed	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using	  a	  Hansatech	  Oxygraph	  oxygen	  electrode	  and	  all	  reaction	  components	  were	  pre-­‐equilibrated	  with	  atmospheric	  dioxygen	  (~250	  µM)	  at	  25oC.	  Reactants	  were	  added	  to	  the	  following	  final	  concentrations:	  50%	  human	  blood	  plasma	  (diluted	  in	  PBS	  buffer),	  10	  µM	  epinephrine,	  500	  nM	  renalase	  and	  30	  µM	  6DHNAD.	  Each	  assay	  was	  initiated	  by	  the	  addition	  of	  6DHNAD,	  following	  either	  a	  5	  minute	  or	  20	  minute	  preincubation	  and	  then	  observed	  for	  an	  additional	  700	  seconds.	  	  
Results.	  
HPLC	  Product	  Analysis:	  Renalase	  is	  claimed	  to	  consume	  neuroactive	  catecholamines,	  chiefly	  epinephrine,	  in	  order	  to	  lower	  blood	  pressure(36).	  To	  demonstrate	  the	  extent	  to	  which	  verified	  active	  renalase	  can	  consume	  epinephrine	  in	  the	  presence	  of	  β-­‐NADH,	  standardized	  HPLC	  chromatograms	  were	  collected	  and	  compared	  to	  controls	  that	  contained	  FAD	  in	  place	  of	  renalase	  (Figure	  5.1).	  150	  µM	  Epinephrine	  was	  combined	  with	  50	  µM	  β-­‐NADH	  (that	  has	  a	  β-­‐NAD+	  impurity).	  The	  sample	  was	  divided	  into	  two	  and	  renalase	  added	  to	  one.	  Both	  samples	  were	  then	  incubated	  for	  10	  minutes	  (Figure	  5.1A).	  Two	  similar	  mixtures	  were	  prepared	  as	  controls	  but	  with	  FAD	  substituted	  for	  renalase	  (Figure	  5.1B).	  Analysis	  of	  the	  chromatograms	  showed	  that	  no	  significant	  consumption	  of	  epinephrine	  could	  be	  observed	  in	  the	  10-­‐minute	  window	  of	  the	  incubation.	  The	  renalase	  sample	  did	  show	  significant	  loss	  of	  β-­‐NADH	  (11	  µM)	  that	  was	  not	  entirely	  accounted	  for	  by	  a	  gain	  in	  the	  β-­‐NAD+	  peak	  area	  (2	  µM).	  This	  fraction	  of	  the	  β-­‐NADH	  was	  accounted	  for	  by	  the	  modest	  dissociation	  constant	  for	  Renox•β-­‐NADH	  complex	  (Kd~600	  µM)	  and	  the	  ~20-­‐fold	  increase	  in	  the	  renalase	  concentration	  (180	  µM)	  during	  filtration	  that	  together	  predict	  the	  11	  µM	  retention.	  (55).	  The	  FAD	  control	  chromatograms	  indicate	  no	  non-­‐enzymatic	  chemistry	  has	  occurred	  within	  the	  10	  minute	  incubation	  window.	  Together	  these	  data	  definitively	  show	  that	  the	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consumption	  of	  epinephrine	  cannot	  be	  detected	  in	  the	  presence	  of	  high	  concentrations	  (9	  µM)	  of	  fully	  active	  renalase.	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Figure	  5.1.	  HPLC	  analysis	  of	  oxidation	  of	  epinephrine	  to	  adrenochrome	  by	  renalase.	  A&B	  were	  separated	  using	  a	  Xterra	  reverse	  phased	  C18	  run	  isocratically	  in	  10	  mM	  Kpi,	  pH	  7.5	  and	  monitored	  at	  260	  nm.	  A:	  The	  blue	  line	  represents	  the	  mixture	  of	  150	  µM	  epinephrine	  and	  50	  µM	  β-­‐NADH	  (4DHNAD)	  in	  PBS	  buffer	  at	  25oC	  before	  the	  addition	  of	  9	  µM	  renalase	  and	  the	  red	  trace	  was	  taken	  after	  the	  addition	  of	  9	  µM	  renalase	  and	  incubation	  for	  10	  minutes	  at	  25oC;	  renalase	  was	  removed	  from	  the	  sample	  by	  centrifugal	  (Amicon)	  ultra-­‐filtration	  prior	  to	  injection.	  B:	  The	  reaction	  described	  in	  A	  was	  repeated	  except	  FAD	  was	  substituted	  for	  renalase.	  	  	  	  
Spectrophotometric	  Evidence	  of	  Neurotransmitter	  Oxidation:	  Renalase	  has	  been	  reported	  to	  oxidize	  catecholamines	  to	  aminochromes	  (Scheme	  5.1)(2).	   It	  has	  also	  been	  proposed	  that	  catecholamines	  modulate	   the	   redox	   activity	   of	   renalase	   to	   the	   extent	   that	   the	   enzyme	   is	  largely	   inactive	   in	   the	   absence	   of	   epinephrine	   (36).	   	   In	   order	   to	   show	   the	   capacity	   of	  renalase	   to	   oxidize	   catecholamines	   to	   form	   aminochromes,	   two	   sets	   of	   reactions	   were	  performed	  one	  in	  the	  presence	  and	  one	  in	  the	  absence	  of	  renalase.	  Aminochromes	  are	  the	  oxidized	  and	  cyclized	  forms	  of	  catecholamines	  that	  have	  a	  puce	  color	  as	  a	  result	  of	  a	  broad	  absorption	  centered	  around	  480	  nm	  (ε480	  ~4020	  M-­‐1cm-­‐1)	  which	  provides	  a	  simple	  physical	  signal	  to	  observe	  their	  accumulation	  in	  solution.	  The	  absorption	  peak	  of	  aminochromes	  is	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sufficiently	   broad	   that	   at	   458	   nm,	   the	   wavelength	   of	   observation	   used,	   the	   extinction	  coefficient	   is	  only	  2%	  lower,	  permitting	  simultaneously	  assessment	  of	   the	  FAD	  coenzyme	  and	   the	   catecholamine	   oxidation/cyclization.	   Three	   common	  neuroactive	   catecholamines	  were	  mixed	  with	  reductant	  (β-­‐NADH	  or	  6DHNAD)	  and	  renalase	  (20	  µM	  final)	  or	  FAD	  (20	  µM	   final).	   In	   the	   first	   control	   β-­‐NADH	   was	   combined	   with	   epinephrine,	   L-­‐DOPA,	   or	  dopamine	  and	   subsequently	  mixed	  with	   renalase	   to	  determine	   if	   renalase	   could	  enhance	  the	  rate	  of	  oxidation	  of	  the	  catechols	  to	  their	  associated	  aminochromes	  in	  the	  presence	  of	  NADH.	  No	  change	  in	  absorbance	  was	  observed	  indicating	  that	  renalase	  does	  not	  promote	  the	   oxidation	   and	   cyclization	   catecholamines.	   As	   a	   control,	   FAD	   was	   substituted	   for	  renalase	   and	   the	   above	   experiment	   repeated.	   This	   data	   showed	   small	   accumulations	   of	  absorption	   (epinephrine,	   0.0035;	   DOPA,	   0.015;	   L-­‐DOPA,	   0.0025)	   equating	   to	   ~	   1-­‐3	   µM	  aminochrome	   after	   300	   seconds,	   indicating	   that	   a	  mixture	   of	  β-­‐NADH	   and	   free	   FAD	   can	  enhance	  the	  rate	  of	  catecholamine	  autoxidation	  and	  that	  renalase	  actually	  provides	  some	  degree	   of	   protection	   from	   this	   chemistry	   presumably	   as	   a	   result	   of	   the	   active	   site	   flavin	  being	   inherently	   unreactive	   with	   β-­‐NAD(P)H	   molecules	   in	   order	   to	   avoid	   wasteful	  diaphorase	  activity.	  	  	   In	  our	  previous	  work	  we	  have	  demonstrated	  that	  renalase	  catalyzes	  rapid	  oxidation	  of	   6DHNAD(P)	   and	   2DHNAD(P)	   to	   β-­‐NAD(P)+	   where	   a	   hydride	   equivalent	   is	   transfered	  from	   the	   nicotinamide	   base	   to	   the	   renalase	   flavin	   coenzyme	   that	   then	   reoxidizes	   by	  reducing	  dioxygen	  to	  form	  hydrogen	  peroxide	  (Scheme	  5.2)	  (54,	  55,	  319).	  In	  order	  to	  show	  the	  extent	  of	   the	   influence	  of	   catecholamines	  on	   the	  kinetics	  of	   this	   chemistry,	   reduction	  and	   reoxidaton	   of	   the	   renalase	   flavin	   coenzyme	   that	   occurs	   in	   single	   turnover	   with	  6DHNAD	  was	  observed	  at	  458	  nm	  (Figure	  5.2B).	  The	  data	  obtained	   indicate	   that	  neither	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epinephrine,	  L-­‐DOPA,	  or	  dopamine	  have	  influence	  on	  the	  catalytic	  behavior	  of	  renalase.	  The	  FAD,	   6DHNAD	   (±	   catecholamines)	   control	   for	   the	   single	   turnover	   reactions	   where	  ostensibly	  the	  same	  as	  those	  for	  FAD,	  β-­‐NADH	  and	  catecholamine	  in	  Figure	  5.1A	  (data	  not	  shown).	  	  
	  
Figure	   5.2.	   Catalytic	   turnover	   of	   renalase	   in	   the	   presence	   of	   neurotransmitters.	   A&B:	  Renalase	   single	   turnover(B)	  and	  control(A)	   stopped-­‐flow	  spectrophotometer	   traces	  were	  observed	   at	   458	   nm	   for	   200	   sec.	   A:	   The	   extent	   of	   auto-­‐oxidation	   of	   epinephrine	   was	  monitored;	   top,	   stopped-­‐flow	   spectrophotometer	   trace	   of	   20	   µM	   renalase	  with	   15	   µM	  β-­‐NADH(4DHNAD)	   in	   the	   absence	   and	   presence	   of	   100	   µM	   catecholamine	   of	   interest	  (epinephrine,	   DOPA,	   L-­‐DOPA);	   bottom;	   stopped-­‐flow	   spectrophotometer	   trace	   of	   20	   µM	  FAD	  with	  15	  µM	  β-­‐NADH(4DHNAD)	  and	  100	  µM	  of	  catecholamine	  of	  interest	  (epinephrine,	  DOPA,	  L-­‐DOPA).	  B:	  Single	  turnover	  of	  20	  µM	  renalase	  with	  15	  µM	  6DHNAD	  in	  the	  absence	  and	  presence	  of	  100	  µM	  catecholamine	  of	  interest	  (epinephrine,	  DOPA,	  L-­‐DOPA).	  	  
Dioxygen	  Consumption	  to	  Assess	  Renalase	  Activity	   in	  Blood	  and	  the	  Affect	  of	  Preincubation:	  There	  are	  three	  near	  constant	  elements	  in	  all	  scientific	  articles	  that	  pertain	  to	  renalase;	  all	  claims	   for	   activity	   involve	   the	   reduction	   of	   dissolved	   dioxygen,	   most	   report	   or	   cite	   that	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catecholamines	   are	   substrates	   and	   the	  majority	   pivot	   their	   investigations	   on	   the	   role	   of	  renalase	   in	   blood(51,	   52).	   Moroever,	   the	   low	   in	   vitro	   catecholamine	   oxidase	   activity	   has	  been	   claimed	   to	   be	   a	   consequence	   of	   a	   “prorenalase”	   form	   that	   is	   largely	   inactive	  when	  separated	   from	   some	   unidentified	   activator	   (2,	   11).	   Given	   that	   renalase	   oxidizes	   2-­‐	   and	  6DHNAD(P)(55),	   does	   renalase	   exhibit	  modified	   catalytic	   behavior	   in	   blood?	   In	   order	   to	  demonstrate	   the	   effects	   of	   preincubation	   with	   catecholamine	   and/or	   blood	   plasma	   we	  conducted	   a	   series	   of	   assays	   using	   an	   oxygen	   electrode	   (Figure	   5.3).	   All	   assays	   had	  6DHNAD	  added	  either	  after	  a	  short	  (5	  min)	  or	  long	  (20	  min)	  preincubation.	  	   In	  Figure	  5.3,	  assays	  1	  &	  6,	  we	  see	  that	  epinephrine	  is	  slow	  to	  oxidize	  and	  does	  not	  promote	  significant	  consumption	  of	  dioxygen	  prior	  to	  or	  after	  the	  addition	  of	  6DHNAD.	  In	  addition,	  assays	  1	  &	  5	  indicate	  that	  the	  basal	  level	  of	  renalase	  activity	  in	  blood	  is	  sufficiently	  low	   to	  be	  below	   the	   sensitivity	  of	   these	  methods.	  Using	  antibody	  detection,	  Zbroch	  et	   al.	  determined	   that	   the	   concentration	   of	   renalase	   in	   plasma	   was	   4	   µg/mL	   (100	   nM)	   (25)	  approximately	  one	   fifth	  of	   the	  exogenous	  concentration	  added	   in	  assays	  2,	  3,	  4,	  7,	  8	  &	  9.	  That	   each	   of	   these	   traces	   show	  marked	   dioxygen	   consumption	  with	   added	   renalase	   and	  those	  without	   show	  no	  dioxygen	   consumption	   (assays	  1	  &	  5)	   suggests	   that	   there	   is	   very	  little	  renalase	  in	  blood	  or	  that	  the	  majority	  of	  it	  is	  inactive.	  Comparison	  of	  assays	  2	  &	  4	  to	  assays	  7	  &	  9	  indicates	  that	  preincubation	  of	  renalase	  in	  plasma	  does	  not	  alter	  its	  behavior.	  Both	   sets	   of	   assays	   indicate	   linear	   consumption	   of	   dioxygen	   that	   is	   equimolar	   to	   the	  amount	  of	  6DHNAD	  added	  and	  then	  cessation	  of	  activity.	  Assays	  2,	  3	  &	  4	  show	  recovery	  of	  approximately	  half	  the	  dioxygen	  consumed	  in	  the	  renalase	  catalytic	  phase	  presumably	  as	  a	  consequence	   of	   catalase	   activity	   in	   the	   plasma.	   Contrary	   to	   claims	   that	   epinephrine	  activates	   renalase	   (36),	   neither	   assay	   1	   or	   6,	   those	   preincubated	   with	   epinephrine	   in	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plasma	  and	  PBS	   respectively,	   show	  any	   evidence	  of	   activity,	   strongly	   suggesting	   that	   the	  circulating	  catecholamine	  does	  not	  activate	  a	  quiescent	  form	  of	  renalase.	  	  
	  
Figure	   5.3.	   The	   Effect	   of	   Catecholamine	   and	   Plasma	   Preincubation.	   Renalase	   activity	   in	  50%	  blood	  plasma	  and	  PBS	  buffer	  was	  determined	  by	  monitoring	  dioxygen	  consumption.	  	  Reactions	  were	  performed	  by	  reacting	  30	  µM	  6DHNAD	  ion	  the	  absence	  or	  presence	  of	  500	  nM	  renalase	  and	  10	  µM	  epinephrine	  in	  either	  PBS	  buffer	  or	  50	  %	  blood	  plasma.	  Traces	  1,	  2,	  6,	  and	  7(from	  top)	  were	  incubated	  at	  25oC	  for	  20	  minutes	  prior	  to	  the	  addition	  of	  6DHNAD	  all	   other	   traces	   were	   incubated	   at	   25oC	   for	   5	   minutes	   before	   6DHNAD	   addition.	   Traces	  were	  	  aligned	  so	  the	  addition	  of	  6DHNAD	  appears	  in	  the	  same	  time	  position	  in	  all	  reactions.	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Discussion.	  
	   The	   chronology	   of	   reported	   activities	   for	   renalase	   elaborate	   the	   erroneous	   initial	  claim.	  In	  the	  progenitor	  article	   it	  was	  proposed	  that	  renalase	  is	  secreted	  by	  the	  kidney	  to	  oxidize	   circulating	   catecholamines	   and	   that	   the	   electrons	   mobilized	   are	   delivered	   to	  dioxygen	   (1).	   However,	   this	   was	   surmised	   only	   from	   the	   data	   obtained	   from	   a	   generic	  oxidase	   assay	   method	   and	   without	   the	   use	   of	   appropriate	   controls.	   Nonetheless,	   the	  association	   of	   renalase	   with	   catecholamines	   continues	   to	   become	   ever	   more	   conflated.	  Catecholamines	  are	  said	  to	  regulate	  the	  activity,	  secretion	  and	  synthesis	  of	  renalase	  (11).	  A	  variety	   of	   complex	   regulatory	   feedback	   pathways	   have	   been	   proposed	   (3,	   5,	   11,	   12,	   14).	  Aminochromes	  are	  claimed	  as	  the	  native	  products	  (2)	  and	  the	  active	  oxidizing	  agent	  is	  said	  to	  be	  superoxide	  (36).	  However,	  the	  extremely	  low	  levels	  of	  claimed	  in	  vitro	  catecholamine	  oxidase	  activity	  has	  been	  cited	  as	  a	  deficit	  by	  a	  number	  of	  researchers	  (48,	  51,	  60)	  and	  this	  was	   then	  rationalized	  by	   invoking	   “prorenalase”	  a	   claimed	  quiescent	   form	  of	   the	  enzyme	  that	   requires	   activation	   (11,	   12)	   that	   occurs	   only	   in	   blood	   in	   the	   presence	   of	   a	  catecholamine	   (11,	   36).	   It	   can	   now	   be	   stated	   with	   some	   certainty	   that	   this	   successive	  affirmative	  set	  of	  claims	  describes	  a	  compounding	  of	  an	  initial	  scientific	  deficit;	  the	  failure	  to	  employ	  appropriate	  control	  reactions	  to	  assess	  catalysis.	  
	   The	   purpose	   of	   this	   study	   is	   to	   clearly	   demonstrate	   that	   renalase	   is	   not	   the	   third	  monoamine	  oxidase.	  The	  apparently	  indelible	  mark	  of	  the	  early	  and	  recent	  activity	  claims	  for	  renalase	  must	  be	  dispelled	  if	  the	  field	  is	  to	  advance	  in	  a	  purposeful	  manner.	  We	  recently	  reported	   two	   isomeric	   forms	   of	   β-­‐NAD(P)H	   as	   substrates	   for	   renalase	   that	   are	   clearly	  catalytically	   consumed	   (Figure	   5.2B)	   and	   have	   redefined	   renalase	   as	   having	   a	   house-­‐
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keeping	  activity	  that	  is	  unrelated	  to	  blood	  pressure	  regulation.	  Renalase	  functions	  instead	  to	  oxidize	  reduced	  forms	  of	  nicotinamide	  adenine	  dinucleotides	  that	  harbor	  the	  hydride	  in	  non-­‐metabolically	  accessible	  positions	  of	  the	  nicotinamide	  base	  (positions	  2	  &	  6).	  We	  have	  proposed	   that	   this	   activity	   exists	   to	   relieve	   inhibition	   of	   primary	   metabolism	   by	   these	  molecules.	  A	  principal	  benefit	  of	  having	  identified	  native	  substrates	  for	  renalase	  is	  that	  we	  can	  now	  test	  the	  validity	  of	  previously	  proposed	  activities	  using	  a	  form	  of	  the	  enzyme	  that	  we	  have	  verified	  is	  fully	  active	  (Figure	  5.2B)	  (55).	  In	  sum	  our	  data	  show	  that	  renalase	  does	  not	   consume	   catecholamines	   (Figures	   5.1	   &	   5.2A),	   is	   not	   kinetically	   regulated	   by	  catecholamines	   (Figure	  5.2B),	   is	   not	   isolated	   in	   an	   inhibited	   form	  and	   as	   such	   cannot	   be	  activated	  by	  blood	  plasma	  or	   catecholamines	   (Figure	  5.3).	   In	   addition,	   our	  data	   suggests	  that	  blood	  has	  very	  little	  if	  any	  active	  renalase	  (Figure	  5.3)	  an	  observation	  that	  is	  consistent	  with	   its	   newly	   identified	   activity	   that	   we	   would	   suggest	   has	   an	   exclusively	  intracellular/metabolic	  role.	  
	   Catecholamines	  form	  hydrogen	  peroxide	  as	  they	  oxidize	  in	  oxygenated	  media.	  That	  the	   initial	  accounts	  of	   renalase	  activity	  did	  not	  employ	  appropriate	  control	   reactions	  and	  reported	  vanishingly	  low	  activity	  undermines	  the	  subsequent	  affirmative	  claims.	  The	  case	  has	  also	  been	  made	  that	  in	  the	  absence	  of	  genuine	  substrates,	  no	  sample	  integrity	  measures	  have	  been	  established	  and	  as	  such	  there	  has	  been	  no	  means	  to	  discriminate	  natively	  folded	  and	  active	  renalase	  from	  misfolded	  inactive	  but	  soluble	  renalase	  (51).	  The	  vast	  majority	  of	  reports	  that	  describe	  direct	  use	  of	  the	  enzyme	  do	  not	  indicate	  the	  color	  of	  the	  protein	  (that	  is	   conspicuously	   yellow)	   or	   the	   unique	   absorption	   maxima	   of	   the	   flavin	   in	   the	   natively	  folded	   enzyme	   (61).	   Nonetheless,	   in	   the	   ten	   years	   since	   its	   initial	   discovery,	   the	   terms	  renalase	  and	  monoamine	  oxidase	  C	  have	  become	  somewhat	  synonymous	  (14,	  301,	  344)	  and	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this	  has	  occurred	  despite	  sound	  argument	  and	  evidence	  to	  the	  contrary	  (48,	  51,	  59).	  In	  this	  article	   we	   have	   presented	   evidence	   that	   verifiably	   active	   renalase	   does	   not	   catalyze	   the	  oxidization	  of	  catecholamines.	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CHAPTER	  VI	  
Bacterial	  Renalase:	  Structure	  and	  Kinetics	  of	  an	  Enzyme	  with	  2-­‐	  and	  6-­‐Dihydro-­‐β-­‐
NAD(P)	  Oxidase	  Activity	  from	  Pseudomonas	  phaseolicola.	  	  Matt	  R.	  Hoag,	  Joseph	  Roman,	  Brett	  A.	  Beaupre,	  Nicholas	  R.	  Silvaggi,	  Graham	  R.	  Moran	  	  
Abstract	  	   Despite	  a	  lack	  of	  convincing	  in	  vitro	  evidence	  and	  a	  number	  of	  sound	  refutations,	  it	  is	   widely	   accepted	   that	   renalase	   is	   an	   enzyme	   unique	   to	   animals	   that	   catalyzes	   the	  oxidative	   degradation	   of	   catecholamines	   in	   blood	   in	   order	   to	   lower	   vascular	   tone.	   Very	  recently,	   we	   identified	   isomers	   of	   β-­‐NAD(P)H	   as	   substrates	   for	   renalase.	   (55)	   These	  molecules	  carry	  the	  hydride	  equivalent	  on	  the	  two	  or	  six	  position	  of	  the	  nicotinamide	  base	  and	   presumably	   arise	   in	   non-­‐specific	   redox	   reactions	   of	   nicotinamide	   dinucleotides.	  Renalase	   serves	   to	   rapidly	   oxidize	   these	   isomers	   to	   form	   β-­‐NAD(P)+	   and	   then	   pass	   the	  electrons	   to	   dioxygen	   forming	  H2O2.	  We	  have	   also	   shown	   that	   these	   substrate	  molecules	  are	  highly	   inhibitory	   to	  dehydrogenase	  enzymes	  and	   thus	  have	  proposed	  an	   intracellular	  metabolic	   role	   for	   this	   enzyme.	  Here	  we	   identify	   a	   renalase	   from	  an	  organism	  without	   a	  circulatory	  system.	  This	  bacterial	  form	  of	  renalase	  has	  the	  same	  substrate	  specificity	  profile	  as	  human	  renalase	  but,	   in	  terms	  of	  binding	  constant	  (Kd),	  shows	  a	  marked	  preference	  for	  substrates	  derived	  from	  β-­‐NAD+.	  However,	  2-­‐dihydroNAD(P)	  substrates	  reduce	  the	  enzyme	  with	  rate	  constants	  (kred)	  that	  greatly	  exceed	  those	  for	  6-­‐dihydroNAD(P)	  substrates.	  Taken	  together,	  kred/Kd	  values	  indicate	  a	  minimum	  20-­‐fold	  preference	  for	  2DHNAD.	  	  We	  also	  offer	  the	  first	  structures	  of	  a	  renalase	  in	  complex	  with	  the	  catalytically	  relevant	  ligands	  β-­‐NAD+	  and	   β-­‐NADH	   (the	   latter	   being	   an	   analog	   of	   the	   substrate(s)).	   These	   structures	   show	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potential	   electrostatic	   repulsion	   interactions	   with	   the	   product	   and	   a	   unique	   binding	  orientation	   for	   the	   substrate	   nicotinamide	   base	   that	   is	   consistent	   with	   the	   identified	  activity.	  	  
Introduction	  	   Renalase	   was	   discovered	   in	   2005	   and	   purported	   to	   be	   a	   flavoprotein	   hormone	  produced	  by	   the	  kidney	   that	   catalyzes	   the	  oxidation	  of	   catecholamines	   in	  order	   to	   lower	  blood	  pressure	  and	  slow	  the	  heart	  (1,	  6).	  However,	  the	  initial	  experiments	  used	  to	  identify	  the	  substrates	  focused	  on	  only	  a	  handful	  of	  molecules	  and	  did	  not	  include	  control	  reactions	  to	   account	   for	   the	   inexorable	   oxidation	   of	   catecholamines	   in	   oxygenated	   buffer.	   Despite	  claimed	   physiological	   verifications	   of	   this	   activity	   (6,	  8-­‐10,	  12,	  13)	   no	   convincing	   in	  vitro	  evidence	  of	  catecholamine	  oxidase	  activity	  has	  been	  offered.	  The	  deficiencies	  in	  the	  original	  methods	  were	  compounded	  in	  subsequent	  claims	  that	  suggested	  an,	  as	  isolated,	  quiescent	  renalase	  state	  and	  ever	  more	  unlikely	  chemistries	  for	  which	  catalysis	  and	  the	  stoichiometry	  were	   not	   established	   (11,	   36).	   A	   number	   of	   researchers	   have	   attempted	   to	   counter	   the	  expanding	   belief	   that	   renalase	   catalysis	   is	   associated	   with	   vascular	   tone,	   by	   either	  questioning	  the	  original	  methods	  used	  to	  establish	  activity	  (48,	  59)	  or	  demonstrating	  that,	  relative	  to	  appropriate	  controls,	  there	  is	  no	  evidence	  of	  catecholamine	  consumption	  by	  the	  enzyme	   (61).	   These	   refutations	   have	   gone	   largely	   unheeded	   and	   the	   preponderance	   of	  scientific	  studies	  pertaining	  to	  renalase	  continue	  to	  be	  predicated	  on	  passive	  acceptance	  of	  an	  unproven	  catalytic	  role	  (2-­‐32,	  37).	  	   We	   have	   recently	   shown	   that	   human	   renalase	   (HsRen)	   is	   indeed	   a	   flavoprotein	  oxidase,	  but	  one	   that	  catalyzes	   the	  oxidation	  of	  β-­‐NAD(P)H	   isomers.	  These	   isomers	  carry	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the	   hydride	   on	   the	   nicotinamide	   base	   in	   the	   non-­‐canonical	   2	   and	   6	   positions	   (2-­‐	   and	   6-­‐dihydroNAD(P))	   (Scheme	   6.1).	   The	   oxidation	   of	   these	   isomers	   occurs	   as	   much	   as	   five	  orders	   of	   magnitude	   more	   rapidly	   than	   any	   prior	   claim	   for	   renalase	   activity	   and	   the	  turnover	   reaction	   with	   these	   molecules	   has	   a	   defined	   stoichiometry	   and	   substrate	  specificity	  profile.	  Moreover,	  we	  have	  proposed	  that	  the	  purpose	  of	  this	  activity	  is	  to	  avoid	  inhibition	  of	  primary	  metabolism	  by	  these	  NAD(P)H	  isomers	  that	  have	  low	  nano-­‐Molar	  Ki	  values	   for	  specific	  dehydrogenases	   (55,	  67,	  68).	   If	  2-­‐	  and	  6-­‐dihydroNAD(P)	  molecules	  are	  prone	  to	  form	  in	  non-­‐enzymatic	  reduction	  reactions	  of	  β-­‐NAD(P)+	  and	  are	  truly	  a	  detriment	  to	   respiratory	   activity,	   it	   is	   reasonable	   to	   assume	   that	   this	   is	   an	   intracellular	   enzymatic	  activity	  that	  will	  exist	  in	  organisms	  that	  do	  not	  have	  a	  circulatory	  system.	  	  
	  
Scheme	  6.1.	  Observed	  activities	  of	  renalase.	  	  The	  structure	  of	  HsRen	  was	  determined	  by	  the	  Aliverti	  group	  in	  2011(60)	  using	  the	  model	  of	  a	  generically	  assigned	  “amine	  oxidase”	  from	  Pseudomonas	  syringae	  (PDB	  ID	  3KKJ)	  whose	   structure	  was	   solved	  and	  deposited	   in	   the	  Protein	  Data	  Bank	   (PDB)	  by	   the	  North	  East	   Structural	   Genomics	   Consortium	   (NESGC).	   While	   not	   highly	   homologous	   with	   the	  HsRen	  primary	  structure	  (19.5%	  identitical),	  this	  protein	  had	  the	  renalase	  fold	  (a	  topology	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that	   is	   common	   to	   numerous	   redox-­‐active	   flavoproteins	   (303-­‐306,	  345,	  346))	   and	   a	   very	  similar	   constellation	   of	   active	   site	   residues	   proximal	   to	   the	   FAD	   isoalloxazine	   (60).	   We	  surmised	  that	   this	  protein	  was	   likely	  a	  bacterial	   form	  of	  renalase.	   In	  this	  article	  we	  show	  that	  this	  “amine	  oxidase”	  from	  Pseudomonas	  syringae	  (van	  Hall	  pathovar	  phaseolicola	  strain	  1448A)	   harbors	   the	   same	   catalytic	   activity	   observed	   for	   HsRen	   but	   with	   unique	   kinetic	  properties	  and	  stark	  substrate	  preferences.	  We	  also	  present	  the	  X-­‐ray	  crystal	  structures	  of	  this	  enzyme	  in	  complex	  with	  nicotinamide	  dinucleotides	  that	  show	  a	  reductive	  pose	  of	  the	  nicotinamide	  base	  with	  respect	  to	  the	  flavin	  cofactor	  that	  is	  consistent	  with	  the	  proposed	  activity.	  	  
Materials	  and	  Methods	  
Materials.	   β-­‐NAD+	   was	   sourced	   from	   Sigma-­‐Aldrich.	   Sodium	   borohydride,	   potassium	  phosphate	  (mono	  and	  dibasic),	  sodium	  formate	  and	  glycerol	  were	  from	  Acros.	  Sep-­‐Pak	  C18	  (35	   cc)	   cartridges	   were	   purchased	   from	   Waters.	   Competent	   NEB5a	   and	   BL21	   DE3	  
Escherichia	  coli	  cells	  were	  obtained	  from	  New	  England	  Biolabs.	  Talon©	  metal	  affinity	  resin	  was	   from	  Thermo-­‐Fisher	   Scientific.	   Sodium	  acetate	  was	  purchased	   from	  Mallinckrodt.	   2-­‐	  and	  6-­‐DHNAD	  and	  2-­‐	  and	  6-­‐DHNADP	  were	  prepared	  using	  an	  adaptation	  of	  our	  previously	  published	   methods	   (55).	   Both	   sets	   of	   substrates	   were	   formed	   by	   sodium	   borohydride	  reduction	  of	  β-­‐NAD+	  or	  β-­‐NADP+.	  The	  products	  of	  reduction,	  β-­‐NAD(P)H,	  2-­‐dihydroNAD(P)	  (2DHNAD(P))	  and	  6-­‐dihydroNAD(P)	  (6DHNAD)	  (and	  residual	  β-­‐NAD(P)+)	  were	  separated	  using	   a	   Waters	   X-­‐Bridge	   19	   x	   250	   mm	   5	   µM	   C18	   column.	   6DHNAD(P)	   molecules	   were	  relatively	  stable	  and	  could	  be	  prepared	  as	  previously	  described	  and	  stored	  indefinitely	  at	  -­‐
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80	  oC,	  whereas	  2DHNAD(P)	  molecules	  were	  unstable	  and	  used	  immediately	  after	  collection	  from	  preparative	  HPLC.	  	  	  
Spectrophotometric	   Quantification.	   Dihydronicotinamide	   chromophore	   extinction	  coefficients	  were	  as	  follows:	  β-­‐NADH,	  β-­‐NADPH	  -­‐	  ε340nm	  =	  6220	  M-­‐1	  cm-­‐1	  (309),	  2DHNAD(P)	  -­‐	  ε394nm	  =	  5360	  M-­‐1cm-­‐1,	  6DHNAD(P)	  -­‐	  ε345nm	  =	  6580	  M-­‐1cm-­‐1	  and	  β-­‐NAD+	  -­‐	  ε260nm	  =	  18800	  M-­‐
1cm-­‐1(55).	   Pseudomonas	   Syringae	   renalase	   (PpRen)	   was	   quantified	   using	   the	   measured	  extinction	  coefficient	  for	  the	  enzyme-­‐bound	  flavin	  (ε452nm	  =	  11,000	  M-­‐1cm-­‐1),	  as	  determined	  using	  an	  SDS	  denaturation	  method	  as	  previously	  described	  (347).	  
	  
Expression	   and	   Purification	   of	   PpRen:	   A	   plasmid	   derived	   from	   pET21a	   (pET21_NESG)	  containing	  the	  gene	  for	  PpRen	  was	  provided	  by	  the	  NESGC.	  This	  construct	  was	  prepared	  by	  PCR	   amplification	   of	   the	   PpRen	   gene	   from	   Pseudomonas	   Syringae	   (van	   Hall	   pathovar	  
phaseolicola	  strain	  1448A)	   followed	  by	   cloning	   into	   the	  Nde	   I	   and	  Xho	   I	   restriction	   sites,	  fusing	  the	  PpRen	  gene	  to	  a	  C-­‐terminal	  6His-­‐tag.	  This	  construct	  has	  a	  single	  variant	  amino	  acid	  from	  what	  is	  reported	  for	  this	  phaseolicola	  strain;	  a	  serine	  is	  coded	  in	  place	  of	  glycine	  145.	  The	  plasmid	  was	   transformed	   into	  competent	  BL21	  DE3	  cells	  and	  plated	  onto	  Luria	  Bertani	   (LB)	   agar	   (100	   µg/mL	   Ampicillin)	   and	   grown	   overnight	   at	   37	   oC.	   Individual	  colonies	  were	  then	  selected	  and	  grown	  in	  LB	  broth	  with	  shaking	  (250	  rpm)	  at	  37	  oC	  until	  growth	   reached	   early	   log	   phase.	   1	   mL	   cell	   stocks	   were	   made	   by	   adding	   filter	   sterilized	  glycerol	  to	  a	  final	  concentration	  of	  20%	  and	  then	  storing	  at	  -­‐80°C.	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   For	   expression,	   1	   mL	   cell	   stocks	   were	   thawed,	   plated	   onto	   LB	   agar,	   100	   µg/mL	  ampicillin,	   and	   grown	  overnight	   at	   37°C	   (100	  µL	   cells/plate).	   The	   lawn	  of	   cells	   obtained	  was	  resuspended	  in	  LB	  broth	  and	  transferred	  to	  LB	  broth	  cultures	  (two	  plates/L	  of	  broth)	  and	   grown	  at	   37oC	   in	   a	   shaking	   incubator	   (220	   rpm)	  until	  mid-­‐log	  phase	   (OD600nm=0.8).	  The	   temperature	  was	   then	   lowered	   to	   17	   oC	   and	   the	   culture	  was	   grown	   to	   OD600nm~1.0	  (~1-­‐2	  hr)	  and	  induced	  with	  0.1	  mM	  IPTG.	  30	  hrs	  after	  induction	  the	  cells	  were	  harvested	  by	   centrifugation	   (4,000	   g	   for	   30	   min)	   and	   subjected	   to	   one	   freeze/thaw	   cycle.	   All	  purification	  steps	  were	  performed	  at	  4°C.	  Cell	  pellets	  were	  resuspended	  in	  20	  mM	  sodium	  HEPES	   buffer	   pH	   7.5	   (approximately	   20	   mL/L	   culture)	   and	   placed	   in	   a	   stainless	   steel	  beaker	  and	  lysed	  by	  sonication	  using	  a	  Branson	  450	  sonicator	  (3	  x	  240	  seconds	  at	  50	  W).	  During	   this	  procedure	   the	  cell	   suspension	  vessel	  was	  seated	   in	  a	   slurry	  of	   ice	  and	  water.	  Lysed	   cells	  were	   centrifuged	   at	   12,800	   x	   g	   for	   30	  min,	   the	   pellet	  was	   discarded	   and	   the	  supernatant	  loaded	  onto	  a	  12.5	  x	  150	  mm	  Co2+	  Talon©	  affinity	  column	  equilibrated	  with	  20	  mM	  sodium	  HEPES	  buffer	  pH	  7.5.	  Initially	  contaminating	  proteins	  were	  eluted	  with	  150	  mL	  of	  10	  mM	   imidazole,	  50	  mM	  sodium	  HEPES	  buffer	  adjusted	   to	  pH	  7.5	  with	  H2SO4,	   then	  a	  gradient	  from	  10	  mM	  to	  300	  mM	  imidazole	  in	  the	  same	  buffer	  was	  used	  to	  elute	  ostensibly	  pure	   PpRen	   as	   a	   single	   symmetrical	   peak.	   Distinctly	   yellow	   fractions	   were	   pooled.	  Imidazole	  was	  removed	  and	  the	  buffer	  exchanged	  to	  10	  mM	  potassium	  phosphate,	  pH	  7.5	  by	  dialysis	  using	  10	  kDa	  nominal	  molecular	  weight	  cut-­‐off	  dialysis	  tubing	  to	  achieve	  a	  net	  ≥100,000-­‐fold	  buffer	  exchange.	  Aliquots	  of	  purified	  concentrated	  renalase	  (<120	  µM)	  were	  then	  stored	  at	  -­‐80°C.	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Analytical	   HPLC:	   Evidence	   of	   the	   substrate	   specificity	   profile	   was	   obtained	   by	   adding	  sodium	  borohydride	  (250	  µM)	  to	  β-­‐NAD(P)+	  (250	  µM).	  The	  sample	  was	  divided	   into	  two	  and	  PpRen	   (30	   µM)	  was	   added	   to	   one	   and	   incubated	   for	   3	  minutes	  while	   the	   other	  was	  frozen	   in	   liquid	   nitrogen.	   PpRen	  was	   then	   removed	   from	   the	   first	   sample	   by	   centrifugal	  ultrafiltration	   using	   a	   0.5	   mL	   Amicon	   10	   kDa	   cutoff	   filter.	   Both	   samples	   were	   then	  chromatographed	   by	   analytical	  HPLC.	   Separation	   of	   the	   resulting	  mixtures	  was	   achieved	  using	  a	  Waters	  X-­‐Bridge	  4.6	  x	  150	  mm,	  3.5	  µM	  C18	  column	  coupled	  to	  a	  Waters	  600E	  pump	  and	   Waters	   2487	   dual	   wavelength	   detector.	   Elution	   of	   components	   of	   the	   mixture	   was	  observed	   simultaneously	   at	   260	   and	   340	   (or	   394)	   nm.	   The	   components	  were	   separated	  isocratically	  at	  1.0	  mL/min	  in	  either	  10	  mM	  (β-­‐NAD+	  derived)	  or	  50	  mM	  (β-­‐NADP+	  derived)	  potassium	  phosphate	  buffer	  pH	  7.5.	  
	  
Reductive	  Half-­‐Reaction	   of	   PpRen	  with	   6DHNAD(P):	  The	   reductive	   half-­‐reaction	   of	   PpRen	  could	  be	  observed	  independent	  of	  subsequent	  oxidative	  processes	  by	  exclusion	  of	  dioxygen	  using	  previously	   published	  methods	   (54).	   Anaerobic	   PpRen	   (5	  mL,	   14-­‐16	  µM)	   in	   20	  mM	  potassium	  phosphate	  buffer	  containing	  1	  mM	  dextrose	  and	  5	  U/mL	  glucose	  oxidase	  (25	  µL,	  25	   units)	  was	  mounted	   onto	   a	  Hitech	   (now	  TgK)	  DX2	   stopped-­‐flow	   instrument	   that	   had	  been	   scrubbed	   of	   residual	   dioxygen	   by	   incubation	   for	   16	   hr	   with	   a	   solution	   of	   1	   mM	  dextrose,	  10	  U/mL	  glucose	  oxidase.	  6DHNAD(P)	  samples	  were	  thawed	  and	  diluted	  to	  target	  concentrations	   in	  water	   containing	  1	  mM	  glucose.	  2DHNAD(P)	  was	   collected	   into	  a	   glass	  syringe	   (that	   had	   a	   small	   amount	   of	   concentrated	   dextrose	   added	   prior	   (≤1	   mM	   final))	  directly	   from	   preparative	   HPLC,	   diluted	   to	   approximate	   target	   concentration	   and	   used	  immediately.	   All	   substrate	   solutions	  were	   sparged	  with	   argon	   gas	   for	   5	  minutes.	   Before	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capturing	   and	  mounting	   the	   substrate	   solution	   to	   the	   stopped	   flow	   instrument,	   10	  µL	  of	  glucose	  oxidase	  (10	  units)	  was	  injected	  via	  the	  luer	  tip.	  	  	   Anaerobic	  PpRen	  and	  substrate	  solutions	  were	  mixed	  and	  reduction	  of	  the	  renalase	  cofactor	  was	  observed	  at	  the	  absorption	  maximum	  of	  the	  PpRen	  FAD,	  452	  nm.	  The	  stability	  of	   the	  6DHNAD	  substrate	  allowed	  for	   it	   to	  be	  prepared	   in	  sufficient	  quantity	   to	  achieve	  a	  high	   range	   of	   concentrations	   ranging	   from	   second	   order	   to	   pseudo-­‐first	   order	   reaction	  conditions.	  The	  pseudo-­‐first	  order	  data	  were	  fit	  to	  a	  linear	  combination	  of	  two	  exponentials	  according	  to	  Equation	  6.1	  using	  Kinetic	  Studio	  software	  (TgK	  Ltd).	  In	  this	  equation	  A1	  and	  A2	  are	  the	  amplitudes	  associated	  with	  the	  first	  and	  second	  rate	  constants,	  k1obs	  and	  k2	  and	  C	  is	   the	  absorbance	  at	   end	  of	   the	   reaction.	  The	  dependence	  of	   the	  observed	   rate	   constants	  (k1obs)	  for	  the	  largest	  amplitude	  phase	  (~90%)	  was	  fit	  to	  the	  hyperbolic	  form	  of	  the	  single-­‐site	  binding	  equation	  (Equation	  6.2)	  according	  to	  Strickland,	  where	  kred	  is	  the	  limiting	  rate	  constant	   for	   reduction	   and	   K6DHNAD(P)	   is	   the	   binding	   constant	   for	   6DHNAD	   (322).	  2DHNAD(P)	  are	  prone	  to	  decompose	  within	  minutes.	  	  Reduction	  data	  for	  these	  substrates	  were	   obtained	   primarily	   from	   second	   order	   reactant	   ratios	   and	   as	   such	   could	   not	   be	   fit	  meaningfully	   to	   linear	   combinations	   of	   exponential	   terms.	   The	   data	   for	   2DHNAD(P)	  substrates	  were	  fit	  to	  a	  the	  mechanism	  depicted	  in	  Scheme	  6.2	  using	  KinTek	  Explorer	  to	  obtain	  the	  dissociation	  constant	  for	  the	  substrate	  (k-­‐1/k1)	  and	  the	  intrinsic	  rate	  constant	  for	  reduction	   (k2).	   The	   concentration	   of	   these	   substrates	   was	   estimated	   by	   recording	   a	  spectrum	  immediately	  prior	  and	  immediately	  after	  each	  kinetic	  observation	  and	  averaging.	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Scheme	  6.2.	  Model	  for	  the	  reductive	  half-­‐reaction.	  	  Equation	  6.1	   	   	  	  𝐴!"#!" = 𝐴! 𝑒!!!!"#! +   𝐴! 𝑒!!!! + 𝐶	  	  Equation	  6.2	   	   𝑘!"# = !!"# !!"#$!(!)(!!!"#$!(!)! !!"#$!(!) )	  	  
Oxidative	  Half-­‐Reaction	  of	  PpRen:	  Reoxidation	   of	   the	   renalase	   cofactor	   in	   the	   presence	   of	  dissolved	   dioxygen	   was	   observed	   by	   double	   mixing	   stopped-­‐flow	   spectrophotometry.	  PpRen	   (16	   µM)	   was	   prepared	   in	   a	   tonometer	   in	   an	   equivalent	   manner	   to	   that	   of	   the	  reductive	  half	  reaction	  (though	  without	  dextrose	  or	  glucose	  oxidase).	  In	  the	  first	  mix,	  this	  solution	   was	   combined	   with	   12	   µM	   6DHNAD.	   The	   reduction	   reaction	   was	   allowed	   to	  proceed	   for	   150	   seconds	   prior	   to	   the	   second	  mix	   that	   introduced	   dissolved	   dioxygen	   of	  defined	   concentration	   (Final	   concentrations	   after	   the	   second	  mix,	   4	   µM	   PpRen,	   3	   µM	  β-­‐NAD+,	  varied	  dioxygen).	  The	  dissolved	  oxygen	  concentration	  in	  this	  solution	  was	  defined	  by	  sparging	   an	   inverted	   syringe	   containing	   10	   mM	   phosphate	   buffer	   pH	   7.5	   with	   blended	  dinitrogen	  and	  dioxygen	  gases	  of	  known	  partial	  pressures	  supplied	  by	  a	  Maxtec	  Maxblend	  gas	   blender.	   The	   concentration	   of	   dissolved	   oxygen	  was	   confirmed	   by	   first	   sparging	   the	  reaction	  chamber	  of	  a	  Hansatech	  dioxygen	  electrode	  filled	  with	  the	  same	  buffer	  to	  define	  the	   equilibrium	   concentration	   of	   dissolved	   dioxygen.	   The	   reduced	   anaerobic	   PpRen	  solution	  was	  then	  mixed	  and	  the	  ensuing	  reoxidation	  observed	  at	  452	  nm.	  The	  data	  were	  fit	  to	   Equation	   6.3	   in	   which	   koxobs	   is	   the	   observed	   rate	   constant	   for	   reoxidation,	   A1	   is	   the	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absorption	   amplitude	   for	   the	   phase	   observed,	   and	   C	   is	   the	   endpoint	   absorbance.	   The	  dependence	  of	  the	  observed	  rate	  constant	  was	  fit	  to	  a	  straight	  line	  that	  passed	  through	  the	  origin	  according	  to	  equation	  6.4	  where	  kox	  is	  the	  second	  order	  rate	  constant	  for	  reoxidation	  and	  [O2]	  is	  the	  concentration	  of	  dioxygen.	  	  Equation	  6.3	   	   	  	  𝐴!"#!" = 𝐴! 𝑒!!!"!#$! + 𝐶	  	  Equation	  6.4	   	   𝑘!"!#$ = 𝑘!"[O!]	  	  	   The	   influence	   of	   β-­‐NAD+	   on	   the	   rate	   constant	   for	   reoxidation	   was	   observed	   by	  similar	  methods	  to	  those	  described	  above	  using	  the	  double	  mixing	  facility	  of	  the	  stopped-­‐flow	  instrument.	  PpRen	  (23.2	  µM)	  was	  mixed	  with	  6DHNAD	  (20	  µM)	  and	  allowed	  to	  age	  for	  150	   seconds.	   This	   mixture	   was	   then	   mixed	   with	   238	   µM	   dioxygen	   and	   the	   reoxidation	  observed	   at	   452	   nm.	   β-­‐NAD+	   (0-­‐4	   mM)	   was	   then	   added	   to	   the	   third	   solution	   and	   the	  experiment	  repeated.	  The	  dependence	  of	  the	  observed	  rate	  constant	  for	  reoxidation	  (koxobs)	  was	   then	   fit	   to	  Equation	  6.5	   to	  determine	   the	   extent	   of	   inhibition	   (Δkox)	   and	   the	  binding	  constant	   for	   β-­‐NAD+	   to	   the	   reduced	   form	   of	   the	   enzyme	   (KNAD+),	   where	   kiox	   is	   the	   rate	  constant	  observed	  in	  the	  absence	  of	  exogenous	  β-­‐NAD+.	  	  Equation	  6.5	   	   𝑘!"!#$ = 𝑘!!" − ( ∆!!" !"#!!!!"!! !"#! )	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The	   Dissociation	   Constants	   for	   the	   PpRenox•b-­‐NADH,	   PpRenox•β-­‐NADPH	   and	   PpRen•SO3	  
adduct	  Complexes:	  The	  dissociation	  constants	  for	  the	  PpRenox•	  β-­‐NADH,	  PpRenox•	  β-­‐NADPH	  and	  PpRen•SO3	  complexes	  were	  measured	  by	  perturbation	  of	  the	  renalase	  flavin	  spectrum	  when	   each	   ligand	  was	   titrated.	   For	   both	   the	   β-­‐NADH	  and	  β-­‐NADPH	   titrations,	   slow	  non-­‐catalytic	  reduction	  of	  the	  PpRen	  flavin	  during	  the	  experiment	  (0.0008	  s-­‐1)	  was	  avoided	  by	  preparing	  eleven	  0.9	  mL	  stocks	  (17	  µM	  for	  β-­‐NADH,	  12	  µM	  for	  	  β-­‐NADPH	  )	  of	  the	  enzyme	  in	  10	  mM	  potassium	  phosphate	  buffer,	  pH	  7.5	  at	  25	   oC.	  To	  each	  0.9	  mL	  aliquot,	  0.1	  mL	  of	  a	  range	  of	  β-­‐NADH	  or	  β-­‐NADPH	  stocks	  were	  added	  and	  the	  spectrum	  recorded.	  As	  such,	  the	  spectrophotometric	   data	   are	   compiled	   from	   eleven	   PpRen	   renalase	   samples	   after	   the	  addition	  of	  β-­‐NADH	  (0-­‐1	  mM)	  or	  β-­‐NADPH	  (0-­‐7	  mM).	  	  	   Titration	   of	   PpRen	   with	   sodium	   sulfite	   formed	   a	   labile	   sulfite	   adduct	   that	   is	  commonly	  observed	  with	  flavoprotein	  oxidases.	  In	  this	  experiment	  7	  µM	  PpRen	  in	  10	  mM	  potassium	   phosphate	   buffer	   pH	   7.5	   (25	   oC)	   was	   titrated	   with	   sulfite	   by	   incremental	  additions	  spanning	  the	  range	  0-­‐310	  mM.	  Spectra	  were	  recorded	  after	  each	  addition.	  	   For	  β-­‐NADH	  and	  sufite	  titrations,	  spectra	  were	  recorded	  using	  a	  Shimadzu	  1800	  UV-­‐Vis	   spectrophotometer.	   For	   the	   β-­‐NADPH	   titration,	   spectra	   were	   recorded	   using	   a	  Shimadzu	   2600	   UV-­‐Vis	   spectrophotometer.	   After	   correction	   for	   dilution,	   the	   changes	   in	  absorption	   at	   492	   nm,	   468	   nm	   and	   452	   nm	   were	   used	   to	   determine	   the	   dissociation	  constants	   for	   the	   Renox•β-­‐NADH,	   Renox•β-­‐NADPH	   and	   the	   Renox•β-­‐NAD+	   complexes	  respectively.	  The	  changes	  in	  absorption	  were	  fit	  to	  the	  quadratic	  solution	  form	  of	  the	  single	  site	   binding	   equation	   (Equation	   6.6)	   in	   which	   [E]	   is	   the	   PpRen	   concentration,	   [EL]	   is	  concentration	   of	   the	   PpRen•ligand	   complex	   and	   KL	   is	   the	   dissociation	   constant	   of	   the	  PpRen•ligand	  complex.	  For	  both	  β-­‐NADH,	  β-­‐NADPH	  and	  sulfite,	  the	  raw	  data	  were	  fit.	  That	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is,	   change	   in	   absorbance	   at	   defined	  wavelengths	  was	   used	   as	   a	  measure	   of	   [EL]	   and	   the	  maximal	  change	  in	  absorbance	  as	  a	  representation	  of	  [E].	  	  
Equation	  6.6	   	   	  [EL] = ! ! ! !  !! ! ! ! ! !  !! !!!( ! ! ! )! 	  	  
Crystallization,	   Structure	   Determination,	   and	   Model	   Refinement.	   Initial	   crystallization	  conditions	  were	  those	  identified	  by	  the	  NESGC	  and	  included	  2	  M	  sodium	  formate,	  100	  mM	  sodium	  acetate	  pH	  4.6	  at	  20	  °C.	  Diffraction-­‐quality	  crystals	  were	  obtained	  by	   the	  hanging	  drop	  vapor	  diffusion	  method.	  The	  droplet	  was	   formed	   from	  three	  1	  µL	  additions;	  1	  µL	  of	  the	  well	   solution,	   1	  µL	   of	   PpRen	   (104	   µM)	   and	   1	  µL	   of	  H2O.	   Crystals	   appeared	   after	   2−4	  days	   and	   grew	   to	   maximal	   dimensions	   of	   ∼200	  μm	  x	  50	  μm	  x	  10	  μm.	   Crystals	   were	  harvested	   from	  the	  hanging	  drops,	  and	  soaked	   for	  1-­‐3	  minutes	   in	  2.5	  M	  sodium	   formate,	  120	  mM	  sodium	  acetate	  pH	  4.7	  with	  20%	  glycerol	  and	  166	  mM	  β-­‐NAD+	  or	  10	  mM	  β-­‐NADH.	  The	   mounted	   crystal	   was	   then	   flashed-­‐cooled	   in	   liquid	   nitrogen.	  Crystals	   were	   initially	  screened	   for	   diffraction	   quality	   using	   the	   rotating	   anode	   X-­‐ray	   source	   at	   Marquette	  University	   (Milwaukee,	   WI).	   X-­‐ray	   diffraction	   data	   for	   PpRen•β-­‐NAD+	  were	   collected	   at	  beamline	  21-­‐ID-­‐D	  of	  the	  Life	  Science	  Collaborative	  Access	  Team	  (LS-­‐CAT)	  at	  the	  Advanced	  Photon	   Source	   (APS).	   Data	   for	   the	   PpRen·β-­‐NADH	   complex	   were	   collected	   at	   LS-­‐CAT	  beamline	  21-­‐ID-­‐F.	  Data	  were	  processed	  with	  HKL2000	  (348).	  	   The	  structure	  of	  PpRen	  was	  determined	  by	  molecular	  replacement	  in	  PHASER	  (349)	  with	   a	   search	  model	   derived	   from	   chain	   A	   of	   the	  P.	   syringae	   Q888A4	   renalase	   structure	  (PDB	   ID	   3KKJ,	   Northeast	   Structural	   Genomics	   Consortium)	   with	   all	   non-­‐protein	   atoms	  removed	   and	   all	   B-­‐factors	   set	   to	   20.0.	   After	   iterative	   cycles	   of	  manual	  model	   building	   in	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COOT	   (350)	   and	   maximum	   likelihood	   based	   refinement	   using	   the	   PHENIX	   package	  (phenix.refine)	  (351),	  ordered	  solvent	  molecules	  were	  added	  in	  phenix.refine	  automatically	  and	  culled	  manually	  in	  COOT.	  After	  adding	  solvent	  atoms,	  the	  FAD	  cofactor	  and	  β-­‐NAD+	  or	  
β-­‐NADH	  were	  added	  to	  the	  model	  in	  COOT.	  During	  the	  last	  rounds	  of	  refinement,	  hydrogen	  atoms	  were	  added	  to	  the	  model	  using	  phenix.reduce	  (352)	  to	  improve	  the	  stereochemistry	  of	   the	  model.	   Positions	   of	  H	   atoms	  were	   refined	  using	   the	   riding	  model	  with	   a	   global	  B-­‐factor.	   Regions	   of	   each	  model	   to	   be	   used	   in	   translation-­‐libration-­‐screw	   (TLS)	   refinement	  were	   identified	   using	   phenix.find_tls_groups	   and	   the	   TLS	   parameters	   were	   refined	   in	  phenix.refine.	   Once	   the	   refinement	   converged,	   the	   model	   was	   validated	   using	   the	   tools	  implemented	  in	  COOT	  and	  PHENIX	  (353),	  (354).	  Side	  chains	  with	  poor	  or	  missing	  electron	  density	  were	  modeled	  in	  favored	  rotameric	  conformations.	  The	  B-­‐factors	  were	  allowed	  to	  refine	  without	  additional	  restraints,	  and	  the	  occupancies	  were	  held	  to	  1.0.	  Data	  collection	  and	  model	   refinement	  statistics	  are	   listed	   in	  Table	  6.1.	  Coordinates	  and	  structure	   factors	  for	   the	  PpRen·β-­‐NAD+	  and	  PpRen·β-­‐NADH	  complexes	  have	  been	  deposited	   in	   the	  Protein	  Data	  Bank	  with	  accession	  codes	  4ZCD	  and	  4ZCC,	  respectively.	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Table	  6.1.	  Crystallographic	  data	  collection	  and	  model	  refinement	  statistics.	  
	   PpRen·β-­‐NAD+	   PpRen·β-­‐NADH	  Space	  group	   C	  2	   P	  21	  Unit	  cell	  parameters	   a=144.7,	  b=37.6,	  c=138.2	  Å	  α=γ=90,	  β=120	  °	   a=63.5,	  b=71.5,	  c=143.8	  Å	  α=γ=90,	  β=97.5	  °	  Resolution	  (Å)	  	  (last	  shell)a	   33.2-­‐1.66	  (1.69-­‐1.66)	   46.2-­‐2.00	  (2.03-­‐2.00)	  Wavelength	  (Å)	   0.97895	   0.97872	  No.	  of	  reflections	   	   	  	  	  	  	  Observed	   286455	  (12871)	   328721	  (15867)	  	  	  	  	  Unique	   76829	  (3588)	   86594	  (4305)	  Completeness	  (%)a	   99.7	  (94.0)	   100.0	  (100.0)	  Rmerge	  (%)a,b	   0.044	  (0.336)	   0.096	  (0.628)	  Multiplicity	   3.7	  (3.6)	   3.8	  (3.7)	  <I/σ(I)>a	   26.3	  (3.7)	   13.7	  (2.2)	  
Model	  Refinement	  Statistics	  Reflections	  in	  work	  set	   73035	   77722	  Reflections	  in	  test	  set	   2971	   2892	  Rcryst	  (Rfree)	   0.151	  (0.176)	   0.170	  (0.215)	  No.	  of	  residues	   651	   1288	  No.	  of	  solvent	  atoms	   748	   736	  Number	  of	  TLS	  groups	   4	   28	  Average	  B-­‐factor	  (Å2)c	   	   	  	  	  	  	  Protein	  atoms	   16.0	   33.1	  	  	  	  	  Ligand	  atoms	   15.5	   32.5	  	  	  	  	  Solvent	   28.8	   36.6	  RMS	  deviations	   	   	  	  	  	  	  Bond	  lengths	  (Å)	   0.012	   0.014	  	  	  	  	  Bond	  angles	  (°)	   1.490	   1.634	  	  Coordinate	  error	  (Å)	   0.15	   0.19	  a	  Values	  in	  parentheses	  apply	  to	  the	  high-­‐resolution	  shell	  indicated	  in	  the	  resolution	  row.	  b	  R	  =	  Σ(||Fobs|-­‐scale*|Fcalc||)	  /	  Σ	  |Fobs|.	  c	  Isotropic	  equivalent	  B	  factors,	  including	  contribution	  from	  TLS	  refinement.	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Results	  
Properties	   of	   PpRen	   and	   Substrate	   Identification:	   PpRen	   can	   be	   expressed	   by	   the	   above	  methods	  to	  yield	  ~17	  mg	  of	  purified	  enzyme	  per	  liter	  of	  culture.	  The	  absorption	  spectrum	  of	   the	  purified	  enzyme	   indicates	   characteristic	   visible	  maxima	   indicative	  of	  bound	   flavin.	  The	  flavin	  maxima	  are	  observed	  at	  380	  nm	  (ε	  =	  10.1	  mM-­‐1cm-­‐1)	  and	  452	  nm	  (ε	  =	  11	  mM-­‐
1cm-­‐1)	  distinct	  from	  those	  observed	  for	  HsRen	  (385	  nm	  (ε	  =	  10.9	  mM-­‐1cm-­‐1),	  458	  nm	  (ε	  =	  11.3	  mM-­‐1cm-­‐1))	  and	  free	  flavin	  (375	  nm	  (ε	  =	  9.7	  mM-­‐1cm-­‐1),	  450	  nm	  (ε	  =	  11.3	  mM-­‐1cm-­‐1)).	  The	   enzyme	   is	   stable	   at	   25	   oC	   and	   below	   in	   phosphate	   buffer	   at	   pH	   7.5,	   but	   prone	   to	  precipitate	  at	  concentrations	  above	  4.5	  mg/mL	  (~120	  µM).	  	  	   Borohydride	  reduction	  of	  β-­‐NAD+	  or	  β-­‐NADP+	  yields	  three	  reduced	  isomers	  of	  each:	  2-­‐dihydroNAD(P)	   (2DHNAD(P)),	   4-­‐dihydroNAD(P)	   (β-­‐NAD(P)H)	   and	   6-­‐dihydroNAD(P)	  (6DHNAD(P)).	  We	  have	  shown	  that	  HsRen	  catalytically	  oxidizes	  both	  2-­‐	  and	  6DHNAD(P)	  to	  form	  β-­‐NAD(P)+	  (55).	  HPLC	  analysis	  indicated	  that	  when	  PpRen	  was	  added	  to	  the	  mixture	  of	   reduction	   products	   only	   2-­‐	   and	   6DHNAD(P)	   molecules	   were	   consumed	   (Figure	   6.1)	  indicating	   that	   this	  Pseudomonas	   form	   of	   renalase	   has	   the	   same	   substrate	   profile	   as	   the	  human.	  When	  chromatographed	  at	  260	  nm,	  where	  the	  adenine	  chromophore	  has	  maximal	  absorption,	  the	  net	  concentration	  lost	  from	  the	  2-­‐	  and	  6DHNADP	  peaks	  (based	  on	  standard	  curves	   for	   each)	   was	   gained	   by	   the	   β-­‐NAD(P)+	   peak	   indicating	   that	   the	   product	   formed	  from	  both	  types	  of	  substrate	  is	  the	  oxidized	  form	  of	  the	  nicotinamide	  dinucleotide	  (Scheme	  6.1).	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Figure	   6.1.	   Analytical	   HPLC	   of	   Renalase	   Turnover	   Reactions	   of	   Borohydride	   Reduced	  Mixtures	  of	  β-­‐NAD(P)H	  Isomers.	  HPLC	  separation	  was	  achieved	  using	  an	  analytical	  Waters	  X-­‐bridge	   C18	   column	   run	   isocratically	   in	   potassium	   phosphate	   buffer	   (10	   mM	   for	   NAD	  derived	   mixtures,	   and	   50	   mM	   for	   NADP	   derived	   mixtures).	   All	   eluting	   species	   were	  detected	  at	  260	  nm,	   the	  absorption	  maximum	  for	   the	  NAD(P)	  adenine	  base.	  A:	  The	  black	  chromatogram	  is	  the	  separation	  of	  the	  components	  formed	  from	  borohydride	  reduction	  of	  
β-­‐NAD+.	  The	  red	  chromatogram	  is	  three	  minutes	  after	  the	  addition	  of	  30	  µM	  PpRen.	  B:	  The	  black	   chromatogram	   is	   the	   separation	   of	   the	   components	   formed	   from	   borohydride	  reduction	  of	  β-­‐NADP+.	  The	  red	  chromatogram	  is	  three	  minutes	  after	  the	  addition	  of	  30	  µM	  PpRen.	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Reductive	   Half-­‐Reaction	   of	   PpRen	   with	   6DHNAD(P):	   The	   reductive	   half-­‐reaction	   was	  observed	   by	  mixing	   PpRen	  with	   varied	   concentrations	   of	   6DHNAD,	   6DHNADP,	   2DHNAD	  and	   2DHNADP,	   in	   the	   absence	   of	   molecular	   oxygen.	   The	   transfer	   of	   a	   hydride	   from	   the	  DHNAD(P)	   substrate	   to	   the	   PpRen	   flavin	   is	   observed	   as	   a	   large	   change	   in	   extinction	  coefficient	  of	  the	  flavin	  as	  it	  converts	  to	  the	  reduced	  state	  (Figure	  6.2).	  The	  equilibrium	  and	  kinetic	   constants	   derived	   from	   these	   experiments	   are	   summarized	   in	   Table	   6.2.	   	   Both	  6DHNAD	  and	  6DNADP	  substrates	  were	  titrated	  and	  the	  largely	  monophasic	  reduction	  and	  hyperbolic	   dependence	   of	   the	   observed	   rate	   constant	   for	   reduction	   indicated	   that	   these	  substrates	   bind	   rapidly	   and	   reversibly	   to	   the	   enzyme	   prior	   to	   hydride	   transfer.	   The	  substrate	  dissociation	   constants	  obtained	   from	   the	   reductive-­‐half	   reaction	  data	   indicated	  relative	  higher	  binding	  affinity	  for	  β-­‐NAD+-­‐derived	  substrates	  (K2DHNAD~36	  µM,	  K6DHNAD~28	  µM)	  compared	  to	  the	  β-­‐NADP+-­‐derived	  substrates	  (K2DHNADP~500	  µM,	  K6DHNADP~1400	  µM).	  This	   apparent	  preference	   for	  β-­‐NAD+-­‐derived	   substrates	   is	   consistent	  with	  our	  proposed	  function	  for	  renalase;	  to	  protect	  primary	  metabolism	  dehydrogenases	  from	  inhibition	  by	  2-­‐	  and	  6DHNAD	  (55).	  However,	  both	  6-­‐dihydro	  substrates	  exhibited	  a	  relative	  slow	  reduction	  rate	   constant	   (kred6DHNAD	   =0.4	   s-­‐1	   and	   kred6DHNAP	   =0.5	   s-­‐1),	   approaching	   three	   orders	   of	  magnitude	  slower	  than	  those	  observed	  for	  the	  the	  2-­‐dihydro	  forms	  (kred2DHNAD~180	  s-­‐1	  and	  
kred2DHNAP~120	   s-­‐1).	   When	   these	   data	   are	   viewed	   as	   a	   ratio	   they	   define	   a	   measure	   of	  substrate	   capture	   (kred/Kd),	   it	   is	   apparent	   that	   PpRen	   has	   a	   twenty-­‐fold	   preference	   for	  2DHNAD	   over	   its	   next	   preferred	   substrate,	   2DHNADP	   (Table	   6.2).	   Both	   β-­‐NAD+-­‐	   and	   β-­‐NADP+-­‐derived	  substrates	  accelerate	   the	  reduction	  rate	  constant	  by	  103-­‐105	  compared	  to	  that	  observed	  for	  β-­‐NADH	  (~0.0008	  s-­‐1	  at	  2	  mM	  β-­‐NADH).	  A	  pronounced	  preference	  for	  the	  position	  of	  the	  nicotinamide	  hydride	  was	  not	  observed	  for	  HsRen	  that	  exhibited	  ostensibly	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the	   same	   dissociation	   constant	   for	   either	   β-­‐NAD+-­‐derived	   substrate	   isomers	   (K2DHNAD,	  K6DHNAD~170	   µM)	   and	   only	  modest	   differences	   in	   the	   reduction	   rate	   constant	   (kred6DHNAD	  ~230	  s-­‐1	  and	  kred2DHNAP	  ~850	  s-­‐1)	  (55).	  	  	  	  	  
Table	  6.2.	  Summary	  of	  Kinetic	  and	  Equilibrium	  Constants	  for	  PpRen.	  
Substrate/Ligand	   Kd	  (µM)	   kred	  (s-­‐1)	   kred/Kd	  (µM-­‐1s-­‐1)	  2DHNAD	   36	  ±	  8	   134	  ±	  2	   3.7	  ±	  0.8	  2DHNADP	   468	  ±	  71	   84	  ±	  3	   0.18	  ±	  0.02	  6DHNAD	   28	  ±	  3	   0.39	  ±	  0.01	   0.014	  ±	  0.002	  6DHNADP	   1380	  ±	  210	   0.50	  ±	  0.05	   3.6	  ±	  0.7	  x	  10-­‐4	  	  
β-­‐NADH	   81	  ±	  7	   ~0.0008	  ±	  0.00001	   9.8	  ±	  0.8	  x	  10-­‐6	  
β-­‐NADPH	   1540	  ±	  370	   n.m.a	   	  
a-­‐	  not	  measured	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Figure	   6.2.	   Kinetics	   of	   the	   Reductive	   Half-­‐Reactions	   of	   PpRen	   with	   Nicotinamide	  Dinucletide	  Substrates.	  Oxidized	  anaerobic	  PpRen	  was	  mixed	  with	  varied	  concentrations	  of	  anaerobic	  substrates	  and	  the	  reduction	  of	  the	  enzyme’s	  cofactor	  was	  observed	  at	  452	  nm.	  
A:	   Reduction	   of	   the	   PpRen	   by	   6DHNAD(P)	   substrates.	   Approximately	   7	   µM	   PpRen	   was	  reacted	  with	  either	  6DHNAD	   (15,	  35,	  50,	  100,	  200,	  400	  µM)	  or	  6DHNADP	   (88,	  170,	  320,	  475,	  613	  µM).	  Traces	  for	  6DHNAD	  are	  offset	  (down)	  for	  clarity.	  B:	  The	  dependence	  of	  the	  observed	  rate	  constant	  for	  reduction	  on	  the	  concentration	  of	  6DHNAD	  and	  6DHNADP	  fit	  to	  the	   hyperbolic	   form	   of	   the	   single	   site	   binding	   equation	   (equation	   2).	   NB:	   observed	   rate	  constants	  obtained	  from	  exponential	  fits	  to	  non-­‐pseudo	  first	  order	  reactant	  concentrations	  for	  6DHNAD	  are	  shown	  as	  open	  circles.	   	  C:	  The	  reduction	  of	  PpRen	  (8	  µM)	  by	  2DHNADP	  (11.3,	  21.5,	  49.8,	  93.0,	  211.9,	  263.8	  µM	  )	  fit	  globally	  (dashed	  lines)	  to	  the	  model	  shown	  in	  Scheme	  6.2.	  D:	  The	  reduction	  of	  PpRen	  (8	  µM)	  by	  2DHNAD	  (6.3,	  13.0,	  19.0,	  26.4,	  45.6,	  72.1,	  97.2,	  163.2	  µM)	  fit	  globally	  (dashed	  lines)	  to	  the	  model	  shown	  in	  Scheme	  6.2.	  For	  C	  and	  D	  concentrations	  are	  based	  on	  the	  average	  of	  two	  spectra,	  one	  recorded	  immediately	  prior	  to	  and	  one	  immediately	  after	  collection	  of	  kinetic	  data.	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Oxidative	  Half-­‐Reaction	  of	  PpRen:	  The	  reoxidation	  of	  PpRen	  was	  observed	  by	  double	  mixing	  stopped	  flow.	  The	  anaerobic	  oxidized	  enzyme	  was	  first	  mixed	  with	  anaerobic	  6DHNAD	  at	  a	  concentration	   sufficient	   to	   reduce	   75%	  of	   the	   enzyme.	   After	   a	   150	   second	   age-­‐time	   that	  accounted	   for	   >6	   half-­‐lives	   for	   the	   predicted	   reduction	   rate	   constant	   at	   the	   reactant	  concentrations	   used,	   the	   partially	   reduced	   enzyme	  was	  mixed	  with	   defined	   pseudo-­‐first	  order	  concentrations	  of	  dioxygen	  and	  observed	  to	  reoxidize	  at	  452	  nm	  (Figure	  6.3A).	  The	  dependence	   of	   the	   observed	   reoxidation	   rate	   constant	   on	   the	   concentration	   of	   dioxygen	  was	   linear	  with	  a	   zero	   intercept	   indicating	  a	   collision-­‐based	   reaction	   (Figure	  6.3A	   inset).	  The	  second	  order	  reoxidation	  rate	  constant	  was	  obtained	  from	  the	  slope	  of	  the	  dependence	  according	   to	  Equation	  6.4	   and	  was	   found	   to	  be	  5x103	  M-­‐1s-­‐1,	   similar	   to	   that	   observed	   for	  HsRen	  (2.9x103	  M-­‐1s-­‐1)	  (54).	  	  	   Exogenous	   β-­‐NAD+	   impeded	   the	   rate	   constant	   for	   reoxidation	   (Figure	   6.3B).	   The	  dependence	   of	   the	   inhibition	   yielded	   a	   dissociation	   constant	   for	   the	   PpRen(red)•β-­‐NAD+	  complex	   of	   230	   µM	   (Figure	   6.3B	   inset),	   7-­‐fold	   higher	   affinity	   than	   the	   same	   complex	   in	  HsRen.	  Suppression	  of	   the	   reoxidation	   rate	   constant	  extrapolated	   to	  ~0	  s-­‐1,	   indicating	  an	  ordered	   product	   release	   mechanism	   in	   which	   β-­‐NAD+	   (and	   presumably	   β-­‐NADP+)	   must	  dissociate	   before	   dioxygen	   can	   react	   with	   the	   reduced	   flavin	   cofactor.	   This	   differs	   from	  HsRen	   whose	   reoxidation	   rate	   constant	   was	   not	   influenced	   by	   exogenous	   nicotinamide	  product	  and	  as	  such	  displayed	  a	  formally	  random	  product	  release	  mecnism	  (54).	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Figure	  6.3.	  Kinetics	  of	  the	  Oxidative	  Half-­‐Reaction	  of	  PpRen.	  A:	  Reoxidation	  of	  PpRen	  in	  the	  presence	   of	   varied	   concentrations	   of	   molecular	   oxygen	   observed	   at	   452	   nm.	   Reduced	  anaerobic	  PpRen	  (3	  µM)	  was	  reacted	  with	  pseudo-­‐first	  order	  concentrations	  (59,	  128,	  210,	  335,	   587	   µM)	   of	   dioxygen.	   Traces	   were	   fit	   to	   Equation	   6.3	   (red	   dashes)	   Inset.	   The	  dependence	   of	   the	   observed	   rate	   constant	   for	   reoxidation	   fit	   to	   Equation	   6.4.	   B:	   The	  dependence	  of	  the	  observed	  rate	  constant	  for	  reoxidation	  on	  the	  concentration	  of	  added	  β-­‐NAD+.	  Traces	  are	  shown	  for	  5.8	  µM	  PpRen	  reoxidizing	  in	  the	  presence	  of	  119	  µM	  dioxygen	  with	  0,	  125,	  250,	  500,	  1000,	  2000,	  4000	  µM	  added	  β-­‐NAD+	  fit	  to	  Equation	  6.3	  (red	  dashes).	  Inset.	  The	  dependence	  of	  the	  observed	  rate	  constant	  for	  reoxidation	  on	  the	  concentration	  of	  exogenous	  β-­‐NAD+	  fit	  to	  equation	  6.5.	  	  	  
	  
The	  Dissociation	  Constants	  for	  the	  PpRenox•β-­‐NADH,	  PpRenox•β-­‐NADPH	  and	  PpRen•SO3	  
adduct	  Complexes:	  The	  dissociation	  constants	  for	  β-­‐NADH	  and	  β-­‐NADPH	  were	  measured	  by	  titration	  and	  observation	  of	  perturbation	  of	  the	  absorption	  spectrum	  of	  the	  PpRen	  FAD	  isoalloxazine	  moiety	  (Figure	  6.4A).	  Consistent	  with	  the	  apparent	  preference	  for	  β-­‐NAD+-­‐derived	  substrates,	  the	  dissociation	  constant	  for	  the	  PpRen•β-­‐NADH	  complex	  was	  found	  to	  be	  ~80	  µM,	  comparable	  to	  that	  for	  the	  2DHNAD	  and	  6DHNAD	  substrates	  (Figure	  6.4).	  This	  low-­‐level	  of	  β-­‐NADH	  isomer	  selectivity	  was	  also	  observed	  in	  the	  human	  enzyme	  (55)	  and	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indicates	  that	  renalases	  are	  not	  able	  to	  discriminate	  between	  each	  of	  the	  reduced	  forms	  of	  
β-­‐NADH	  and	  therefore	  function	  in	  a	  partially	  inhibitory	  ligand	  environment.	  However,	  the	  PpRen•β-­‐NADH	  dissociation	  constant	  is	  seven-­‐fold	  lower	  than	  that	  measured	  for	  the	  human	  enzyme,	  facilitating	  soaking	  strategies	  intended	  to	  form	  this	  complex	  in	  the	  crystal	  state	  (vide	  infra).	  Consistent	  with	  the	  dissociation	  constants	  measured	  in	  the	  reductive	  half	  reaction	  for	  6DHNADP	  and	  2DHNADP,	  the	  dissociation	  constant	  for	  β-­‐NADPH	  was	  observed	  to	  be	  19-­‐fold	  larger	  than	  that	  for	  β-­‐NADH.	  	   Flavin-­‐sulfite	  adduct	  formation	  is	  a	  peculiar	  characteristic	  of	  many	  oxidase	  enzymes.	  The	  Aliverti	  group	  showed	  that	  natively	  folded	  HsRen	  formed	  a	  dissociable	  sulfite	  adduct	  with	  the	  flavin	  cofactor	  (60).	  In	  order	  to	  offer	  an	  additional	  reactivity	  correlation	  to	  HsRen,	  we	  titrated	  sulfite	  to	  PpRen	  (Figure	  6.4B).	  Characteristic	  bleaching	  of	  the	  long	  wavelength	  transitions	   of	   the	   flavin	   spectrum	   were	   observed	   along	   with	   the	   appearance	   of	   a	   UV-­‐transition	  at	  ~320	  nm.	  When	  the	  data	  obtained	  at	  452	  nm	  were	  fit	  to	  the	  quadratic	  solution	  of	   the	   single-­‐site	   binding	   equation,	   a	   dissociation	   constant	   for	   sulfite	   of	   105	   mM	   was	  obtained,	  substantially	  weaker	  than	  the	  sulfite	  affinity	  observed	  for	  HsRen	  (KSO3	  =	  1.8	  mM).	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Figure	   6.4.	   Measurement	   of	   the	   Dissociation	   Constants	   for	   the	   PpRenox•β-­‐NADH,	  PpRenox•β-­‐NADPH	   	   and	   PpRen•SO3	   Complexes.	   A:	   Flavin	   difference	   spectra	   and	   binding	  isotherms	  for	  the	  association	  of	  NADH	  and	  NADPH	  	  with	  PpRen.	  For	  the	  PpRenox•β-­‐NADH	  titration	  (black),	  17	  µM	  PpRen	  was	  titrated	  with	  NADH	  (0-­‐1	  mM)	  and	  the	  spectrum	  at	  each	  ligand	   concentration	   recorded.	  The	  observed	   absorption	   changes	   in	   the	   spectrum	  at	  494	  nm	   were	   fit	   to	   Equation	   5	   (inset).	   For	   the	   PpRenox•β-­‐NADPH	   titration	   (green),	   12	   µM	  PpRen	  was	  titrated	  with	  NADPH	  (0-­‐7	  mM)	  and	  the	  spectrum	  at	  each	  ligand	  concentration	  recorded.	  The	  observed	  absorption	  changes	  in	  the	  spectrum	  at	  468	  nm	  were	  fit	  to	  Equation	  6.5	   (inset).	   B:	   The	   titration	   of	   PpRen	   (10	   µM)	   with	   sulfite	   (0-­‐310	   mM).	   The	   observed	  absorption	  changes	  in	  the	  spectrum	  at	  452	  nm	  were	  fit	  to	  Equation	  5	  (inset).	  	  	  	  	  
Structure	  of	  the	  PpRen•β-­‐NAD+	  and	  PpRen•β-­‐NADH	  complexes:	  PpRen	  proved	  highly	  apt	  to	  form	  crystals.	  Both	  rectangular	  rods	  and	  hexagonal	  plates	  were	  obtained	  using	  the	  conditions	  that	  were	  provided	  with	  the	  PDB	  ID	  3KKJ	  structure	  deposited	  by	  the	  NESGC.	  Only	  the	  plate-­‐like	  crystals	  displayed	  uniform	  high	  diffraction.	  By	  soaking,	  structures	  of	  the	  PpRen•β-­‐NAD+	  (1.78	  Å)	  and	  PpRen•β-­‐NADH	  (2.0	  Å)	  complexes	  were	  obtained	  (Table	  6.1).	  Respectively,	  these	  structures	  are	  the	  PpRenox•product	  (EP)	  complex	  and	  a	  close	  representation	  of	  the	  PpRen•substrate	  (ES)	  complex.	  For	  both	  structures	  two	  protomers	  of	  PpRen	  are	  arranged	  together	  with	  a	  large	  primarily	  Van	  der	  Waals	  contact	  interface	  of	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~1100	  Å2	  in	  which	  no	  ionic	  pairs	  and	  only	  8	  hydrogen	  bonds	  contribute	  to	  association	  of	  the	  protomers.	  	  	   Despite	   low	  sequence	   identity	  (19%),	   the	   fold	  of	  PpRen	  is	  highly	  similar	   to	  that	  of	  HsRen	   (PDB	   ID	   3QJ4)	  with	   an	  RMSD	  of	   2.1	  Å	   for	   298/326	  Cα	   carbons	   (Figure	   6.5).	   It	   is	  interesting	  to	  note	  that	  the	  initial	  structure	  of	  PpRen	  deposited	  in	  the	  PDB	  (ID	  3KKJ)	  was	  the	   search	   model	   used	   to	   solve	   the	   structure	   of	   HsRen	   by	   molecular	   replacement.	   This	  study	   therefore	   serves	   as	   the	   functional	   assignment	   of	   the	   3KKJ	   protein,	   annotated	  previously	  as	  an	  amine	  oxidase.	  The	   renalase	   fold	   is	  not	   characteristic	   to	   renalase	  and	   is	  observed	   with	   numerous	   redox-­‐active	   flavoproteins	   (60).	   However,	   the	   constellation	   of	  conserved	  active	   site	   residues	   is	  unique	   to	   renalase	  activity	   (Figure	  6.6).	  Consistent	  with	  the	   observations	   of	  Milani	   et	   al,	   (that	   pertain	   to	   renalase	   sequences	   from	  Animalia)	   the	  active	  site	  opening	  is	  lined	  with	  three	  aromatic	  residues.	  In	  two	  of	  the	  three	  positions	  only	  the	  aromatic	  character	  of	  the	  side	  chain	  is	  conserved	  (PpRen	  W212,	  F204	  corresponding	  to	  F223,	  Y214	  in	  HsRen)	  whilst	  the	  third	  is	  a	  conserved	  tyrosine	  (PpRen	  Y57	  corresponding	  to	  Y62	  in	  HsRen).	  The	  inner	  surfaces	  of	  the	  active	  site	  pack	  closely	  to	  the	  si	  face	  of	  the	  flavin	  isoalloxazine	   and	   provide	   a	   substrate	   binding	   cavity	   adjacent	   to	   the	   re	   face.	   Conserved	  residues	  that	  line	  the	  substrate-­‐binding	  cavity	  are	  H232	  (HsRen	  H245)	  and	  W276	  (HsRen	  W288).	  A	  guanidino	  group	  is	  supplied	  by	  R280	  (HsRen	  Q292)	  and	  a	  similar	  placement	  of	  a	  guanidino	  group	  is	  accomplished	   in	  HsRen	  from	  R193	  (PpRen	  T185)	  that	   is	  conserved	   in	  the	  Animalia	  and	  extends	  from	  a	  different	  element	  of	  secondary	  structure.	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Figure	   6.5.	   Superposition	   of	   the	  PpRen•β-­‐NADH	  and	  HsRen	  Tertiary	   Structures.	  PpRen•β-­‐NADH	  is	  depicted	  in	  blue	  and	  HsRen	  is	  depicted	  in	  green	  (PDB	  ID	  3QJ4).	  	  
	  
	  
	   The	  primary	  advancement	  in	  understanding	  the	  chemistry	  of	  renalase	  was	  that	  the	  PpRen	  structures	  were	  solved	  with	  catalytically	  relevant	  ligands	  occupying	  the	  active	  site	  cavity.	  Stereo	  views	  of	  the	  active	  site	  with	  both	   ligands	  and	  representative	   ligand	  density	  are	   depicted	   in	   Figure	   6.6.	   The	   PpRen•β-­‐NADH	   complex	   structure	   provides	   a	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representation	  of	  the	  ES	  complex.	  The	  reduced	  nicotinamide	  base	  of	  β-­‐NADH	  has	  an	  overall	  neutral	  charge	  and	  is	  ostensibly	  isosteric	  with	  the	  bases	  of	  2DHNAD(P)	  or	  6DHNAD(P)	  and	  presumably	  localizes	  in	  a	  position	  similar	  to	  that	  of	  the	  native	  substrates.	  Evidence	  of	  this	  is	  that	  the	  2-­‐position	  of	  the	  base	  is	  most	  proximal	  to	  the	  N5	  of	  the	  isoalloxazine	  (3.6	  Å),	  the	  assumed	  position	  of	  hydride	  delivery,	   in	  an	  analogous	  position	   to	   that	  observed	   in	  other	  NAD(P)H/isoalloxazine	   complexes	   (327,	   355)	   (Figure	   6.7B	   &	   C).	   No	   evidence	   for	   partial	  occupancy	   of	   a	   6-­‐position	   reduction	   conformer	   is	   observed,	   suggestive	   of	   the	   apparent	  preference	   for	  2DHNAD(P)	   isomers	   that	  were	  observed	   to	   reduce	   the	   enzyme	  ~500-­‐fold	  more	  rapidly	  than	  6DHNAD(P)	  isomers	  (Figure	  6.2,	  Table	  6.2).	  One	  possible	  explanation	  for	  this	   apparent	   conformer	   bias	   is	   that	   threonine	   185	   (that	   occupies	   the	   position	   of	   a	  conserved	  arginine	  in	  animal	  renalases,	  see	  below)	  donates	  an	  apparent	  hydrogen	  bond	  to	  the	  nicotinamide	  amide	  oxygen,	  stabilizing	  the	  pose	  that	  promotes	  donation	  of	  the	  hydride	  from	   the	   2-­‐position	   (Figure	   6.6	   &	   6.7).	   Manually	   flipping	   the	   nicotinamide	   base	   in	   the	  PpRen•β-­‐NADH	  model	   followed	   by	   additional	   refinement	   did	   not	   substantially	   alter	   the	  electron	   density	   for	   the	   pyridyl	   ring	   (data	   not	   shown).	   In	   this	   alternate	   pose	   a	   potential	  interaction	   is	   observed	   from	   the	   dihydronicotinamide	   amido	   nitrogen	   to	   the	   backbone	  carbonyl	  of	  G307.	  The	  PpRen•β-­‐NAD+	  structure	  is	  that	  of	  the	  product	  complex.	  Despite	  1.78	  Å	  resolution,	  the	  electron	  density	  map	  for	  this	  complex	  indicated	  very	  low	  occupancy	  of	  the	  base	   and	   the	   ribose	   that	   form	   the	   nicotinamide	   nucleoside.	   It	   is	   suggested	   that	   the	  proximity	  of	  the	  R280	  (R193	  in	  HsRen)	  guanidino	  group	  plays	  an	  important	  role	  in	  ejecting	  the	  positively	  charged	  nicotinamide	  product	  (β-­‐NAD(P)+)	  from	  the	  active	  site.	  We	  observe	  that	  the	  guanidino	  group	  is	  displaced	  in	  the	  PpRen•β-­‐NAD+	  structure	  from	  the	  position	  it	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occupies	  in	  the	  PpRen•β-­‐NADH	  complex	  structure	  by	  2.6	  Å,	  suggesting	  a	  charge	  repulsion	  interaction.	  	  	   The	  ADP	  moiety	  of	  both	  ligands	  is	  anchored	  in	  the	  same	  position	  on	  the	  surface	  of	  the	   protein	   (Figure	   6.7).	   In	   this	   binding	   pose	   the	   two	   ribose	   units	   emerge	   from	   the	  pyrophosphate	  moiety	   approximately	   parallel	   to	   one	   another,	   a	   position	   that	   places	   the	  respective	  3’-­‐hydroxyl	  groups	  within	  2.9	  Å.	  This	  conformation	  does	  not	  provide	  an	  obvious	  explanation	  for	  the	  observed	  substrate	  binding	  preference	  of	  PpRen	  where	  β-­‐NAD+-­‐derived	  substrates	  bind	  ~50-­‐fold	  more	  tightly	  than	  those	  derived	  from	  β-­‐NADP+.	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Figure	  6.6.	  The	  Active	  Site	  of	  the	  PpRen	  β-­‐NADH	  and	  β-­‐NAD+	  complexes.	  A:	  Stereoview	  for	  the	   PpRen•β-­‐NAD+	   complex	   showing	   the	   2|Fo|−|Fc|	   simulated	   annealing	   composite	   omit	  electron	   density	   of	   the	   ligand	   (black)	   contoured	   at	   1.0σ	   and	   |Fo|−|Fc|	   electron	   density	  contoured	  at	  3.0σ	  (green)	  and	  -­‐3.0σ	  (red).	  B:	  Stereoview	  for	  the	  PpRen•β-­‐NADH	  complex	  showing	  the	  2|Fo|−|Fc|	  simulated	  annealing	  composite	  omit	  electron	  density	  of	   the	   ligand	  (black)	  contoured	  at	  1.0σ	  and	  |Fo|−|Fc|	  electron	  density	  contoured	  at	  3.0σ	  (green)	  and	  -­‐3.0σ	  (red).	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Figure	   6.7.	  The	  Reductive	  Pose	  of	  Nicotinamide	  Dinucleotide	  Substrates.	   A:	  The	  relative	  positions	  of	  β-­‐NADH	  and	  FAD	  on	  the	  solvent	  accessible	  surface	  of	  PpRen.	  B:	  The	  reductive	  complex	  of	   glutathione	   reductase	   in	   complex	  with	  β-­‐NADH	   (PDB	   ID	  1GRB)	  depicting	   the	  position	   of	   the	   nicotinamide	   4-­‐position	   3.4	   Å	   from	   the	   flavin	   isoalloxazine	   N5.	   C:	   The	  reductive	  complex	  of	  PpRen	  in	  complex	  with	  β-­‐NADH	  (PDB	  ID	  4ZCC)	  depicting	  the	  position	  of	  the	  nicotinamide	  2-­‐position	  3.6	  Å	  from	  the	  flavin	  isoalloxazine	  N5.	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Discussion	  
	   The	   current	   consensus	   understanding	   for	   the	   function	   of	   renalase	   is	   that	   it	   is	   an	  animal	  enzyme/hormone	  whose	  catalytic	  activity	  lowers	  blood	  pressure	  and	  modulates	  the	  contraction	  rate	  of	  the	  heart	  by	  oxidative	  consumption	  of	  catecholamine	  substrates	  (critical	  evaluations	   of	   this	   claimed	   catalytic	   role	   are	   available	   (356-­‐358)).	   This	   entrenched	  perception	  of	  the	  catalytic	  function	  of	  this	  enzyme	  has	  persisted	  in	  the	  literature	  since	  the	  progenitor	  article	  claimed	  to	  simultaneously	  discover	  the	  enzyme,	  its	  catalytic	  activity	  and	  its	   physiological	   role	   (1).	   We,	   and	   others,	   have	   disputed	   this	   claim	   and	   have	   offered	  evidence	  and	  counter	  arguments	  that	  undermine	  the	  link	  to	  catecholamines(48,	  51,	  54,	  55,	  
59,	   61,	   347).	   Moreover,	   the	   recent	   discovery	   by	   our	   group	   that	   renalase	   has	   genuine	  catalytic	   behavior	   with	   two	   β-­‐NAD(P)H	   isomers	   (55)	   casts	   further	   doubt	   over	   the	  extracellular	   catecholamine	  oxidase	  activity	   claim.	  This	  new	  activity	   for	   renalase	   is	  more	  consistent	  with	  an	  intracellular	  house-­‐keeping	  metabolic	  function.	  In	  this	  role	  β-­‐NAD(P)H	  isomers	   that	   we	   presume	   to	   arise	   in	   non-­‐specific	   reduction	   events	   and	   inhibit	  dehydrogenase	   enzymes	   are	   recycled	   back	   to	   the	   nicotinamide	   dinucleotide	   pool	   by	  oxidation	   (forming	   β-­‐NAD(P)+).	   Such	   an	   activity	   would	   be	   expected	   to	   be	   generally	  advantageous	  to	  living	  organisms	  and	  therefore	  likely	  to	  be	  detectable	  in	  Kingdoms	  outside	  the	  Animalia.	  In	  this	  article	  we	  present	  the	  first	  account	  of	  a	  bacterial	  form	  of	  renalase.	  In	  addition	  to	  the	  substrate	  profile,	  kinetics	  of	  catalysis	  and	  substrate/ligand	  preferences,	  we	  also	   show	   the	   structures	   of	   the	   enzyme	   in	   complexes	   with	   catalytically	   relevant	   NAD	  ligands	  that	  have	  poses	  consistent	  with	  this	  newly	  identified	  activity.	  	  	   PpRen	   was	   first	   identified	   in	   2009	   by	   the	   NESGC	   and	   in	   the	   absence	   of	   known	  function	   given	   a	   generic,	   amine	  oxidase	  designation	   (PDB	   ID	  3KKJ).	   In	   2011,	   the	  Aliverti	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group	   solved	   the	   structure	   of	   HsRen	   using	   3KKJ	   as	   a	   search	   model	   in	   a	   molecular	  replacement	   strategy	   (PDB	   ID	   3Qj4)	   (60).	   The	   striking	   similarity	   of	   the	   apparent	   active	  sites	  of	  HsRen	  and	  3KKJ	   led	  us	   to	   conclude	   that	   the	  3KKJ	   structure	  was	   from	  a	  bacterial	  form	  of	  renalase.	  The	  data	  obtained	  with	  this	  enzyme	  support	  that	  it	  has	  the	  same	  function	  as	   HsRen.	   In	   the	   presence	   of	   a	   mixture	   of	   2DHNAD(P),	   4DHNAD(P)	   (β-­‐NAD(P)H)	   and	  6DHNAD(P)	   PpRen	   oxidizes	   only	   the	   2-­‐	   and	   6-­‐dihydro	   isomers	   as	  was	   observed	   for	   the	  human	  enzyme	  (Figure	  6.1).	  Both	  β-­‐NAD+-­‐	  and	  β-­‐NADP+-­‐derived	  substrates	  induce	  relative	  rapid	   reduction	   of	   the	   PpRen	   flavin	   isoalloxazine	   ring	   and	   induce	   multiple	   turnovers	  indicating	  that	  they	  are	  genuine	  substrates	  for	  PpRen	  (Figure	  6.2).	  	  	   We	   have	   proposed	   that	   the	   true	   function	   of	   renalase	   is	   to	   scavenge	   NAD(P)H	  isomers	   to	   alleviate	   inhibition	   of	   primary	   metabolism.	   Solely	   in	   terms	   of	   dissociation	  constant,	   the	   substrate	   preference	   of	   PpRen	   would	   appear	   to	   be	   for	   β-­‐NAD+-­‐derived	  substrates.	   Both	   2DHNAD	   and	   6DHNAD	  bind	   10-­‐50-­‐fold	  more	   tightly	   than	   do	   2DHNADP	  and	  6DHNADP	  (Figure	  6.2).	  However,	  substrate	  preference	  (or	  scavenging	  efficiency)	   is	  a	  function	   of	   both	   dissociation	   constant	   and	   the	   rate	   constant	   for	   the	   largely	   irreversible	  hydride	   transfer	   to	   the	   flavin	   and	   the	   6-­‐dihydro	   substrates	   reduce	   PpRen	   considerably	  more	  slowly	  than	  the	  2-­‐dihydro	  substrates.	  When	  the	  relative	  rate	  constants	  for	  reduction	  and	  dissociation	  constants	  are	  compared	  as	  a	  ratio	  (kred/Kd),	  PpRen	  has	  a	  300-­‐500–fold	  preference	   for	   2-­‐DHNAD(P)	   substrates.	   It	   is	   conceivable	   that	   this	   substrate	   preference	  mirrors	  a	  2DHNAD(P)	  inhibitory	  susceptibility	  of	  one	  or	  more	  of	  the	  primary	  metabolism	  dehydrogenases	  in	  P.	  phaseolicola.	  The	  structures	  of	  PpRen•β-­‐NADH	  and	  PpRen•β-­‐NAD+	  do	  not	   reveal	   the	  basis	   of	  β-­‐NAD+-­‐derived	   isomer	  binding	   selectivity	   (Figure	  6.3	  &	  6.4A).	   In	  both	  the	  PpRen•β-­‐NADH	  and	  PpRen•β-­‐NAD+	  structures	  the	  oxygen	  atom	  of	  the	  2-­‐hydroxyl	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of	  the	  adenine	  nucleotide	  riboside	  has	  no	  interacting	  residue	  or	  steric	  constraint	  within	  an	  8	  Å	  sphere	  (Figure	  6.7A).	  	   It	  would	  appear	  that	  renalase’s	  primary	  catalytic	  purpose	  is	  to	  accept	  the	  hydride,	  as	  reoxidation	  of	  the	  enzyme	  occurs	  with	  a	  rate	  constant	  only	  20-­‐fold	  greater	  than	  that	  of	  free	  FADH2	  autoxidation	  and	  so	  is	  only	  modestly	  catalyzed	  (308,	  325)	  (Figure	  6.3).	  This	  is	  unlike	  most	  dioxygen-­‐reactive	  flavoproteins	  that	  tend	  to	  have	  reoxidation	  rate	  constants	  at	  least	  two	  or	  three	  orders	  of	  magnitude	  more	  rapid	  than	  that	  of	  free	  flavin	  (308,	  359,	  360).	  There	  is	   no	   spectrophotometric	   evidence	   for	   the	   dissociation	   of	   the	   β-­‐NAD(P)+	   product	   in	   the	  reductive	  half	  reaction,	  but	  its	  egress	  is	  assumed	  to	  be	  rapid	  compared	  to	  the	  rate	  constant	  for	  reoxidation	  at	  atmospheric	   levels	  of	  dioxygen	  (~1	  s-­‐1)	  (Figures	  6.3	  &	  6.6).	  Scheme	  6.3	  provides	   a	   summary	   of	   the	   kinetic	   and	   chemical	   mechanism	   conclusions	   for	   PpRen	   in	  turnover	  with	  the	  preferred	  substrate,	  2DHNAD,	  that	  were	  made	  from	  our	  observations.	  In	  this	  scheme	  the	  substrates	  bind	  rapidly	  and	  transfers	  a	  hydride	  to	  the	  flavin	  isoalloxazine	  N5.	  The	   release	  of	  products	  has	  an	  obligate	  order	   in	  which	  β-­‐NAD(P)+	  dissociates	  before	  dioxygen	  reacts	  with	  the	  reduced	  flavin.	  This	  ordered	  release	  of	  products	   is	  based	  on	  the	  observation	   that	   exogenous	   β-­‐NAD+	   can	   completely	   suppress	   the	   reoxidation	   of	   the	  enzyme.	   Once	  β-­‐NAD(P)+	   has	   dissociated	   the	   flavin	   reoxidizes	  with	   a	   rate	   constant	   that	  would	  be	  the	  in	  vitro	  rate-­‐limiting	  process	  under	  conditions	  of	  atmospheric	  dioxygen.	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Scheme	  6.3.	  Catalytic	  cycle	  of	  PpRen.	  	  	   The	  PpRen	  structures	  represent	  a	  significant	  advancement	  in	  our	  understanding	  of	  the	  catalysis	  of	   this	  enzyme.	  Together,	   the	  PpRen•β-­‐NADH	  and	  PpRen•β-­‐NAD+	  structures	  offer	   evidence	   of	   the	   nature	   of	   the	   ES	   and	   EP	   complexes	   respectively.	   The	   reduction	  reaction	  catalyzed	  by	  renalase	  is	  exceedingly	  simple:	  the	  transfer	  of	  a	  hydride	  equivalent	  to	  the	   isoalloxazine	   of	   a	   flavin.	   The	   primary	   difference	   between	   this	   and	   numerous	   other	  enzymes	   is	   that	   the	   substrate	   nicotinamide	   is	   bound	   to	   afford	   hydride	   transfer	   from	  alternate	  positions	  of	  the	  pyridyl	  base	  (Figure	  6.7).	  Possibly	  the	  most	  interesting	  aspect	  of	  renalase	  chemistry	  is	  that	  it	  accommodates	  reduction	  from	  both	  the	  2	  and	  6	  positions	  and	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therefore	  must	  have	  binding	  modes	  for	  both	  substrate	  types.	  The	  structure	  of	  PpRen	  with	  
β-­‐NADH	  bound	  has	  the	  nicotinamide	  positioned	  such	  that	  the	  2-­‐position	  of	  the	  base	  is	  3.6	  Å	  from	   and	   directly	   over	   the	   N5	   of	   the	   isoalloxazine	   ring	   (Figure	   6.7C).	   No	   evidence	   of	   a	  flipped,	   6-­‐position	   reduction	   conformation,	   in	   the	   form	  of	   amide	  density	   in	   the	   alternate	  meta-­‐position,	   in	   respect	   to	   the	   pyridyl	   nitrogen,	   is	   observed.	   Moreover,	   no	   density	  indicative	  of	  a	  lateral	  displacement	  of	  the	  nicotinamide	  to	  place	  the	  6	  position	  proximal	  to	  the	  flavin	  N5	  is	  observed.	  As	  such	  it	  would	  appear	  that	  the	  rapid	  reduction	  rate	  constants	  observed	   with	   2DHNAD(P)	   substrates	   are	   due	   to	   a	   more	   naturally	   optimized	   position	  whose	  conformer	  was	  selected	  in	  the	  crystalline	  state	  by	  the	  hydrogen	  bonding	  interaction	  with	  threonine	  185.	  	  	   Consistent	   with	   the	   relatively	   simple	   reaction	   being	   catalyzed,	   the	   number	   of	  conserved	  active	  site	   residues	   in	  renalase	   is	   small.	  The	   inner	  surface	  of	   the	   flavin	  re-­‐face	  substrate	  cavity	  has	  only	  three	  fully	  conserved	  residues,	  H232,	  R280	  and	  W276.	  Formally	  R280	   is	   not	   positionally	   conserved,	   as	   it	   extends	   from	   a	   different	   secondary	   structural	  element	   in	   the	  bacterial	  enzyme	  (R193	   in	  HsRen).	  However,	   the	  guanidino	  group	  of	  both	  residues	  resides	  in	  similar	  positions	  in	  the	  active	  site.	  It	  is	  posited	  that	  this	  charged	  residue	  is	   responsible	   for	   expulsion	   of	   the	   oxidized	   nicotinamide	   after	   hydride	   transfer	   and	  potentially	   facilitates	   the	   reduction	   chemistry	   by	   promoting	   the	   formation	   of	   the	  dihydroflavin	  anion.	  H232	  is	  conserved	  in	  all	  known	  or	  annotated	  forms	  of	  renalase	  (H245	  in	   HsRen).	   This	   residue	   is	   not	   required	   for	   acid/base	   chemistry	   in	   the	   reductive	   half	  reaction	  but	  may	  serve	  to	  add	  to	  the	  positive	  potential	  toward	  the	  internal	  reaches	  of	  the	  active	  site.	  H232	  may	  participate	   in	  acid/base	  chemistry	   in	   the	  oxidative	  half	   reaction	  by	  shuttling	   protons	   to	   aid	   rapid	   elimination	   of	   hydrogen	   peroxide	   from	   a	   transient	   C4a-­‐
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(hydro)peroxyflavin	   during	   the	   oxidative	   half-­‐reaction.	   This	   histidine	   is	   positioned	   5.0	   Å	  from	  the	  flavin	  N5	  and	  C4a	  positions	  with	  both	  the	  β-­‐NADH	  and	  β-­‐NAD+	  ligands	  bound.	  	   This	   study	   identifies	   the	   first	   known	   bacterial	   form	   of	   renalase.	   Defining	   true	  catalytic	   substrates	   for	   the	   human	   enzyme	   has	   both	   prompted	   re-­‐evaluation	   of	   the	   true	  function	  of	  this	  enzyme	  and	  provided	  a	  means	  to	  definitively	  identify	  this	  activity	  in	  other	  organisms,	   including	   those	  without	   circulatory	   systems.	   In	   regard	   to	   the	   catalytic	   role	   of	  renalase,	   it	   has	   become	   very	   clear	   that	   claims	   concerning	   activity	   with	   catecholamines	  were	  quite	  incorrect,	  and	  were	  based	  on	  the	  propensity	  of	  such	  molecules	  to	  autoxidize	  in	  the	   presence	   of	   dioxygen.	   The	   elaboration	   of	   these	   claims	   throughout	   the	   last	   decade	  warrants	  some	  retrospection.	  While	  the	  observations	   included	  here	  and	  in	  prior	  work	  do	  not	  rule-­‐out	  a	  non-­‐catalytic	  moonlighting	  influence	  on	  vascular	  tone,	  they	  do	  argue	  strongly	  that	   the	   catalytic	   role	   of	   renalase	   serves	   an	   intracellular	   function	   that	   eliminates	   an	  inhibition	  of	  primary	  metabolism	  by	  β-­‐NAD(P)H	  isomers.	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  December	  2011-­‐	  July	  2012	  Research	  Assistant	  -­‐	  Consultant	   	  
• Measured	  enzyme	  kinetics	  using	  UV	  spectroscopy	  and	  dissolved	  oxygen.	  	  
• Responsible	  for	  designing	  experiments	  to	  measure	  enzyme	  inhibition	  using	  multiple	  biochemical	  techniques	  
	  
National	  Sea	  Grant	  College	  Program	  of	  Wisconsin	  	  Invasive	  Species	  Monitoring	   	   	   	   	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  May	  2008-­‐	  August	  2009	  	  
• Responsible	  for	  enforcing	  DNR	  recreational	  vehicle	  guidelines	  for	  proper	  invasive	  species	  sanitation.	  
• Independently	  responsible	  for	  collecting	  and	  reporting	  numerical	  samples	  for	  invasive	  species	  research.	   	   	  
	  	  
Teaching	  Experience	  
	  
University	  of	  Wisconsin-­‐Milwaukee	   	   	   	   	  	  	  	  	  	  	  	  	  August	  2012-­‐	  May	  2014	  
Teaching	  Assistant	   	   	   	   	  
• Chemistry	  501,	  Intro	  to	  Biochemistry	  
• Chemistry	  603,	  Biochemistry	  Lab	  
• Chemistry	  102,	  General	  Chemistry	  I	  
• Chemistry	  102,	  General	  Chemistry	  Lab	  I	  	  	  	  	  
	  	   226	  
Awards	  	  
	  
• Outstanding	  Graduate	  Student	  Award	   	   	   	   	   	  	  	  Spring	  2016	  
• UW-­‐Milwaukee	  Chancellors	  Graduate	  Award	   	   	  	  	  	  	  	  	  August	  2012	  -­‐	  May	  2014	  
• Support	  for	  Undergraduate	  Research	  (SURF)	  	   	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  May	  2012	  –	  August	  2012	  
	  
Conferences	  &	  Activities	  	  
• Enzyme	  Mechanisms	  Conference.	  Galveston,	  TX	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  January,	  2015	  
Presented	  research	  poster	  
	  
• Midwest	  Enzyme	  Chemistry	  Conference.	  Chicago,	  IL	  	   	   	  	  	  	   October	  2014	  
Presented	  research	  poster	  
	  
• Young	  Chemists	  Committee.	  Milwaukee,	  WI	   	   	   	  	  	  	  	  	  	  	  	  	  November	  2013	  
Presented	  research	  
	  
• Midwest	  Enzyme	  Chemistry	  Conference.	  Chicago,	  IL	  	   	   	  	  	  	   	  October	  2013	  
Presented	  research	  poster	  	  
	  	  	  	  	  	  	  
